


## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, August 31, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L11	L10 AND beta-amyloid 1-28	8
<input type="checkbox"/>	L10	L9 AND antibody	1848
<input type="checkbox"/>	L9	(beta-amyloid OR amyloid-beta OR Abeta)	2993
<input type="checkbox"/>	L8	L7 AND beta	176
<input type="checkbox"/>	L7	L6 AND amyloid	187
<input type="checkbox"/>	L6	(530/387.1,388.1,388.2,389.1,390.5.CCLS.)	4382
<input type="checkbox"/>	L5	L4 AND amyloid	83
<input type="checkbox"/>	L4	424/130.1,135.1,141.1.CCLS.	1905
<input type="checkbox"/>	L3	Solomon.IN.	5805
<input type="checkbox"/>	L2	Solomon-B.IN.	19
<input type="checkbox"/>	L1	(Solomon-Beka.IN.)	17

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
 Search PubMed for beta-amyloid AND antibody AND 1-28 Go Clear  
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text  
 Items 1-8 of 8 One page.

1: [Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J](#) Related Articles, Links

Humoral immune response to fibrillar beta-amyloid peptide.  
 Biochemistry. 2003 Oct 14;42(40):11682-92.  
 PMID: 14529278 [PubMed - indexed for MEDLINE]

2: [Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Hoffmann MM, Huttlinger M, Wieland H, Marz W](#) Related Articles, Links

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.  
 J Lipid Res. 1999 Mar;40(3):447-55.  
 PMID: 10064733 [PubMed - indexed for MEDLINE]

3: [Arai Y, Suzuki A, Mizuguchi M, Takashima S](#) Related Articles, Links

Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.  
 Brain Dev. 1997 Jun;19(4):290-4.  
 PMID: 9187481 [PubMed - indexed for MEDLINE]

4: [Solomon B, Koppel R, Frankel D, Hanan-Aharon E](#) Related Articles, Links

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.  
 Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.  
 PMID: 9108113 [PubMed - indexed for MEDLINE]

5: [Xu S, Gaskin F](#) Related Articles, Links

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.  
 Mech Ageing Dev. 1997 Mar;94(1-3):213-22.  
 PMID: 9147373 [PubMed - indexed for MEDLINE]

6: [Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H](#) Related Articles, Links

Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
 Neurobiol Aging. 1996 May-Jun;17(3):405-14.  
 PMID: 8725902 [PubMed - indexed for MEDLINE]

7: [Solomon B, Koppel R, Hanan E, Katzav T](#) Related Articles, Links

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.  
 Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5.  
 PMID: 8552659 [PubMed - indexed for MEDLINE]


8: [Gaskin F, Finley J, Fang Q, Xu S, Fu SM](#) Related Articles, Links

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.  
 J Exp Med. 1993 Apr 1;177(4):1181-6.  
 PMID: 8459212 [PubMed - indexed for MEDLINE]

Display	Summary	Show:	500	Sort	Send to	Text
---------	---------	-------	-----	------	---------	------

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

3/12/2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book  
 Search PubMed for Stern AND 1989 AND beta Go Clear  
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview  
 Help | FAQ  
 Tutorial  
 New/Noteworthy  
 E-Utilities

PubMed Services  
 Journals Database  
 MeSH Database  
 Single Citation Matcher  
 Batch Citation Matcher  
 Clinical Queries  
 LinkOut  
 Cubby


Related Resources  
 Order Documents  
 NLM Gateway  
 TOXNET  
 Consumer Health  
 Clinical Alerts  
 ClinicalTrials.gov  
 PubMed Central


Display Summary Show: 500 Sort Send to Text  
 Items 1-15 of 15 One page.

- ☐ 1: Greenwald P, Stern HR. [Related Articles, Links](#)  
**Role of biology and prevention in aerodigestive tract cancers.**  
 J Natl Cancer Inst Monogr. 1992;(13):3-14.  
 PMID: 1389693 [PubMed - indexed for MEDLINE]
- ☐ 2: Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA. [Related Articles, Links](#)  
**Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.**  
 J Biol Chem. 1990 May 25;265(15):8558-65.  
 PMID: 2187868 [PubMed - indexed for MEDLINE]
- ☐ 3: Moore BJ, Inokuchi T, Horwitz BA, Stern J. [Related Articles, Links](#)  
**Maternal brown fat metabolism returns to control level by four weeks postweaning in rats.**  
 J Nutr. 1989 Dec;119(12):1992-8.  
 PMID: 2695604 [PubMed - indexed for MEDLINE]
- ☐ 4: Rutka JT, Rosenblum ML, Stern R, Ralston HJ 3rd, Dougherty D, Giblin J, DeArmond S. [Related Articles, Links](#)  
**Isolation and partial purification of growth factors with TGF-like activity from human malignant gliomas.**  
 J Neurosurg. 1989 Dec;71(6):875-83.  
 PMID: 2585080 [PubMed - indexed for MEDLINE]
- ☐ 5: Stern MH, Lipkowitz S, Aurias A, Griscelli C, Thomas G, Kirsch IR. [Related Articles, Links](#)  
**Inversion of chromosome 7 in ataxia telangiectasia is generated by a rearrangement between T-cell receptor beta and T-cell receptor gamma genes.**  
 Blood. 1989 Nov 1;74(6):2076-80.  
 PMID: 2529926 [PubMed - indexed for MEDLINE]
- ☐ 6: Stern N, Eggena P, Chandler W, Tuck ML. [Related Articles, Links](#)  
**Effects of central and peripheral dopamine antagonism on aldosterone secretion: evidence for adrenal mechanism.**  
 Am J Physiol. 1989 Oct;257(4 Pt 1):E588-94.  
 PMID: 2679132 [PubMed - indexed for MEDLINE]
- ☐ 7: Brewster ME, Simpkins JW, Hora MS, Stern WC, Bodor N. [Related Articles, Links](#)  
**The potential use of cyclodextrins in parenteral formulations.**  
 J Parenter Sci Technol. 1989 Sep-Oct;43(5):231-40. Review.  
 PMID: 2681643 [PubMed - indexed for MEDLINE]
- ☐ 8: Goldcy SH, Stern GA, Oblon DJ, Mendenhall NP, Smith LJ, Duque RE. [Related Articles, Links](#)  
**Immunophenotypic characterization of an unusual T-cell lymphoma presenting as anterior uveitis. A clinicopathologic case report.**





Arch Ophthalmol. 1989 Sep;107(9):1349-53.  
PMID: 2675806 [PubMed - indexed for MEDLINE]

-  **9:** [Rinke de Wit TF, Vloemans AA, van den Elsen PJ, Ward J, Sutcliffe RC, Glazebrook J, Haworth A, Stern PL](#) [Related Articles, Links](#)


 Novel human MHC class I genes are expressed by tumour cell lines representing embryonic and extraembryonic tissues.


J Immunogenet. 1989 Aug-Oct;16(4-5):391-6.  
PMID: 2639910 [PubMed - indexed for MEDLINE]

-  **10:** [Stern MD, Weisman HF, Renlund DG, Gerstenblith G, Hano O, Blank PS, Lakatta EG](#) [Related Articles, Links](#)

 Laser backscatter studies of intracellular Ca<sup>2+</sup> oscillations in isolated hearts.


Am J Physiol. 1989 Aug;257(2 Pt 2):H665-73.  
PMID: 2504061 [PubMed - indexed for MEDLINE]

-  **11:** [Gronke RS, VanDusen WJ, Garsky VM, Jacobs JW, Sardana MK, Stern AM, Friedman PA](#) [Related Articles, Links](#)


 Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX.


Proc Natl Acad Sci U S A. 1989 May;86(10):3609-13.  
PMID: 2726737 [PubMed - indexed for MEDLINE]

-  **12:** [Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS](#) [Related Articles, Links](#)

 Are topical corticosteroids useful in phototherapy for psoriasis?


J Am Acad Dermatol. 1989 May;20(5 Pt 1):748-54.  
PMID: 2654215 [PubMed - indexed for MEDLINE]

-  **13:** [Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM](#) [Related Articles, Links](#)

 Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system.


Am J Pathol. 1989 May;134(5):973-8.  
PMID: 2524164 [PubMed - indexed for MEDLINE]

-  **14:** [Bantleon HP, Droschl H, Stern G](#) [Related Articles, Links](#)

 [Different applications of various wire alloys in fixed appliance technic]

Inf Orthod Kieferorthop. 1989 2D QUARTER;21(2):173-83. German.  
PMID: 2639865 [PubMed - indexed for MEDLINE]

-  **15:** [Daems D, Boens N, De Schryver FC](#) [Related Articles, Links](#)


 Fluorescence quenching with lindane in small unilamellar L, alpha-dimyristoylphosphatidylcholine vesicles.

Eur Biophys J. 1989;17(1):25-36.  
PMID: 2473894 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**

Write to the Help Desk  
NCBI | NLM | NIH  
Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search PubMed for [ ] Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Am J Pathol. 1989 May;134(5):973-8.[Related Articles, Links](#)

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources

Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system.**

**Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM.**


Department of Pathology and Laboratory Medicine (Neuropathology),  
University of Pennsylvania School of Medicine.

Studies were conducted to identify neural cells that synthesize and/or process cerebral amyloid using antisera and monoclonal antibodies (MAbs) raised to synthetic peptides based on the first 28 amino acids of the amyloid beta-protein. Using rabbit and mouse antisera, and 7 MAbs, sections of neocortex, hippocampus, cerebellum, and spinal cord from Alzheimer's disease (AD), Down's syndrome (DS), and control cases were probed. The antibodies produced 3 distinct immunohistochemical patterns: 1) staining restricted to neuritic plaque and blood vessel amyloid only (antisera, 1 of 7 MAbs); 2) immunoreactivity confined to cytoplasmic granules in diverse neuronal, glial (astrocytes, ependyma) and other (leptomeningeal, perivascular, choroid plexus) cells (1 of 7 MAbs); 3) a summation of these 2 patterns (5 of 7 MAbs). Controls resembled the AD and DS cases, except for a paucity of immunoreactive plaques and blood vessels in the controls. Immunoreactivity was reduced or removed by the peptides used to produce these antibodies. Formalin- and Bouins-fixed tissues reacted weakly or not at all with these antibodies while microwave denatured tissues reacted very intensely with them. Specific staining was enhanced by treatment of the tissue sections with Triton X-100, NaDodSO<sub>4</sub>, or trypsin. These studies significantly extend earlier studies that localized amyloid beta-protein precursor mRNA to human brain cells, and they suggest that the beta-protein, its precursor, and/or fragments thereof may exist in diverse neural cell types in AD, DS, and control brains.

PMID: 2524164 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
 Search PubMed for 10D5 Go Clear  
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview  
 Help | FAQ  
 Tutorial  
 New/Noteworthy  
 E-Utilities

PubMed Services

Journals Database  
 MeSH Database  
 Single Citation Matcher  
 Batch Citation Matcher  
 Clinical Queries  
 LinkOut  
 Caddy

Related Resources

Order Documents  
 NLM Gateway  
 TOXNET  
 Consumer Health  
 Clinical Alerts  
 ClinicalTrials.gov  
 PubMed Central

Display Summary Show: 500 Sort Send to Text  
 Items 1-12 of 12 One page.

☐ 1: [Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Beutera ML, Martinez-Murillo R, Martinez A, Rodrigo J.](#) Related Articles, Links

Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease.  
 Histol Histopathol. 2004 Jul;19(3):823-44.  
 PMID: 15168346 [PubMed - indexed for MEDLINE]

☐ 2: [Yamaguchi H, Harada A.](#) Related Articles, Links

Supramolecular formation of antibodies with viologen dimers: utilization for amplification of methyl viologen detection signals in surface plasmon resonance sensor.  
 Biomacromolecules. 2002 Nov-Dec;3(6):1163-9.  
 PMID: 12425652 [PubMed - indexed for MEDLINE]

☐ 3: [Bacskaï BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT.](#) Related Articles, Links

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.  
 J Neurosci. 2002 Sep 15;22(18):7873-8.  
 PMID: 12223540 [PubMed - indexed for MEDLINE]

☐ 4: [Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jordan R, Li X.](#) Related Articles, Links

Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma.  
 Matrix Biol. 2002 Apr;21(3):297-307.  
 PMID: 12009335 [PubMed - indexed for MEDLINE]

☐ 5: [Parvizi J, Van Hoesen GW, Damasio A.](#) Related Articles, Links

The selective vulnerability of brainstem nuclei to Alzheimer's disease.  
 Ann Neurol. 2001 Jan;49(1):53-66.  
 PMID: 11198297 [PubMed - indexed for MEDLINE]

☐ 6: [Parvizi J, Van Hoesen GW, Damasio A.](#) Related Articles, Links

Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease.  
 Ann Neurol. 2000 Sep;48(3):344-53.  
 PMID: 10976641 [PubMed - indexed for MEDLINE]

☐ 7: [Jackson T, Sheppard D, Denyer M, Blakemore W, King AM.](#) Related Articles, Links

The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus.  
 J Virol. 2000 Jun;74(11):4949-56.  
 PMID: 10799568 [PubMed - indexed for MEDLINE]

☐ 8: [Frenkel D, Balass M, Katchalski-Katzir E, Solomon B.](#) Related Articles, Links

High affinity binding of monoclonal antibodies to the sequential epitope



EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.

J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.

PMID: 10229123 [PubMed - indexed for MEDLINE]

☐ **9:** [Frenkel D, Balass M, Solomon B.](#)

[Related Articles, Links](#)



N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.

J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.

PMID: 9688328 [PubMed - indexed for MEDLINE]

☐ **10:** [Huang X, Wu J, Spong S, Sheppard D.](#)

[Related Articles, Links](#)



The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin.

J Cell Sci. 1998 Aug;111 (Pt 15):2189-95.

PMID: 9664040 [PubMed - indexed for MEDLINE]

☐ **11:** [Johnstone EM, Babbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP.](#)

[Related Articles, Links](#)



Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.

Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.

PMID: 8607830 [PubMed - indexed for MEDLINE]

☐ **12:** [Walker LC, Price DL, Voytko ML, Schenk DB.](#)

[Related Articles, Links](#)



Labeling of cerebral amyloid in vivo with a monoclonal antibody.

J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.

PMID: 8021711 [PubMed - indexed for MEDLINE]

Display  Show:


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search  for     
Limits Preview/Index History Clipboard Details

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

Show:

☐ 1: J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.

[Related Articles, Links](#)

## Labeling of cerebral amyloid in vivo with a monoclonal antibody.

Walker LC, Price DL, Voytko ML, Schenk DB.

Department of Pathology, Johns Hopkins University School of Medicine,  
Baltimore, MD 21205-2196.

We assessed the ability of a murine monoclonal antibody to bind selectively to beta-amyloid in the brains of living nonhuman primates. To circumvent the blood-brain barrier, we injected unlabeled antibody 10D5 (murine whole IgG1 and/or Fab fragments) into the cerebrospinal fluid of the cisterna magna in three aged monkeys. A control animal was given an intracisternal injection of nonimmune mouse whole IgG plus Fab. Twenty-four hours later, the animals were perfused and prepared for immunohistochemical detection of bound murine immunoglobulin in brain. All three experimental animals showed selective binding of 10D5 to approximately 5-15% of amyloid deposits in cerebral cortex, primarily near the cortical surface. There was no labeling in the control animal. In vivo-labeled deposits were confirmed to be beta-amyloid by electron microscopy and by in vitro immunohistochemistry in adjacent sections. The animals tolerated the injection well, although some polymorphonuclear leukocytes infiltrated portions of the subarachnoid space and superficial neocortex. These results provide the first demonstration that it may be feasible to selectively direct a tagged monoclonal antibody to beta-amyloid in the brain for therapeutic or diagnostic purposes. With enhancement of labeling efficiency, the method also may be useful for studying the progression of beta-amyloidosis in experimental animals using emission tomography.

PMID: 8021711 [PubMed - indexed for MEDLINE]

Show:


[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
 Search PubMed for beta-amyloid AND antibody Go Clear  
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-471 of 471

One page.

- ☐ 1: [De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST](#) Links

☐ Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A {beta} oligomerization.

FASEB J. 2004 Sep;18(12):1366-1372.

PMID: 15333579 [PubMed - as supplied by publisher]

- ☐ 2: [Sadowski M, Pankiewicz J, Scholtzeva H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T](#) Related Articles, Links

☐ A Synthetic Peptide Blocking the Apolipoprotein E/{beta}-Amyloid Binding Mitigates {beta}-Amyloid Toxicity and Fibril Formation in Vitro and Reduces {beta}-Amyloid Plaques in Transgenic Mice.

Am J Pathol. 2004 Sep;165(3):937-948.

PMID: 15331417 [PubMed - as supplied by publisher]

- ☐ 3: [Sortino MA, Chisari M, Merlo S, Vancheri C, Caruso M, Nicoletti F, Canonico PL, Copani A](#) Related Articles, Links

☐ Glia mediates the neuroprotective action of estradiol on {beta}-amyloid-induced neuronal death.

Endocrinology. 2004 Aug 12 [Epub ahead of print]

PMID: 15308615 [PubMed - as supplied by publisher]

- ☐ 4: [Yasuoka K, Hirata K, Kuraoka A, He JW, Kawabuchi M](#) Related Articles, Links

☐ Expression of amyloid precursor protein-like molecule in astroglial cells of the subventricular zone and rostral migratory stream of the adult rat forebrain.

J Anat. 2004 Aug;205(2):135-46.

PMID: 15291796 [PubMed - in process]

- ☐ 5: [Liu R, McAllister C, Lyubchenko Y, Sierks MR](#) Related Articles, Links

☐ Proteolytic Antibody Light Chains Alter beta-Amyloid Aggregation and Prevent Cytotoxicity.

Biochemistry. 2004 Aug 10;43(31):9999-10007.

PMID: 15287727 [PubMed - in process]

- ☐ 6: [Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR](#) Related Articles, Links

☐ Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.

Biochemistry. 2004 Jun 8;43(22):6959-67.










PMID: 15170333 [PubMed - indexed for MEDLINE]





















- ☐ 7: [Schultz C, Ghebremedhin E, Del Tredici K, Rub U, Braak H](#) Related Articles, Links

☐ High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe.

Neurobiol Aging. 2004 Mar;25(3):397-405.

PMID: 15123344 [PubMed - indexed for MEDLINE]

-  **8:** [Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK.](#) [Related Articles, Links](#)  
**Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain.**  
 J Neurosci. 2004 Apr 7;24(14):3592-9.  
 PMID: 15071107 [PubMed - indexed for MEDLINE]
-  **9:** [Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF.](#) [Related Articles, Links](#)  
**Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice.**  
 Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1136-45. Epub 2004 Mar 09.  
 PMID: 15007564 [PubMed - in process]
-  **10:** [Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Moller HJ.](#) [Related Articles, Links](#)  
**Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.**  
 J Neural Transm. 2004 Mar;111(3):247-72. Epub 2003 Dec 03. Review.  
 PMID: 14991453 [PubMed - indexed for MEDLINE]
-  **11:** [Bozzo C, Lombardi G, Santoro C, Canonico PL.](#) [Related Articles, Links](#)  
**Involvement of beta(1) integrin in betaAP-induced apoptosis in human neuroblastoma cells.**  
 Mol Cell Neurosci. 2004 Jan;25(1):1-8.  
 PMID: 14962735 [PubMed - indexed for MEDLINE]
-  **12:** [Sondag CM, Combs CK.](#) [Related Articles, Links](#)  
**Amyloid precursor protein mediates proinflammatory activation of monocytic lineage cells.**  
 J Biol Chem. 2004 Apr 2;279(14):14456-63. Epub 2004 Jan 19.  
 PMID: 14732706 [PubMed - indexed for MEDLINE]
-  **13:** [Muresan Z, Muresan V.](#) [Related Articles, Links](#)  
**A phosphorylated, carboxy-terminal fragment of beta-amyloid precursor protein localizes to the splicing factor compartment.**  
 Hum Mol Genet. 2004 Mar 1;13(5):475-88. Epub 2004 Jan 13.  
 PMID: 14722157 [PubMed - in process]
-  **14:** [Yang W, Sopper MM, Leystra-Lantz C, Strong MJ.](#) [Related Articles, Links](#)  
**Microtubule-associated tau protein positive neuronal and glial inclusions in ALS.**  
 Neurology. 2003 Dec 23;61(12):1766-73.  
 PMID: 14694044 [PubMed - indexed for MEDLINE]
-  **15:** [Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W.](#) [Related Articles, Links](#)  
**A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease.**  
 Neurobiol Dis. 2003 Dec;14(3):365-79.  
 PMID: 14678754 [PubMed - indexed for MEDLINE]
-  **16:** [Cai J, Wang SZ, Peng Y, Zhong YW, Ji ZJ, Yuan JG, Qiang BQ.](#) [Related Articles, Links](#)  
**[Cloning and expression of human single-chain Fv antibody against amyloid beta peptide involved in Alzheimer's disease]**  
 Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Oct;25(5):557-62. Chinese.  
 PMID: 14650158 [PubMed - indexed for MEDLINE]


-  **17:** [Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR.](#) [Related Articles, Links](#)  
 **Degradation of beta-amyloid by proteolytic antibody light chains.**  
 Biochemistry. 2003 Dec 9;42(48):14328-34.  
 PMID: 14640701 [PubMed - indexed for MEDLINE]
-  **18:** [Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, Tian W, Sadzikava N, Ross TM, Head E, Cribbs DH, Agadjanyan MG.](#) [Related Articles, Links](#)  
 **Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.**  
 Eur J Immunol. 2003 Dec;33(12):3232-41.  
 PMID: 14635031 [PubMed - indexed for MEDLINE]
-  **19:** [Kojouharova MS, Tsacheva IG, Tchorbadjieva ML, Reid KB, Kishore U.](#) [Related Articles, Links](#)  
 **Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies.**  
 Biochim Biophys Acta. 2003 Nov 3;1652(1):64-74.  
 PMID: 14580997 [PubMed - indexed for MEDLINE]
-  **20:** [Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J.](#) [Related Articles, Links](#)  
 **Humoral immune response to fibrillar beta-amyloid peptide.**  
 Biochemistry. 2003 Oct 14;42(40):11682-92.  
 PMID: 14529278 [PubMed - indexed for MEDLINE]
-  **21:** [Wang DS, Iwata N, Hama E, Saido TC, Dickson DW.](#) [Related Articles, Links](#)  
 **Oxidized neprilysin in aging and Alzheimer's disease brains.**  
 Biochem Biophys Res Commun. 2003 Oct 10;310(1):236-41.  
 PMID: 14511676 [PubMed - indexed for MEDLINE]
-  **22:** [Lehman EJ, Kulane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT.](#) [Related Articles, Links](#)  
 **Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse.**  
 Hum Mol Genet. 2003 Nov 15;12(22):2949-56. Epub 2003 Sep 23.  
 PMID: 14506131 [PubMed - indexed for MEDLINE]
-  **23:** [Xu D, Yang CH, Wang LN.](#) [Related Articles, Links](#)  
 **[Prevalence and characteristics of cerebral amyloid angiopathy in the elderly]**  
 Zhonghua Nei Ke Za Zhi. 2003 Aug;42(8):541-4. Chinese.  
 PMID: 14505543 [PubMed - indexed for MEDLINE]
-  **24:** [Solomon B.](#) [Related Articles, Links](#)  
 **Immunological approach for the treatment of Alzheimer's disease.**  
 J Mol Neurosci. 2003;20(3):283-6.  
 PMID: 14501009 [PubMed - indexed for MEDLINE]
-  **25:** [Chauhan NB, Siegel GJ.](#) [Related Articles, Links](#)  
 **Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.**  
 J Neurosci Res. 2003 Oct 1;74(1):142-7.  
 PMID: 13130516 [PubMed - indexed for MEDLINE]
-  **26:** [Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C.](#) [Related Articles, Links](#)  
 **Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid**



peptide42.

Arch Neurol. 2003 Sep;60(9):1202-6.

PMID: 12975284 [PubMed - indexed for MEDLINE]

-  **27:** [Celsi F, Ferri A, Casciati A, D'Ambrosi N, Rotilio G, Costa A, Volonte C, Carri MT.](#) [Related Articles, Links](#)



**Overexpression of superoxide dismutase 1 protects against beta-amyloid peptide toxicity: effect of estrogen and copper chelators.**

Neurochem Int. 2004 Jan;44(1):25-33.

PMID: 12963085 [PubMed - indexed for MEDLINE]


-  **28:** [LeVine H 3rd.](#) [Related Articles, Links](#)



**Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide.**

Arch Biochem Biophys. 2003 Sep 1;417(1):112-22.

PMID: 12921787 [PubMed - indexed for MEDLINE]

-  **29:** [Mazur-Kolecka B, Kowal D, Sukontasup T, Dickson D, Frackowiak J.](#) [Related Articles, Links](#)



**The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA).**

Brain Res. 2003 Sep 5;983(1-2):48-57.

PMID: 12914965 [PubMed - indexed for MEDLINE]


-  **30:** [Okuyama R, Marshall S.](#) [Related Articles, Links](#)



**UDP-N-acetylglucosaminyl transferase (OGT) in brain tissue: temperature sensitivity and subcellular distribution of cytosolic and nuclear enzyme.**

J Neurochem. 2003 Sep;86(5):1271-80.

PMID: 12911634 [PubMed - indexed for MEDLINE]


-  **31:** [Torp R, Ottersen OP, Cotman CW, Head E.](#) [Related Articles, Links](#)



**Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing.**

Neuroscience. 2003;120(2):291-300.

PMID: 12890502 [PubMed - indexed for MEDLINE]


-  **32:** [Schwab C, Hosokawa M, Akiyama H, McGeer PL.](#) [Related Articles, Links](#)



**Familial British dementia: colocalization of furin and ABri amyloid.**

Acta Neuropathol (Berl). 2003 Sep;106(3):278-84. Epub 2003 Jul 16.

PMID: 12883829 [PubMed - indexed for MEDLINE]


-  **33:** [Tang K, Wang C, Shen C, Sheng S, Ravid R, Jing N.](#) [Related Articles, Links](#)



**Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639.**

Eur J Neurosci. 2003 Jul;18(1):102-8.

PMID: 12859342 [PubMed - indexed for MEDLINE]


-  **34:** [Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB.](#) [Related Articles, Links](#)












**Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.**










J Immunol. 2003 Jul 15;171(2):812-20.


PMID: 12847249 [PubMed - indexed for MEDLINE]

-  **35:** [Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C.](#) [Related Articles, Links](#)

Subacute meningoencephalitis in a subset of patients with AD after

-  **Abeta42 immunization.**  
Neurology. 2003 Jul 8;61(1):46-54.  
PMID: 12847155 [PubMed - indexed for MEDLINE]
-  **36:** Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M. [Related Articles](#), [Links](#)  
**Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.**  
Brain. 2003 Sep;126(Pt 9):1935-9. Epub 2003 Jun 23.  
PMID: 12821522 [PubMed - indexed for MEDLINE]
-  **37:** Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. [Related Articles](#), [Links](#)  
**Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice.**  
Behav Neurosci. 2003 Jun;117(3):478-84.  
PMID: 12802876 [PubMed - indexed for MEDLINE]
-  **38:** Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE. [Related Articles](#), [Links](#)  
**Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice.**  
Life Sci. 2003 Jun 20;73(5):555-62.  
PMID: 12770611 [PubMed - indexed for MEDLINE]
-  **39:** Hoek C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbrecht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. [Related Articles](#), [Links](#)  
**Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.**  
Neuron. 2003 May 22;38(4):547-54.  
PMID: 12765607 [PubMed - indexed for MEDLINE]
-  **40:** Li G, Percontino L, Sun Q, Qazi AS, Frederikse PH. [Related Articles](#), [Links](#)  
**Beta-amyloid secretases and beta-amyloid degrading enzyme expression in lens.**  
Mol Vis. 2003 May 1;9:179-83.  
PMID: 12740567 [PubMed - indexed for MEDLINE]
-  **41:** Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE. [Related Articles](#), [Links](#)  
**Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.**  
J Protein Chem. 2003 Jan;22(1):31-40.  
PMID: 12739896 [PubMed - indexed for MEDLINE]
-  **42:** Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. [Related Articles](#), [Links](#)  
**Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.**  
J Neurosci. 2003 May 1;23(9):3745-51.  
PMID: 12736345 [PubMed - indexed for MEDLINE]
-  **43:** Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ. [Related Articles](#), [Links](#)  
**Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane.**  
J Biol Chem. 2003 Jul 18;278(29):26687-94. Epub 2003 May 07.  
PMID: 12736250 [PubMed - indexed for MEDLINE]

-  **44:** [Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.](#) [Related Articles, Links](#)  
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.  
JAMA. 2003 Apr 23-30;289(16):2094-103.  
PMID: 12709467 [PubMed - indexed for MEDLINE]
-  **45:** [Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA.](#) [Related Articles, Links](#)  
Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".  
Vaccine. 2003 May 16;21(17-18):2197-206.  
PMID: 12706711 [PubMed - indexed for MEDLINE]
-  **46:** [Patel JR, Brewer GJ.](#) [Related Articles, Links](#)  
Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid.  
J Neurosci Res. 2003 May 15;72(4):527-36.  
PMID: 12704814 [PubMed - indexed for MEDLINE]
-  **47:** [Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S.](#) [Related Articles, Links](#)  
Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome.  
Brain Dev. 2003 Apr;25(3):180-5.  
PMID: 12689696 [PubMed - indexed for MEDLINE]
-  **48:** [Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG.](#) [Related Articles, Links](#)  
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.  
Int Immunol. 2003 Apr;15(4):505-14.  
PMID: 12663680 [PubMed - indexed for MEDLINE]
-  **49:** [Dodart JC, Bales KR, Paul SM.](#) [Related Articles, Links](#)  
Immunotherapy for Alzheimer's disease: will vaccination work?  
Trends Mol Med. 2003 Mar;9(3):85-7. Review.  
PMID: 12657428 [PubMed - indexed for MEDLINE]
-  **50:** [Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M.](#) [Related Articles, Links](#)  
Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.  
Cell Death Differ. 2003 Jan;10(1):134-41.  
PMID: 12655302 [PubMed - indexed for MEDLINE]
-  **51:** [Li Y, Liu L, Barger SW, Griffin WS.](#) [Related Articles, Links](#)  
Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.  
J Neurosci. 2003 Mar 1;23(5):1605-11.  
PMID: 12629164 [PubMed - indexed for MEDLINE]
-  **52:** [Cai J, Wang S, Zhong Y, Cheng J, Ji Z, Sheng S, Zhang C.](#) [Related Articles, Links](#)  
Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40.  
Neuroreport. 2003 Feb 10;14(2):265-8.  
PMID: 12598743 [PubMed - indexed for MEDLINE]


 **53:** [Luo X, Weber GA, Zheng J, Gendelman HE, Ikezu T.](#) [Related Articles, Links](#)



**Clq-calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease.**

J Neuroimmunol. 2003 Feb;135(1-2):62-71.

PMID: 12576225 [PubMed - indexed for MEDLINE]


 **54:** [Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.](#) [Related Articles, Links](#)



**Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.**

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 03.

PMID: 12566568 [PubMed - indexed for MEDLINE]


 **55:** [Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH.](#) [Related Articles, Links](#)



**Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.**

Neurosci Lett. 2003 Feb 20;338(1):5-8.

PMID: 12565127 [PubMed - indexed for MEDLINE]


 **56:** [Frenkel D, Dewachter I, Van Leuven F, Solomon B.](#) [Related Articles, Links](#)



**Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.**

Vaccine. 2003 Mar 7;21(11-12):1060-5.

PMID: 12559780 [PubMed - indexed for MEDLINE]

 **57:** [Meske V, Albert F, Richter D, Schwarze J, Ohm TG.](#) [Related Articles, Links](#)



**Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.**

Eur J Neurosci. 2003 Jan;17(1):93-102.

PMID: 12534972 [PubMed - indexed for MEDLINE]


 **58:** [Blasko I, Grubeck-Loebenstein B.](#) [Related Articles, Links](#)



**Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.**

Drugs Aging. 2003;20(2):101-13. Review.

PMID: 12534311 [PubMed - indexed for MEDLINE]


 **59:** [Ehehalt R, Keller P, Haass C, Thiele C, Simons K.](#) [Related Articles, Links](#)



**Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts.**

J Cell Biol. 2003 Jan 6;160(1):113-23. Epub 2003 Jan 06.

PMID: 12515826 [PubMed - indexed for MEDLINE]

 **60:** [Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K.](#) [Related Articles, Links](#)



**Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.**

J Neurosci. 2003 Jan 1;23(1):29-33.

PMID: 12514198 [PubMed - indexed for MEDLINE]


 **61:** [Friedland RP.](#) [Related Articles, Links](#)



**Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease.**


Ann N Y Acad Sci. 2002 Nov;977:387-90. Review.

PMID: 12480777 [PubMed - indexed for MEDLINE]

 **62:** [Solomon B, Frenkel D.](#)[Related Articles, Links](#)**Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.**


J Neural Transm Suppl. 2002;(62):321-5.

PMID: 12456075 [PubMed - indexed for MEDLINE]

 **63:** [Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J.](#)[Related Articles, Links](#)**A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker?**


J Neural Transm Suppl. 2002;(62):87-95.

PMID: 12456054 [PubMed - indexed for MEDLINE]

 **64:** [Leclercq PD, Stephenson MS, Murray LS, McIntosh TK, Graham DL, Gentleman SM.](#)[Related Articles, Links](#)**Simple morphometry of axonal swellings cannot be used in isolation for dating lesions after traumatic brain injury.**


J Neurotrauma. 2002 Oct;19(10):1183-92.

PMID: 12427327 [PubMed - indexed for MEDLINE]

 **65:** [Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M.](#)[Related Articles, Links](#)**Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).**


J Neuroimmunol. 2002 Nov;132(1-2):49-59.

PMID: 12417433 [PubMed - indexed for MEDLINE]

 **66:** [Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ.](#)[Related Articles, Links](#)**Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.**


Nat Neurosci. 2002 Dec;5(12):1288-93.

PMID: 12402041 [PubMed - indexed for MEDLINE]

 **67:** [Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM.](#)[Related Articles, Links](#)**Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.**


Nat Med. 2002 Nov;8(11):1270-5. Epub 2002 Oct 15.

PMID: 12379846 [PubMed - indexed for MEDLINE]

 **68:** [Capsoni S, Giannotta S, Cattaneo A.](#)[Related Articles, Links](#)**Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.**


Mol Cell Neurosci. 2002 Sep;21(1):15-28.

PMID: 12359148 [PubMed - indexed for MEDLINE]

 **69:** [Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Molter HJ, Farlow M, Oertel WH, Sommer N, Du Y.](#)[Related Articles, Links](#)**Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.**











Ann Neurol. 2002 Aug;52(2):253-6.

PMID: 12210803 [PubMed - indexed for MEDLINE]

 **70:** [Pan W, Solomon B, Maness LM, Kastin AJ.](#)[Related Articles, Links](#)**Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.**

Exp Biol Med (Maywood). 2002 Sep;227(8):609-15.

PMID: 12192102 [PubMed - indexed for MEDLINE]

-  **71:** [Kovaacs GG, Zerbi P, Voigtlander T, Strohschneider M, Trabattoni G, Hainfellner JA, Budka H](#) [Related Articles, Links](#)  
**The prion protein in human neurodegenerative disorders.**  
 Neurosci Lett. 2002 Sep 6;329(3):269-72.  
 PMID: 12183028 [PubMed - indexed for MEDLINE]
-  **72:** [Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, Zlokovic BV, Kalra VK](#) [Related Articles, Links](#)  
**Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium.**  
 Am J Physiol Cell Physiol. 2002 Sep;283(3):C895-904.  
 PMID: 12176746 [PubMed - indexed for MEDLINE]
-  **73:** [Behr D, Wrigley JD, Owens AP, Shearman MS](#) [Related Articles, Links](#)  
**Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.**  
 J Neurochem. 2002 Aug;82(3):563-75.  
 PMID: 12153480 [PubMed - indexed for MEDLINE]
-  **74:** [Wirhys O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA](#) [Related Articles, Links](#)  
**Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.**  
 Brain Pathol. 2002 Jul;12(3):275-86.  
 PMID: 12146796 [PubMed - indexed for MEDLINE]
-  **75:** [Clamagirand C, Joulie C, Panchal M, Sekhri R, Hanquez C, Cohen P, Rholam M](#) [Related Articles, Links](#)  
**Specific cleavage of beta-amyloid peptides by a metallopeptidase from *Xenopus laevis* skin secretions.**  
 Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):751-9.  
 PMID: 12128061 [PubMed - in process]
-  **76:** [Mohajeri MH, Wollmer MA, Nitsch RM](#) [Related Articles, Links](#)  
**Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.**  
 J Biol Chem. 2002 Sep 20;277(38):35460-5. Epub 2002 Jul 08.  
 PMID: 12105192 [PubMed - indexed for MEDLINE]
-  **77:** [Morley JE, Farr SA, Flood JF](#) [Related Articles, Links](#)  
**Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice.**  
 Neurobiol Learn Mem. 2002 Jul;78(1):125-38.  
 PMID: 12071671 [PubMed - indexed for MEDLINE]
-  **78:** [Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z](#) [Related Articles, Links](#)  
**Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.**  
 Neurosci Lett. 2002 Jun 28;326(2):117-20.  
 PMID: 12057842 [PubMed - indexed for MEDLINE]
-  **79:** [Stone JR, Okonkwo DO, Singleton RH, Mutlu LK, Helm GA, Povlishock JT](#) [Related Articles, Links](#)  
**Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury.**  
 J Neurotrauma. 2002 May;19(5):601-14.  
 PMID: 12042095 [PubMed - indexed for MEDLINE]
-  **80:** [DeGiorgio LA, Shimizu Y, Chun HS, Kim YS, Sugama S, Son JH](#) [Related Articles, Links](#)

Joh TH, Volpe BT.



**Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy.**

Brain Res. 2002 May 31;938(1-2):38-44.

PMID: 12031533 [PubMed - indexed for MEDLINE]

**81:** Frenkel D, Solomon B.

[Related Articles](#), [Links](#)



**Filamentous phage as vector-mediated antibody delivery to the brain.**

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5675-9.

PMID: 11960022 [PubMed - indexed for MEDLINE]

**82:** Nagele RG, D'Andrea MR, Anderson WJ, Wang HY.

[Related Articles](#), [Links](#)



**Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease.**

Neuroscience. 2002;110(2):199-211.

PMID: 11958863 [PubMed - indexed for MEDLINE]

**83:** Mbebi C, See V, Mercken L, Pradier L, Muller U, Loeffler JP.

[Related Articles](#), [Links](#)



**Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway.**

J Biol Chem. 2002 Jun 7;277(23):20979-90. Epub 2002 Mar 04.

PMID: 11877414 [PubMed - indexed for MEDLINE]

**84:** Toro VC, Tehranian R, Zetterstrom M, Eriksson G, Langel U, Bartfai T, Iverfeld K.

[Related Articles](#), [Links](#)



**Increased gene expression of interleukin-1alpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment.**

J Mol Neurosci. 2001 Dec;17(3):341-50.

PMID: 11859930 [PubMed - indexed for MEDLINE]

**85:** Frenkel D, Solomon B.

[Related Articles](#), [Links](#)



**Towards Alzheimer's beta-amyloid vaccination.**

Biologicals. 2001 Sep-Dec;29(3-4):243-7.

PMID: 11851323 [PubMed - indexed for MEDLINE]

**86:** Thal DR, Ghebremedhin E, Haass C, Schultz C.

[Related Articles](#), [Links](#)



**UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain.**

Clin Neuropathol. 2002 Jan-Feb;21(1):35-40.

PMID: 11846043 [PubMed - indexed for MEDLINE]

**87:** Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ.

[Related Articles](#), [Links](#)



**A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice.**

Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2332-7. Epub 2002 Feb 12.

PMID: 11842183 [PubMed - indexed for MEDLINE]

**88:** Schenk D, Games D, Seubert P.

[Related Articles](#), [Links](#)



**Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.**

J Mol Neurosci. 2001 Oct;17(2):259-67. Review.

PMID: 11816797 [PubMed - indexed for MEDLINE]

**89:** Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ.


[Related Articles](#), [Links](#)




**Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging.**

Neurobiol Aging. 2002 Mar-Apr;23(2):161-70.


PMID: 11804699 [PubMed - indexed for MEDLINE]


-  **90:** Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrinou J, Hardy J, Morgan D. [Related Articles](#), [Links](#)

 **Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels.**

DNA Cell Biol. 2001 Nov;20(11):731-6.


PMID: 11788051 [PubMed - indexed for MEDLINE]


-  **91:** Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. [Related Articles](#), [Links](#)

 **Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.**

DNA Cell Biol. 2001 Nov;20(11):723-9.


PMID: 11788050 [PubMed - indexed for MEDLINE]


-  **92:** Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyimbazi J, Siew LT, Troncoso JC. [Related Articles](#), [Links](#)

 **beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology.**

DNA Cell Biol. 2001 Nov;20(11):713-21.

PMID: 11788049 [PubMed - indexed for MEDLINE]


-  **93:** Lemere CA, Maron R, Selkoe DJ, Weiner HL. [Related Articles](#), [Links](#)

 **Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease.**

DNA Cell Biol. 2001 Nov;20(11):705-11.


PMID: 11788048 [PubMed - indexed for MEDLINE]


-  **94:** Solomon B. [Related Articles](#), [Links](#)

 **Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.**

DNA Cell Biol. 2001 Nov;20(11):697-703.

PMID: 11788047 [PubMed - indexed for MEDLINE]


-  **95:** Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. [Related Articles](#), [Links](#)

 **CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils.**

Am J Pathol. 2002 Jan;160(1):101-12.


PMID: 11786404 [PubMed - indexed for MEDLINE]


-  **96:** Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S. [Related Articles](#), [Links](#)

 **Specificity and sensitivity of betaAPP in head injury.**

Clin Neuropathol. 2001 Nov-Dec;20(6):263-71.


PMID: 11758782 [PubMed - indexed for MEDLINE]

-  **97:** Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. [Related Articles](#), [Links](#)



















 **Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.**

J Neurochem. 2001 Nov;79(3):595-605.

PMID: 11701763 [PubMed - indexed for MEDLINE]

-  **98:** Szpak GM, Lewandowska E, Lechowicz W, Bertrand E, Wierzbicka Bobrowicz T, Gwiazda E, Pasennik E, Kosno-Kruszewska E, Lipczynska-Lojkowska W, Bochynska A, Fiszer U. [Related Articles](#), [Links](#)



-  **Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study.**  
Folia Neuropathol. 2001;39(2):63-71.  
PMID: 11680637 [PubMed - indexed for MEDLINE]
-  **99:** [Toupalik P, Bouska I, Chadova I.](#) [Related Articles, Links](#)
-  **[Differences in immunohistochemical findings in traumatic and hypoxic changes in the central nervous system]**  
Soud Lek. 2001 Jul;46(3):34-6. Czech.  
PMID: 11669015 [PubMed - indexed for MEDLINE]
-  **100:** [Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH.](#) [Related Articles, Links](#)
-  **The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.**  
Eur J Biochem. 2001 Oct;268(20):5329-36.  
PMID: 11606195 [PubMed - indexed for MEDLINE]
-  **101:** [Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Kuiper SL, Oostveen JA, Weaver RJ, Boller JA, Gurney ME.](#) [Related Articles, Links](#)
-  **Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.**  
Ann Neurol. 2001 Oct;50(4):468-75.  
PMID: 11601499 [PubMed - indexed for MEDLINE]
-  **102:** [von Bernhardt R, Ramirez G, Matile H, Dobeli H.](#) [Related Articles, Links](#)
-  **Immobilized amyloid precursor protein constructs: a tool for the in vitro screening of glial cell reactivity.**  
Eur J Neurosci. 2001 Sep;14(6):946-56.  
PMID: 11595033 [PubMed - indexed for MEDLINE]
-  **103:** [Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C.](#) [Related Articles, Links](#)
-  **Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome.**  
Neurobiol Dis. 2001 Oct;8(5):792-806.  
PMID: 11592849 [PubMed - indexed for MEDLINE]
-  **104:** [Thatté U.](#) [Related Articles, Links](#)
-  **AN-1792 (Elan).**  
Curr Opin Investig Drugs. 2001 May;2(5):663-7. Review.  
PMID: 11569944 [PubMed - indexed for MEDLINE]
-  **105:** [Gotz J, Chen F, van Dorpe J, Nitsch RM.](#) [Related Articles, Links](#)
-  **Formation of neurofibrillary tangles in P301 tau transgenic mice induced by Abeta 42 fibrils.**  
Science. 2001 Aug 24;293(5534):1491-5.  
PMID: 11520988 [PubMed - indexed for MEDLINE]
-  **106:** [Monsonogo A, Maron R, Zota V, Selkoe DJ, Weiner HL.](#) [Related Articles, Links](#)
-  **Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.**  
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21.  
PMID: 11517335 [PubMed - indexed for MEDLINE]
-  **107:** [Brayden DJ, Templeton L, McClean S, Barbour R, Huang J, Nguyen M, Ahern D, Motter R, Johnson-Wood K, Vasquez N.](#) [Related Articles, Links](#)

Schenk D, Seubert P.



**Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.**

Vaccine. 2001 Jul 20;19(30):4185-93.

PMID: 11457544 [PubMed - indexed for MEDLINE]

☐ **108:** Toupalik P, Bouska I, Jezkova J.

[Related Articles](#), [Links](#)



**[Effect of autolysis on histochemical examinations of the central nervous system]**

Soud Lek. 2001 Apr;46(2):18-20. Czech.

PMID: 11455721 [PubMed - indexed for MEDLINE]

☐ **109:** Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S.

[Related Articles](#), [Links](#)



**Possible reverse transport of beta-amyloid peptide across the blood-brain barrier.**

Acta Neurochir Suppl. 2000;76:73-7.

PMID: 11450095 [PubMed - indexed for MEDLINE]

☐ **110:** Singleton RH, Stone JR, Okonkwo DO, Pellicane AJ, Povlishock JT.

[Related Articles](#), [Links](#)



**The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury.**

J Neurotrauma. 2001 Jun;18(6):607-14.

PMID: 11437083 [PubMed - indexed for MEDLINE]

☐ **111:** Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M.

[Related Articles](#), [Links](#)



**Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.**

Neurosci Lett. 2001 Jul 13;307(2):101-4.

PMID: 11427310 [PubMed - indexed for MEDLINE]

☐ **112:** Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO.

[Related Articles](#), [Links](#)



**Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.**

Bull Exp Biol Med. 2001 Feb;131(2):127-9.

PMID: 11391392 [PubMed - indexed for MEDLINE]

☐ **113:** Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T.

[Related Articles](#), [Links](#)



**beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.**

Neuroscience. 2001;104(2):299-310.

PMID: 11377835 [PubMed - indexed for MEDLINE]

☐ **114:** Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuyama S.

[Related Articles](#), [Links](#)



**Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons.**

Eur J Neurosci. 2001 May;13(9):1653-7.

PMID: 11359517 [PubMed - indexed for MEDLINE]

☐ **115:** Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR.


[Related Articles](#), [Links](#)



**Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice.**

Neuroreport. 2001 May 8;12(6):1151-4.

PMID: 11338182 [PubMed - indexed for MEDLINE]


 **116:** [Chong YH, Sung JH, Shin SA, Chung JH, Suh YH.](#)

[Related Articles, Links](#)



Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1.

J Biol Chem. 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16.  
PMID: 11306564 [PubMed - indexed for MEDLINE]


 **117:** [Englund P, Jacobsson SO, Fowler CJ.](#)

[Related Articles, Links](#)



Investigation into the effects of amyloid (1-42) beta-peptide upon basal and antigen-stimulated hexosaminidase and serotonin release from rat RBL-2H3 basophilic leukemia cells.

Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61.  
PMID: 11294005 [PubMed - indexed for MEDLINE]


 **118:** [Cedazo-Minguez A, Wiehager B, Winblad B, Huttlinger M, Cowburn RF.](#)

[Related Articles, Links](#)



Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts.

Neurochem Int. 2001 Jun;38(7):615-25.  
PMID: 11290387 [PubMed - indexed for MEDLINE]


 **119:** [Frenkel D, Kariv N, Solomon B.](#)

[Related Articles, Links](#)



Generation of auto-antibodies towards Alzheimer's disease vaccination.

Vaccine. 2001 Mar 21;19(17-19):2615-9.  
PMID: 11257400 [PubMed - indexed for MEDLINE]


 **120:** [Duker NJ, Sperling J, Soprano KJ, Druin DP, Davis A, Ashworth R.](#)

[Related Articles, Links](#)



beta-Amyloid protein induces the formation of purine dimers in cellular DNA.

J Cell Biochem. 2001;81(3):393-400.  
PMID: 11255222 [PubMed - indexed for MEDLINE]


 **121:** [Gerlai R.](#)

[Related Articles, Links](#)



Alzheimer's disease: beta-amyloid hypothesis strengthened!

Trends Neurosci. 2001 Apr;24(4):199. No abstract available.  
PMID: 11249992 [PubMed - indexed for MEDLINE]


 **122:** [Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T.](#)

[Related Articles, Links](#)



Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids.

Neurosci Res. 2001 Mar;39(3):313-7.  
PMID: 11248371 [PubMed - indexed for MEDLINE]


 **123:** [Husemann J, Silverstein SC.](#)

[Related Articles, Links](#)



Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain.

Am J Pathol. 2001 Mar;158(3):825-32.  
PMID: 11238031 [PubMed - indexed for MEDLINE]


 **124:** [D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH.](#)


[Related Articles, Links](#)





Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.


Histopathology. 2001 Feb;38(2):120-34.  
PMID: 11207825 [PubMed - indexed for MEDLINE]


-  **125:** [Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G.](#) [Related Articles, Links](#)

 **Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.**  
Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.  
PMID: 11162251 [PubMed - indexed for MEDLINE]


-  **126:** [Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, Morley JE.](#) [Related Articles, Links](#)


 **Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.**  
Peptides. 2000 Dec;21(12):1769-75.  
PMID: 11150636 [PubMed - indexed for MEDLINE]


-  **127:** [Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF.](#) [Related Articles, Links](#)


 **Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory.**  
Peptides. 2000 Dec;21(12):1761-7.  
PMID: 11150635 [PubMed - indexed for MEDLINE]


-  **128:** [Lin B, Ginsberg MD, Busto R.](#) [Related Articles, Links](#)


 **Hyperglycemic but not normoglycemic global ischemia induces marked early intraneuronal expression of beta-amyloid precursor protein.**  
Brain Res. 2001 Jan 5;888(1):107-116.  
PMID: 11146057 [PubMed - indexed for MEDLINE]


-  **129:** [Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E.](#) [Related Articles, Links](#)


 **Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.**  
Amyloid. 2000 Dec;7(4):245-58.  
PMID: 11132093 [PubMed - indexed for MEDLINE]


-  **130:** [Sudo H, Jiang H, Yasukawa T, Hashimoto Y, Niikura T, Kawasumi M, Matsuda S, Takeuchi Y, Aiso S, Matsuoka M, Murayama Y, Nishimoto I.](#) [Related Articles, Links](#)


 **Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein.**  
Mol Cell Neurosci. 2000 Dec;16(6):708-23.  
PMID: 11124892 [PubMed - indexed for MEDLINE]

-  **131:** [Seiffert D, Mitchell T, Stern AM, Roach A, Zhan Y, Grzanna R.](#) [Related Articles, Links](#)

 **Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing.**  
Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26.  
PMID: 11113538 [PubMed - indexed for MEDLINE]

-  **132:** [Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK.](#) [Related Articles, Links](#)

 **beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.**  
Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81.  
PMID: 11078691 [PubMed - indexed for MEDLINE]

 **133:** [Frenkel D, Katz O, Solomon B.](#)


[Related Articles](#), [Links](#)



**Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.**

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9.

PMID: 11027345 [PubMed - indexed for MEDLINE]

 **134:** [Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M.](#)


[Related Articles](#), [Links](#)



**CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.**

J Neurosci. 2000 Oct 15;20(20):7587-94.

PMID: 11027218 [PubMed - indexed for MEDLINE]

 **135:** [Rossner S, Beck M, Stahl T, Mendla K, Schliebs R, Bigl V.](#)


[Related Articles](#), [Links](#)



**Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation.**

Eur J Neurosci. 2000 Sep;12(9):3191-200.

PMID: 10998103 [PubMed - indexed for MEDLINE]

 **136:** [Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M,](#)

[Related Articles](#), [Links](#)

[Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H,](#)


[Mitsui S, Yamaguchi N.](#)



**Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.**

Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26.

PMID: 10997858 [PubMed - indexed for MEDLINE]

 **137:** [Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic J, Winblad B, Bogdanovi.](#)


[Related Articles](#), [Links](#)



**nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease.**

Exp Neurol. 2000 Sep;165(1):12-26.

PMID: 10964481 [PubMed - indexed for MEDLINE]

 **138:** [Taguchi J, Fujii A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Y, Wada I, Yamada T.](#)


[Related Articles](#), [Links](#)



**Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain.**

Acta Neuropathol (Berl). 2000 Aug;100(2):153-60.

PMID: 10963362 [PubMed - indexed for MEDLINE]

 **139:** [DeGiorgio LA, DeGiorgio N, Milner TA, Conti B, Volpe BT.](#)


[Related Articles](#), [Links](#)



**Neurotoxic APP C-terminal and beta-amyloid domains colocalize in the nuclei of substantia nigra pars reticulata neurons undergoing delayed degeneration.**

Brain Res. 2000 Aug 25;874(2):137-46.

PMID: 10960598 [PubMed - indexed for MEDLINE]

 **140:** [Tanabe Y, Ishizu H, Ishiguro K, Itoh N, Terada S, Haraguchi T, Kawai K, Kuroda S.](#)


[Related Articles](#), [Links](#)



**Tau pathology in diffuse neurofibrillary tangles with calcification (DNTC): biochemical and immunohistochemical investigation.**

Neuroreport. 2000 Aug 3;11(11):2473-7.

PMID: 10943706 [PubMed - indexed for MEDLINE]


 **141:** [Helmuth L.](#)

[Related Articles](#), [Links](#)



**Alzheimer's congress. Further progress on a beta-amyloid vaccine.**

Science. 2000 Jul 21;289(5478):375. No abstract available.  
PMID: 10939941 [PubMed - indexed for MEDLINE]

-  **142:** Stone JR, Singleton RH, Povlishock JT.


[Related Articles, Links](#)



**Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury.**

Brain Res. 2000 Jul 21;871(2):288-302.

PMID: 10899295 [PubMed - indexed for MEDLINE]

-  **143:** Kaneko I, Kubo T, Morimoto K.


[Related Articles, Links](#)



**[Neurotoxicity of beta-amyloid]**

Nippon Yakurigaku Zasshi. 2000 Feb;115(2):67-77. Review. Japanese.

PMID: 10876793 [PubMed - indexed for MEDLINE]

-  **144:** Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DL, Nicoll JA.

[Related Articles, Links](#)



**beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.**

Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32.

PMID: 10840275 [PubMed - indexed for MEDLINE]

-  **145:** Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH.


[Related Articles, Links](#)



**A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis.**

J Neurochem. 2000 Jun;74(6):2331-42.

PMID: 10820193 [PubMed - indexed for MEDLINE]

-  **146:** Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ.


[Related Articles, Links](#)



**Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.**

Ann N Y Acad Sci. 2000 Apr;903:335-44.

PMID: 10818523 [PubMed - indexed for MEDLINE]

-  **147:** Brown WR, Moody DM, Thore CR, Challa VR.


[Related Articles, Links](#)



**Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis.**

Ann N Y Acad Sci. 2000 Apr;903:39-45.

PMID: 10818487 [PubMed - indexed for MEDLINE]

-  **148:** Frenkel D, Solomon B, Benhar I.


[Related Articles, Links](#)



**Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.**

J Neuroimmunol. 2000 Jul 1;106(1-2):23-31.

PMID: 10814779 [PubMed - indexed for MEDLINE]

-  **149:** Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC.


[Related Articles, Links](#)



**Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.**

J Neurosci. 2000 May 15;20(10):3606-11.

PMID: 10804202 [PubMed - indexed for MEDLINE]

-  **150:** Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC.

[Related Articles, Links](#)





















**Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells.**

J Neurosci Res. 2000 May 1;60(3):401-11.




















PMID: 10797543 [PubMed - indexed for MEDLINE]

-  **151:** Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW.

[Related Articles, Links](#)

-  **Region-specific age at onset of beta-amyloid in dogs.**  
Neurobiol Aging. 2000 Jan-Feb;21(1):89-96.  
PMID: 10794853 [PubMed - indexed for MEDLINE]
-  **152:** Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, Lott IT, Cotman CW. [Related Articles](#), [Links](#)
-  **Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs.**  
Exp Neurol. 2000 May;163(1):111-22.  
PMID: 10785449 [PubMed - indexed for MEDLINE]
-  **153:** Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C. [Related Articles](#), [Links](#)
-  **Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.**  
Nat Cell Biol. 2000 Apr;2(4):205-11.  
PMID: 10783238 [PubMed - indexed for MEDLINE]
-  **154:** Brazil ML, Chung H, Maxfield FR. [Related Articles](#), [Links](#)
-  **Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia.**  
J Biol Chem. 2000 Jun 2;275(22):16941-7.  
PMID: 10747968 [PubMed - indexed for MEDLINE]
-  **155:** Salinero O, Moreno-Flores MT, Wandosell F. [Related Articles](#), [Links](#)
-  **Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease.**  
J Neurosci Res. 2000 Apr 1;60(1):87-97.  
PMID: 10723071 [PubMed - indexed for MEDLINE]
-  **156:** Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. [Related Articles](#), [Links](#)
-  **Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.**  
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60.  
PMID: 10677483 [PubMed - indexed for MEDLINE]
-  **157:** Cescato R, Dumermuth E, Spiess M, Paganetti PA. [Related Articles](#), [Links](#)
-  **Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis.**  
J Neurochem. 2000 Mar;74(3):1131-9.  
PMID: 10693945 [PubMed - indexed for MEDLINE]
-  **158:** Matsumoto A. [Related Articles](#), [Links](#)
-  **The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate.**  
Neuroreport. 2000 Feb 7;11(2):373-7.  
PMID: 10674489 [PubMed - indexed for MEDLINE]
-  **159:** Yoshiyama Y, Asahina M, Hattori T. [Related Articles](#), [Links](#)
-  **Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain.**  
Acta Neuropathol (Berl). 2000 Feb;99(2):91-5.  
PMID: 10672313 [PubMed - indexed for MEDLINE]
-  **160:** Toro F, Lopera F, Ossa I, Madrigal L, Mira A, Diaz A, Parra S. [Related Articles](#), [Links](#)

[Detection of antibodies to beta-amyloid in carriers of E280A mutation in

-  the presenilin-1 gene]  
Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish.  
PMID: 10652730 [PubMed - indexed for MEDLINE]
-  **161:** Al-Abed Y, Bucala R. Related Articles, Links  
 Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts.  
Bioconjug Chem. 2000 Jan-Feb;11(1):39-45.  
PMID: 10639083 [PubMed - indexed for MEDLINE]
-  **162:** Campbell E, Pearson RC, Parkinson D. Related Articles, Links  
 Methods to uncover an antibody epitope in the KPI domain of Alzheimer's amyloid precursor protein for immunohistochemistry in human brain.  
J Neurosci Methods. 1999 Nov 15;93(2):133-8.  
PMID: 10634498 [PubMed - indexed for MEDLINE]
-  **163:** Frederikse PH, Zigler SJ Jr, Farnsworth PN, Carper DA. Related Articles, Links  
 Prion protein expression in mammalian lenses.  
Curr Eye Res. 2000 Feb;20(2):137-43.  
PMID: 10617916 [PubMed - indexed for MEDLINE]
-  **164:** Webster SD, Tenner AJ, Poulos TL, Cribbs DH. Related Articles, Links  
 The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.  
Neurobiol Aging. 1999 May-Jun;20(3):297-304.  
PMID: 10588577 [PubMed - indexed for MEDLINE]
-  **165:** Jung SS, Gauthier S, Cashman NR. Related Articles, Links  
 Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease.  
Neurobiol Aging. 1999 May-Jun;20(3):249-57.  
PMID: 10588572 [PubMed - indexed for MEDLINE]
-  **166:** Nakano S, Akiguchi I, Nakamura S, Sato H, Kawashima S, Kimura J. Related Articles, Links  
 Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.  
Neurology. 1999 Nov 10;53(8):1671-6.  
PMID: 10563611 [PubMed - indexed for MEDLINE]
-  **167:** Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. Related Articles, Links  
 The role of cholesterol in the biosynthesis of beta-amyloid.  
Neuroreport. 1999 Jun 3;10(8):1699-705.  
PMID: 10501560 [PubMed - indexed for MEDLINE]
-  **168:** Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H. Related Articles, Links  
 Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.  
Arch Neurol. 1999 Sep;56(9):1111-8.  
PMID: 10488812 [PubMed - indexed for MEDLINE]
-  **169:** Guenette SY, Chen J, Ferland A, Haass C, Capell A, Tanzi RE. Related Articles, Links  
 hFE65L influences amyloid precursor protein maturation and secretion.  
J Neurochem. 1999 Sep;73(3):985-93.  
PMID: 10461887 [PubMed - indexed for MEDLINE]



 **170:** [Kurt MA, Davies DC, Kidd M.](#) [Related Articles, Links](#)



**beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: an electron microscope study.**

Exp Neurol. 1999 Jul;158(1):221-8.

PMID: 10448435 [PubMed - indexed for MEDLINE]

 **171:** [Markaryan A, Morozova I, Lee BS, Kaplan A.](#) [Related Articles, Links](#)



**Atypical processing of amyloid precursor fusion protein by proteolytic activity in *Pichia pastoris*.**

Biochem Biophys Res Commun. 1999 Aug 19;262(1):263-8. Erratum in: Biochem

Biophys Res Commun 1999 Sep 24;263(2):596.

PMID: 10448103 [PubMed - indexed for MEDLINE]

 **172:** [Gonzalo-Ruiz A.](#) [Related Articles, Links](#)



**[Changes in neurotransmission systems after the injection of beta-amyloid protein beta (12-28) in the hypothalamus and anterior thalamus of the rat]**

Rev Neurol. 1999 May 16-31;28(10):931-41. Review. Spanish.

PMID: 10416226 [PubMed - indexed for MEDLINE]


 **173:** [Schroder R, Linke RP.](#) [Related Articles, Links](#)



**Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern.**

Virchows Arch. 1999 Jun;434(6):551-60.

PMID: 10394892 [PubMed - indexed for MEDLINE]


 **174:** [Yuan H, Zhai P, Anderson LM, Pan J, Thimmapaya B, Koo EH, Marquez-Sterling NR.](#) [Related Articles, Links](#)



**Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons.**

J Neurosci Methods. 1999 Apr 1;88(1):45-54.

PMID: 10379578 [PubMed - indexed for MEDLINE]


 **175:** [Fonseca ML, Head E, Velazquez P, Cotman CW, Tenner AJ.](#) [Related Articles, Links](#)



**The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.**

Exp Neurol. 1999 Jun;157(2):277-88.

PMID: 10364440 [PubMed - indexed for MEDLINE]


 **176:** [Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN.](#) [Related Articles, Links](#)



**Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner.**

Neuroscience. 1999;90(4):1217-26.

PMID: 10338292 [PubMed - indexed for MEDLINE]


 **177:** [Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S.](#) [Related Articles, Links](#)



**Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells.**

Eur J Neurosci. 1999 Jun;11(6):1907-13.

PMID: 10336659 [PubMed - indexed for MEDLINE]


 **178:** [Oehmichen M, Theuerkauf I, Meissner C.](#) [Related Articles, Links](#)



**Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI.**

Acta Neuropathol (Berl). 1999 May;97(5):491-4.

PMID: 10334486 [PubMed - indexed for MEDLINE]


 **179:** [Johnson G, Moore SW](#)

[Related Articles, Links](#)



The adhesion function on acetylcholinesterase is located at the peripheral anionic site.

Biochem Biophys Res Commun. 1999 May 19;258(3):758-62.  
PMID: 10329459 [PubMed - indexed for MEDLINE]


 **180:** [Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, Haste R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA](#)

[Related Articles, Links](#)



Platelets and DAMI megakaryocytes possess beta-secretase-like activity.

J Lab Clin Med. 1999 May;133(5):507-15.  
PMID: 10235134 [PubMed - indexed for MEDLINE]


 **181:** [Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, Spitzfaden C, Wadsworth H, Wood SJ, Markwell RE](#)

[Related Articles, Links](#)



Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.

Biochem J. 1999 May 15;340 ( Pt 1):283-9.  
PMID: 10229684 [PubMed - indexed for MEDLINE]

 **182:** [Frenkel D, Balass M, Katchalski-Katzir E, Solomon B](#)

[Related Articles, Links](#)



High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.

J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.  
PMID: 10229123 [PubMed - indexed for MEDLINE]


 **183:** [Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD](#)

[Related Articles, Links](#)



Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia.

Acta Neuropathol (Berl). 1999 Apr;97(4):359-68.  
PMID: 10208275 [PubMed - indexed for MEDLINE]


 **184:** [Pike CJ](#)

[Related Articles, Links](#)



Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease.

J Neurochem. 1999 Apr;72(4):1552-63.  
PMID: 10098861 [PubMed - indexed for MEDLINE]


 **185:** [Fabrizi C, Businaro R, Lauro GM, Starace G, Fumagalli L](#)

[Related Articles, Links](#)



Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.

Exp Neurol. 1999 Feb;155(2):252-9.  
PMID: 10072300 [PubMed - indexed for MEDLINE]


 **186:** [Winkler K, Scharnagl H, Tisliar U, Hoschutzky H, Friedrich J, Hoffmann MM, Huttlinger M, Wieland H, Marz W](#)

[Related Articles, Links](#)



Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.

J Lipid Res. 1999 Mar;40(3):447-55.  
PMID: 10064733 [PubMed - indexed for MEDLINE]


 **187:** [Huber G, Thompson A, Gruninger F, Mechler H, Hochstrasser R, Hauri HP, Malherbe P](#)

[Related Articles, Links](#)



cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?

J Neurochem. 1999 Mar;72(3):1215-23.  
PMID: 10037494 [PubMed - indexed for MEDLINE]


-  **188:** [Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B](#) [Related Articles, Links](#)



The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction.

J Neurosci. 1999 Mar 1;19(5):1717-27.

PMID: 10024358 [PubMed - indexed for MEDLINE]


-  **189:** [Ohara S, Tsukada M, Ikeda S](#) [Related Articles, Links](#)



On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.

Acta Neuropathol (Berl). 1999 Jan;97(1):85-90.

PMID: 9930899 [PubMed - indexed for MEDLINE]


-  **190:** [Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA](#) [Related Articles, Links](#)



Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.

Acta Neuropathol (Berl). 1999 Feb;97(2):113-8.

PMID: 9928821 [PubMed - indexed for MEDLINE]

-  **191:** [Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M](#) [Related Articles, Links](#)



Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage.

Brain Res. 1999 Feb 6;818(1):105-17.

PMID: 9914443 [PubMed - indexed for MEDLINE]

-  **192:** [Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E](#) [Related Articles, Links](#)



Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition.

Exp Neurol. 1998 Dec;154(2):573-82.

PMID: 9878192 [PubMed - indexed for MEDLINE]


-  **193:** [Leanza G](#) [Related Articles, Links](#)



Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions.

Neurosci Lett. 1998 Nov 20;257(1):53-6.

PMID: 9857964 [PubMed - indexed for MEDLINE]


-  **194:** [Jin LW, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, Martin GM](#) [Related Articles, Links](#)



Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.

Am J Pathol. 1998 Dec;153(6):1679-86.

PMID: 9846957 [PubMed - indexed for MEDLINE]

-  **195:** [Daly J 4th, Lahiri DK, Justus DE, Kotwal GJ](#) [Related Articles, Links](#)



Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain.

Life Sci. 1998;63(23):2121-31.


PMID: 9839536 [PubMed - indexed for MEDLINE]

-  **196:** [Ohshita T, Nakatani A, Hiroi Y](#) [Related Articles, Links](#)



Purification by column chromatographies of beta-amyloid precursor proteins and their association with other 95 kDa protein in rat brain.


J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1-2):107-18.  
PMID: 9824223 [PubMed - indexed for MEDLINE]

-  **197:** [Kraszpulski M, Soininen H, Riekkinen P Sr, Alafuzoff I.](#) [Related Articles, Links](#)



**Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in human brain tissue.**

Histochem Cell Biol. 1998 Oct;110(4):439-45.  
PMID: 9792423 [PubMed - indexed for MEDLINE]

-  **198:** [Mizuno T, Haass C, Michikawa M, Yanagisawa K.](#) [Related Articles, Links](#)



**Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells.**


Biochim Biophys Acta. 1998 Aug 14;1373(1):119-30.  
PMID: 9733943 [PubMed - indexed for MEDLINE]

-  **199:** [Yilmazer-Hanke DM.](#) [Related Articles, Links](#)



**Pathogenesis of Alzheimer-related neuritic plaques: AT8 immunoreactive dystrophic neurites precede argyrophilic neurites in plaques of the entorhinal region, hippocampal formation, and amygdala.**

Clin Neuropathol. 1998 Jul-Aug;17(4):194-8.  
PMID: 9707333 [PubMed - indexed for MEDLINE]

-  **200:** [Hock C, Golombowski S, Muller-Spahn F, Peschel O, Riederer A, Probst A, Mandelkow E, Unger J.](#) [Related Articles, Links](#)



**Histological markers in nasal mucosa of patients with Alzheimer's disease.**

Eur Neurol. 1998 Jul;40(1):31-6.  
PMID: 9693230 [PubMed - indexed for MEDLINE]

-  **201:** [Munch G, Cunningham AM, Riederer P, Braak E.](#) [Related Articles, Links](#)



**Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.**

Brain Res. 1998 Jun 15;796(1-2):307-10.  
PMID: 9689484 [PubMed - indexed for MEDLINE]

-  **202:** [Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW.](#) [Related Articles, Links](#)



**Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.**


Brain Res. 1998 Jun 15;796(1-2):187-97.  
PMID: 9689469 [PubMed - indexed for MEDLINE]

-  **203:** [Frenkel D, Balass M, Solomon B.](#) [Related Articles, Links](#)



**N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.**


J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.  
PMID: 9688328 [PubMed - indexed for MEDLINE]

-  **204:** [Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG.](#) [Related Articles, Links](#)



**Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis.**

J Neurosci Res. 1998 Jun 15;52(6):691-8.  
PMID: 9669318 [PubMed - indexed for MEDLINE]

-  **205:** [Hoshino S, Tamaoka A, Takahashi M, Kobayashi S, Furukawa T, Oaki Y, Mori O, Matsuno S, Shoji S, Inonata M, Teramoto A.](#) [Related Articles, Links](#)



**Emergence of immunoreactivities for phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in rat brain.**

Neuroreport. 1998 Jun 1;9(8):1879-83.

PMID: 9665619 [PubMed - indexed for MEDLINE]


-  **206:** Terryberry JW, Thor G, Peter JB. [Related Articles](#), [Links](#)



**Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.**

Neurobiol Aging. 1998 May-Jun;19(3):205-16.

PMID: 9661995 [PubMed - indexed for MEDLINE]


-  **207:** McGille GS, Guidry C, Dacheux RF. [Related Articles](#), [Links](#)



**Antigenic changes of rabbit retinal Muller cells in culture.**

Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1453-61.

PMID: 9660494 [PubMed - indexed for MEDLINE]

-  **208:** Miguel-Hidalgo JJ, Alvarez A, Cacabelos R. [Related Articles](#), [Links](#)



**Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system.**

Cell Tissue Res. 1998 Jul;293(1):75-86.

PMID: 9634599 [PubMed - indexed for MEDLINE]


-  **209:** Salinero O, Garrido JJ, Wandosell F. [Related Articles](#), [Links](#)



**Amyloid precursor protein proteoglycan is increased after brain damage.**

Biochim Biophys Acta. 1998 Apr 28;1406(3):237-50.

PMID: 9630651 [PubMed - indexed for MEDLINE]

-  **210:** Nakamura Y, Yamamoto M, Kumamaru E. [Related Articles](#), [Links](#)



**A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin.**

Brain Res. 1998 May 18;793(1-2):47-53.

PMID: 9630508 [PubMed - indexed for MEDLINE]


-  **211:** Spuler S, Emslie-Smith A, Engel AG. [Related Articles](#), [Links](#)



**Amyloid myopathy: an underdiagnosed entity.**

Ann Neurol. 1998 Jun;43(6):719-28.

PMID: 9629841 [PubMed - indexed for MEDLINE]


-  **212:** Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. [Related Articles](#), [Links](#)



**Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels.**

J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9.

PMID: 9600229 [PubMed - indexed for MEDLINE]

-  **213:** Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K. [Related Articles](#), [Links](#)



**Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein.**

J Clin Lab Anal. 1998;12(3):172-8.

PMID: 9591705 [PubMed - indexed for MEDLINE]


-  **214:** Rossner S. [Related Articles](#), [Links](#)



**Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease.**

Int J Dev Neurosci. 1997 Nov;15(7):835-50. Review.


PMID: 9568532 [PubMed - indexed for MEDLINE]


-  **215:** Varner JA, Jensen KF, Horvath W, Isaacson RL. [Related Articles](#), [Links](#)





**Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity.**


Brain Res. 1998 Feb 16;784(1-2):284-98.  
PMID: 9518651 [PubMed - indexed for MEDLINE]


-  **216:** [Minn A, Schubert M, Neiss WF, Muller-Hill B.](#) [Related Articles, Links](#)


 **Enhanced GFAP expression in astrocytes of transgenic mice expressing the human brain-specific trypsinogen IV.**  
Glia. 1998 Apr;22(4):338-47.  
PMID: 9517566 [PubMed - indexed for MEDLINE]


-  **217:** [Murai H, Pierce JE, Raghupathi R, Smith DH, Saatman KE, Trojanowski JQ, Lee VM, Loring JF, Eckman C, Younkin S, McIntosh TK.](#) [Related Articles, Links](#)

 **Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury.**  
J Comp Neurol. 1998 Mar 23;392(4):428-38.  
PMID: 9514508 [PubMed - indexed for MEDLINE]


-  **218:** [Dwork AJ, Liu D, Kaufman MA, Prohovnik I.](#) [Related Articles, Links](#)


 **Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes.**  
Clin Neuropathol. 1998 Jan-Feb;17(1):45-9.  
PMID: 9496540 [PubMed - indexed for MEDLINE]


-  **219:** [Friedman LM, Matsuda Y, Lazarovici P.](#) [Related Articles, Links](#)


 **The microbial alkaloid toxin staurosporine blocks the phorbol ester-induced increase in beta-amyloid precursor protein in PC12 cells.**  
Nat Toxins. 1997;5(5):173-9.  
PMID: 9496375 [PubMed - indexed for MEDLINE]


-  **220:** [Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM.](#) [Related Articles, Links](#)


 **Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice.**  
Neuroscience. 1998 Jan;82(1):171-80.  
PMID: 9483513 [PubMed - indexed for MEDLINE]


-  **221:** [Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazu K, Fukutani Y, Mukai M, Koshino E.](#) [Related Articles, Links](#)

 **KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains.**  
Dement Geriatr Cogn Disord. 1998 Jan-Feb;9(1):13-9.  
PMID: 9469259 [PubMed - indexed for MEDLINE]

-  **222:** [Dickson TC, Saunders HL, Vickers JC.](#) [Related Articles, Links](#)











 **Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease.**  
Neuropathol Appl Neurobiol. 1997 Dec;23(6):483-91.  
PMID: 9460714 [PubMed - indexed for MEDLINE]

-  **223:** [Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G.](#) [Related Articles, Links](#)


 **Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease.**  
Acta Neuropathol (Berl). 1997 Dec;94(6):519-24.  
PMID: 9444352 [PubMed - indexed for MEDLINE]

-  **224:** [Jen A, Wickenden C, Rohan de Silva HA, Patel AJ.](#) [Related Articles, Links](#)

Preparation and purification of antisera against different regions or


-  isoforms of beta-amyloid precursor protein.  
Brain Res Brain Res Protoc. 1997 Dec 1;2(1):23-30.  
PMID: 9438067 [PubMed - indexed for MEDLINE]
-  **225:** [Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C, Huberman M.](#) Related Articles, Links  
Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures.  
Neuroreport. 1997 Nov 10;8(16):3577-80.  
PMID: 9427329 [PubMed - indexed for MEDLINE]
-  **226:** [Zambrano N, De Renzis S, Minopoli G, Faraonio R, Donini V, Scaloni A, Cimino F, Russo T.](#) Related Articles, Links  
DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter.  
Biochem J. 1997 Nov 15;328 ( Pt 1):293-300.  
PMID: 9359867 [PubMed - indexed for MEDLINE]
-  **227:** [Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowski AW.](#) Related Articles, Links  
Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia.  
Acta Neurochir Suppl (Wien). 1997;70:247-9.  
PMID: 9416336 [PubMed - indexed for MEDLINE]
-  **228:** [Gearing M, Levey AI, Mirra SS.](#) Related Articles, Links  
Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers.  
J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70.  
PMID: 9413285 [PubMed - indexed for MEDLINE]
-  **229:** [An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F, Tavolato B, Scaravilli F.](#) Related Articles, Links  
Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS.  
J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8.  
PMID: 9370237 [PubMed - indexed for MEDLINE]
-  **230:** [Goodwin JL, Kehrli ME Jr, Uemura E.](#) Related Articles, Links  
Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide.  
Brain Res. 1997 Sep 12;768(1-2):279-86.  
PMID: 9369326 [PubMed - indexed for MEDLINE]
-  **231:** [Lahiri DK, Farlow MR, Sambamurti K, Nall C.](#) Related Articles, Links  
The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells.  
Life Sci. 1997;61(20):1985-92.  
PMID: 9366505 [PubMed - indexed for MEDLINE]
-  **232:** [Matsumoto A, Minami M, Matsumoto R.](#) Related Articles, Links  
The beta-amyloid epitope masking activity in human brain is identified as albumin.  
Neuroreport. 1997 Oct 20;8(15):3297-301.  
PMID: 9351660 [PubMed - indexed for MEDLINE]
-  **233:** [Lahiri DK, Farlow MR, Nurnberger Jr JI, Greig NH.](#) Related Articles, Links  
Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.  
Ann N Y Acad Sci. 1997 Sep 26;826:416-21.

PMID: 9329715 [PubMed - indexed for MEDLINE]

 **234:** [Sasaki S, Iwata M.](#)[Related Articles, Links](#)**Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis.**


Acta Neuropathol (Berl). 1997 Oct;94(4):338-44.

PMID: 9341934 [PubMed - indexed for MEDLINE]

 **235:** [Garcia-Ladona FJ, Huss Y, Frey P, Ghandour MS.](#)[Related Articles, Links](#)**Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: in situ hybridization and immunocytochemical detection.**


J Neurosci Res. 1997 Oct 1;50(1):50-61.

PMID: 9379493 [PubMed - indexed for MEDLINE]

 **236:** [Shea TB, Prabhakar S, Ekinici FJ.](#)[Related Articles, Links](#)**Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system.**


J Neurosci Res. 1997 Sep 15;49(6):759-68.

PMID: 9335263 [PubMed - indexed for MEDLINE]

 **237:** [Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kinata K, Kinsella MG, Wight TN, Snow AD.](#)[Related Articles, Links](#)**Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus.**

Glia. 1997 Oct;21(2):228-43.

PMID: 9336237 [PubMed - indexed for MEDLINE]

 **238:** [Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM.](#)[Related Articles, Links](#)**Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.**


J Biol Chem. 1997 Oct 3;272(40):25135-42.

PMID: 9312124 [PubMed - indexed for MEDLINE]

 **239:** [Brewer GJ.](#)[Related Articles, Links](#)**Effects of acidosis on the distribution of processing of the beta-amyloid precursor protein in cultured hippocampal neurons.**


Mol Chem Neuropathol. 1997 Jun;31(2):171-86.

PMID: 9376023 [PubMed - indexed for MEDLINE]

 **240:** [Yamada T, Tsuboi Y, Takahashi M.](#)[Related Articles, Links](#)**Interrelationship between beta-amyloid deposition and complement-activated oligodendroglia.**


Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72.

PMID: 9298627 [PubMed - indexed for MEDLINE]

 **241:** [Dewji NN, Singer SJ.](#)[Related Articles, Links](#)**Cell surface expression of the Alzheimer disease-related presenilin proteins.**

Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31.

PMID: 9275228 [PubMed - indexed for MEDLINE]

 **242:** [Cataldo AM, Barnett JL, Pieroni C, Nixon RA.](#)[Related Articles, Links](#)





Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

J Neurosci. 1997 Aug 15;17(16):6142-51.

PMID: 9236226 [PubMed - indexed for MEDLINE]



**243:** [Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B.](#) Related Articles, Links



The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.

FEBS Lett. 1997 Jul 28;412(2):341-5.

PMID: 9256248 [PubMed - indexed for MEDLINE]



**244:** [Ohsawa I, Takamura C, Kohsaka S.](#) Related Articles, Links



The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.

Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65.

PMID: 9223426 [PubMed - indexed for MEDLINE]



**245:** [Luth HJ, Arendt T.](#) Related Articles, Links



Co-expression of APP with cNOS but not iNOS after cortical injury in rat.

Neuroreport. 1997 Jul 7;8(9-10):2321-4.

PMID: 9243633 [PubMed - indexed for MEDLINE]



**246:** [Giometto B, An SF, Groves M, Scaravilli T, Geddes JF, Miller R, Tavolato B, Beckett AA, Scaravilli F.](#) Related Articles, Links



Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.

Ann Neurol. 1997 Jul;42(1):34-40.

PMID: 9225683 [PubMed - indexed for MEDLINE]



**247:** [Haas C, Cazorla P, Miguel CD, Valdivieso F, Vazquez J.](#) Related Articles, Links



Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Biochem J. 1997 Jul 1;325 ( Pt 1):169-75.

PMID: 9224643 [PubMed - indexed for MEDLINE]



**248:** [Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, Patel AJ.](#) Related Articles, Links



Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes.

Brain Res Mol Brain Res. 1997 Jul;47(1-2):147-56.

PMID: 9221912 [PubMed - indexed for MEDLINE]



**249:** [Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H, Itoh Y.](#) Related Articles, Links



Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits.

Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81.

PMID: 9210972 [PubMed - indexed for MEDLINE]



**250:** [Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T.](#) Related Articles, Links





















Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.



















Psychiatry Clin Neurosci. 1997 Jun;51(3):135-8.

PMID: 9225377 [PubMed - indexed for MEDLINE]



**251:** [Arai Y, Suzuki A, Mizuguchi M, Takashima S.](#) Related Articles, Links


-  **Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.**  
Brain Dev. 1997 Jun;19(4):290-4.  
PMID: 9187481 [PubMed - indexed for MEDLINE]
-  **252:** [Mielke JG, Murphy MP, Maritz J, Bengualid KM, Ivy GO.](#) [Related Articles, Links](#)
-  **Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.**  
Neurosci Lett. 1997 May 23;227(3):169-72.  
PMID: 9185677 [PubMed - indexed for MEDLINE]
-  **253:** [Sasaki A, Iijima M, Yokoo H, Shoji M, Nakazato Y.](#) [Related Articles, Links](#)
-  **Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study.**  
Brain Res. 1997 May 2;755(2):193-201.  
PMID: 9175887 [PubMed - indexed for MEDLINE]
-  **254:** [Solomon B, Koppel R, Frankel D, Hanan-Aharon E.](#) [Related Articles, Links](#)
-  **Disaggregation of Alzheimer beta-amyloid by site-directed mAb.**  
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.  
PMID: 9108113 [PubMed - indexed for MEDLINE]
-  **255:** [Xu S, Gaskin F.](#) [Related Articles, Links](#)
-  **Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.**  
Mech Ageing Dev. 1997 Mar;94(1-3):213-22.  
PMID: 9147373 [PubMed - indexed for MEDLINE]
-  **256:** [Koo EH.](#) [Related Articles, Links](#)
-  **Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production.**  
Mol Med. 1997 Mar;3(3):204-11.  
PMID: 9100226 [PubMed - indexed for MEDLINE]
-  **257:** [Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM.](#) [Related Articles, Links](#)
-  **Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice.**  
Am J Pathol. 1997 Feb;150(2):417-27.  
PMID: 9033257 [PubMed - indexed for MEDLINE]
-  **258:** [Marambaud P, Chevallier N, Barelli H, Wilk S, Checler F.](#) [Related Articles, Links](#)
-  **Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells.**  
J Neurochem. 1997 Feb;68(2):698-703.  
PMID: 9003058 [PubMed - indexed for MEDLINE]
-  **259:** [Walter J, Capell A, Hung AY, Langen H, Schnolzer M, Thinakaran G, Sisodia SS, Selkoe DJ, Haass C.](#) [Related Articles, Links](#)
-  **Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations.**  
J Biol Chem. 1997 Jan 17;272(3):1896-903.  
PMID: 8999878 [PubMed - indexed for MEDLINE]
-  **260:** [McDermott JR, Gibson AM.](#) [Related Articles, Links](#)

-  **Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.**  
Neurochem Res. 1997 Jan;22(1):49-56.  
PMID: 9021762 [PubMed - indexed for MEDLINE]
-  **261:** Drache B, Diehl GE, Beyreuther K, Perlmutter LS, König G. [Related Articles](#), [Links](#)
-  **Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states.**  
J Neurosci Res. 1997 Jan 1;47(1):98-108.  
PMID: 8981243 [PubMed - indexed for MEDLINE]
-  **262:** Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R. [Related Articles](#), [Links](#)
-  **Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain.**  
Neurosci Lett. 1996 Dec 20;220(3):159-62.  
PMID: 8994217 [PubMed - indexed for MEDLINE]
-  **263:** Sihag RK, Cataldo AM. [Related Articles](#), [Links](#)
-  **Brain beta-spectrin is a component of senile plaques in Alzheimer's disease.**  
Brain Res. 1996 Dec 16;743(1-2):249-57.  
PMID: 9017252 [PubMed - indexed for MEDLINE]
-  **264:** Hirai T, Kojima S, Shimada A, Umemura T, Sakai M, Itakura C. [Related Articles](#), [Links](#)
-  **Age-related changes in the olfactory system of dogs.**  
Neuropathol Appl Neurobiol. 1996 Dec;22(6):531-9.  
PMID: 9004244 [PubMed - indexed for MEDLINE]
-  **265:** Nielson KA, Cummings BJ, Cotman CW. [Related Articles](#), [Links](#)
-  **Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex.**  
Brain Res. 1996 Nov 25;741(1-2):284-93.  
PMID: 9001734 [PubMed - indexed for MEDLINE]
-  **266:** Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. [Related Articles](#), [Links](#)
-  **Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.**  
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5.  
PMID: 8917563 [PubMed - indexed for MEDLINE]
-  **267:** Su JH, Cummings BJ, Cotman CW. [Related Articles](#), [Links](#)
-  **Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments.**  
Brain Res. 1996 Nov 11;739(1-2):79-87.  
PMID: 8955927 [PubMed - indexed for MEDLINE]
-  **268:** Jung SS, Nalbantoglu J, Cashman NR. [Related Articles](#), [Links](#)
-  **Alzheimer's beta-amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study.**  
J Neurosci Res. 1996 Nov 1;46(3):336-48.  
PMID: 8933373 [PubMed - indexed for MEDLINE]
-  **269:** Yokota M, Saido TC, Tani E, Yamaura I, Minami N. [Related Articles](#), [Links](#)

Cytotoxic fragment of amyloid precursor protein accumulates in



hippocampus after global forebrain ischemia.  
J Cereb Blood Flow Metab. 1996 Nov;16(6):1219-23.  
PMID: 8898694 [PubMed - indexed for MEDLINE]

 **270:** Dewji NN, Singer SJ.

[Related Articles](#), [Links](#)



Specific transcellular binding between membrane proteins crucial to Alzheimer disease.

Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12575-80.  
PMID: 8901624 [PubMed - indexed for MEDLINE]


 **271:** Stephens DJ, Austen BM.

[Related Articles](#), [Links](#)



Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells.

J Neurosci Res. 1996 Oct 15;46(2):211-25.  
PMID: 8915898 [PubMed - indexed for MEDLINE]


 **272:** De Bleecker JL, Ertl BB, Engel AG.

[Related Articles](#), [Links](#)



Patterns of abnormal protein expression in target formations and unstructured cores.


Neuromuscul Disord. 1996 Oct;6(5):339-49.  
PMID: 8938698 [PubMed - indexed for MEDLINE]

 **273:** Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Fujimori O, Ojika K. [Related Articles](#), [Links](#)



Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation.


Neuropathol Appl Neurobiol. 1996 Oct;22(5):440-5.  
PMID: 8930956 [PubMed - indexed for MEDLINE]

 **274:** Kuo H, Ingram DK, Walker LC, Tian M, Hengemihle JM, Jucker M. [Related Articles](#), [Links](#)



Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains.


Neuroscience. 1996 Oct;74(3):733-40.  
PMID: 8884769 [PubMed - indexed for MEDLINE]

 **275:** Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. [Related Articles](#), [Links](#)



Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.

J Exp Med. 1996 Oct 1;184(4):1425-33.  
PMID: 8879214 [PubMed - indexed for MEDLINE]


 **276:** De La Monte SM, Carlson RI, Brown NV, Wands JR.

[Related Articles](#), [Links](#)



Profiles of neuronal thread protein expression in Alzheimer's disease.

J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50.  
PMID: 8858001 [PubMed - indexed for MEDLINE]

 **277:** Castillo GM, Cummings JA, Ngo C, Yang W, Snow AD.

[Related Articles](#), [Links](#)



Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain.

J Biochem (Tokyo). 1996 Aug;120(2):433-44.  
PMID: 8889831 [PubMed - indexed for MEDLINE]

 **278:** Brewer GL.

[Related Articles](#), [Links](#)



Thrombin causes cell spreading and redistribution of beta-amyloid immunoreactivity in cultured hippocampal neurons.

J Neurochem. 1996 Jul;67(1):119-30.

PMID: 8666982 [PubMed - indexed for MEDLINE]

279:

Nomura Y, Yamanaka Y, Kitamura Y, Arima T, Ohnuki T, Oomura Y, Sasaki K, Nagashima K, Ihara Y.

[Related Articles, Links](#)



Senescence-accelerated mouse. Neurochemical studies on aging.

Ann N Y Acad Sci. 1996 Jun 15;786:410-8.

PMID: 8687038 [PubMed - indexed for MEDLINE]

280:

Brown AM, Tummo DM, Spruyt MA, Jacobsen JS, Sonnenberg-Reines J.

[Related Articles, Links](#)



Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates.

J Neurochem. 1996 Jun;66(6):2436-45.

PMID: 8632167 [PubMed - indexed for MEDLINE]

281:

Fukuchi K, Ohman T, Dang N, Smith AC, Furlong CE, Martin GM.

[Related Articles, Links](#)



Overexpressions of cDNAs for beta-amyloid precursor proteins 695, 751, and 770 enhance the secretion of beta-amyloid precursor protein derivatives and the survival of P19-derived neurons.

J Neurochem. 1996 May;66(5):2201-4.

PMID: 8780054 [PubMed - indexed for MEDLINE]

282:

Fraser SP, Suh YH, Chong YH, Djamgoz MB.

[Related Articles, Links](#)



Membrane currents induced in *Xenopus* oocytes by the C-terminal fragment of the beta-amyloid precursor protein.

J Neurochem. 1996 May;66(5):2034-40.

PMID: 8780033 [PubMed - indexed for MEDLINE]

283:

Koo EH, Squazzo SL, Selkoe DJ, Koo CH.

[Related Articles, Links](#)



Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody.

J Cell Sci. 1996 May;109 (Pt 5):991-8.

PMID: 8743946 [PubMed - indexed for MEDLINE]

284:

Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H.

[Related Articles, Links](#)



Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Neurobiol Aging. 1996 May-Jun;17(3):405-14.

PMID: 8725902 [PubMed - indexed for MEDLINE]

285:

Nelson PT, Saper CB.

[Related Articles, Links](#)



Injections of okadaic acid, but not beta-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep.

Neurosci Lett. 1996 Apr 19;208(2):77-80.

PMID: 8859894 [PubMed - indexed for MEDLINE]

286:

Johnstone EM, Babbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP.

[Related Articles, Links](#)



Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.











Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.

PMID: 8607830 [PubMed - indexed for MEDLINE]

287:

Zhang M, Olsson Y.


[Related Articles, Links](#)

-  **Beta-amyloid precursor protein accumulates in axons around hematogenous metastases of the human brain: immunohistochemical observations.**  
Clin Neuropathol. 1996 Mar-Apr;15(2):74-8.  
PMID: 8925600 [PubMed - indexed for MEDLINE]
-  **288:** Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, Snowdon DA, Markesbery WR, Geddes JW. Related Articles, Links  
**Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains.**  
Neurobiol Aging. 1996 Mar-Apr;17(2):249-57.  
PMID: 8744406 [PubMed - indexed for MEDLINE]
-  **289:** Liberski PP, Yanagihara R, Brown P, Kordek R, Kloszewska I, Bratosiewicz J, Gajdusek DC. Related Articles, Links  
**Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses.**  
Neurodegeneration. 1996 Mar;5(1):95-9.  
PMID: 8731388 [PubMed - indexed for MEDLINE]
-  **290:** Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Related Articles, Links  
**Localization and cell association of C1q in Alzheimer's disease brain.**  
Exp Neurol. 1996 Mar;138(1):22-32.  
PMID: 8593893 [PubMed - indexed for MEDLINE]
-  **291:** Yasuhara O, Schwab C, Matsuo A, Kim SU, Steele JC, Akiguchi I, Kimura J, McGeer EG, McGeer PL. Related Articles, Links  
**Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam.**  
Neurosci Lett. 1996 Feb 23;205(2):107-10.  
PMID: 8907328 [PubMed - indexed for MEDLINE]
-  **292:** Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Related Articles, Links  
**Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle.**  
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1314-9.  
PMID: 8577761 [PubMed - indexed for MEDLINE]
-  **293:** Konig G, Graham P, Bushnell A, Webster S, Wunderlich D, Perlmutter LS. Related Articles, Links  
**Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide.**  
Ann N Y Acad Sci. 1996 Jan 17;777:344-55.  
PMID: 8624111 [PubMed - indexed for MEDLINE]
-  **294:** McGeer PL, McGeer EG. Related Articles, Links  
**Anti-inflammatory drugs in the fight against Alzheimer's disease.**  
Ann N Y Acad Sci. 1996 Jan 17;777:213-20. Review.  
PMID: 8624086 [PubMed - indexed for MEDLINE]
-  **295:** Solomon B, Koppel R, Hanan E, Katzav T. Related Articles, Links  
**Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.**  
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5.  
PMID: 8552659 [PubMed - indexed for MEDLINE]
-  **296:** Lahiri DK, Farlow MR. Related Articles, Links  
**Differential effect of tacrine and physostigmine on the secretion of the**

beta-amyloid precursor protein in cell lines.

J Mol Neurosci. 1996 Spring;7(1):41-9.

PMID: 8835781 [PubMed - indexed for MEDLINE]


-  **297:** [Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM.](#) [Related Articles, Links](#)



Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.

Acta Neuropathol (Berl). 1996;91(6):633-41.

PMID: 8781663 [PubMed - indexed for MEDLINE]

-  **298:** [Akaaboune M, Verdier-Sahuque M, Lachkar S, Festoff BW, Hantai D.](#) [Related Articles, Links](#)



Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro.

J Cell Physiol. 1995 Dec;165(3):503-11.

PMID: 7593229 [PubMed - indexed for MEDLINE]


-  **299:** [Saito Y, Buciak J, Yang J, Pardridge WM.](#) [Related Articles, Links](#)



Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31.

PMID: 7479757 [PubMed - indexed for MEDLINE]


-  **300:** [Link CD.](#) [Related Articles, Links](#)



Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans.

Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72.

PMID: 7568134 [PubMed - indexed for MEDLINE]


-  **301:** [Matsumoto A, Matsumoto R, Baba H, Fujiwara Y.](#) [Related Articles, Links](#)



A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate.

Neurosci Lett. 1995 Aug 11;195(3):171-4.

PMID: 8584202 [PubMed - indexed for MEDLINE]


-  **302:** [Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK.](#) [Related Articles, Links](#)



LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation.

Cell. 1995 Jul 28;82(2):331-40.

PMID: 7543026 [PubMed - indexed for MEDLINE]

-  **303:** [Banati RB, Gehrmann J, Wiessner C, Hossmann KA, Kreutzberg GW.](#) [Related Articles, Links](#)



Glial expression of the beta-amyloid precursor protein (APP) in global ischemia.

J Cereb Blood Flow Metab. 1995 Jul;15(4):647-54.

PMID: 7790414 [PubMed - indexed for MEDLINE]

-  **304:** [Kida E, Wisniewski KE, Wisniewski HM.](#) [Related Articles, Links](#)



Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain.

Neurosci Lett. 1995 Jun 30;193(2):105-8.

PMID: 7478152 [PubMed - indexed for MEDLINE]


-  **305:** [Griffith LS, Mathes M, Schmitz B.](#) [Related Articles, Links](#)



Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine.

J Neurosci Res. 1995 Jun 1;41(2):270-8.

PMID: 7650762 [PubMed - indexed for MEDLINE]

-  **306:** [Saito F, Tani A, Miyatake T, Yanagisawa K.](#) [Related Articles, Links](#)



N-linked oligosaccharide of beta-amyloid precursor protein (beta APP) of C6 glioma cells: putative regulatory role in beta APP processing.

Biochem Biophys Res Commun. 1995 May 25;210(3):703-10.

PMID: 7763244 [PubMed - indexed for MEDLINE]


-  **307:** [Yamada T, Kobayashi T.](#) [Related Articles, Links](#)



The mutation in amyloid precursor protein inhibits both alpha- and beta-secretion.

Neurosci Lett. 1995 May 19;191(1-2):103-6.

PMID: 7659274 [PubMed - indexed for MEDLINE]

-  **308:** [Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin F.](#) [Related Articles, Links](#)



VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.

Clin Immunol Immunopathol. 1995 May;75(2):159-67.

PMID: 7704974 [PubMed - indexed for MEDLINE]


-  **309:** [Greenberg SM, Kosik KS.](#) [Related Articles, Links](#)



Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons.

Neurobiol Aging. 1995 May-Jun;16(3):403-7; discussion 407-8.

PMID: 7566349 [PubMed - indexed for MEDLINE]


-  **310:** [Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S.](#) [Related Articles, Links](#)



Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?

Neuroreport. 1995 Apr 19;6(6):866-8.

PMID: 7612872 [PubMed - indexed for MEDLINE]

-  **311:** [Oohira A, Kushima Y, Matsui E, Watanabe E.](#) [Related Articles, Links](#)



Detection of Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate both in the juvenile rat brain and in the conditioned medium of primary cultured astrocytes.

Neurosci Lett. 1995 Apr 7;189(1):25-8.

PMID: 7603617 [PubMed - indexed for MEDLINE]


-  **312:** [Pike CJ, Cummings BJ, Cotman CW.](#) [Related Articles, Links](#)



Early association of reactive astrocytes with senile plaques in Alzheimer's disease.

Exp Neurol. 1995 Apr;132(2):172-9.

PMID: 7789457 [PubMed - indexed for MEDLINE]

-  **313:** [Yamazaki T, Selkoe DJ, Koo EH.](#) [Related Articles, Links](#)




Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons.

J Cell Biol. 1995 Apr;129(2):431-42.

PMID: 7721945 [PubMed - indexed for MEDLINE]

[Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL.](#)



 **314:** [Yoshioka T, Alkon DL.](#)

[Related Articles](#), [Links](#)



**Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20.**

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4.

PMID: 7708775 [PubMed - indexed for MEDLINE]

 **315:** [Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I.](#)


[Related Articles](#), [Links](#)



**Ligand-dependent G protein coupling function of amyloid transmembrane precursor.**

J Biol Chem. 1995 Mar 3;270(9):4205-8.

PMID: 7876177 [PubMed - indexed for MEDLINE]

 **316:** [Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ.](#)


[Related Articles](#), [Links](#)



**Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner.**

J Neurosci. 1995 Mar;15(3 Pt 2):2157-67.

PMID: 7891158 [PubMed - indexed for MEDLINE]

 **317:** [Palacios G, Mengod G, Tortosa A, Ferrer I, Palacios JM.](#)

[Related Articles](#), [Links](#)



**Increased beta-amyloid precursor protein expression in astrocytes in the gerbil hippocampus following ischaemia: association with proliferation of astrocytes.**

Eur J Neurosci. 1995 Mar 1;7(3):501-10.

PMID: 7773447 [PubMed - indexed for MEDLINE]

 **318:** [Walker DG, Kim SU, McGeer PL.](#)


[Related Articles](#), [Links](#)



**Complement and cytokine gene expression in cultured microglial derived from postmortem human brains.**

J Neurosci Res. 1995 Mar 1;40(4):478-93.

PMID: 7616608 [PubMed - indexed for MEDLINE]

 **319:** [Van Gool D, De Strooper B, Van Leuven F, Dom R.](#)

[Related Articles](#), [Links](#)



**Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease.**

Dementia. 1995 Mar-Apr;6(2):63-8.

PMID: 7606281 [PubMed - indexed for MEDLINE]

 **320:** [Armstrong RA, Winsper SJ, Blair JA.](#)

[Related Articles](#), [Links](#)



**Hypothesis: is Alzheimer's disease a metal-induced immune disorder?**

Neurodegeneration. 1995 Mar;4(1):107-11.

PMID: 7600179 [PubMed - indexed for MEDLINE]

 **321:** [McRae A, Gilland E, Bona E, Hagberg H.](#)


[Related Articles](#), [Links](#)



**Microglia activation after neonatal hypoxic-ischemia.**

Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52.

PMID: 7743644 [PubMed - indexed for MEDLINE]

 **322:** [Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S.](#)

[Related Articles](#), [Links](#)



**Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.**

Neuron. 1995 Feb;14(2):457-66.

PMID: 7857653 [PubMed - indexed for MEDLINE]


 **323:** [Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL.](#)

[Related Articles](#), [Links](#)



**Interaction of beta-amyloid peptides with integrins in a human nerve cell line.**

Neurosci Lett. 1995 Jan 16;184(1):25-8.  
PMID: 7739799 [PubMed - indexed for MEDLINE]

-  **324:** Cabal A, Aloñso-Cortina V, Gonzalez-Vazquez LO, Naves FJ, Del Valle ME, Vega JA. [Related Articles, Links](#)



beta-Amyloid precursor protein (beta APP) in human gut with special reference to the enteric nervous system.


Brain Res Bull. 1995;38(5):417-23.  
PMID: 8665264 [PubMed - indexed for MEDLINE]

-  **325:** Schwab C, Steele JC, Akiyama H, McGeer EG, McGeer PL. [Related Articles, Links](#)



Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia.


Acta Neuropathol (Berl). 1995;90(3):287-98.  
PMID: 8525803 [PubMed - indexed for MEDLINE]

-  **326:** Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Sica RE. [Related Articles, Links](#)



Early onset Alzheimer's disease in a South American pedigree from Argentina.

Acta Neurol Scand. 1995 Jan;91(1):6-13.  
PMID: 7732777 [PubMed - indexed for MEDLINE]

-  **327:** Triarhou LC, Sola C, Mengod G, Garcia-Ladona FJ, Landwehrmeyer B, Ghetti B, Palacios JM. [Related Articles, Links](#)



Ventral mesencephalic grafts in the neostriatum of the weaver mutant mouse: structural molecule and receptor studies.


Cell Transplant. 1995 Jan-Feb;4(1):39-48.  
PMID: 7728332 [PubMed - indexed for MEDLINE]

-  **328:** Mena R, Edwards P, Perez-Olivera O, Wischik CM. [Related Articles, Links](#)



Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease.


Acta Neuropathol (Berl). 1995;89(1):50-6.  
PMID: 7709731 [PubMed - indexed for MEDLINE]

-  **329:** Jakes R, Harrington CR, Spillantini MG, Goedert M, Klug A. [Related Articles, Links](#)



Characterisation of an antibody relevant to the neuropathology of Alzheimer disease.


Alzheimer Dis Assoc Disord. 1995 Spring;9(1):47-51.  
PMID: 7605621 [PubMed - indexed for MEDLINE]

-  **330:** Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamamoto T. [Related Articles, Links](#)



Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells.


Acta Neuropathol (Berl). 1995;89(3):199-203.  
PMID: 7538720 [PubMed - indexed for MEDLINE]

-  **331:** Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. [Related Articles, Links](#)



Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum.




















Brain Res. 1994 Dec 19;667(1):138-42.  
PMID: 7895077 [PubMed - indexed for MEDLINE]

-  **332:** Oda T, Pasinetti GM, Osterburg JHH, Anderson C, Johnson SA, Finch CE. [Related Articles, Links](#)



Purification and characterization of brain clusterin.

Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6.  
PMID: 7980587 [PubMed - indexed for MEDLINE]

-  **333:** [O'Brien TJ, McKelvie PA, Vrodos N.](#) [Related Articles, Links](#)
-  **Bilateral trigeminal amyloidoma: an unusual case of trigeminal neuropathy with a review of the literature. Case report.**  
J Neurosurg. 1994 Nov;81(5):780-3. Review.  
PMID: 7931626 [PubMed - indexed for MEDLINE]
-  **334:** [Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J.](#) [Related Articles, Links](#)
-  **Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies.**  
Clin Neuropathol. 1994 Nov-Dec;13(6):306-14.  
PMID: 7851045 [PubMed - indexed for MEDLINE]
-  **335:** [McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG.](#) [Related Articles, Links](#)
-  **Pathological proteins in senile plaques.**  
Tohoku J Exp Med. 1994 Nov;174(3):269-77.  
PMID: 7761992 [PubMed - indexed for MEDLINE]
-  **336:** [Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM.](#) [Related Articles, Links](#)
-  **Monoclonal antibody to the C-terminus of beta-amyloid.**  
Neuroreport. 1994 Oct 27;5(16):2117-20.  
PMID: 7865758 [PubMed - indexed for MEDLINE]
-  **337:** [Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA.](#) [Related Articles, Links](#)
-  **Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease.**  
Brain Res. 1994 Oct 24;661(1-2):35-42.  
PMID: 7834382 [PubMed - indexed for MEDLINE]
-  **338:** [Sherriff FE, Bridges LR, De Souza DS.](#) [Related Articles, Links](#)
-  **Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity.**  
Neuroreport. 1994 Oct 3;5(15):1897-900.  
PMID: 7531003 [PubMed - indexed for MEDLINE]
-  **339:** [Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich D, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al.](#) [Related Articles, Links](#)
-  **Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation.**  
Eur J Biochem. 1994 Sep 1;224(2):265-71.  
PMID: 7523115 [PubMed - indexed for MEDLINE]
-  **340:** [van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Swaab DF.](#) [Related Articles, Links](#)
-  **The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas.**  
Brain Res. 1994 Aug 29;655(1-2):97-109.  
PMID: 7812796 [PubMed - indexed for MEDLINE]
-  **341:** [Durham HD, Minotti S, Dooley NP, Nalbantoglu J.](#) [Related Articles, Links](#)
-  **Expression of the intermediate filament-associated protein related to beta-amyloid precursor protein is developmentally regulated in cultured cells.**  
J Neurosci Res. 1994 Aug 15;38(6):629-39.  
PMID: 7807580 [PubMed - indexed for MEDLINE]
-  **342:** [Heinonen O, Soininen H, Syrjanen S, Neittaanmaki H, Paljarvi L.](#) [Related Articles, Links](#)

Kosunen O, Syrjänen K, Riekkinen P, Sr.



beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study.

Arch Neurol. 1994 Aug;51(8):799-804.

PMID: 8042928 [PubMed - indexed for MEDLINE]

☐ **343:** Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA.

[Related Articles](#), [Links](#)



Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13.

PMID: 7888086 [PubMed - indexed for MEDLINE]

☐ **344:** Singh VK.

[Related Articles](#), [Links](#)



Studies of neuroimmune markers in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81.

PMID: 7534089 [PubMed - indexed for MEDLINE]

☐ **345:** Snyder SW, Wang GT, Barrett L, Lador US, Casuto D, Lee CM,

[Related Articles](#), [Links](#)

Krafft GA, Holzman RB, Holzman TF.



Complement C1q does not bind monomeric beta-amyloid.

Exp Neurol. 1994 Jul;128(1):136-42.

PMID: 8070518 [PubMed - indexed for MEDLINE]

☐ **346:** Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y.

[Related Articles](#), [Links](#)



Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Neuron. 1994 Jul;13(1):45-53.

PMID: 8043280 [PubMed - indexed for MEDLINE]

☐ **347:** Walker LC, Price DL, Voytko ML, Schenk DB.

[Related Articles](#), [Links](#)



Labeling of cerebral amyloid in vivo with a monoclonal antibody.

J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.

PMID: 8021711 [PubMed - indexed for MEDLINE]

☐ **348:** Banati RB, Gehrmann J, Kreutzberg GW.

[Related Articles](#), [Links](#)



Glial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion.

Neuroreport. 1994 Jun 27;5(11):1359-61.

PMID: 7919199 [PubMed - indexed for MEDLINE]

☐ **349:** Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E,

[Related Articles](#), [Links](#)

Ihara Y, Kawashima S.



Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus.

J Biol Chem. 1994 May 27;269(21):15253-7.

PMID: 8195161 [PubMed - indexed for MEDLINE]

☐ **350:** Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L,

[Related Articles](#), [Links](#)

Gambetti P.



Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603.

PMID: 8185615 [PubMed - indexed for MEDLINE]

☐ **351:** Schmidt ML, DiDario AG, Lee VM, Trojanowski JQ.

[Related Articles](#), [Links](#)



An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in

## Alzheimer disease.

FEBS Lett. 1994 May 9;344(1):69-73.

PMID: 8181568 [PubMed - indexed for MEDLINE]

- ☐ **352:** Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B. [Related Articles, Links](#)



Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Am J Pathol. 1994 May;144(5):1082-8.

PMID: 8178931 [PubMed - indexed for MEDLINE]

- ☐ **353:** Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. [Related Articles, Links](#)



Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease.

J Neuropathol Exp Neurol. 1994 May;53(3):231-8.

PMID: 8176406 [PubMed - indexed for MEDLINE]

- ☐ **354:** Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D. [Related Articles, Links](#)



Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy.

J Neurobiol. 1994 May;25(5):503-14.

PMID: 8071658 [PubMed - indexed for MEDLINE]

- ☐ **355:** Matsumoto A, Fujiwara Y. [Related Articles, Links](#)



Ca(2+)-dependent 68-kilodalton protease in familial Alzheimer's disease cells cleaves the N-terminus of beta-amyloid.

Biochemistry. 1994 Apr 5;33(13):3941-8.

PMID: 8142398 [PubMed - indexed for MEDLINE]

- ☐ **356:** Beeson JG, Shelton ER, Chan HW, Gage FH. [Related Articles, Links](#)



Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies.

J Comp Neurol. 1994 Apr 1;342(1):78-96.

PMID: 8207129 [PubMed - indexed for MEDLINE]

- ☐ **357:** Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. [Related Articles, Links](#)



Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.

J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25.

PMID: 8163989 [PubMed - indexed for MEDLINE]

- ☐ **358:** Bilak M, Askanas V, Engel WK. [Related Articles, Links](#)



Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions.

Synapse. 1994 Apr;16(4):280-3.

PMID: 8059338 [PubMed - indexed for MEDLINE]

- ☐ **359:** Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Nolan CC, Anderton BH, Leigh PN. [Related Articles, Links](#)


















beta-Amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin.





















Brain Res. 1994 Mar 21;640(1-2):25-32.


PMID: 8004453 [PubMed - indexed for MEDLINE]

- ☐ **360:** Bickel U, Lee VM, Trojanowski JQ, Pardridge WM. [Related Articles, Links](#)

Development and in vitro characterization of a cationized monoclonal

-  antibody against beta A4 protein: a potential probe for Alzheimer's disease.  
Bioconjug Chem. 1994 Mar-Apr;5(2):119-25.  
PMID: 8031874 [PubMed - indexed for MEDLINE]
-  **361:** [Loffler J, Langui D, Probst A, Huber G.](#) Related Articles, Links  
Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex.  
Neurochem Int. 1994 Mar;24(3):281-8.  
PMID: 8025536 [PubMed - indexed for MEDLINE]
-  **362:** [Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K.](#) Related Articles, Links  
Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.  
Am J Pathol. 1994 Feb;144(2):337-47.  
PMID: 8311117 [PubMed - indexed for MEDLINE]
-  **363:** [Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G.](#) Related Articles, Links  
 Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid.  
Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5(8):following 1014.  
PMID: 8025246 [PubMed - indexed for MEDLINE]
-  **364:** [Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG.](#) Related Articles, Links  
 An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain.  
Neuron. 1994 Jan;12(1):219-34.  
PMID: 8292358 [PubMed - indexed for MEDLINE]
-  **365:** [Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ.](#) Related Articles, Links  
 Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.  
Am J Pathol. 1994 Jan;144(1):177-87.  
PMID: 8291607 [PubMed - indexed for MEDLINE]
-  **366:** [Westarp ME, Foring B, Rasmussen H, Schraff S, Mertens T, Kornhuber HH.](#) Related Articles, Links  
 Retroviral synthetic peptide serum antibodies in human sporadic amyotrophic lateral sclerosis.  
Peptides. 1994;15(2):207-14.  
PMID: 8008625 [PubMed - indexed for MEDLINE]
-  **367:** [Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA.](#) Related Articles, Links  
 Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology.  
Acta Neuropathol (Berl). 1994;88(4):371-8.  
PMID: 7839831 [PubMed - indexed for MEDLINE]
-  **368:** [Zemlan FP, Vogelsang GD, McLaughlin L, Dean GE.](#) Related Articles, Links  
 Alzheimer's paired helical filaments: amyloid precursor protein epitope mapping.  
Brain Res Bull. 1994;33(4):387-92.  
PMID: 7510209 [PubMed - indexed for MEDLINE]

-  **369:** [Cummings BJ, Su JH, Cotman CW.](#) [Related Articles, Links](#)  
 **Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease.**  
 Exp Neurol. 1993 Dec;124(2):315-25.  
 PMID: 8287930 [PubMed - indexed for MEDLINE]
-  **370:** [Sussman MA, Bilak M, Kedes L, Engel WK, Askanas V.](#) [Related Articles, Links](#)  
 **Tropomodulin is highly concentrated at the postsynaptic domain of human and rat neuromuscular junctions.**  
 Exp Cell Res. 1993 Dec;209(2):388-91.  
 PMID: 8262158 [PubMed - indexed for MEDLINE]
-  **371:** [Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS.](#) [Related Articles, Links](#)  
 **Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease.**  
 Neurobiol Aging. 1993 Nov-Dec;14(6):589-96.  
 PMID: 8295661 [PubMed - indexed for MEDLINE]
-  **372:** [Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB.](#) [Related Articles, Links](#)  
 **Characterization of beta-amyloid peptide from human cerebrospinal fluid.**  
 J Neurochem. 1993 Nov;61(5):1965-8.  
 PMID: 8229004 [PubMed - indexed for MEDLINE]
-  **373:** [Jucker M, Walker LC, Kibbey MC, Kleinman HK, Ingram DK.](#) [Related Articles, Links](#)  
 **Localization of a laminin-binding protein in brain.**  
 Neuroscience. 1993 Oct;56(4):1009-22.  
 PMID: 8284032 [PubMed - indexed for MEDLINE]
-  **374:** [Higgins LS, Catalano R, Quon D, Cordell B.](#) [Related Articles, Links](#)  
 **Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology.**  
 Ann N Y Acad Sci. 1993 Sep 24;695:224-7.  
 PMID: 8239286 [PubMed - indexed for MEDLINE]
-  **375:** [Askanas V, Bilak M, Engel WK, Leclerc A, Tome F.](#) [Related Articles, Links](#)  
 **Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions.**  
 Neurosci Lett. 1993 Sep 3;159(1-2):111-4.  
 PMID: 8264949 [PubMed - indexed for MEDLINE]
-  **376:** [Uchida K, Okuda R, Yamaguchi R, Tateyama S, Nakayama H, Goto N.](#) [Related Articles, Links](#)  
 **Double-labeling immunohistochemical studies on canine senile plaques and cerebral amyloid angiopathy.**  
 J Vet Med Sci. 1993 Aug;55(4):637-42.  
 PMID: 8399746 [PubMed - indexed for MEDLINE]
-  **377:** [Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM.](#) [Related Articles, Links](#)  
 **Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.**  
 Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):238S. No abstract available.  
 PMID: 8224394 [PubMed - indexed for MEDLINE]
-  **378:** [Miklosy J.](#) [Related Articles, Links](#)  
 **Alzheimer's disease--a spirochetosis?**  
 Neuroreport. 1993 Jul;4(7):841-8.  
 PMID: 8369471 [PubMed - indexed for MEDLINE]

 **379:** [Leclerc A, Tome FM, Fardeau M.](#)

[Related Articles](#), [Links](#)



**Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study.**

Neuromuscul Disord. 1993 Jul;3(4):283-91.

PMID: 8268725 [PubMed - indexed for MEDLINE]

 **380:** [Singhrao SK, Neal JW, Newman GR.](#)


[Related Articles](#), [Links](#)



**Corpora amylacea could be an indicator of neurodegeneration.**

Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76.

PMID: 8355813 [PubMed - indexed for MEDLINE]

 **381:** [Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor F Jr.](#)


[Related Articles](#), [Links](#)



**The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals.**

Neuropathol Appl Neurobiol. 1993 Jun;19(3):261-8.

PMID: 8355812 [PubMed - indexed for MEDLINE]

 **382:** [DeWitt DA, Silver J, Canning DR, Perry G.](#)


[Related Articles](#), [Links](#)



**Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease.**

Exp Neurol. 1993 Jun;121(2):149-52.

PMID: 8339766 [PubMed - indexed for MEDLINE]

 **383:** [Fukuchi K, Sopher B, Furlong CE, Smith AC, Dang N, Martin GM.](#)


[Related Articles](#), [Links](#)



**Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein.**

Neurosci Lett. 1993 May 14;154(1-2):145-8.

PMID: 8361630 [PubMed - indexed for MEDLINE]

 **384:** [Stoll J, Balbo A, Ault B, Rapoport SI, Fine A.](#)


[Related Articles](#), [Links](#)



**Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology.**

Brain Res. 1993 May 7;610(2):295-304.

PMID: 8319091 [PubMed - indexed for MEDLINE]

 **385:** [Scott SA, Johnson SA, Zarow C, Perlmutter LS.](#)


[Related Articles](#), [Links](#)



**Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia.**

Exp Neurol. 1993 May;121(1):113-8.

PMID: 8495706 [PubMed - indexed for MEDLINE]

 **386:** [Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL.](#)


[Related Articles](#), [Links](#)



**Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease.**

Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51.

PMID: 8476427 [PubMed - indexed for MEDLINE]

 **387:** [Lahiri DK.](#)


[Related Articles](#), [Links](#)



**The stability of beta-amyloid precursor protein in nine different cell types.**

Biochem Mol Biol Int. 1993 Apr;29(5):849-58.

PMID: 8508138 [PubMed - indexed for MEDLINE]

 **388:** [Gaskin F, Finley J, Fang Q, Xu S, Fu SM.](#)

[Related Articles](#), [Links](#)

**Human antibodies reactive with beta-amyloid protein in Alzheimer's**





disease.

J Exp Med. 1993 Apr 1;177(4):1181-6.

PMID: 8459212 [PubMed - indexed for MEDLINE]

**389:** Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE.

Related Articles, Links



Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.

Neuron. 1993 Feb;10(2):243-54.

PMID: 8094963 [PubMed - indexed for MEDLINE]

**390:** Bucci L, Ding W, Delacourte A, Fillit H.

Related Articles, Links



Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.

Brain Res. 1993 Jan 22;601(1-2):154-63.

PMID: 8431762 [PubMed - indexed for MEDLINE]

**391:** Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al.

Related Articles, Links



Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.

Nature. 1993 Jan 21;361(6409):260-3.

PMID: 7678698 [PubMed - indexed for MEDLINE]

**392:** Nelson PT, Marton L, Saper CB.

Related Articles, Links



Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study.

Brain Res. 1993 Jan 15;600(2):285-97.

PMID: 8094642 [PubMed - indexed for MEDLINE]

**393:** Wisniewski HM, Weigel J.

Related Articles, Links



Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation.

Acta Neuropathol (Berl). 1993;85(6):586-95.

PMID: 8337937 [PubMed - indexed for MEDLINE]

**394:** Su JH, Cummings BJ, Cotman CW.

Related Articles, Links



Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.

Neuroscience. 1992 Dec;51(4):801-13.

PMID: 1488123 [PubMed - indexed for MEDLINE]

**395:** Perlmutter LS, Scott SA, Barron E, Chui HC.

Related Articles, Links



MHC class II-positive microglia in human brain: association with Alzheimer lesions.

J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci Res 1993 Jun 15;35(3):346.

PMID: 1484388 [PubMed - indexed for MEDLINE]

**396:** Lahiri DK, Nall C, Farlow MR.

Related Articles, Links



The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells.

Biochem Int. 1992 Dec;28(5):853-60.

PMID: 1288495 [PubMed - indexed for MEDLINE]

**397:** Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortega M, Cotman C, Vaught JL, Neve RL.

Related Articles, Links




Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the

## Alzheimer amyloid precursor in the brain.

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61.

PMID: 1438289 [PubMed - indexed for MEDLINE]

-  **398:** Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. [Related Articles](#), [Links](#)



## Complement activation by beta-amyloid in Alzheimer disease.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20.

PMID: 1438191 [PubMed - indexed for MEDLINE]


-  **399:** Brewer GJ, Ashford JW. [Related Articles](#), [Links](#)



## Human serum stimulates Alzheimer markers in cultured hippocampal neurons.

J Neurosci Res. 1992 Nov;33(3):355-69.

PMID: 1335088 [PubMed - indexed for MEDLINE]


-  **400:** Palacios G, Palacios JM, Mengod G, Frey P. [Related Articles](#), [Links](#)



## Beta-amyloid precursor protein localization in the Golgi apparatus in neurons and oligodendrocytes. An immunocytochemical structural and ultrastructural study in normal and axotomized neurons.

Brain Res Mol Brain Res. 1992 Oct;15(3-4):195-206.

PMID: 1331676 [PubMed - indexed for MEDLINE]


-  **401:** Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. [Related Articles](#), [Links](#)



## Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Nature. 1992 Sep 24;359(6393):325-7.

PMID: 1406936 [PubMed - indexed for MEDLINE]

-  **402:** Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. [Related Articles](#), [Links](#)



## Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Nature. 1992 Sep 24;359(6393):322-5.

PMID: 1383826 [PubMed - indexed for MEDLINE]

-  **403:** Dooley NP, Gauthier S, Durham HD. [Related Articles](#), [Links](#)



## Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts.

J Neurosci Res. 1992 Sep;33(1):60-7.

PMID: 1453484 [PubMed - indexed for MEDLINE]


-  **404:** Askanas V, Engel WK, Alvarez RB. [Related Articles](#), [Links](#)



## Strong immunoreactivity of beta-amyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions.

Neurosci Lett. 1992 Aug 31;143(1-2):96-100.

PMID: 1436686 [PubMed - indexed for MEDLINE]

-  **405:** Murphy GM Jr, Greenberg BD, Ellis WG, Forno LS, Salamat SM, Gonzalez-DeWhitt PA, Lowery DE, Tinklenberg JR, Eng LF. [Related Articles](#), [Links](#)



## Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.

Am J Pathol. 1992 Aug;141(2):357-61.

PMID: 1386714 [PubMed - indexed for MEDLINE]

-  **406:** Lippa CF, Smith TW. [Related Articles](#), [Links](#)

**The indusium griseum in Alzheimer's disease: an immunocytochemical study.**

J Neurol Sci. 1992 Aug;111(1):39-45.

PMID: 1328542 [PubMed - indexed for MEDLINE]

**407:** [Shioi J, Anderson JP, Ripellino JA, Robakis NK.](#)[Related Articles, Links](#)**Chondroitin sulfate proteoglycan form of the Alzheimer's beta-amyloid precursor.**

J Biol Chem. 1992 Jul 15;267(20):13819-22.

PMID: 1629183 [PubMed - indexed for MEDLINE]

**408:** [Mizuguchi M, Ikeda K, Kim SU.](#)[Related Articles, Links](#)**Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures.**

Brain Res. 1992 Jul 3;584(1-2):219-25.

PMID: 1515940 [PubMed - indexed for MEDLINE]

**409:** [Festoff BW, Rao JS, Chen M.](#)[Related Articles, Links](#)**Protease nexin I, thrombin- and urokinase-inhibiting serpin, concentrated in normal human cerebrospinal fluid.**

Neurology. 1992 Jul;42(7):1361-6.

PMID: 1620346 [PubMed - indexed for MEDLINE]

**410:** [Rogers J, Schultz J, Brachova L, Lue LF, Webster S, Bradt B, Cooper NR, Moss DE.](#)[Related Articles, Links](#)**Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.**

Res Immunol. 1992 Jul-Aug;143(6):624-30. Review. No abstract available.

PMID: 1455054 [PubMed - indexed for MEDLINE]

**411:** [Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ.](#)[Related Articles, Links](#)**Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease.**

Neurology. 1992 Jul;42(7):1315-22.

PMID: 1377804 [PubMed - indexed for MEDLINE]

**412:** [Askanas V, Engel WK, Alvarez RB.](#)[Related Articles, Links](#)**Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis.**

Am J Pathol. 1992 Jul;141(1):31-6.

PMID: 1321564 [PubMed - indexed for MEDLINE]

**413:** [Caputo CB, Sobel IR, Scott CW, Brunner WF, Barth PT, Blowers DP.](#)[Related Articles, Links](#)**Association of the carboxy-terminus of beta-amyloid protein precursor with Alzheimer paired helical filaments.**

Biochem Biophys Res Commun. 1992 Jun 30;185(3):1034-40.

PMID: 1627127 [PubMed - indexed for MEDLINE]

**414:** [Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ.](#)[Related Articles, Links](#)**Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.**

Nature. 1992 Jun 11;357(6378):500-3.

PMID: 1608449 [PubMed - indexed for MEDLINE]

**415:** [Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW.](#)[Related Articles, Links](#)**Aggregation of the amyloid precursor protein within degenerating neurons**



and dystrophic neurites in Alzheimer's disease.

Neuroscience. 1992 Jun;48(4):763-77.

PMID: 1378573 [PubMed - indexed for MEDLINE]



**416:** [Mizuguchi M, Ikeda K, Kim SU.](#)

[Related Articles, Links](#)



beta-Amyloid precursor protein of Alzheimer's disease in cultured bovine oligodendrocytes.

J Neurosci Res. 1992 May;32(1):34-42.

PMID: 1629942 [PubMed - indexed for MEDLINE]



**417:** [McGeer PL, Akiyama H, Kawamata T, Yamada T, Walker DG, Ishii T.](#)

[Related Articles, Links](#)



Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy.

J Neurosci Res. 1992 Mar;31(3):428-42.

PMID: 1640495 [PubMed - indexed for MEDLINE]



**418:** [Askanas V, Engel WK, Alvarez RB, Glenner GG.](#)

[Related Articles, Links](#)



beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis.

Lancet. 1992 Feb 29;339(8792):560-1. No abstract available.

PMID: 1346915 [PubMed - indexed for MEDLINE]



**419:** [Ohgami T, Kitamoto T, Tateishi J.](#)

[Related Articles, Links](#)



Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions.

Neurosci Lett. 1992 Feb 17;136(1):75-8.

PMID: 1635670 [PubMed - indexed for MEDLINE]



**420:** [Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV.](#)

[Related Articles, Links](#)



Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human beta amyloid precursor protein.

J Immunol Methods. 1992 Feb 14;147(1):1-11.

PMID: 1371794 [PubMed - indexed for MEDLINE]



**421:** [Delvaux A, Van der Elst L, Octave JN.](#)

[Related Articles, Links](#)



Inhibition of trypsin by the beta-amyloid protein precursor. A comparative study between transfected cells, human brain and cerebrospinal fluid.

FEBS Lett. 1992 Feb 3;297(1-2):124-6.

PMID: 1551418 [PubMed - indexed for MEDLINE]



**422:** [Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M.](#)

[Related Articles, Links](#)



SP-40,40 is a constituent of Alzheimer's amyloid.

Acta Neuropathol (Berl). 1992;83(3):260-4.

PMID: 1373021 [PubMed - indexed for MEDLINE]



**423:** [Barcikowska M, Kujawa M, Wisniewski H.](#)

[Related Articles, Links](#)



beta-Amyloid deposits within the cerebellum of persons older than 80 years of age.

Neuropatol Pol. 1992;30(3-4):285-93.

PMID: 1340921 [PubMed - indexed for MEDLINE]



**424:** [Frautschy SA, Baird A, Cole GM.](#)


[Related Articles, Links](#)



Effects of injected Alzheimer beta-amyloid cores in rat brain.


Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6.

PMID: 1924295 [PubMed - indexed for MEDLINE]

 **425:** [Ito H, Hirano H, Yen SH, Kato S.](#)[Related Articles, Links](#)**Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam.**


Neuropathol Appl Neurobiol. 1991 Oct;17(5):365-73.

PMID: 1758569 [PubMed - indexed for MEDLINE]

 **426:** [Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G.](#)[Related Articles, Links](#)**Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.**


Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552-6.

PMID: 1652752 [PubMed - indexed for MEDLINE]

 **427:** [Price JL, Davis PB, Morris JC, White DL.](#)[Related Articles, Links](#)**The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.**


Neurobiol Aging. 1991 Jul-Aug;12(4):295-312.

PMID: 1961359 [PubMed - indexed for MEDLINE]

 **428:** [Chen M, Yankner BA.](#)[Related Articles, Links](#)**An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types.**


Neurosci Lett. 1991 Apr 29;125(2):223-6.

PMID: 1715534 [PubMed - indexed for MEDLINE]

 **429:** [Knops J, Johnson-Wood K, Schenk DB, Sinha S, Lieberburg I, McConlogue L.](#)[Related Articles, Links](#)**Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.**


J Biol Chem. 1991 Apr 15;266(11):7285-90.

PMID: 1901866 [PubMed - indexed for MEDLINE]

 **430:** [Fraser PE, Duffy LK, O'Malley MB, Nguyen J, Inouye H, Kirschner DA.](#)[Related Articles, Links](#)**Morphology and antibody recognition of synthetic beta-amyloid peptides.**


J Neurosci Res. 1991 Apr;28(4):474-85.

PMID: 1908024 [PubMed - indexed for MEDLINE]

 **431:** [Matsumoto A, Fujiwara Y.](#)[Related Articles, Links](#)**Abnormal and deficient processing of beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells.**


Biochem Biophys Res Commun. 1991 Mar 15;175(2):361-5.

PMID: 1902089 [PubMed - indexed for MEDLINE]

 **432:** [Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et al.](#)[Related Articles, Links](#)**Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay.**

J Neurochem. 1991 Mar;56(3):1037-42.

PMID: 1899691 [PubMed - indexed for MEDLINE]

 **433:** [Pendlebury WW, Iole ED, Tracy RP, Dill BA.](#)[Related Articles, Links](#)**Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment.**

Ann Neurol. 1991 Feb;29(2):210-3.

PMID: 1901466 [PubMed - indexed for MEDLINE]

-  **434:** [Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D.](#) [Related Articles, Links](#)



Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques.

Am J Pathol. 1991 Feb;138(2):373-84.

PMID: 1704190 [PubMed - indexed for MEDLINE]


-  **435:** [Takahashi H, Hirokawa K, Ando S, Obata K.](#) [Related Articles, Links](#)



Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5.

Acta Neuropathol (Berl). 1991;81(6):626-31.

PMID: 1909079 [PubMed - indexed for MEDLINE]

-  **436:** [Becker L, Mito T, Takashima S, Onodera K.](#) [Related Articles, Links](#)



Growth and development of the brain in Down syndrome.

Prog Clin Biol Res. 1991;373:133-52. Review.

PMID: 1838182 [PubMed - indexed for MEDLINE]

-  **437:** [Zhao XH, Schoenheit C, Duffy LK.](#) [Related Articles, Links](#)



A heparin-binding protein from neuroblastoma cells: immunological comparison to beta-amyloid precursor protein.

Comp Biochem Physiol A. 1991;100(3):715-8.

PMID: 1685979 [PubMed - indexed for MEDLINE]

-  **438:** [Breen KC, Bruce M, Anderton BH.](#) [Related Articles, Links](#)



Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion.

J Neurosci Res. 1991 Jan;28(1):90-100.

PMID: 1645774 [PubMed - indexed for MEDLINE]


-  **439:** [Yankner BA, Caceres A, Duffy LK.](#) [Related Articles, Links](#)



Nerve growth factor potentiates the neurotoxicity of beta amyloid.

Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3.

PMID: 2174172 [PubMed - indexed for MEDLINE]

-  **440:** [Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN.](#) [Related Articles, Links](#)



Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.

Am J Pathol. 1990 Nov;137(5):1253-70.

PMID: 2146882 [PubMed - indexed for MEDLINE]

-  **441:** [Bodmer S, Podlisny MB, Selkoe DJ, Heid I, Fontana A.](#) [Related Articles, Links](#)



Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease.

Biochem Biophys Res Commun. 1990 Sep 14;171(2):890-7.

PMID: 2119582 [PubMed - indexed for MEDLINE]


-  **442:** [Kanemaru K, Hasegawa M, Shimada H, Ihara Y.](#) [Related Articles, Links](#)






































The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section.

Am J Pathol. 1990 Sep;137(3):677-87.

PMID: 1698030 [PubMed - indexed for MEDLINE]

-  **443:** [Tate-Ostrow B, Majocha RE, Walcott EC, Ventosa-Michelman M, Marotta CA.](#) [Related Articles, Links](#)

-  Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein.  
J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45.  
PMID: 2126439 [PubMed - indexed for MEDLINE]
-  **444:** [Shelton ER, Cohn R, Fish L, Obermolte R, Tahilramani R, Nestor JJ, Chan HW](#) [Related Articles, Links](#)
-  Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies.  
J Neurochem. 1990 Jul;55(1):60-9.  
PMID: 2113083 [PubMed - indexed for MEDLINE]
-  **445:** [Wolf D, Quon D, Wang Y, Cordell B](#) [Related Articles, Links](#)
-  Identification and characterization of C-terminal fragments of the beta-amyloid precursor produced in cell culture.  
EMBO J. 1990 Jul;9(7):2079-84.  
PMID: 1694126 [PubMed - indexed for MEDLINE]
-  **446:** [Stern RA, Trojanowski JQ, Lee VM](#) [Related Articles, Links](#)
-  Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood.  
FEBS Lett. 1990 May 7;264(1):43-7.  
PMID: 1692541 [PubMed - indexed for MEDLINE]
-  **447:** [Spillantini MG, Goedert M, Jakes R, Klug A](#) [Related Articles, Links](#)
-  Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease.  
Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51.  
PMID: 2111023 [PubMed - indexed for MEDLINE]
-  **448:** [Singhrao S, Cole G, Henderson WJ, Newman GR](#) [Related Articles, Links](#)
-  LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease.  
Histochem J. 1990 May;22(5):257-68.  
PMID: 1966829 [PubMed - indexed for MEDLINE]
-  **449:** [Spillantini MG, Goedert M, Jakes R, Klug A](#) [Related Articles, Links](#)
-  Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease.  
Proc Natl Acad Sci U S A. 1990 May;87(10):3952-6.  
PMID: 1692627 [PubMed - indexed for MEDLINE]
-  **450:** [Cataldo AM, Nixon RA](#) [Related Articles, Links](#)
-  Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.  
Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5.  
PMID: 1692625 [PubMed - indexed for MEDLINE]
-  **451:** [Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ](#) [Related Articles, Links](#)
-  Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.  
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53.  
PMID: 1690426 [PubMed - indexed for MEDLINE]
-  **452:** [Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H](#) [Related Articles, Links](#)

-  Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.  
Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9.  
PMID: 2106318 [PubMed - indexed for MEDLINE]
-  **453:** Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Related Articles, Links
-  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.  
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5.  
PMID: 1689489 [PubMed - indexed for MEDLINE]
-  **454:** Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Benes FM, Marotta CA. Related Articles, Links
-  Alzheimer cortical neurons containing abundant amyloid mRNA. Relationship to amyloid deposition and senile plaques.  
J Psychiatr Res. 1990;24(1):37-50.  
PMID: 2195164 [PubMed - indexed for MEDLINE]
-  **455:** Dewji NN, Shelton ER, Adler MJ, Chan HW, Seegmiller JE, Coronel C. Related Articles, Links
-  Processing of Alzheimer's disease-associated beta-amyloid precursor protein.  
J Mol Neurosci. 1990;2(1):19-27.  
PMID: 2124135 [PubMed - indexed for MEDLINE]
-  **456:** Murphy GM Jr, Eng LF, Cordell B, Wang Y, Ellis WG, Meissner L, Tinklenberg JR. Related Articles, Links
-  Beta-amyloid precursor detected in human cerebral cortex.  
Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17.  
PMID: 2113696 [PubMed - indexed for MEDLINE]
-  **457:** Takahashi H, Kurashima C, Utsuyama M, Hirokawa K. Related Articles, Links
-  Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.  
Acta Neuropathol (Berl). 1990;80(3):260-5.  
PMID: 1698004 [PubMed - indexed for MEDLINE]
-  **458:** Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski ML, Frangione B. Related Articles, Links
-  Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.  
J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8.  
PMID: 1688925 [PubMed - indexed for MEDLINE]
-  **459:** Suenaga T, Hirano A, Llena JF, Ksiazek-Reding H, Yen SH, Dickson DW. Related Articles, Links
-  Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.  
J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40.  
PMID: 1688924 [PubMed - indexed for MEDLINE]
-  **460:** Palmert MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan HW, Usiak M, Selkoe DJ, Perry G, Younkin SG. Related Articles, Links
-  Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein.  
Biochem Biophys Res Commun. 1989 Nov 30;165(1):182-8.  
PMID: 2480122 [PubMed - indexed for MEDLINE]




-  **461:** [Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M.](#) [Related Articles, Links](#)



**An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles.**

J Gerontol. 1989 Nov;44(6):B156-9.

PMID: 2681356 [PubMed - indexed for MEDLINE]


-  **462:** [Siman R, Card JP, Nelson RB, Davis LG.](#) [Related Articles, Links](#)



**Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage.**

Neuron. 1989 Sep;3(3):275-85.

PMID: 2518369 [PubMed - indexed for MEDLINE]


-  **463:** [Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG.](#) [Related Articles, Links](#)



**The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.**

Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42.

PMID: 2503832 [PubMed - indexed for MEDLINE]


-  **464:** [Takio K, Hasegawa M, Titani K, Ihara Y.](#) [Related Articles, Links](#)



**Identification of beta protein precursor in newborn rat brain.**

Biochem Biophys Res Commun. 1989 May 15;160(3):1296-301.

PMID: 2499330 [PubMed - indexed for MEDLINE]


-  **465:** [Anderson J, Wallace W, Snyder S, Haroutunian V, Roberts JL, Lieberburg I.](#) [Related Articles, Links](#)



**Cellular forms of the rat and human beta-amyloid precursor protein (BAPP).**

Brain Res. 1989 Jan 30;478(2):391-8.

PMID: 2647209 [PubMed - indexed for MEDLINE]


-  **466:** [Benes FM, Reifel JL, Majocha RE, Marotta CA.](#) [Related Articles, Links](#)



**Evidence for a diffusional model of Alzheimer amyloid A4 (beta-amyloid) deposition during neuritic plaque formation.**

Neuroscience. 1989;33(3):483-8.

PMID: 2700016 [PubMed - indexed for MEDLINE]


-  **467:** [Bird TD, Lampe TH, Nemens EJ, Sumi SM, Nochlin D, Schellenberg GD, Wijsman EM.](#) [Related Articles, Links](#)



**Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry.**

Prog Clin Biol Res. 1989;317:229-34.

PMID: 2602419 [PubMed - indexed for MEDLINE]


-  **468:** [Gentleman SM, Bruton C, Allsop D, Lewis SJ, Polak JM, Roberts GW.](#) [Related Articles, Links](#)



**A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits.**

Histochemistry. 1989;92(4):355-8.

PMID: 2478507 [PubMed - indexed for MEDLINE]


-  **469:** [Wisniewski HM, Wen GY, Kim KS.](#) [Related Articles, Links](#)



**Comparison of four staining methods on the detection of neuritic plaques.**

Acta Neuropathol (Berl). 1989;78(1):22-7.

PMID: 2472039 [PubMed - indexed for MEDLINE]

-  **470:** [Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG.](#) [Related Articles, Links](#)

**Antisera to an amino-terminal peptide detect the amyloid protein**



precursor of Alzheimer's disease and recognize senile plaques.

Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7.

PMID: 3140814 [PubMed - indexed for MEDLINE]

☐ **471:** [Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oltersdorf T](#) [Related Articles, Links](#)



Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues.

Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5.

PMID: 3140239 [PubMed - indexed for MEDLINE]

Display  Show:  Sort  Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37

welcome to STN international! Enter x:x  
\* \* \* \* \* Welcome to STN International \* \* \* \* \*  
\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:36:58 ON 31 AUG 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'AQUALINE' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:37:08 ON 31 AUG 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:37:08 ON 31 AUG 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'CAPLUS' ENTERED AT 15:37:08 ON 31 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:37:08 ON 31 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'FOMAD' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'HEALSAFE' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:37:08 ON 31 AUG 2004  
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'NIOSTIC' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:37:08 ON 31 AUG 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:37:08 ON 31 AUG 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:37:08 ON 31 AUG 2004

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:37:08 ON 31 AUG 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:37:08 ON 31 AUG 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:37:08 ON 31 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:37:08 ON 31 AUG 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA).

FILE 'WPIDS' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 15:37:08 ON 31 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

=> S amyloid-beta OR beta-amyloid OR Abeta

23 FILES SEARCHED...

38 FILES SEARCHED...

63 FILES SEARCHED...

L1 101603 AMYLOID-BETA OR BETA-AMYLOID OR ABETA

=> S L1 AND antibody

25 FILES SEARCHED...

59 FILES SEARCHED...

L2 16298 L1 AND ANTIBODY

=> DUP REM L2

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING IS APPROXIMATELY 8% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 19% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 51% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 60% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 68% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 80% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 90% COMPLETE FOR L2

PROCESSING IS APPROXIMATELY 96% COMPLETE FOR L2

PROCESSING COMPLETED FOR L2

L3 9071 DUP REM L2 (7227 DUPLICATES REMOVED)

=> S L3 AND 1-28

14 FILES SEARCHED...

27 FILES SEARCHED...

41 FILES SEARCHED...

59 FILES SEARCHED...

64 FILES SEARCHED...

69 FILES SEARCHED...

L4 469 L3 AND 1-28

=> D L4 1-469

L4 ANSWER 1 OF 469 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV  
on STN

ACCESSION NUMBER: 1998:6139 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 006795

CHANGE DATE: Jun 21, 2004

GENERIC NAME: Celecoxib

SYNONYM: SC 58635; YM 177; Zycel

CHEMICAL NAME: Benzenesulfonamide, 4-(1,1,1-trifluoromethyl-5-(4-methylphenyl) pyrazol-1-yl)-

TRADE NAME: Celebra(R); Celebrex(R); Niflam(R); Onsenal(R)

MOLECULAR FORMULA: C17 H14 F3 N3 O2 S

CAS REGISTRY NO.: 169590-42-5

STRUCTURE:

/ Structure 1 in file .gra /

RELATED CAS REG. NO.: 194044-54-7

EPHMRA ATC CODE: A16A Other Alimentary Tract and Metabolism Products; L1 Antineoplastics; L1X All Other Antineoplastic; M1A3 Coxibs; N2B Non-Narcotics and Anti-Pyretics; N7D9 All other anti-Alzheimer products

WHO ATC CODE: A16A Other Alimentary Tract and Metabolism Products; L01 Antineoplastic Agents; L01X Other Antineoplastic Agents; M01A-H Coxibs; M01A-H01 Celecoxib; N02B Other Analgesics and Antipyretics; N07X Other Nervous System Drugs

HIGHEST DEV. PHASE: Launched

COMPANY INFORMATION

ORIGINATOR: Pfizer (United States)

PARENT: Pfizer

LICENSEE: Roemmers; Yamanouchi

OTHER: Zydus-Cadila

## OTHER SOURCES:

800973514; 800712861; 800743413; 800950955; 800839353;  
 800837873; 800726754; 800726737; 800755209; 800937449;  
 800863310; 800844220; 800818414; 800827845; 800860047;  
 800935615; 800837487; 800857797; 800743415; 800852321;  
 800837422; 800831388; 800444812; 800482402; 800772000;  
 800950401; 800909538; 800940410; 800479359; 800829655;  
 800786768; 800786769; 800756763; 800743412; 800756770;  
 800784217; 800739681; 800830480  
 7988

## WORD COUNT:

- L4 ANSWER 2 OF 469 BIOENG COPYRIGHT 2004 CSA on STN  
 AN 2004317885 BIOENG  
 DN 4004187  
 TI Monoclonal \*\*\*antibodies\*\*\* inhibit in vitro fibrillar aggregation of  
 the Alzheimer \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide  
 AU Solomon, B; Koppel, R; Hanan, E; Katzav, T  
 CS Dep. Mol. Microbiol. and Biotechnol., George S. Wise Fac. Life Sci.,  
 Tel-Aviv Univ., Ramat Aviv 69978, Israel  
 SO Proceedings of the National Academy of Sciences, USA [PROC. NATL. ACAD.  
 SCI. USA], vol. 93, no. 1, pp. 452-455, 1996  
 ISSN: 0027-8424  
 DT Journal  
 LA English  
 SL English  
 OS CSA Neurosciences Abstracts; Medical and Pharmaceutical Biotechnology  
 Abstracts
- L4 ANSWER 3 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 2004:2023 BIOSIS  
 DN PREV200400004998  
 TI Humoral immune response to fibrillar \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
 peptide.  
 AU Miller, David L. [Reprint Author]; Currie, Julia R.; Mehta, Pankaj D.;  
 Potempska, Anna; Hwang, Yu-Wen; Wegiel, Jerzy  
 CS New York State Institute for Basic Research in Developmental Disabilities,  
 1050 Forest Hill Road, Staten Island, NY, 10314, USA  
 davidlm.interport@rcn.com  
 SO Biochemistry, (October 14 2003) Vol. 42, No. 40, pp. 11682-11692. print.  
 ISSN: 0006-2960 (ISSN print).  
 DT Article  
 LA English  
 ED Entered STN: 17 Dec 2003  
 Last Updated on STN: 17 Dec 2003
- L4 ANSWER 4 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 2001:577634 BIOSIS  
 DN PREV200100577634  
 TI \*\*\*Antibody\*\*\* -mediated attenuation of Ab-toxicity.  
 AU Chauhan, N. B. [Reprint author]; Siegel, G. J. [Reprint author]; Lichtor,  
 T.  
 CS Neurology, Hines VA, Hines, IL, USA  
 SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 854. print.  
 Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San  
 Diego, California, USA. November 10-15, 2001.  
 ISSN: 0190-5295.  
 DT Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LA English  
 ED Entered STN: 12 Dec 2001  
 Last Updated on STN: 25 Feb 2002
- L4 ANSWER 5 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1999:180840 BIOSIS  
 DN PREV199900180840  
 TI Competition of \*\*\*Abeta\*\*\* amyloid peptide and apolipoprotein E for  
 receptor-mediated endocytosis.  
 AU Winkler, Karl [Reprint author]; Scharnagl, Hubert; Tisljar, Ursula;  
 Hoschuetzky, Heinz; Friedrich, Isolde; Hoffmann, Michael M.; Huettinger,  
 Manfred; Wieland, Heinrich; Maerz, Winfried  
 CS Department of Clinical Chemistry, Albert Ludwigs-University, Freiburg,  
 Germany  
 SO Journal of Lipid Research, (March, 1999) Vol. 40, No. 3, pp. 447-455.

CODEN: JLPRAW. ISSN: 0022-2275.

DT Article  
 LA English  
 ED Entered STN: 5 May 1999  
 Last Updated on STN: 5 May 1999

L4 ANSWER 6 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1997:433580 BIOSIS  
 DN PREV199799732783  
 TI \*\*\*Beta\*\*\* - \*\*\*Amyloid\*\*\* -induced neurotoxicity of a hybrid septal  
 cell line associated with increased tau phosphorylation and expression of  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* precursor protein.  
 AU Le, Weidong; Xie, Wen Jie; Kong, Rong; Appel, Stanley H. [Reprint author]  
 CS Dep. Neurol., Baylor Coll. Med., 6501 Fannin NB302, Houston, TX 77030, USA  
 SO Journal of Neurochemistry, (1997) Vol. 69, No. 3, pp. 978-985.  
 CODEN: JONRA9. ISSN: 0022-3042.

DT Article  
 LA English  
 ED Entered STN: 8 Oct 1997  
 Last Updated on STN: 8 Oct 1997

L4 ANSWER 7 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1997:309787 BIOSIS  
 DN PREV199799617590  
 TI Development and aging changes in the expression of amyloid precursor  
 protein in Down syndrome brains.  
 AU Arai, Yasuhiro [Reprint author]; Suzuki, Arata; Mizuguchi, Masashi;  
 Takashima, Sachio  
 CS Dep. Mental Retardation Birth Defect Res., Natl. Inst. Neurosci., Natl.  
 Cent. Neurol. Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187, Japan  
 SO Brain and Development, (1997) Vol. 19, No. 4, pp. 290-294.  
 ISSN: 0387-7604.

DT Article  
 LA English  
 ED Entered STN: 26 Jul 1997  
 Last Updated on STN: 26 Jul 1997

L4 ANSWER 8 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1997:274581 BIOSIS  
 DN PREV199799566299  
 TI Increased incidence of anti- \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
 autoantibodies secreted by Epstein-Barr virus transformed B cell lines  
 from patients with Alzheimer's disease.  
 AU Xu, Shihua; Gaskin, Felicia [Reprint author]  
 CS Dep. Psychiatric Med., Univ. Virginia, Sch. Med., Health Sci. Cent. No.  
 203, Charlottesville, VA 22908, USA  
 SO Mechanisms of Ageing and Development, (1997) Vol. 94, No. 1-3, pp.  
 213-222.  
 CODEN: MAGDA3. ISSN: 0047-6374.

DT Article  
 LA English  
 ED Entered STN: 24 Jun 1997  
 Last Updated on STN: 24 Jun 1997

L4 ANSWER 9 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
 STN  
 AN 1997:221477 BIOSIS  
 DN PREV199799513193  
 TI Disaggregation of Alzheimer \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* by  
 site-directed mAb.  
 AU Solomon, Beka [Reprint author]; Koppel, Rela; Frankel, Dan; Hanan-Aharon,  
 Eilat  
 CS Dep. Molecular Microbiol. Biotechnol., Tel Aviv Univ., Ramat Aviv 69978,  
 Israel  
 SO Proceedings of the National Academy of Sciences of the United States of  
 America, (1997) Vol. 94, No. 8, pp. 4109-4112.  
 CODEN: PNASA6. ISSN: 0027-8424.

DT Article  
 LA English  
 ED Entered STN: 22 May 1997  
 Last Updated on STN: 22 May 1997



STN  
AN 1996:425067 BIOSIS  
DN PREV199699156123  
TI Diffuse plaques contain C-terminal A-beta-42 and not A-beta-40: Evidence from cats and dogs.  
AU Cummings, Brian J. [Reprint author]; Satou, Takao; Head, Elizabeth; Milgram, Norton W.; Cole, Greg M.; Savage, Mary J.; Podlisny, Marcia B.; Selkoe, Dennis J.; Siman, Robert; Greenberg, Barry D.; Cotman, Carl W.  
CS Lab. Molecular Neurosciences, Mailman Res. Cent., McLean Hosp., 115 Mill Street, Belmont, MA 02178, USA  
SO Neurobiology of Aging, (1996) Vol. 17, No. 4, pp. 653-659.  
CODEN: NEAGDO. ISSN: 0197-4580.  
DT Article  
LA English  
ED Entered STN: 26 Sep 1996  
Last Updated on STN: 26 Sep 1996

L4 ANSWER 11 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1996:336064 BIOSIS  
DN PREV199699058420  
TI \*\*\*Antibodies\*\*\* to \*\*\*amyloid\*\*\* \*\*\*beta\*\*\* protein (A-beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
AU Tamaoka, Akira; Endoh, Riuko; Shoji, Shin'ichi; Takahashi, Hiroshi; Hirokawa, Katsuiku; Teplow, David B.; Selkoe, Dennis J.; Mori, Hiroshi [Reprint author]  
CS Dep. Molecular Biol., Tokyo Inst. Psychiatry, 2-1-8 Kamikitazawa, Setagayaku, Tokyo 156, Japan  
SO Neurobiology of Aging, (1996) Vol. 17, No. 3, pp. 405-414.  
CODEN: NEAGDO. ISSN: 0197-4580.  
DT Article  
LA English  
ED Entered STN: 26 Jul 1996  
Last Updated on STN: 26 Sep 1996

L4 ANSWER 12 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1995:537375 BIOSIS  
DN PREV199598551675  
TI Surface phosphorylation by ecto-protein kinase C in brain neurons: A target for Alzheimer's \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptides.  
AU Hogan, Michael V.; Pawlowska, Zofia; Yang, Hui-Ai; Kornecki, Elizabeth; Ehrlich, Yigal H. [Reprint author]  
CS Program Neurosci., CSI/CUNY, Building 6S, Room 320, 2800 Victory Blvd., Staten Island, NY 10314, USA  
SO Journal of Neurochemistry, (1995) Vol. 65, No. 5, pp. 2022-2030.  
CODEN: JONRA9. ISSN: 0022-3042.  
DT Article  
LA English  
ED Entered STN: 14 Dec 1995  
Last Updated on STN: 27 Jan 1996

L4 ANSWER 13 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1995:365811 BIOSIS  
DN PREV199598380111  
TI Differential binding of vascular cell-derived proteoglycans (Perlecan, Biglycan, Decorin, and Versican) to the \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* protein of Alzheimer's disease.  
AU Snow, Alan D. [Reprint author]; Kinsella, Michael G.; Parks, Esther; Sekiguchi, Raymond T.; Miller, John D.; Kimata, Koji; Wight, Thomas N.  
CS Dep. Pathology, Box 356480, Univ. Washington, Seattle, WA 98195-6480, USA  
SO Archives of Biochemistry and Biophysics, (1995) Vol. 320, No. 1, pp. 84-95.  
CODEN: ABBIA4. ISSN: 0003-9861.  
DT Article  
LA English  
ED Entered STN: 30 Aug 1995  
Last Updated on STN: 30 Aug 1995

L4 ANSWER 14 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1995:342263 BIOSIS  
DN PREV199598356563  
TI Intracellular A-beta-1-42 Aggregates Stimulate the Accumulation of Stable,

Transfected Cells.  
 AU Yang, Austin J.; Knauer, Mary; Burdick, Debra A.; Glabe, Charles [Reprint author]  
 CS Dep. Mol. Biol., Univ. California, Irvine, CA 92717, USA  
 SO Journal of Biological Chemistry, (1995) Vol. 270, No. 24, pp. 14786-14792.  
 CODEN: JBCHA3. ISSN: 0021-9258.  
 DT Article  
 LA English  
 ED Entered STN: 10 Aug 1995  
 Last Updated on STN: 13 Sep 1995

L4 ANSWER 15 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 1993:368684 BIOSIS  
 DN PREV199396054359  
 TI Alpha-1-Antichymotrypsin binding to Alzheimer A-beta peptides is sequence specific and induces fibril disaggregation in vitro.  
 AU Fraser, Paul E. [Reprint author]; Nguyen, Jack T.; McLachlan, Donald R.; Abraham, Carmela R.; Kirschner, Daniel A.  
 CS Centre Research Neurodegenerative Diseases, Tanz Neurosci. Building, Univ. Toronto, 6 Queen's Park Crescent West, Toronto, ON M5S 1A8, Canada  
 SO Journal of Neurochemistry, (1993) Vol. 61, No. 1, pp. 298-305.  
 CODEN: JONRA9. ISSN: 0022-3042.  
 DT Article  
 LA English  
 ED Entered STN: 6 Aug 1993  
 Last Updated on STN: 8 Aug 1993

L4 ANSWER 16 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 1993:255079 BIOSIS  
 DN PREV199395134254  
 TI Monoclonal \*\*\*antibody\*\*\* to beta peptide, recognizing amyloid deposits, neuronal cells and lipofuscin pigments in systemic organs.  
 AU Takahashi, Hiroshi; Utsuyama, Masanori; Kurashima, Chieri; Mori, Hiroshi; Hirokawa, Katsuiku [Reprint author]  
 CS Brain Res. Inst., University Tokyo, Japan  
 SO Acta Neuropathologica, (1993) Vol. 85, No. 2, pp. 159-166.  
 CODEN: ANPTAL. ISSN: 0001-6322.  
 DT Article  
 LA English  
 ED Entered STN: 21 May 1993  
 Last Updated on STN: 22 May 1993

L4 ANSWER 17 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 1993:252221 BIOSIS  
 DN PREV199395131396  
 TI Human \*\*\*antibodies\*\*\* reactive with \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* protein in Alzheimer's disease.  
 AU Gaskin, Felicia [Reprint author]; Finley, James; Fang, Qiang; Xu, Shihua; Fu, Shu Man  
 CS Dep. Psychiatry, Box 203, Univ. Virginia Health Sci. Cent., Charlottesville, VA 22908, USA  
 SO Journal of Experimental Medicine, (1993) Vol. 177, No. 4, pp. 1181-1186.  
 CODEN: JEMEA9. ISSN: 0022-1007.  
 DT Article  
 LA English  
 ED Entered STN: 21 May 1993  
 Last Updated on STN: 13 Jul 1993

L4 ANSWER 18 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
 AN 1991:274918 BIOSIS  
 DN PREV199192007533; BA92:7533  
 TI MORPHOLOGY AND \*\*\*ANTIBODY\*\*\* RECOGNITION OF SYNTHETIC \*\*\*BETA\*\*\* \*\*\*AMYLOID\*\*\* PEPTIDES.  
 AU FRASER P E [Reprint author]; DUFFY L K; O'MALLEY M B; NGUYEN J; INOUE H; KIRSCHNER D A  
 CS NEUROL RES, CHILDREN'S HOSPITAL, ENDERS 2, 320 LONGWOOD AVE, BOSTON, MASS 02115, USA  
 SO Journal of Neuroscience Research, (1991) Vol. 28, No. 4, pp. 474-485.  
 CODEN: JNREDK. ISSN: 0360-4012.  
 DT Article  
 FS BA

ED Entered STN: 13 Jun 1991  
Last Updated on STN: 13 Jun 1991

L4 ANSWER 19 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1991:51666 BIOSIS  
DN PREV199191029947; BA91:29947  
TI DEVELOPMENTAL AND AGING CHANGES IN THE EXPRESSION PATTERNS OF \*\*\*BETA\*\*\*  
\*\*\*AMYLOID\*\*\* IN THE BRAINS OF NORMAL AND DOWN SYNDROME CASES.  
AU TAKASHIMA S [Reprint author]; KURUTA H; MITO T; NISHIZAWA M; KUNISHITA T;  
TABIRA T  
CS DEP MENTAL RETARDATION BIRTH DEFECT RES, NATL INST NEUROSCI, NCNP, 4-1-1  
OGAWAHIGASHIMACHI, KODAIRA, TOKYO 187, JPN  
SO Brain and Development, (1990) Vol. 12, No. 4, pp. 367-371.  
ISSN: 0387-7604.  
DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 10 Jan 1991  
Last Updated on STN: 10 Jan 1991

L4 ANSWER 20 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
AN 2004-01358 BIOTECHDS  
TI Treating, preventing and/or diagnosing a condition related to  
\*\*\*Abeta\*\*\* expression, such as anxiety or mood disorders, including  
Alzheimer's disease, depression, and schizophrenia, by administering an  
anti- \*\*\*Abeta\*\*\* \*\*\*antibody\*\*\* to the subject;  
involving vector-mediated gene transfer and expression in host cell  
for use in gene therapy  
AU GERLAI R T  
PA LILLY and CO ELI  
PI WO 2003090772 6 Nov 2003  
AI WO 2003-US10473 17 Apr 2003  
PRAI US 2002-375462 25 Apr 2002; US 2002-375462 25 Apr 2002  
DT Patent  
LA English  
OS WPI: 2003-865528 [80]

L4 ANSWER 21 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
AN 2003-13421 BIOTECHDS  
TI Novel analog of amyloid precursor protein or \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* for treating Alzheimer's disease, has amyloid precursor  
protein/ \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* incorporating B-cell epitope of  
amyloid protein and foreign T-helper epitope;  
vector-mediated gene transfer and expression in host cell for  
recombinant vaccine and Alzheimer disease therapy  
AU RASMUSSEN P B; JENSEN M R; NIELSEN K G; KOEFOED P; DEGAN F D  
PA PHARMEXA AS  
PI WO 2003015812 27 Feb 2003  
AI WO 2002-DK547 20 Aug 2002  
PRAI US 2002-373027 16 Apr 2002; DK 2001-1231 20 Aug 2001  
DT Patent  
LA English  
OS WPI: 2003-312718 [30]

L4 ANSWER 22 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN  
AN 1994-12231 BIOTECHDS  
TI Monoclonal \*\*\*antibody\*\*\* specific for \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
or a derivative;  
prepared by hybridoma construction and useful for Alzheimer disease  
diagnosis and therapy  
PA Takeda-Chem.  
PI WO 9417197 4 Aug 1994  
AI WO 1994-JP89 24 Jan 1994  
PRAI JP 1993-334773 28 Dec 1993; JP 1993-10132 25 Jan 1993  
DT Patent  
LA Japanese  
OS WPI: 1994-264110 [32]

L4 ANSWER 23 OF 469 CANCERLIT on STN  
AN 97189236 CANCERLIT  
DN 97189236 PubMed ID: 9037507  
TI Preferential adsorption, internalization and resistance to degradation of  
the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in  
differentiated PC12 cells.

CS Department of Molecular Biology, University of California, Irvine 92697, USA.  
 NC AG00538 (NIA)  
 GM07311 (NIGMS)  
 NS31230 (NINDS)  
 SO BRAIN RESEARCH, (1997 Jan 23) 746 (1-2) 275-84.  
 Journal code: 0045503. ISSN: 0006-8993.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS MEDLINE; Priority Journals  
 OS MEDLINE 97189236  
 EM 199704  
 ED Entered STN: 19970618  
 Last Updated on STN: 19970618

L4 ANSWER 24 OF 469 CANCERLIT on STN  
 AN 96352571 CANCERLIT  
 DN 96352571 PubMed ID: 8717367  
 TI The helix-loop-helix transcription factor USF interacts with the basal promoter of human amyloid precursor protein.  
 AU Bourbonniere M; Nalbantoglu J  
 CS Department of Neurology and Neurosurgery, McGill University, Montreal, Que, Canada.  
 SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1996 Jan) 35 (1-2) 304-8.  
 Journal code: 8908640. ISSN: 0169-328X.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS MEDLINE; Priority Journals  
 OS MEDLINE 96352571  
 EM 199610  
 ED Entered STN: 19961106  
 Last Updated on STN: 19970509

L4 ANSWER 25 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:610650 CAPLUS  
 TI The SAMP8 mouse as a model for Alzheimer disease: Studies from Saint Louis University  
 AU Morley, J. E.; Banks, W. A.; Kumar, V. B.; Farr, S. A.  
 CS GRECC St. Louis VAMC, Saint Louis University, St. Louis, MO, USA  
 SO International Congress Series (2004), 1260 (Senescence-Accelerated Mouse (SAM)), 23-28  
 CODEN: EXMDA4; ISSN: 0531-5131  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English

L4 ANSWER 26 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:946065 CAPLUS  
 DN 138:38056  
 TI Mutant forms of cholera holotoxin as an adjuvant  
 IN Green, Bruce A.; Holmes, Randall K.; Jobling, Michael G.; Zhu, Duzhang  
 PA American Cyanamid Company, USA; Government of the United States of America as Represented by the Uniformed Services University of the Health Sciences  
 SO PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098369	A2	20021212	WO 2002-US21008	20020605
	WO 2002098369	A3	20030220		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1404279	A2	20040407	EP 2002-756368	20020605

1E, SI, LT, LV, FI, RO, MK, CY, AL, TR  
PRAI US 2001-296531P P 20010607  
WO 2002-US21008 W 20020605

L4 ANSWER 27 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:927177 CAPLUS

DN 138:23639

TI \*\*\*Amyloid\*\*\* . \*\*\*beta\*\*\* . peptide fragment linked to helper T  
cell epitope for prevention and treatment of Alzheimer's disease

IN Wang, Chang Yi

PA United Biomedical, Inc., USA

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096350	A2	20021205	WO 2002-US10293	20020402
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003068325	A1	20030410	US 2001-865294	20010525
PRAI	US 2001-865294	A	20010525		

L4 ANSWER 28 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:152212 CAPLUS

DN 135:134171

TI Sandwich-type enzyme immunoassay for amyloid A4 protein in cerebrospinal fluid from patients with head trauma

AU Pirim, Ibrahim

CS Department of Biochemistry, Ataturk University, Erzurum, 25240, Turk.

SO Turkish Journal of Medical Sciences (2001), 31(1), 47-50

CODEN: TJMEEA; ISSN: 1300-0144

PB Scientific and Technical Research Council of Turkey

DT Journal

LA English

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:511887 CAPLUS

DN 125:192578

TI Apolipoprotein E uptake is increased by \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptides and reduced by blockade of the LDL receptor

AU Beffert, Uwe; Aumont, Nicole; Dea, Doris; Davignon, Jean; Poirier, Judes

CS Douglas Hosp. Res. Cent., McGill Univ., Montreal, QC, H4H 1R3, Can.

SO Neurodegenerative Diseases: Molecular and Cellular Mechanisms and  
Therapeutic Advances, [Proceedings of the Washington International Spring  
Symposium], 15th, Washington, D. C., May 15-17, 1995 (1996), Meeting Date  
1995, 103-108. Editor(s): Fiskum, Gary. Publisher: Plenum, New York, N.  
Y.

CODEN: 63GLAO

DT Conference

LA English

L4 ANSWER 30 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:489436 CAPLUS

DN 125:139684

TI Inhibitory effect of monoclonal \*\*\*antibodies\*\*\* on Alzheimer's .  
\*\*\*beta\*\*\* . - \*\*\*amyloid\*\*\* peptide aggregation

AU Hanan, Eilat; Solomon, Beka

CS Faculty Life Sciences, Tel-Aviv University, Ramat Aviv, 69978, Israel

SO Amyloid (1996), 3(2), 130-133

CODEN: AIJJET; ISSN: 1350-6129

PB Parthenon Publishing

DT Journal

LA English

L4 ANSWER 31 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1994:577060 CAPLUS  
 DN 121:177060  
 TI The monoclonal \*\*\*antibody\*\*\* Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas  
 AU van de Nes, J. A. P.; Sluiter, A. A.; Pool, C. W.; Kamphorst, W.; Ravid, R.; Swaab, D. F.  
 CS Netherlands Institute for Brain Research, Amsterdam, Neth.  
 SO Brain Research (1994), 655(1-2), 97-109  
 CODEN: BRREAP; ISSN: 0006-8993  
 DT Journal  
 LA English

L4 ANSWER 32 OF 469 CIN COPYRIGHT 2004 ACS on STN  
 AN 25(10):10502V CIN  
 TI A Mab to prevent Alzheimer's disease and a connection to an apoptosis gene  
 SO Biotechnol. News, 9 Feb 1996 (960209), 16(4), p. 4. ISSN: 0273-3226;  
 CODEN: BINWEY.  
 LA English

L4 ANSWER 33 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAE35672 peptide DGENE  
 TI Novel peptide immunogen comprising a helper T cell epitope, an N-terminal fragment of \*\*\*amyloid\*\*\* \*\*\*beta\*\*\* peptide linked to the epitope, and optionally a spacer, useful for preventing or treating Alzheimer's disease -  
 IN Wang C Y  
 PA (UNBI-N) UNITED BIOMEDICAL INC.  
 PI WO 2002096350 A2 20021205 77p  
 AI WO 2002-US10293 20020402  
 PRAI US 2001-865294 20010525  
 DT Patent  
 LA English  
 OS 2003-201258 [19]  
 DESC Human \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* peptide (residues \*\*\*1\*\*\* - \*\*\*28\*\*\* ).

L4 ANSWER 34 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN ABP72693 Protein DGENE  
 TI Novel analog of amyloid precursor protein or \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* for treating Alzheimer's disease, has amyloid precursor protein/ \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* incorporating B-cell epitope of amyloid protein and foreign T-helper epitope -  
 IN Rasmussen P B; Jensen M R; Nielsen K G; Koefoed P; Degan F D  
 PA (PHAR-N) PHARMEXA AS.  
 PI WO 2003015812 A2 20030227 122p  
 AI WO 2002-DK547 20020820  
 PRAI DK 2001-1231 20010820  
 US 2001-337543P 20011022  
 DK 2002-558 20020416  
 US 2002-373027P 20020416  
 DT Patent  
 LA English  
 OS 2003-312718 [30]  
 CR N-PSDB: ABZ81991  
 DESC Human amyloid precursor protein.

L4 ANSWER 35 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82664 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

AN AAB82663 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 37 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82662 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 38 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82661 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 39 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82660 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 40 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82659 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.

AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 41 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82658 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's  
disease, comprises administering antigenic all-D peptide, e.g. as  
vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent  
fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 42 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82657 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's  
disease, comprises administering antigenic all-D peptide, e.g. as  
vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent  
fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 43 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82656 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's  
disease, comprises administering antigenic all-D peptide, e.g. as  
vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent  
fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 44 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82655 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's  
disease, comprises administering antigenic all-D peptide, e.g. as  
vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent  
fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.



L4 ANSWER 45 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82654 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 46 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82653 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 47 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82652 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 48 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82651 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 49 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82650 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F

PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 50 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82649 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 51 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82648 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 52 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82647 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 53 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82646 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]

L4 ANSWER 54 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82645 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 55 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82644 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 56 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82643 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 57 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82642 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
 IN Chalifour R; Hebert L; Kong X; Gervais F  
 PA (NEUR-N) NEUROCHEM INC.  
 PI WO 2001039796 A2 20010607 31p  
 AI WO 2000-CA1413 20001129  
 PRAI US 1999-168594 19991129  
 US 2000-724842 20001128  
 DT Patent  
 LA English  
 OS 2001-441458 [47]  
 DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 58 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAB82641 Peptide DGENE  
 TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -

PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 59 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82640 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 60 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82639 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 61 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82638 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 62 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82637 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English

DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 63 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82636 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 64 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82635 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 65 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82634 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 66 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82633 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 67 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82632 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent

IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 68 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82631 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 69 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82630 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 70 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82629 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 71 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82628 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent

OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 72 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82627 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 73 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82626 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 74 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82625 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 75 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82624 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 76 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82623 Peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as

ribriillogenesis and associated cellular toxicity -  
IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.  
PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128  
DT Patent  
LA English  
OS 2001-441458 [47]  
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 77 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
AN AAB82622 peptide DGENE  
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of \*\*\*antibodies\*\*\* to prevent fibrillogenesis and associated cellular toxicity -

IN Chalifour R; Hebert L; Kong X; Gervais F  
PA (NEUR-N) NEUROCHEM INC.

PI WO 2001039796 A2 20010607 31p  
AI WO 2000-CA1413 20001129  
PRAI US 1999-168594 19991129  
US 2000-724842 20001128

DT Patent

LA English

OS 2001-441458 [47]

DESC \*\*\*Amyloid\*\*\* - \*\*\*beta\*\*\* peptide.

L4 ANSWER 78 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN AAR60371 peptide DGENE

TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
PA (TAKE) TAKEDA CHEM IND LTD.

PI WO 9417197 A1 19940804 116p  
AI WO 1994-JP89 19940124  
PRAI JP 1993-10132 19930125  
JP 1993-19035 19930205  
JP 1993-286985 19931116  
JP 1993-334773 19931228

DT Patent

LA Japanese

OS 1994-264110 [32]

DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-16).

L4 ANSWER 79 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN AAR60370 peptide DGENE

TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
PA (TAKE) TAKEDA CHEM IND LTD.

PI WO 9417197 A1 19940804 116p  
AI WO 1994-JP89 19940124  
PRAI JP 1993-10132 19930125  
JP 1993-19035 19930205  
JP 1993-286985 19931116  
JP 1993-334773 19931228

DT Patent

LA Japanese

OS 1994-264110 [32]

DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (35-43).

L4 ANSWER 80 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN AAR60369 peptide DGENE

TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
PA (TAKE) TAKEDA CHEM IND LTD.

PI WO 9417197 A1 19940804 116p  
AI WO 1994-JP89 19940124  
PRAI JP 1993-10132 19930125



JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (25-35).

L4 ANSWER 81 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60368 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ).

L4 ANSWER 82 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60367 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-43).

L4 ANSWER 83 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60366 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-42).

L4 ANSWER 84 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60365 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent

OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-41).

L4 ANSWER 85 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60364 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* , such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228

DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-40).

L4 ANSWER 86 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60363 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* , such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228

DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-39).

L4 ANSWER 87 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60362 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* , such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228

DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (1-38).

L4 ANSWER 88 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAR60373 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* , such as Alzheimer's disease

IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228

DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (18-28).

AN AAR60372 peptide DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC \*\*\*Beta\*\*\* - \*\*\*amyloid\*\*\* (17-28).

L4 ANSWER 90 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAQ70434 DNA DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC Human amyloid precursor protein anti-sense oligonucleotide.

L4 ANSWER 91 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN AAQ70433 DNA DGENE  
 TI \*\*\*Antibodies\*\*\* recognising specific parts of \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* - can be used for diagnosis of diseases implicating  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*, such as Alzheimer's disease  
 IN Kitada C; Odaka A; Suzuki N  
 PA (TAKE) TAKEDA CHEM IND LTD.  
 PI WO 9417197 A1 19940804 116p  
 AI WO 1994-JP89 19940124  
 PRAI JP 1993-10132 19930125  
 JP 1993-19035 19930205  
 JP 1993-286985 19931116  
 JP 1993-334773 19931228  
 DT Patent  
 LA Japanese  
 OS 1994-264110 [32]  
 DESC Human amyloid precursor protein sense oligonucleotide.

L4 ANSWER 92 OF 469 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS  
 RESERVED. on STN  
 AN 97344335 EMBASE  
 DN 1997344335  
 TI Neuroimaging of vessel amyloid in Alzheimer's disease.  
 AU Friedland R.P.; Kalaria R.; Berridge M.; Miraldi F.; Hedera P.; Reno J.;  
 Lyle L.; Marotta C.A.  
 CS R.P. Friedland, Department of Neurology, Case Western Reserve, University  
 School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, United  
 States. rpf2@po.cwru.edu  
 SO Annals of the New York Academy of Sciences, (1997) 826/- (242-247).  
 Refs: 30  
 ISSN: 0077-8923 CODEN: ANYAA  
 CY United States  
 DT Journal; Conference Article  
 FS 008 Neurology and Neurosurgery  
 023 Nuclear Medicine  
 037 Drug Literature Index  
 LA English  
 SL English

L4 ANSWER 93 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN

T1 SOLUBLE CYCLIC ANALOGUES OF \*\*\*BETA\*\*\* \*\*\*AMYLOID\*\*\* PEPTIDE  
 IN Bernhagen Jorgen (DE); Brunner Herwig (DE); Kapurniotu Afroditi (DE)  
 PA Unassigned Or Assigned To Individual (68000)  
 PI US 2004116337 A1 20040617  
 AI US 2001-250581 20011221  
 WO 2001-EP15181 20011221  
 20011221 PCT 371 date  
 20011221 PCT 102(e) date  
 PRAI DE 2001-101014309 20010113  
 FI US 2004116337 20040617  
 DT Utility; Patent Application - First Publication  
 FS CHEMICAL  
 APPLICATION  
 CLMN 25  
 GI 2 Figure(s).  
 FIGS. 1 and 2 show electron micrographs of the fibril-forming behavior of  
 c beta-AP128 (1A), beta-AP ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ) (1B), (Lys17,  
 Asp21) beta-AP ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ) (linear control peptide) (1C)  
 and betaAP ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ) (2A) and a 1:1 mixtures of beta-AP  
 ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ) and c beta-AP128 (2B).  
 FIG. 3 shows schematically the structure of a peptide having an  
 intramolecular bridge according to the invention and of the linear  
 control peptide.

L4 ANSWER 94 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 10323911 IFIPAT;IFIUDB;IFICDB  
 TI IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF  
 ALZHEIMER'S DISEASE; A PEPTIDE IMMUNOGEN OF ABOUT 20 TO 100 AMINO ACIDS  
 LONG COMPRISING: A HELPER T CELL (TH) EPITOPE, AN N-TERMINAL FRAGMENT OF  
 A BETA 1-42 PEPTIDE, CONSISTING FROM 10-28 AMINO ACID RESIDUES  
 IN Wang Chang Yi  
 PA Unassigned Or Assigned To Individual (68000)  
 PI US 2003068325 A1 20030410  
 AI US 2001-865294 20010525  
 FI US 2003068325 20030410  
 DT Utility; Patent Application - First Publication  
 FS CHEMICAL  
 APPLICATION  
 CLMN 80  
 GI 2 Figure(s).  
 FIGS. 1a, 1b, 1c, 1d, 1e and 1f are photographs showing Immunoperoxidase  
 staining of serial sections from 2 AD brains, using Avidin-Biotinylated  
 \*\*\*Antibody\*\*\* Complex (ABC) method with immune and preimmune sera at  
 1:100 dilution under 10 x magnification. FIGS. 1a, and 1d show  
 significant binding of \*\*\*antibodies\*\*\* to both senile plaques and A  
 beta plaques (both labelled as "P") on thioflavine S positive blood  
 vessels (labelled as "BV"). The \*\*\*antibodies\*\*\* were generated in  
 guinea pigs using A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* -epsilon K-MVF Th1-16  
 (SEQ ID NO:74) prepared in ISA51 water-in-oil emulsion. FIGS. 1b and 1e  
 show the cross reactivity of \*\*\*antibodies\*\*\* raised against the same  
 peptide immunogen in CFA/ICFA. FIGS. 1c and 1f show brain sections using  
 preimmune sera.  
 FIGS. 2a, 2b, 2c, 2d, and 2e are photographs showing Immunoperoxidase  
 staining of serial sections of AD brain with immune and preimmune sera at  
 1:100 dilution and under 40 x magnification. FIGS. 2a and 2d showed that  
 the \*\*\*antibodies\*\*\* in guinea pigs immunized with A beta \*\*\*1\*\*\*  
 - \*\*\*28\*\*\* -epsilon K-MVF Th-1-16 (SEQ ID NO:74) prepared in ISA51  
 water-in-oil emulsion strongly stained the plaques (P) forming a pattern  
 of cores. FIG. 2b is a photograph of the staining pattern of AD pig brain  
 sections using the same immunogen in CFA/ICFA formulation. The anti-sera  
 reacted predominantly with plaques on the blood vessels (BV). FIG. 2c is  
 a photograph of a guinea pig brain section with preimmune serum and  
 showed no staining. FIG. 2e shows the brain section with hyperimmune sera  
 generated by immunization with A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* peptide  
 alone in CFA/ICFA showing a surprisingly weak staining pattern despite  
 the strong reactivity with A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* by ELISA.

L4 ANSWER 95 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 10016325 IFIPAT;IFIUDB;IFICDB  
 TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO  
 NEURONS; PREVENTION COMPLEXING  
 IN GIULIAN DANA  
 PA Unassigned Or Assigned To Individual (68000)  
 PPA Baylor College of Medicine (Probable)  
 PI US 2001016327 A1 20010823

RL1 US 1996-717551 19960920 DIVISION 6071493  
FI US 2001016327 20010823  
US 6071493  
US 6475742 20021105  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
CLMN 99  
GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorecamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50 = 10  $\mu$ M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from human brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorecamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for HLA-DR(+) microglial clusters (scored as mean number of clusters per mm<sup>2</sup> in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0.0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Nissl stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0  $\mu$ l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of human embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, DiI-ac-LDL Bar=40  $\mu$ m, FIG. 7A; 25  $\mu$ M FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding

there is a 5-fold increase in receptor mRNA surrounding the SpheraA beta 1-42 when compared to undamaged control tissue or SpheraBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with DiI-ac-LDL (0.5 nmoles injected). FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1.0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar= 30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10  $\mu$ M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100  $\mu$ M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100  $\mu$ M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal injury. Importantly, this protective effect did not occur with quinolinic acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MAP 2 \*\*\*antibodies\*\*\* found in control hippocampal cultures (1,200 cells per  $\text{mm}^2$ ) that were supplemented with microglia (500 per  $\text{mm}^2$ ). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic human A beta 1-42 (1  $\mu$  mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar= 20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to human A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the N-terminus of the peptide (A beta 1-11, A beta 1-16, and A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* ) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1  $\mu$  mole/l) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM) modification of Tyr10; diethylpyrocarbonate (DEPC) modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10  $\mu$  moles/l). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BsA (which bind to scavenger receptors) or Spheres A beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive

(chondroitinase ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either Spheres A beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased Spheres A beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50  $\mu$ g/ml) or A beta 1-16 (10  $\mu$ moles/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500  $\mu$ g/ml) or acetylated LDL (ac-LDL, 200  $\mu$ g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mM), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation. FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1  $\mu$ moles/l) in solution and or Spheres A beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10  $\mu$ moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta. Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of \*\*\*beta\*\*\* -

\*\*\*Amyloid\*\*\* peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 to bind to Spheres A beta 1-42, the ability of A beta 1-42 to induce microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA= not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIGS. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar= 25  $\mu$ m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values  $\pm$  standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400  $\mu$ moles/l) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10  $\mu$ m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta.

FIGS. 20A-E displays soluble fractions of native plaques induce microglial



exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta. As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar= 25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar= 5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/l on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm<sup>2</sup> when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta. These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED<sub>50</sub> of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm<sup>2</sup>; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/l A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) hippocampal neurons (FIG. 22B) that are undamaged after addition of conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/l A beta 1-42 (FIG. 22F). Bar= 25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm<sup>2</sup>). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43-microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar= 20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm<sup>2</sup>) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuron-specific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodendroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIG. 24E and 24G, respectively). Bar= 10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+ A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays human microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmoles/l), S4 (220 mu mole/l), and S5 (250 mu mole/l)) elicit human microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40



microglia, while smaller AP fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by human cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by human or rat microglia exposed to 1  $\mu$  mole/liter of the human forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of human A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and human microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1  $\mu$  mole/l A beta 1-42 (Rat/A beta 1-42) and human cells with fraction S5 (containing 250  $\mu$  mole/l of native A beta 1-42) from solubilized neuritic/core plaques (Human/S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100  $\mu$  M; catalase, 25 units/ml; glutathione, 100  $\mu$  M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10  $\mu$  M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (A beta 7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10  $\mu$  M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH2O with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A shows a phase photomicrograph of rat microglial cell adhering to Sepharose bead coupled to human A beta 1-42 peptides. FIG. 27B shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker DiI-ac-LDL; Bar= 20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* also promoted bead binding, while A beta 17-43 did not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm<sup>2</sup>) after 4 hour incubation at 37 degrees C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the N-terminus-containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between human and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 96 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 10016324 IFIPAT;IFIUDB;IFICDB  
 TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO  
 NEURONS; PREVENTION COMPLEXING  
 IN GIULIAN DANA  
 PA Unassigned Or Assigned To Individual (68000)  
 PPA Baylor College of Medicine (Probable)  
 PI US 2001016326 A1 20010823

RL1 US 1996-717551 19960920 DIVISION 6071493  
FI US 2001016326 20010823  
US 6071493  
US 6451544 20020917  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
CLMN 99  
GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorecamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50=10  $\mu$ M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from human brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorecamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for HLA-DR(+) microglial clusters (scored as mean number of clusters per mm<sup>2</sup> in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0.0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Nissl stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0  $\mu$ l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of human embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, Dil-ac-LDL Bar=40  $\mu$ m, FIG. 7A; 25  $\mu$ m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding

there is a 5-fold increase in receptor mRNA surrounding the SpheraA beta 1-42 when compared to undamaged control tissue or SpheraBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with Dil-ac-LDL (0.5 nmoles injected). FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1.0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar=30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10  $\mu$ M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100  $\mu$ M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100  $\mu$ M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal injury. Importantly, this protective effect did not occur with quinolinic acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MA beta 2

\*\*\*antibodies\*\*\* found in control hippocampal cultures (1,200 cells per mm<sup>2</sup>) that were supplemented with microglia (500 per mm<sup>2</sup>). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic human A beta 1-42 (1  $\mu$ M) for 72 hours resulting in a dramatic loss of neurons (Bar=20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to human A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the N-terminus of the peptide (A beta 1-11, A beta 1-16, and A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* ) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1  $\mu$ M) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)-modification of Tyr10; diethylpyrocarbonate (DEPC)-modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10  $\mu$ M). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. SpheresA beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of

lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either SpheresA beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50  $\mu$ g/ml) or A beta 1-16 (10  $\mu$ moles/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500  $\mu$ g/ml) or acetylated LDL (ac-LDL, 200  $\mu$ g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mM), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1  $\mu$ moles/l) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10  $\mu$ moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta. Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of \*\*\*beta\*\*\* -  
\*\*\*Amyloid\*\*\* peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 to bind to SpheresA beta 1-42, the ability of A beta 1-42 to induce microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA=not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIG. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar=25  $\mu$ m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values  $\pm$  standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400  $\mu$ moles/l) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10  $\mu$ m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta.

FIGS. 20A-E displays soluble fractions of native plaques induce microglial

exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta. As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar =25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar=5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/l on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm<sup>2</sup> when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta. These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED<sub>50</sub> of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm<sup>2</sup>; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/l A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) hippocampal neurons (FIG. 22B) that are undamaged after addition of conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/l A beta 1-42 (FIG. 22F). Bar =25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm<sup>2</sup>). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43-microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar=20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm<sup>2</sup>) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuron-specific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodendroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIGS. 24E and 24G, respectively). Bar=10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays human microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/l), S4 (220 nmole/l), and S5 (250 nmole/l)) elicit human microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40 and



while smaller A beta fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by human cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by human or rat microglia exposed to 1 mu mole/liter of the human forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of human A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and human microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 mu mole/l A beta 1-42 (Rat/A beta 1-42) and human cells with fraction S5 (containing 250 nmole/l of native A beta 1-42) from solubilized neuritic/core plaques (Human/S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100 mu M; catalase, 25 units/ml; glutathione, 100 mu M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10 mu M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (AP7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 mu M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH2O with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A shows a phase photomicrograph of rat microglial cell adhering to Sepharose bead coupled to human A beta 1-42 peptides. FIG. 27B shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker Dil-ac-LDL; Bar=20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta \*\*\*1\*\*\* - \*\*\*28\*\*\* also promoted bead binding, while A beta 17-43 did not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm2) after 4 hour incubation at 37 C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the N-terminus-containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between human and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 97 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN  
AN 04045610 IFIPAT;IFIUDB;IFICDB  
TI DISCORDANT HELIX STABILIZATION FOR PREVENTION OF AMYLOID FORMATION  
IN Johansson Jan (SE)  
PI US 6716589 B2 20040406  
US 2002143105 A1 20021003  
AI US 2001-988842 20011119  
PRAI US 2000-251662P 20001206 (Provisional)

F1 US 6716589 20040406  
 US 2002143105 20021003  
 DT Utility; Granted Patent - Utility, with Pre-Grant Publication  
 FS CHEMICAL  
 GRANTED  
 MRN 012778 MFN: 0340  
 CLMN 26  
 GI 14 Drawing Sheet(s), 20 Figure(s).

FIG. 1 is a bar graph that depicts the occurrence of alpha-helical segments with high beta-strand propensities. The number of protein segments are plotted versus the lengths of the segments for which experimentally determined alpha-helices coincide with beta-strands predicted with a PHD reliability index greater-than-or-equals 5 for all residues. The PDB codes are given for the proteins from which the helices with greater-than-or-equals 7 residues emanate. Codes in bold identify proteins that form amyloid fibrils in vivo, and italics denote proteins shown to form fibrils. The outcome of predictions for prion proteins from human (hPrP) and mouse (mPrP) are indicated. The PDB codes represent, in alphabetical order: 1aa0=fibrin deletion mutant (Bacteriophage T4), 1aura=carboxylesterase (*Pseudomonas fluorescens*), 1b10(sPrP)=prion protein (Syrian hamster), 1b2va=heme-binding protein A (*Serratia marcescens*), 1b5ea=dCMP hydroxymethylase (Bacteriophage T4), 1b8oa=purine nucleoside phosphorylase (*Bos taurus*), 1ba6= **\*\*\*beta\*\*\*** **\*\*\*amyloid\*\*\*** protein (*Homo sapiens*), 1bct=bacteriorhodopsin (*Halobacterium halobium*), 1b11=parathyroid hormone receptor (*Homo sapiens*), 1cpo=chloroperoxidase (*Leptoxiphium fumago*), 1cv8=staphopain (*Staphylococcus aureus*), 1ecra=replication terminator protein (*Escherichia coli*), 1ggtb=coagulation factor XIII (*Homo sapiens*), 1h2as=hydrogenase (*Desulfovibrio vulgaris*), 1iab=astacin (*Astacus astacus*), 1jkmb=brefeldin A esterase (*Bacillus subtilis*), 1kpta=killer toxin (*Ustilago maydis*), 1lml=leishmanolysin (*Leishmania major*), 1mhdb=smad MH1 domain (*Homo sapiens*), 1mma=transcription factor MVM1 (*Saccharomyces cerevisiae*), 1mtyd=methane monooxygenase (*Methylococcus capsulatus*), 1nom=DNA polymerase beta (*Rattus norvegicus*), 1noza=DNA polymerase (Bacteriophage T4), 1pbv=sec7 domain of exchange factor ARNO (*Homo sapiens*), 1quta=lytic transglycosylase Slt35 (*Escherichia coli*), 1smd=salivary amylase (*Homo sapiens*), 1spf (SP-C)=surfactant-associated protein C (*Sus scrofa*), 1sra=osteonectin (*Homo sapiens*), 1taha=lipase (*Burkholderia glumae*), 1tca=lipase B (*Candida antarctica*), 1vns=chloroperoxidase (*Curvularia inaequalis*), 1wer=Ras-GTPase-activating domain of p120GAP (*Homo sapiens*), 2er1=pheromone Er1 (*Eurplotes raikovi*), 2ifo=inovirus (*Xanthomonas oryzae*), 2occk=cytochrome C oxidase (*Bos taurus*), 2sqca=squalene-hopene cyclase (*Alicyclobacillus acidocaldarius*), 3aig=adamalysin II (*Crotalus adamanteus*), 3pte=transpeptidase (*Xstreptomyces R61*).

FIGS. 2A-2B are a set of diagrams that depict the characteristics of long discordant helix segments. Amino acid sequences, together with determined and predicted secondary structure elements for sequences having greater-than-or-equals 9-residue discordant segments are shown. Also shown are those discordant segments of A beta, mouse PrP, and human PrP. The proteins are grouped by the length of their discordant stretch. The experimentally determined helical segments are drawn as blue cylinders in the bottom row of each case in which the amino acid sequences and residue positions in the PDB entries of the corresponding proteins are given (Top to bottom in each set: Set 16 contains SEQ ID NOS:4-6; Set 15 contains SEQ ID NOS:7 and 8; Set 8 contains SEQ ID NO:9; Set 13 contains SEQ ID NOS:10 and 11; Set 12 contains SEQ ID NOS:12 and 13; Set 10 contains SEQ ID NOS:14 and 15; Set 11 contains SEQ ID NOS:16-18; Set 9 contains SEQ ID NOS: 19-20 (top row left to right) and 21-23 (bottom row left to right)). The locations of the beta -strands predicted by PHD are visualized by yellow strands in the middle row of each case, wherein the reliability index for each residue is shown. The Chou-Fasman-based predictions averaged for 6-residue segments are plotted above residue 3 in each segment and given in the top row of each case. E and e denote extended structures (i.e., beta-strands) predicted with high and low probability, respectively, as in Chou and Fasman (1978, Adv. Enzymol. 47:45-148), and H and h represent predicted helical structures in an analogous manner.

FIG. 3 is a diagram that depicts the amino acid sequence (bottom row; SEQ ID NO:24) and predicted secondary structure by PHD and according to Chou-Fasman analysis for a polyleucine analogue of SP-C (lung surfactant protein C). The PHD predictions including reliability indices are given in the middle row and the ChouFasman data in the top row, but in this case an alpha-helix is predicted by both methods, symbolized by a blue cylinder for the PHD prediction.

FIG. 4 is a graph that depicts data from an experiment in which the relative amounts of SP-C(squares) and SP-C(Leu) (triangles) remaining in

time points after solubilization were measured.

FIG. 5 is a set of diagrams that depict the experimentally determined and predicted secondary structures of positions \*\*\*1\*\*\* - \*\*\*28\*\*\* of A beta (SEQ ID NO:25; top) and a variant of A beta (\*\*\*1\*\*\* - \*\*\*28\*\*\* ) in which three residues have been changed to alanine (K16A, L17A, F20A) (SEQ ID NO:26; bottom). Symbols are as described for FIGS. 2 and 4.

FIGS. 6A-6C are graphs depicting the effects various tripeptides on fibril formation by A beta (14-23) (FIG. 6A), A beta (12-24) (FIG. 6B), and A beta (1-40) (FIG. 6C). Unless otherwise indicated, the tripeptides have free N- and C-termini. The results are representative for two to three independent experiments.

FIG. 7 is a graph depicting the effects of various tripeptides and tetrapeptides on fibril formation by A beta (14-23).

FIG. 8 is a graph depicting the effects of the peptides KAD, AAA, and KFFE (SEQ ID NO:1) on A beta (1-40) aggregation. Samples were analyzed in duplicate.

FIGS. 9A-9E depict the fibrillar structures of A beta (1-40) formed in the absence of tripeptide (9A), in the presence of KAD (9B), acetyl-KAD-amide (9C), AAA (9D), or acetyl-AAA-amide (9E).

FIG. 10 depicts the KAD peptide in an energy-minimized conformation (top structure), the KAD peptide in an extended conformation (middle structure), and the KFFE (SEQ ID NO:1) peptide in an extended conformation (bottom structure). The amino and carboxyl groups of the charged side-chains are on the same side of the polypeptide backbone in KAD and the distances between them are then shown. In KFFE, the charged side-chains are on opposite sides of the polypeptide backbone.

FIG. 11A depicts the charge separation of A beta (15-23) in alpha-helical and beta-strand conformations. The figure shows the A beta (15-23) region in helical conformation, symbolized by the cylinder. The charged side-chains Lys16, Glu22 and Asp23 are shown.

FIG. 11B depicts the charge separation of A beta (15-23) in alpha-helical and beta-strand conformations. The A beta (1523) region is modeled in beta-strand/extended conformation, indicated by the wavy strand. The charged side-chains are shown. For the helical conformation, the distances between the epsilon-amino group of Lys16 and the gamma-carboxyl group of Glu22 and the beta-carboxyl group of Asp23 are shown, and for the extended conformation the Lys16-Glu22 distance is indicated.

FIG. 12 is a model of A beta fibril formation and the associated effects of helix-stabilizing agents. The upper row depicts the transformations that helical A beta peptides are thought to undergo to form beta-sheet fibrils. Monomeric A beta in aqueous solution is structurally disordered (i.e. it interconverts between different structures including alphahelical and beta-strand conformations) and A beta in extended conformation will be able to polymerize via the formation of intermolecular contacts in beta-sheets. Compounds that can interact preferentially with helical A beta (here represented by the doubly charged ligand) will shift the equilibrium from the extended conformation and thereby reduce formation of fibrils. The cylinder represents the helix centered around residues 16-23 of A beta and the + and - signs represent Lys16 and Glu22/Asp23, respectively.

L4 ANSWER 98 OF 469 JICST-Eplus COPYRIGHT 2004 JST on STN  
 AN 920642317 JICST-Eplus  
 TI Immunohistochemical Studies on Canine Cerebral Amyloid Angiopathy and Senile Plaques.  
 AU UCHIDA K; TANI Y; UETSUKA K; NAKAYAMA H; GOTO N  
 CS Univ. Tokyo, Tokyo, JPN  
 SO J Vet Med Sci, (1992) vol. 54, no. 4, pp. 659-667. Journal Code: F0905A (Fig. 14, Tbl. 2, Ref. 35)  
 ISSN: 0916-7250  
 CY Japan  
 DT Journal; Article  
 LA English  
 STA New

L4 ANSWER 99 OF 469 MEDLINE on STN  
 AN 2004243118 MEDLINE  
 DN PubMed ID: 14985339  
 TI Copper depletion down-regulates expression of the Alzheimer's disease \*\*\*amyloid\*\*\* - \*\*\*beta\*\*\* precursor protein gene.  
 AU Bellingham Shayne A; Lahiri Debomoy K; Maloney Bryan; La Fontaine Sharon; Multhaup Gerd; Camakaris James  
 CS Department of Genetics, The University of Melbourne, Parkville, Victoria 3010, Australia.  
 NC AG 18739 (NIA)



SO Journal of biological chemistry, (2004 May 7) 279 (19) 20378-86.  
 CY Journal code: 2985121R. ISSN: 0021-9258.  
 DT United States  
 LA Journal; Article; (JOURNAL ARTICLE)  
 FS English  
 EM Priority Journals  
 ED 200406  
 Entered STN: 20040515  
 Last Updated on STN: 20040616  
 Entered Medline: 20040615

L4 ANSWER 100 OF 469 MEDLINE on STN  
 AN 96067122 MEDLINE  
 DN PubMed ID: 7588622  
 TI Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence.  
 AU De Strooper B; Simons M; Multhaup G; Van Leuven F; Beyreuther K; Dotti C G  
 CS Cell Biology Program, European Molecular Biology Laboratory, Heidelberg, Germany.  
 SO EMBO journal, (1995 Oct 16) 14 (20) 4932-8.  
 CY Journal code: 8208664. ISSN: 0261-4189.  
 DT ENGLAND: United Kingdom  
 LA Journal; Article; (JOURNAL ARTICLE)  
 FS English  
 EM Priority Journals  
 ED 199512  
 Entered STN: 19960124  
 Last Updated on STN: 19980206  
 Entered Medline: 19951221

L4 ANSWER 101 OF 469 MEDLINE on STN  
 AN 90099541 MEDLINE  
 DN PubMed ID: 2513586  
 TI A study of beta protein precursor using antiserum against a synthetic peptide ( \*\*\*1\*\*\* - \*\*\*28\*\*\* ).  
 AU Harigaya Y; Shoji M; Yamaguchi H; Hirai S; Takatama M  
 CS Department of Neurology, Gunma University School of Medicine, Japan.  
 SO Progress in clinical and biological research, (1989) 317 945-52.  
 CY Journal code: 7605701. ISSN: 0361-7742.  
 DT United States  
 LA Journal; Article; (JOURNAL ARTICLE)  
 FS English  
 EM Priority Journals  
 ED 199001  
 Entered STN: 19900328  
 Last Updated on STN: 19980206  
 Entered Medline: 19900131

L4 ANSWER 102 OF 469 MEDLINE on STN  
 AN 88138281 MEDLINE  
 DN PubMed ID: 3277908  
 TI Immunohistochemical study of cerebral amyloid angiopathy: use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor.  
 AU Vinters H V; Pardridge W M; Yang J  
 CS Department of Pathology, UCLA Medical Center 90024.  
 SO Human pathology, (1988 Feb) 19 (2) 214-22.  
 CY Journal code: 9421547. ISSN: 0046-8177.  
 DT United States  
 LA Journal; Article; (JOURNAL ARTICLE)  
 FS English  
 EM Priority Journals  
 ED 198803  
 Entered STN: 19900308  
 Last Updated on STN: 19980206  
 Entered Medline: 19880328

L4 ANSWER 103 OF 469 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.  
 on STN  
 AN 96:700116 SCISEARCH  
 GA The Genuine Article (R) Number: VH858  
 TI SPECIFIC DOMAINS OF \*\*\*BETA\*\*\* - \*\*\*AMYLOID\*\*\* FROM ALZHEIMER PLAQUE  
 ELICIT NEURON KILLING IN HUMAN MICROGLIA  
 AU GIULIAN D (Reprint); HAVERKAMP L J; YU J H; KARSHIN W; TOM D; LI J;

CS BAYLOR COLL MED, DEPT NEUROL, ALZHEIMERS DIS RES CTR, HOUSTON, TX, 77030  
(Reprint); BAYLOR COLL MED, DEPT PATHOL, ALZHEIMERS DIS RES CTR, HOUSTON,  
TX, 77030; SUN HLTH RES INST, HALDERMAN LAB ALZHEIMERS DIS RES, SUN CITY,  
AZ, 85351

CYA USA

SO JOURNAL OF NEUROSCIENCE, (01 OCT 1996) Vol. 16, No. 19, pp. 6021-6037.  
ISSN: 0270-6474.

DT Article; Journal

FS LIFE

LA ENGLISH

REC Reference Count: 73  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L4 ANSWER 104 OF 469 USPATFULL on STN

AN 2004:215966 USPATFULL

TI Inhibitors of Memapsin 2 and use thereof

IN Tang, Jordan J. N., Edmond, OK, UNITED STATES  
Ghosh, Arun K., River Forest, IL, UNITED STATES

PA Oklahoma Medical Research Foundation, Oklahoma City, OK, UNITED STATES  
(U.S. corporation)  
The Board of Trustees of the University of Illinois, Urbana, IL, UNITED  
STATES (U.S. corporation)

PI US 2004167075 A1 20040826

AI US 2004-820953 A1 20040408 (10)

RLI Continuation of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING

PRAI US 1999-141363P 19990628 (60)  
US 1999-168060P 19991130 (60)  
US 2000-177836P 20000125 (60)  
US 2000-178368P 20000127 (60)  
US 2000-210292P 20000608 (60)

DT Utility

FS APPLICATION

LN.CNT 2388

INCL INCLM: 514/014.000  
INCLS: 530/326.000

NCL NCLM: 514/014.000  
NCLS: 530/326.000

IC [7]  
ICM: A61K038-10  
ICS: C07K007-08

L4 ANSWER 105 OF 469 USPATFULL on STN

AN 2004:211476 USPATFULL

TI Polynucleotide encoding neuromedin U receptor

IN Harland, Lee, Kent, UNITED KINGDOM

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6780611 B1 20040824

AI US 2000-684725 20001006 (9)

PRAI GB 1999-23888 19991008

DT Utility

FS GRANTED

LN.CNT 3220

INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500

NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500

IC [7]  
ICM: C12N015-00  
ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04

EXF 536/23.5; 536/23.1; 536/24.3; 435/320.1; 435/325; 435/252.3; 435/254.11;  
435/254.2; 435/69.1; 435/254.1; 435/455

L4 ANSWER 106 OF 469 USPATFULL on STN

AN 2004:203958 USPATFULL

TI Novel heterocyclic derivatives

IN Kakihana, Mitsuru, Hyogo, JAPAN  
Kato, Kaneyoshi, Hyogo, JAPAN  
Mori, Masaaki, Ibaraki, JAPAN  
Yamashita, Toshiro, Ibaraki, JAPAN

PI US 2004157850 A1 20040812

AI US 2003-474963 A1 20031016 (10)  
WO 2002-JP4148 20020425

PRAI JP 2001-128677 20010426  
JP 2002-43523 20020220

DT Utility

LN.CNT 5569  
INCL INCLM: 514/249.000  
INCLS: 514/314.000; 544/349.000; 546/167.000  
NCL NCLM: 514/249.000  
NCLS: 514/314.000; 544/349.000; 546/167.000  
IC [7]  
ICM: C07D043-04  
ICS: C07D041-04; A61K031-498; A61K031-4709  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 469 USPATFULL on STN  
AN 2004:197463 USPATFULL  
TI Modified carbamate-containing prodrugs and methods of synthesizing same  
IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES  
Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES  
Dyakonov, Tatyana A., Durham, NC, UNITED STATES  
PI US 2004152769 A1 20040805  
AI US 2003-703647 A1 20031107 (10)  
PRAI US 2002-424796P 20021109 (60)  
US 2003-483676P 20030630 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2938  
INCL INCLM: 514/478.000  
INCLS: 514/615.000; 514/114.000  
NCL NCLM: 514/478.000  
NCLS: 514/615.000; 514/114.000  
IC [7]  
ICM: A61K031-66  
ICS: A61K031-325; A61K031-16  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 469 USPATFULL on STN  
AN 2004:190681 USPATFULL  
TI Aspartyl protease inhibitors  
IN Yang, Wenjin, Foster City, CA, UNITED STATES  
PI US 2004147454 A1 20040729  
AI US 2003-731922 A1 20031210 (10)  
RLI Continuation-in-part of Ser. No. US 2003-462127, filed on 16 Jun 2003,  
PENDING  
PRAI WO 2003-US18858 20030616  
US 2002-430693P 20021203 (60)  
US 2002-389194P 20020617 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4176  
INCL INCLM: 514/019.000  
INCLS: 514/357.000; 514/408.000; 546/335.000; 546/336.000; 548/567.000  
NCL NCLM: 514/019.000  
NCLS: 514/357.000; 514/408.000; 546/335.000; 546/336.000; 548/567.000  
IC [7]  
ICM: A61K038-04  
ICS: C07D213-56; A61K031-44; A61K031-40; C07D207-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 469 USPATFULL on STN  
AN 2004:190160 USPATFULL  
TI 94 human secreted proteins  
IN Ruben, Steven M., Brookeville, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Young, Paul, Gaithersburg, MD, UNITED STATES  
Florence, Kimberly, Rockville, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Mucenski, Michael, Cincinnati, OH, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Olsen, Henrik, Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Moore, Paul A., North Bethesda, MD, UNITED STATES  
Komatsoulis, George, Silver Spring, MD, UNITED STATES

PI US 2004146930 A1 20040729  
AI US 2004-800834 A1 20040316 (10)  
RLI Division of Ser. No. US 2002-115123, filed on 4 Apr 2002, PENDING  
Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, GRANTED, Pat.  
No. US 6475753 Continuation-in-part of Ser. No. WO 1999-US13418, filed  
on 15 Jun 1999, PENDING  
PRAI US 1998-89507P 19980616 (60)  
US 1998-89508P 19980616 (60)  
US 1998-89509P 19980616 (60)  
US 1998-89510P 19980616 (60)  
US 1998-90112P 19980622 (60)  
US 1998-90113P 19980622 (60)

DT Utility  
FS APPLICATION

LN.CNT 18341

INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;  
530/388.100

NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;  
530/388.100

IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 469 USPATFULL on STN

AN 2004:184612 USPATFULL

TI Methods for analysis of spectral data and their applications:  
atherosclerosis/coronary heart disease

IN Nicholson, Jeremy Kirk, London, UNITED KINGDOM  
Holmes, Elaine, London, UNITED KINGDOM  
Lindon, John Christopher, London, UNITED KINGDOM  
Brindle, Joanne Tracey, London, UNITED KINGDOM  
Grainger, David John, Cambridge, UNITED KINGDOM

PI US 2004142496 A1 20040722  
AI US 2003-475573 A1 20031022 (10)  
WO 2002-GB1854 20020423

PRAI GB 2001-9930 20010423  
GB 2001-17428 20010717

DT Utility  
FS APPLICATION

LN.CNT 5700

INCL INCLM: 436/536.000  
INCLS: 600/410.000

NCL NCLM: 436/536.000  
NCLS: 600/410.000

IC [7]  
ICM: A61B005-05  
ICS: G01N033-536

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 469 USPATFULL on STN

AN 2004:184452 USPATFULL

TI Method for determining skin stress or skin ageing in vitro

IN Petersohn, Dirk, Koeln, GERMANY, FEDERAL REPUBLIC OF  
Conradt, Marcus, Pretoria, SOUTH AFRICA

Hofmann, Kay, Koeln, GERMANY, FEDERAL REPUBLIC OF

PI US 2004142335 A1 20040722  
AI US 2003-450797 A1 20030917 (10)  
WO 2001-EP15178 20011220

PRAI DE 2001-100121 20010103

DT Utility  
FS APPLICATION

LN.CNT 11268

INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000

IC [7]  
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 469 USPATFULL on STN

AN 2004:184069 USPATFULL

TI Death domain containing receptor 5

IN Ni, Jian, Rockville, MD, UNITED STATES

yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)  
 PA US 2004141952 A1 20040722  
 PI US 2004-774622 A1 20040210 (10)  
 AI  
 RLI Continuation of Ser. No. US 2001-874138, filed on 6 Jun 2001, GRANTED,  
 Pat. No. US 6743625 Continuation of Ser. No. US 2000-565009, filed on 4  
 May 2000, PENDING Continuation-in-part of Ser. No. US 1998-42583, filed  
 on 17 Mar 1998, PENDING  
 PRAI US 1999-148939P 19990813 (60)  
 US 1999-133238P 19990507 (60)  
 US 1999-132498P 19990504 (60)  
 US 1997-54021P 19970729 (60)  
 US 1997-40846P 19970317 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 8875  
 INCL INCLM: 424/085.100  
 INCLS: 424/131.100; 514/012.000; 514/192.000; 514/210.090; 514/200.000  
 NCL NCLM: 424/085.100  
 NCLS: 424/131.100; 514/012.000; 514/192.000; 514/210.090; 514/200.000  
 IC [7]  
 ICM: A61K038-19  
 ICS: A61K038-17; A61K039-395; A61K031-496; A61K031-704; A61K031-545;  
 A61K031-397; A61K031-407  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 469 USPATFULL on STN  
 AN 2004:179126 USPATFULL  
 TI Amyloid immunization and Cox-2 inhibitors for the treatment of  
 alzheimer's disease  
 IN Robertson, David W., Glenview, IL, UNITED STATES  
 Krafft, Grant A., Glenview, IL, UNITED STATES LR  
 PA Pharmacia Corporation (U.S. corporation)  
 PI US 2004138296 A1 20040715  
 AI US 2003-627357 A1 20030725 (10)  
 PRAI US 2002-402760P 20020812 (60)  
 US 2002-402778P 20020812 (60)  
 US 2002-402674P 20020812 (60)  
 US 2002-402655P 20020812 (60)  
 US 2002-402773P 20020812 (60)  
 US 2002-402675P 20020812 (60)  
 US 2002-402676P 20020812 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2898  
 INCL INCLM: 514/461.000  
 INCLS: 514/467.000; 514/314.000; 514/568.000  
 NCL NCLM: 514/461.000  
 NCLS: 514/467.000; 514/314.000; 514/568.000  
 IC [7]  
 ICM: A61K031-4709  
 ICS: A61K031-19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 469 USPATFULL on STN  
 AN 2004:177787 USPATFULL  
 TI Death domain containing receptor 5  
 IN Ni, Jian, Germantown, MD, UNITED STATES  
 Gentz, Reiner L., Belo Horizonte, BRAZIL  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Human Genome Sciences, Inc. (U.S. corporation)  
 PA US 2004136951 A1 20040715  
 PI US 2003-648825 A1 20030827 (10)  
 AI  
 RLI Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000,  
 PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar  
 1998, PENDING  
 PRAI US 2002-413747P 20020927 (60)  
 US 2002-406307P 20020828 (60)  
 US 1999-148939P 19990813 (60)  
 US 1999-133238P 19990507 (60)  
 US 1999-132498P 19990504 (60)  
 US 1997-54021P 19970729 (60)  
 US 1997-40846P 19970317 (60)

FS APPLICATION  
LN.CNT 12832  
INCL INCLM: 424/085.100  
INCLS: 424/131.100  
NCL NCLM: 424/085.100  
NCLS: 424/131.100  
IC [7]  
ICM: A61K038-19  
ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 469 USPATFULL on STN  
AN 2004:172618 USPATFULL  
TI Aspartyl protease inhibitors  
IN Yang, Wenjin, Foster City, CA, UNITED STATES  
Cary, Douglas R., San Francisco, CA, UNITED STATES  
Jacobs, Jeffrey W., San Mateo, CA, UNITED STATES  
Lu, Wanli, Burlingame, CA, UNITED STATES  
Lu, Yafan, South San Francisco, CA, UNITED STATES  
Sun, Jian, San Mateo, CA, UNITED STATES  
Zhong, Min, Foster City, CA, UNITED STATES

PI US 2004132782 A1 20040708  
AI US 2003-462127 A1 20030616 (10)  
PRAI US 2002-430693P 20021203 (60)  
US 2002-389194P 20020617 (60)

DT Utility  
FS APPLICATION

LN.CNT 6959

INCL INCLM: 514/357.000  
INCLS: 514/408.000; 514/534.000; 514/599.000; 514/634.000; 514/620.000;  
514/603.000; 546/329.000; 548/571.000; 560/041.000; 564/086.000;  
564/163.000; 564/237.000

NCL NCLM: 514/357.000  
NCLS: 514/408.000; 514/534.000; 514/599.000; 514/634.000; 514/620.000;  
514/603.000; 546/329.000; 548/571.000; 560/041.000; 564/086.000;  
564/163.000; 564/237.000

IC [7]  
ICM: A61K031-44  
ICS: A61K031-40; A61K031-165; A61K031-155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 469 USPATFULL on STN  
AN 2004:171998 USPATFULL  
TI Novel beta-secretase and modulation of beta-secretase activity  
IN Zhong, Ziyang, Union City, CA, UNITED STATES  
Cordell, Barbara, Palo Alto, CA, UNITED STATES  
Quon, Diana Hom, Redwood City, CA, UNITED STATES  
Liu, Yu-Wang, Santa Clara, CA, UNITED STATES  
Xu, Qiang, Cupertino, CA, UNITED STATES  
Schimmoller, Frauke, Menlo Park, CA, UNITED STATES  
Hyslop, Paul Andrew, Indianapolis, IN, UNITED STATES  
Johnstone, Edward Marion, Indianapolis, IN, UNITED STATES  
Little, Sheila Parks, Indianapolis, IN, UNITED STATES  
Queener, Stephen Wyatt, Indianapolis, IN, UNITED STATES  
Yin, Tinggui, Indianapolis, IN, UNITED STATES

PI US 2004132159 A1 20040708  
AI US 2003-740865 A1 20031218 (10)  
RLI Division of Ser. No. US 2000-566746, filed on 9 May 2000, ABANDONED  
PRAI US 1999-134074P 19990513 (60)

DT Utility  
FS APPLICATION

LN.CNT 1628

INCL INCLM: 435/226.000  
INCLS: 514/001.000  
NCL NCLM: 435/226.000  
NCLS: 514/001.000

IC [7]  
ICM: C12N009-64  
ICS: A61K031-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 469 USPATFULL on STN  
AN 2004:166084 USPATFULL  
TI Aminoethanol derivatives  
IN Kori, Masakuni, Hyogo, JAPAN

Fuse, Hiromitsu, Ibaraki, JAPAN  
Yamamoto, Toshihiro, Osaka, JAPAN  
PI US 2004127574 A1 20040701  
AI US 2003-470351 A1 20030725 (10)  
WO 2002-JP532 20020125  
PRAI JP 2001-19280 20010126  
DT Utility  
FS APPLICATION  
LN.CNT 25402  
INCL INCLM: 514/651.000  
INCLS: 564/355.000  
NCL NCLM: 514/651.000  
NCLS: 564/355.000  
IC [7]  
ICM: A61K031-137  
ICS: C07C215-30  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 469 USPATFULL on STN  
AN 2004:166065 USPATFULL  
TI Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease  
IN Snow, Alan D., Lynnwood, WA, UNITED STATES  
Nguyen, Beth P., Bothell, WA, UNITED STATES  
Castillo, Gerardo M., Seattle, WA, UNITED STATES  
Sanders, Virginia J., Seattle, WA, UNITED STATES  
Lake, Thomas P., Snohomish, WA, UNITED STATES  
Larsen, Lesley, Dunedin, NEW ZEALAND  
Weavers, Rex T., Dunedin, NEW ZEALAND  
Lorimer, Stephen D., Dunedin, NEW ZEALAND  
Larsen, David S., Dunedin, NEW ZEALAND  
Coffen, David L., San Diego, CA, UNITED STATES  
Coffen, Charlotte, Belcamp, MD, UNITED STATES LR  
PI US 2004127555 A1 20040701  
AI US 2003-452851 A1 20030530 (10)  
PRAI US 2002-385144P 20020531 (60)  
US 2002-409100P 20020909 (60)  
US 2002-412272P 20020920 (60)  
US 2002-435880P 20021220 (60)  
US 2003-463104P 20030414 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3898  
INCL INCLM: 514/464.000  
INCLS: 514/646.000; 514/649.000; 514/706.000; 514/721.000; 514/734.000;  
514/689.000; 549/435.000; 564/336.000; 568/047.000; 568/337.000  
NCL NCLM: 514/464.000  
NCLS: 514/646.000; 514/649.000; 514/706.000; 514/721.000; 514/734.000;  
514/689.000; 549/435.000; 564/336.000; 568/047.000; 568/337.000  
IC [7]  
ICM: A61K031-34  
ICS: A61K031-137; C07C049-786; A61K031-075; A61K031-12; A61K031-095  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 469 USPATFULL on STN  
AN 2004:166004 USPATFULL  
TI Alpha-(N-sulfonamido)acetamide derivatives as \*\*\*beta\*\*\* -  
\*\*\*amyloid\*\*\* inhibitors  
IN Parker, Michael F., Higganum, CT, UNITED STATES  
McElhone, Katharine E., Cromwell, CT, UNITED STATES  
Mate, Robert A., Waterbury, CT, UNITED STATES  
Bronson, Joanne J., Durham, CT, UNITED STATES  
Gai, Yonghua, Killingworth, CT, UNITED STATES  
Bergstrom, Carl P., Madison, CT, UNITED STATES  
Marcin, Lawrence R., Bethany, CT, UNITED STATES  
Macor, John E., Guilford, CT, UNITED STATES  
PI US 2004127494 A1 20040701  
AI US 2002-326365 A1 20021220 (10)  
PRAI US 2001-344322P 20011220 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6526  
INCL INCLM: 514/227.500  
INCLS: 514/237.800; 514/255.020; 514/357.000; 514/408.000; 514/317.000;

514/211.030; 540/544.000; 544/059.000; 544/060.000; 544/167.000;  
544/383.000; 546/159.000; 546/229.000; 546/331.000; 548/470.000;  
548/503.000; 548/950.000; 564/086.000  
NCL NCLM: 514/227.500  
NCLS: 514/237.800; 514/255.020; 514/357.000; 514/408.000; 514/317.000;  
514/416.000; 514/419.000; 514/602.000; 514/313.000; 514/210.200;  
514/211.030; 540/544.000; 544/059.000; 544/060.000; 544/167.000;  
544/383.000; 546/159.000; 546/229.000; 546/331.000; 548/470.000;  
548/503.000; 548/950.000; 564/086.000

IC [7]  
ICM: A61K031-541  
ICS: A61K031-5377; A61K031-495; A61K031-496; A61K031-4709; A61K031-454;  
A61K031-405; A61K031-4035; A61K031-397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 469 USPATFULL on STN

AN 2004:159212 USPATFULL

TI Compositions useful as inhibitors of rock and other protein kinases

IN Cao, Jingrong, Newton, MA, UNITED STATES

Gao, Huai, Natick, MA, UNITED STATES

Green, Jeremy, Burlington, MA, UNITED STATES

Marhefka, Craig, Belmont, MA, UNITED STATES

PI US 2004122016 A1 20040624

AI US 2003-696862 A1 20031030 (10)

PRAI US 2002-422441P 20021030 (60)

US 2003-476433P 20030606 (60)

US 2003-476691P 20030606 (60)

US 2003-479903P 20030619 (60)

DT Utility

FS APPLICATION

LN.CNT 4366

INCL INCLM: 514/252.050

INCLS: 514/255.050; 514/256.000; 514/342.000; 544/238.000; 544/331.000;  
544/333.000; 544/405.000; 514/089.000

NCL NCLM: 514/252.050

NCLS: 514/255.050; 514/256.000; 514/342.000; 544/238.000; 544/331.000;  
544/333.000; 544/405.000; 514/089.000

IC [7]

ICM: A61K031-506

ICS: A61K031-501; A61K031-497; A61K031-675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 469 USPATFULL on STN

AN 2004:159143 USPATFULL

TI Compounds which inhibit beta-secretase activity and methods of use  
thereof

IN Ghosh, Arun K., River Forest, IL, UNITED STATES

Tang, Jordan J. N., Edmond, OK, UNITED STATES

Bilcer, Geoffrey, Oklahoma City, OK, UNITED STATES

Chang, Wanpin, Edmond, OK, UNITED STATES

Hong, Lin, Oklahoma City, OK, UNITED STATES

Koelsch, Gerald E., Oklahoma City, OK, UNITED STATES

Loy, Jeffrey A., Norman, OK, UNITED STATES

Turner, Robert T., III, Oklahoma City, OK, UNITED STATES

Devasumadram, Thippeswamy, Edmond, OK, UNITED STATES

PA Oklahoma Medical Research Foundation, Oklahoma City, OK, UNITED STATES  
(U.S. corporation)

The Board of Trustees of the University of Illinois, Urbana, IL, UNITED  
STATES (U.S. corporation)

PI US 2004121947 A1 20040624

AI US 2002-281092 A1 20021023 (10)

RLI Continuation-in-part of Ser. No. US 2001-32818, filed on 28 Dec 2001,  
PENDING Continuation-in-part of Ser. No. WO 2001-US50826, filed on 28  
Dec 2001, PENDING

PRAI US 2001-275756P 20010314 (60)

US 2000-258705P 20001228 (60)

US 2001-335952P 20011023 (60)

US 2001-333545P 20011127 (60)

US 2002-348464P 20020114 (60)

US 2002-348615P 20020114 (60)

US 2002-390804P 20020620 (60)

US 2002-397557P 20020719 (60)

US 2002-397619P 20020719 (60)

DT Utility

FS APPLICATION



INCL INCLM: 514/012.000  
INCLS: 514/007.000; 530/350.000  
NCL NCLM: 514/012.000  
NCLS: 514/007.000; 530/350.000

IC [7]  
ICM: A61K038-16  
ICS: C07K014-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 469 USPATFULL on STN  
AN 2004:151477 USPATFULL  
TI Interleukin 17 receptor-like protein  
IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Ruben, Steven M., Brookeville, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)  
PI US 2004115698 A1 20040617  
AI US 2003-645702 A1 20030822 (10)  
RLI Division of Ser. No. US 2001-796844, filed on 2 Mar 2001, PENDING  
Continuation-in-part of Ser. No. WO 2000-US5759, filed on 6 Mar 2000,  
PENDING Continuation-in-part of Ser. No. WO 1999-US21048, filed on 15  
Sep 1999, PENDING Continuation-in-part of Ser. No. US 1999-268311, filed  
on 16 Mar 1999, GRANTED, Pat. No. US 6482923 Continuation-in-part of  
Ser. No. US 1998-154219, filed on 16 Sep 1998, GRANTED, Pat. No. US  
6635443 Continuation-in-part of Ser. No. US 1999-268311, filed on 16 Mar  
1999, GRANTED, Pat. No. US 6482923 Continuation-in-part of Ser. No. US  
1999-268311, filed on 16 Mar 1999, GRANTED, Pat. No. US 6482923  
Continuation-in-part of Ser. No. US 1998-154219, filed on 16 Sep 1998,  
GRANTED, Pat. No. US 6635443 Continuation-in-part of Ser. No. US  
1998-154219, filed on 16 Sep 1998, GRANTED, Pat. No. US 6635443  
PRAI WO 1998-US19121 19980916  
US 2000-187015P 20000306 (60)  
US 1997-59133P 19970917 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 11515  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C07K014-715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 469 USPATFULL on STN  
AN 2004:146966 USPATFULL  
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor  
IN Barta, Thomas E, Evanston, IL, United States  
Becker, Daniel P, Glenview, IL, United States  
Bedell, Louis J, Mt. Prospect, IL, United States  
Boehm, Terri L, Ballwin, MO, United States  
Carroll, Jeffrey N, Collinsville, IL, United States  
DeCrescenzo, Gary A, St. Charles, MO, United States  
Fobian, Yvette M, Wildwood, MO, United States  
Freskos, John N, Clayton, MO, United States  
Getman, Daniel P, Chesterfield, MO, United States  
McDonald, Joseph J, Ballwin, MO, United States  
Li, Madeleine H, Vernon Hills, IL, United States  
Hockerman, Susan L, Lincolnwood, IL, United States  
Howard, Susan C, Fenton, MO, United States  
Kolodziej, Steve A, Ballwin, MO, United States  
Mischke, Deborah A, Defiance, MO, United States  
Rico, Joseph G, Ballwin, MO, United States  
Stehle, Nathan W, Ballwin, MO, United States  
Tollefson, Michael B, Hainesville, IL, United States  
Vernier, William F, St. Louis, MO, United States  
Villamil, Clara I, Glenview, IL, United States  
PA Pharmacia Corporation, St. Louis, MO, United States (U.S. corporation)  
PI US 6750228 B1 20040615  
AI US 2000-570731 20000512 (9)  
RLI Continuation-in-part of Ser. No. US 1999-311837, filed on 14 May 1999  
Continuation-in-part of Ser. No. US 1999-256948, filed on 24 Feb 1999,  
now abandoned  
PRAI US 1998-101080P 19980918 (60)  
US 1998-95501 19980806 (90)

US 1997-66007P 1997/1114 (60)  
DT Utility  
FS GRANTED  
LN.CNT 9861  
INCL INCLM: 514/316.000  
INCLS: 514/318.000; 514/328.000; 514/330.000; 546/189.000; 546/193.000;  
546/220.000; 546/225.000  
NCL NCLM: 514/316.000  
NCLS: 514/318.000; 514/328.000; 514/330.000; 546/189.000; 546/193.000;  
546/220.000; 546/225.000  
IC [7]  
ICM: A61K031-445  
ICS: C07D211-06  
EXF 514/316; 514/328; 514/318; 514/330; 546/189; 546/193; 546/220; 546/225  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 469 USPATFULL on STN  
AN 2004:145132 USPATFULL  
TI Aromatic sulfone hydroxamic acids and their use as protease inhibitors  
IN Freskos, John N., Clayton, MO, UNITED STATES  
Fobian, Yvette M., Wildwood, MO, UNITED STATES  
Barta, Thomas E., Evanston, IL, UNITED STATES  
Becker, Daniel P., Glenview, IL, UNITED STATES  
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES  
Boehm, Terri L., Ballwin, MO, UNITED STATES  
Carroll, Jeffery N., Columbia, IL, UNITED STATES  
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES  
Hockerman, Susan L., Chicago, IL, UNITED STATES  
Kassab, Darren J., Wildwood, MO, UNITED STATES  
Kolodziej, Steve A., Ballwin, MO, UNITED STATES  
McDonald, Joseph, Wildwood, MO, UNITED STATES  
Mischke, Deborah A., Defiance, MO, UNITED STATES  
Norton, Monica B., St. Louis, MO, UNITED STATES  
Rico, Joseph G., Ballwin, MO, UNITED STATES  
Talley, John J., Cambridge, MA, UNITED STATES  
Villamil, Clara I., Glenview, IL, UNITED STATES  
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES  
PI US 2004110805 A1 20040610  
AI US 2003-657034 A1 20030905 (10)  
RLI Division of Ser. No. US 2002-142737, filed on 10 May 2002, PENDING  
PRAI US 2001-290375P 20010511 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15248  
INCL INCLM: 514/357.000  
INCLS: 514/575.000; 514/408.000; 546/336.000; 548/577.000; 562/621.000;  
514/534.000  
NCL NCLM: 514/357.000  
NCLS: 514/575.000; 514/408.000; 546/336.000; 548/577.000; 562/621.000;  
514/534.000  
IC [7]  
ICM: A61K031-44  
ICS: A61K031-40; A61K031-19; A61K031-24  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 469 USPATFULL on STN  
AN 2004:141189 USPATFULL  
TI Isoxazoline derivative and a process for the preparation thereof  
IN Kim, Eunice Eun-Kyeong, Daejeon, KOREA, REPUBLIC OF  
Park, Mi-Jeong, Daejeon, KOREA, REPUBLIC OF  
Lee, Tae-Hee, Daejeon, KOREA, REPUBLIC OF  
Chang, Hye-Kyung, Daejeon, KOREA, REPUBLIC OF  
Park, Tae-Kyo, Daejeon, KOREA, REPUBLIC OF  
Kang, Chang-Yuil, Seoul, KOREA, REPUBLIC OF  
Kim, Young-Myeong, Chunchon, KOREA, REPUBLIC OF  
Moon, Kwang-Yul, Daejeon, KOREA, REPUBLIC OF  
Oh, Young-Leem, Daejeon, KOREA, REPUBLIC OF  
Min, Chang-Hee, Daejeon, KOREA, REPUBLIC OF  
Chung, Hyun-Ho, Daejeon, KOREA, REPUBLIC OF  
PA LG Chem Investment Ltd., Seoul, KOREA, REPUBLIC OF (non-U.S.  
corporation)  
PI US 6747050 B1 20040608  
WO 2001021600 20010329  
AI US 2002-88288 20020315 (10)  
WO 2000-KR1047 20000918

KR 1999-48608 19991104  
DT Utility  
FS GRANTED  
LN.CNT 3777  
INCL INCLM: 514/378.000  
INCLS: 548/240.000; 546/146.000; 546/169.000; 514/307.000; 514/314.000  
NCL NCLM: 514/378.000  
NCLS: 514/307.000; 514/314.000; 546/146.000; 546/169.000; 548/240.000  
IC [7]  
ICM: A61K031-42  
ICS: A61K031-422; C07D261-04  
EXF 548/240; 514/378  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 469 USPATFULL on STN  
AN 2004:139439 USPATFULL  
TI Protein kinase inhibitors and uses thereof  
IN Cochran, John, Marshfield, MA, UNITED STATES  
Green, Jeremy, Burlington, MA, UNITED STATES  
Hale, Michael R., Bedford, MA, UNITED STATES  
Ledford, Brian, Attleboro, MA, UNITED STATES  
Maltais, Francois, Tewksbury, MA, UNITED STATES  
Nanthakumar, Suganthini, Newton, MA, UNITED STATES  
PI US 2004106615 A1 20040603  
AI US 2003-639784 A1 20030812 (10)  
PRAI US 2002-403256P 20020814 (60)  
US 2002-416802P 20021008 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5486  
INCL INCLM: 514/242.000  
INCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000;  
544/331.000  
NCL NCLM: 514/242.000  
NCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000;  
544/331.000  
IC [7]  
ICM: A61K031-53  
ICS: A61K031-501; A61K031-506; C07D043-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 469 USPATFULL on STN  
AN 2004:139422 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting \*\*\*Beta\*\*\*  
\*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Thompson, Richard C., Frankfort, IN, UNITED STATES  
Wilkie, Stephen, Indianapolis, IN, UNITED STATES  
Stack, Douglas R., Fishers, IN, UNITED STATES  
Vanmeter, Eldon E., Greenwood, IN, UNITED STATES  
Shi, Qing, Carmel, IN, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Martinsville, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2004106598 A1 20040603  
AI US 2003-392332 A1 20030320 (10)  
RLI Division of Ser. No. US 1999-338191, filed on 22 Jun 1999, GRANTED, Pat.  
No. US 6569851  
PRAI US 1998-160067P 19980622 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 12955  
INCL INCLM: 514/212.030  
INCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000  
NCL NCLM: 514/212.030  
NCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000  
IC [7]

ICS: A61K031-445; A61K031-4015; A61K031-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 469 USPATFULL on STN  
AN 2004:127588 USPATFULL  
TI Antiamyloid phenylsulfonamides: N-alkanol derivatives  
IN Smith, David W., Madison, CT, UNITED STATES  
Parker, Michael F., Higganum, CT, UNITED STATES  
PI US 2004097572 A1 20040520  
AI US 2003-626299 A1 20030724 (10)  
PRAI US 2002-400241P 20020801 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 937  
INCL INCLM: 514/400.000  
INCLS: 514/534.000; 514/562.000; 514/602.000; 548/338.100; 560/012.000;  
562/430.000; 564/084.000  
NCL NCLM: 514/400.000  
NCLS: 514/534.000; 514/562.000; 514/602.000; 548/338.100; 560/012.000;  
562/430.000; 564/084.000  
IC [7]  
ICM: A61K031-4172  
ICS: A61K031-195; A61K031-24; A61K031-18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 469 USPATFULL on STN  
AN 2004:127511 USPATFULL  
TI Method for treating fibrotic diseases or other indications IIIC  
IN Wagle, Dilip, New York, NY, UNITED STATES  
Gall, Martin, Morristown, NJ, UNITED STATES  
Bell, Stanley C., Narberth, PA, UNITED STATES  
LaVoie, Edmond J., Princeton Junction, NJ, UNITED STATES  
PI US 2004097495 A1 20040520  
AI US 2003-691839 A1 20031023 (10)  
RLI Continuation of Ser. No. US 2001-36857, filed on 31 Dec 2001, PENDING  
PRAI US 2000-259294P 20001229 (60)  
US 2001-259238P 20010102 (60)  
US 2001-296246P 20010606 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3287  
INCL INCLM: 514/227.500  
INCLS: 514/383.000; 514/396.000; 514/406.000; 514/231.200; 514/252.100;  
514/315.000; 514/365.000; 514/374.000; 514/242.000; 514/252.010;  
514/255.050; 514/256.000; 514/336.000  
NCL NCLM: 514/227.500  
NCLS: 514/383.000; 514/396.000; 514/406.000; 514/231.200; 514/252.100;  
514/315.000; 514/365.000; 514/374.000; 514/242.000; 514/252.010;  
514/255.050; 514/256.000; 514/336.000  
IC [7]  
ICM: A61K031-54  
ICS: A61K031-535; A61K031-497; A61K031-445; A61K031-425  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 469 USPATFULL on STN  
AN 2004:126956 USPATFULL  
TI \*\*\*ANTIBODIES\*\*\* AGAINST INTERLEUKIN-17 RECEPTOR LIKE PROTEIN  
IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2004096935 A1 20040520  
AI US 2001-796844 A1 20010302 (9)  
RLI Continuation-in-part of Ser. No. WO 2000-US5759, filed on 6 Mar 2000,  
UNKNOWN  
PRAI WO 1998-US19121 19980916  
US 2000-187015P 20000306 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 11562  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C12P021-02  
ICS: C12N005-06; C07K014-705; C07H021-04; C07K014-715

L4 ANSWER 131 OF 469 USPATFULL on STN  
 AN 2004:116758 USPATFULL  
 TI Method of reducing aluminum levels in the central nervous system  
 IN Croom, Jr., Warren J., Cary, NC, United States  
 Berg, Brian M., Sanford, NC, United States  
 Taylor, Ian L., Kiawah Island, SC, United States  
 PA North Carolina State University, Raleigh, NC, United States (U.S.  
 corporation)  
 MUSC Foundation for Research Development, Charleston, SC, United States  
 (U.S. corporation)  
 PI US 6734166 B1 20040511  
 AI US 2000-499980 20000208 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1603  
 INCL INCLM: 514/012.000  
 INCLS: 514/002.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
 514/017.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000;  
 530/327.000; 530/328.000; 530/329.000  
 NCL NCLM: 514/012.000  
 NCLS: 514/002.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
 514/017.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000;  
 530/327.000; 530/328.000; 530/329.000  
 IC [7]  
 ICM: A61K038-16  
 ICS: A61K038-10; A61K038-05  
 EXF 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/2; 530/324-329;  
 530/309  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 469 USPATFULL on STN  
 AN 2004:114812 USPATFULL  
 TI Combination therapy using 1-aminocyclohexane derivatives and  
 acetylcholinesterase inhibitors  
 IN Moebius, Hans-Joerg, Frankfurt Am Main, GERMANY, FEDERAL REPUBLIC OF  
 PI US 2004087658 A1 20040506  
 AI US 2003-691895 A1 20031023 (10)  
 PRAI US 2002-420918P 20021024 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3764  
 INCL INCLM: 514/579.000  
 NCL NCLM: 514/579.000  
 IC [7]  
 ICM: A61K031-13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 469 USPATFULL on STN  
 AN 2004:114174 USPATFULL  
 TI Stable macroscopic membranes formed by self-assembly of amphiphilic  
 peptides and uses therefor  
 IN Holmes, Todd, Belmont, MA, UNITED STATES  
 Zhang, Shuguang, Lexington, MA, UNITED STATES  
 Rich, Alexander, Cambridge, MA, UNITED STATES  
 DiPersio, C. Michael, Norton, MA, UNITED STATES  
 Lockshin, Curtis, Lexington, MA, UNITED STATES  
 PI US 2004087013 A1 20040506  
 AI US 2003-390472 A1 20030317 (10)  
 RLI Continuation of Ser. No. US 1997-824515, filed on 26 Mar 1997, GRANTED,  
 Pat. No. US 5987623 Continuation of Ser. No. US 1994-293284, filed on 22  
 Aug 1994, GRANTED, Pat. No. US 5955343 Continuation-in-part of Ser. No.  
 US 1992-973326, filed on 28 Dec 1992, ABANDONED  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2512  
 INCL INCLM: 435/325.000  
 INCLS: 530/329.000  
 NCL NCLM: 435/325.000  
 NCLS: 530/329.000  
 IC [7]  
 ICM: C12N005-02  
 ICS: C07K007-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN  
TI  
IN

2004:114036 USPATFULL  
Novel proteins and nucleic acids encoding same  
Agee, Michele L., Wallingford, CT, UNITED STATES  
Alsobrook, John P., II, Madison, CT, UNITED STATES  
Berghs, Constance, New Haven, CT, UNITED STATES  
Boldog, Ferenc L., North Haven, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
Chant, John S., Branford, CT, UNITED STATES  
Chaudhuri, Amitabha, Madison, CT, UNITED STATES  
DiPippo, Vincent A., East Haven, CT, UNITED STATES  
Edinger, Shlomit R., New Haven, CT, UNITED STATES  
Eisen, Andrew, Rockville, MD, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES  
Gorman, Linda, Branford, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Ji, Weizhen, Branford, CT, UNITED STATES  
Kekuda, Ramesh, Norwalk, CT, UNITED STATES  
Khrantsov, Nikolai V., Branford, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
MacDougall, John R., Hamden, CT, UNITED STATES  
Mezes, Peter S., Old Lyme, CT, UNITED STATES  
Miller, Charles E., Guilford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
Ooi, Chean Eng., Branford, CT, UNITED STATES  
Ort, Tatiana, Milford, CT, UNITED STATES  
Padigar, Muralidhara, Branford, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Rieger, Daniel K., Branford, CT, UNITED STATES  
Rothenberg, Mark E., Clinton, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Spaderna, Steven K., Berlin, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
Vernet, Corine A.M., Branford, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES  
Zhong, Mei, Branford, CT, UNITED STATES

PI  
AI  
PRAI

US 2004086875	A1	20040506
US 2002-287226	A1	20021104 (10)
US 2001-334421P		20011130 (60)
US 2002-354392P		20020204 (60)
US 2002-360148P		20020227 (60)
US 2002-364000P		20020313 (60)
US 2002-404821P		20020820 (60)
US 2001-334526P		20011130 (60)
US 2002-354409P		20020204 (60)
US 2002-364227P		20020313 (60)
US 2001-334027P		20011128 (60)
US 2001-331641P		20011120 (60)
US 2001-335610P		20011115 (60)
US 2001-333461P		20011127 (60)
US 2002-403619P		20020815 (60)
US 2001-336664P		20011204 (60)
US 2002-361925P		20020305 (60)
US 2002-405631P		20020823 (60)
US 2001-333072P		20011106 (60)
US 2001-338314P		20011207 (60)
US 2002-354393P		20020204 (60)
US 2002-361790P		20020305 (60)
US 2002-364182P		20020313 (60)
US 2002-353288P		20020201 (60)
US 2002-362230P		20020305 (60)
US 2002-364181P		20020313 (60)
US 2001-338390P		20011207 (60)
US 2002-361833P		20020305 (60)
US 2002-405368P		20020823 (60)
US 2001-339008P		20011210 (60)
US 2002-362625P		20020305 (60)
US 2002-364197P		20020313 (60)
US 2002-401594P		20020807 (60)
US 2002-405402P		20020823 (60)
US 2001-339006P		20011210 (60)
US 2002-353280P		20020201 (60)

US	2002-405496P	20020823	(60)
US	2001-333072P	20011106	(60)
US	2001-338626P	20011105	(60)
US	2001-348283P	20011109	(60)
US	2001-335610P	20011115	(60)
US	2001-331641P	20011120	(60)
US	2001-331630P	20011120	(60)
US	2001-332152P	20011121	(60)
US	2001-334300P	20011129	(60)
US	2002-401787P	20020807	(60)
US	2002-396703P	20020717	(60)
US	2002-401552P	20020806	(60)
US	2001-336576P	20011204	(60)
US	2001-335610P	20011115	(60)
US	2002-381621P	20020517	(60)
US	2002-383675P	20020528	(60)
US	2002-406125P	20020826	(60)
US	2001-338543P	20011116	(60)
US	2001-339286P	20011211	(60)
US	2001-336576P	20011204	(60)
US	2001-333912P	20011128	(60)

DT Utility  
FS APPLICATION  
LN.CNT 37497

INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000;  
530/350.000; 536/023.200

NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000;  
530/350.000; 536/023.200

IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;  
A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 469 USPATFULL on STN

AN 2004:108140 USPATFULL

TI Azole derivatives and fused bicyclic azole derivatives as therapeutic agents

IN Mjalli, Adnan M.M., Jamestown, NC, UNITED STATES  
Andrews, Robert C., Jamestown, NC, UNITED STATES  
Gopalaswamy, Ramesh, Jamestown, NC, UNITED STATES  
Hari, Anitha, High Point, NC, UNITED STATES  
Avor, Kwasi S., High Point, NC, UNITED STATES  
Qabajja, Ghassan, High Point, NC, UNITED STATES  
Guo, Xiao-Chuan, High Point, NC, UNITED STATES  
Gupta, Suparna, Greensboro, NC, UNITED STATES  
Jones, David R., Asheboro, NC, UNITED STATES  
Chen, Xin, High Point, NC, UNITED STATES

PI US 2004082542 A1 20040429  
AI US 2003-382203 A1 20030305 (10)  
PRAI US 2002-361983P 20020305 (60)

DT Utility  
FS APPLICATION  
LN.CNT 15091

INCL INCLM: 514/063.000  
INCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000;  
514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000;  
548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000

NCL NCLM: 514/063.000  
NCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000;  
514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000;  
548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000

IC [7]  
ICM: A61K031-695  
ICS: A61K031-4709; A61K031-517; A61K031-519; A61K031-426; A61K031-422;  
A61K031-4162

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 469 USPATFULL on STN

AN 2004:103677 USPATFULL

TI Single nucleotide polymorphisms in genes

IN Lander, Eric S., Cambridge, MA, United States  
Cargill, Michele, Gaithersburg, MD, United States

PA Bolk, Stacey, West Roxbury, MA, United States  
Daley, George Q., Weston, MA, United States  
McCarthy, Jeanette J., San Diego, CA, United States  
Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)  
Whitehead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)  
PI US 6727063 B1 20040427  
AI US 2000-657472 20000907 (9)  
PRAI US 2000-220947P 20000726 (60)  
US 2000-225724P 20000816 (60)  
US 1999-153357P 19990910 (60)  
DT Utility  
FS GRANTED  
LN.CNT 14015  
INCL INCLM: 435/006.000  
INCLS: 435/091.100; 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 435/091.100; 435/091.200  
IC [7]  
ICM: C12Q001-68  
ICS: C12P019-34  
EXF 435/6; 435/91.1; 435/91.2; 536/23.1; 536/24.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 469 USPATFULL on STN  
AN 2004:101757 USPATFULL  
TI Lactam compound  
IN Koenig, Thomas Mitchell, Camby, IN, UNITED STATES  
Mitchell, David, Indianapolis, IN, UNITED STATES  
Nissen, Jeffrey Scott, Indianapolis, IN, UNITED STATES  
PI US 2004077627 A1 20040422  
AI US 2003-415057 A1 20030903 (10)  
WO 2001-US27796 20011102  
DT Utility  
FS APPLICATION  
LN.CNT 1843  
INCL INCLM: 514/212.070  
INCLS: 540/523.000  
NCL NCLM: 514/212.070  
NCLS: 540/523.000  
IC [7]  
ICM: A61K031-55  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 469 USPATFULL on STN  
AN 2004:101158 USPATFULL  
TI Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis  
IN Mannick, Elizabeth E., 1234 Joseph Street, New Orleans, LA, UNITED STATES 70115  
Liu, Zhiyun, 8100 Cambridge Street, #143, Houston, TX, UNITED STATES 77054  
Serrano, Maria-Stella, 3721 Lilac Lane, Metairie, LA, UNITED STATES 70001  
PI US 2004077020 A1 20040422  
AI US 2003-432785 A1 20031120 (10)  
WO 2001-US45096 20011130  
DT Utility  
FS APPLICATION  
LN.CNT 2607  
INCL INCLM: 435/007.100  
NCL NCLM: 435/007.100  
IC [7]  
ICM: G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 469 USPATFULL on STN  
AN 2004:94708 USPATFULL  
TI Molecular toxicology modeling  
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES  
Porter, Mark, Gaithersburg, MD, UNITED STATES  
Johnson, Kory, Gaithersburg, MD, UNITED STATES  
Higgs, Brandon, Gaithersburg, MD, UNITED STATES  
Castle, Arthur, Gaithersburg, MD, UNITED STATES



PI	US 2004072160	AI	20040415
AI	US 2002-152319	AI	20020522 (10)
PRAI	US 2001-292335P		20010522 (60)
	US 2001-297523P		20010613 (60)
	US 2001-298925P		20010619 (60)
	US 2001-303810P		20010710 (60)
	US 2001-303807P		20010710 (60)
	US 2001-303808P		20010710 (60)
	US 2001-315047P		20010828 (60)
	US 2001-324928P		20010927 (60)
	US 2001-330867P		20011101 (60)
	US 2001-330462P		20011022 (60)
	US 2001-331805P		20011121 (60)
	US 2001-336144P		20011206 (60)
	US 2001-340873P		20011219 (60)
	US 2002-357843P		20020221 (60)
	US 2002-357842P		20020221 (60)
	US 2002-357844P		20020221 (60)
	US 2002-364134P		20020315 (60)
	US 2002-370206P		20020408 (60)
	US 2002-370247P		20020408 (60)
	US 2002-370144P		20020408 (60)
	US 2002-371679P		20020412 (60)
	US 2002-372794P		20020417 (60)
DT	Utility		
FS	APPLICATION		
LN.CNT	27909		
INCL	INCLM: 435/006.000		
	INCLS: 435/091.200; 436/084.000		
NCL	NCLM: 435/006.000		
	NCLS: 435/091.200; 436/084.000		
IC	[7]		
	ICM: C12Q001-68		
	ICS: C12P019-34; G01N033-20		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
L4	ANSWER 140 OF 469 USPATFULL on STN		
AN	2004:89118 USPATFULL		
TI	Novel human proteins, polynucleotides encoding them and methods of using the same		
IN	Shimkets, Richard A., Guilford, CT, UNITED STATES		
	Taupier, Raymond J., JR., East Haven, CT, UNITED STATES		
	Burgess, Catherine E., Wethersfield, CT, UNITED STATES		
	Zerhusen, Bryan D., Branford, CT, UNITED STATES		
	Mezes, Peter S., Old Lyme, CT, UNITED STATES		
	Rastelli, Luca, Guilford, CT, UNITED STATES		
	Malyankar, Uriel M., Branford, CT, UNITED STATES		
	Grosse, William M., Branford, CT, UNITED STATES		
	Alsobrook, John P., II, Madison, CT, UNITED STATES		
	Lepley, Denise M., Branford, CT, UNITED STATES		
	Spytek, Kimberly Ann, New Haven, CT, UNITED STATES		
	Li, Li, Branford, CT, UNITED STATES		
	Edinger, Shlomit, New Haven, CT, UNITED STATES		
	Gerlach, Valerie, Branford, CT, UNITED STATES		
	Ellerman, Karen, Branford, CT, UNITED STATES		
	MacDougall, John R., Hamden, CT, UNITED STATES		
	Gunther, Erik, Branford, CT, UNITED STATES		
	Millet, Isabelle, Milford, CT, UNITED STATES		
	Stone, David J., Guilford, CT, UNITED STATES		
	Smithson, Glennda, Guilford, CT, UNITED STATES		
	Szekeres, Edward S., JR., Branford, CT, UNITED STATES		
	Ji, Weizhen, Branford, CT, UNITED STATES		
PI	US 2004068095	AI	20040408
AI	US 2002-96625	AI	20020313 (10)
RLI	Continuation-in-part of Ser. No. US 2001-972211, filed on 5 Oct 2001, PENDING		
PRAI	US 2001-275892P		20010314 (60)
	US 2001-296860P		20010608 (60)
DT	Utility		
FS	APPLICATION		
LN.CNT	14761		
INCL	INCLM: 530/350.000		
NCL	NCLM: 530/350.000		
IC	[7]		
	ICM: C07K001-00		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 469 USPATFULL on STN  
AN 2004:88568 USPATFULL  
TI Prevention and treatment of amyloid-associated disorders  
IN Hyslop, Paul Andrew, Indianapolis, IN, UNITED STATES  
Miller, Foy Dean, Camby, IN, UNITED STATES  
Higgins, Linda S., Palo Alto, CA, UNITED STATES  
Catalano, Rosanne, Hayward, CA, UNITED STATES  
Cordell, Barbara, Palo Alto, CA, UNITED STATES  
Puchacz, Elzbieta, Pleasanton, CA, UNITED STATES  
PI US 2004067538 A1 20040408  
AI US 2003-624950 A1 20030721 (10)  
RLI Division of Ser. No. US 2000-608640, filed on 30 Jun 2000, GRANTED, Pat.  
No. US 6596474  
PRAI US 1999-142175P 19990701 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1260  
INCL INCLM: 435/007.200  
NCL NCLM: 435/007.200  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 469 USPATFULL on STN  
AN 2004:85245 USPATFULL  
TI Methods for inhibiting diabetic complications  
IN Khalifah, Raja, Overland Park, KS, United States  
Hudson, Billy G., Lenexa, KS, United States  
PA Kansas University Medical Center, Kansas City, KS, United States (U.S.  
corporation)  
PI US 6716858 B1 20040406  
AI US 1999-416915 19991013 (9)  
RLI Continuation-in-part of Ser. No. US 1997-971285, filed on 17 Nov 1997,  
now patented, Pat. No. US 6228858 Continuation-in-part of Ser. No. US  
1996-711555, filed on 10 Sep 1996, now patented, Pat. No. US 5985857  
PRAI US 1995-3268P 19950828 (60)  
US 1998-104276P 19981014 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3293  
INCL INCLM: 514/345.000  
INCLS: 514/349.000; 514/350.000; 514/354.000; 514/356.000  
NCL NCLM: 514/345.000  
NCLS: 514/349.000; 514/350.000; 514/354.000; 514/356.000  
IC [7]  
ICM: A61K031-44  
EXF 514/345; 514/349; 514/350; 514/354; 514/356

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 469 USPATFULL on STN  
AN 2004:85238 USPATFULL  
TI Compounds, methods and pharmaceutical compositions for treating cellular  
damage, such as neural or cardiovascular tissue damage  
IN Li, Jia-He, Cockeysville, MD, United States  
Zhang, Jie, Ellicott City, MD, United States  
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S.  
corporation)  
PI US 6716828 B1 20040406  
AI US 2001-781195 20010213 (9)  
RLI Division of Ser. No. US 1999-387767, filed on 1 Sep 1999  
DT Utility  
FS GRANTED  
LN.CNT 3327  
INCL INCLM: 514/080.000  
INCLS: 544/232.000; 544/233.000; 514/081.000; 514/248.000  
NCL NCLM: 514/080.000  
NCLS: 514/081.000; 514/248.000; 544/232.000; 544/233.000  
IC [7]  
ICM: C07D491-04  
ICS: C07D498-04; C07F009-141; A61K031-47; A61K031-50  
EXF 544/233; 544/232; 514/248; 514/80; 514/81

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 469 USPATFULL on STN  
AN 2004:83519 USPATFULL  
TI Benzofuran derivatives  
IN Boddupalli, Sekhar, San Jose, CA, UNITED STATES  
Walkinshaw, Gail, San Jose, CA, UNITED STATES  
Wang, Bing, Cupertino, CA, UNITED STATES  
PI US 2004063975 A1 20040401  
AI US 2003-667280 A1 20030917 (10)  
RLI Continuation-in-part of Ser. No. US 2003-361141, filed on 6 Feb 2003,  
GRANTED, Pat. No. US 6653346  
PRAI US 2002-355331P 20020207 (60)  
US 2002-429584P 20021127 (60)

DT Utility  
FS APPLICATION

LN.CNT 3181

INCL INCLM: 549/462.000

INCLS: 514/469.000

NCL NCLM: 549/462.000

NCLS: 514/469.000

IC [7]

ICM: C07D307-93

ICS: A61K031-343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 469 USPATFULL on STN  
AN 2004:78840 USPATFULL  
TI Death domain containing receptors  
IN Yu, Guo-Liang, Berkeley, CA, United States  
Ni, Jian, Rockville, MD, United States  
Dixit, Vishva M., Los Altos Hills, CA, United States  
Gentz, Reiner L., Rockville, MD, United States  
Dillon, Patrick J., Carlsbad, CA, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6713061 B1 20040330  
AI US 2000-557908 20000421 (9)  
RLI Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997,  
now patented, Pat. No. US 6153402  
PRAI US 1999-136741P 19990528 (60)  
US 1999-130488P 19990422 (60)  
US 1997-37341P 19970206 (60)  
US 1996-28711P 19961017 (60)  
US 1996-13285P 19960312 (60)

DT Utility  
FS GRANTED

LN.CNT 8849

INCL INCLM: 424/185.100

INCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;  
536/023.500

NCL NCLM: 424/185.100

NCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;  
536/023.500

IC [7]

ICM: A61K039-00

ICS: C07K014-705

EXF 530/350; 536/23.5; 435/69.1; 424/185.1; 424/192.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 469 USPATFULL on STN  
AN 2004:77121 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James A., Indianapolis, IN, UNITED STATES

mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2004058900 A1 20040325  
AI US 2003-336767 A1 20030106 (10)  
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING  
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25655  
INCL INCLM: 514/183.000  
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;  
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000  
NCL NCLM: 514/183.000  
NCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;  
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000  
IC [7]  
ICM: A61K031-553  
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 469 USPATFULL on STN  
AN 2004:70714 USPATFULL  
TI Fused pyrazole derivatives bieng protein kinase inhibitors  
IN Alberti, Michael John, Research Triangle Park, NC, UNITED STATES  
Baldwin, Ian, Stevenage, UNITED KINGDOM  
Cheung, Mui, Research Triangle Park, NC, UNITED STATES  
Cockerill, Stuart, Stevenage, UNITED KINGDOM  
Harris, Philip, Stevenage, UNITED KINGDOM  
Jung, David, Research Triangle Park, NC, UNITED STATES  
Peckham, Gregory, Research Triangle Park, NC, UNITED STATES  
Peel, Michael, Research Triangle Park, NC, UNITED STATES  
Badiang, Jennifer, Research Triangle Park, NC, UNITED STATES  
Stevens, Kirk, Research Triangle Park, NC, UNITED STATES  
Veal, James, Research Triangle Park, NC, UNITED STATES

PI US 2004053942 A1 20040318  
AI US 2003-362146 A1 20030707 (10)  
WO 2001-GB3783 20010822  
PRAI GB 2000-20556 20000822  
GB 2000-20576 20000822  
DT Utility  
FS APPLICATION  
LN.CNT 4935  
INCL INCLM: 514/256.000  
INCLS: 514/303.000; 544/333.000; 546/113.000  
NCL NCLM: 514/256.000  
NCLS: 514/303.000; 544/333.000; 546/113.000  
IC [7]  
ICM: A61K031-506  
ICS: C07D471-02; A61K031-4745  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 469 USPATFULL on STN  
AN 2004:69595 USPATFULL  
TI Dihydropyrazolopyridine compounds and pharmaceutical use thereof  
IN Kohara, Toshiyuki, Tokyo, JAPAN  
Fukunaga, Kenji, Tokyo, JAPAN  
Fujimura, Masatake, Tokyo, JAPAN  
Hanano, Tokushi, Tokyo, JAPAN  
Okabe, Hirotaka, Tokyo, JAPAN  
PI US 2004052822 A1 20040318  
AI US 2003-631847 A1 20030801 (10)  
RLI Continuation-in-part of Ser. No. WO 2002-JP829, filed on 1 Feb 2002,  
UNKNOWN  
PRAI JP 2001-26379 20010202  
JP 2001-81238 20010321  
JP 2001-304707 20010928  
JP 2002-230581 20020807

FS APPLICATION  
LN.CNT 10081  
INCL INCLM: 424/280.100  
NCL NCLM: 424/280.100  
IC [7]

ICM: A61K045-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 469 USPATFULL on STN  
AN 2004:64333 USPATFULL  
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor  
IN Barta, Thomas E., Evanston, IL, UNITED STATES  
Becker, Daniel P., Glenview, IL, UNITED STATES  
Boehm, Terri L., Ballwin, MO, UNITED STATES  
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES  
Freskos, John N., Clayton, MO, UNITED STATES  
Getman, Daniel P., Chesterfield, MO, UNITED STATES  
McDonald, Joseph J., Wildwood, MO, UNITED STATES  
Villamil, Clara I., Glenview, IL, UNITED STATES  
Bedell, Louis John, Mt. Prospect, IL, UNITED STATES  
Carroll, Jeffery N., Columbia, IL, UNITED STATES  
Fletcher, Theresa R., Kirkwood, MO, UNITED STATES  
Hockerman, Susan Landis, Lincolnwood, IL, UNITED STATES  
Kolodziej, Stephen A., Ballwin, MO, UNITED STATES  
Li, Madeleine H., Vernon Hills, IL, UNITED STATES  
Mischke, Deborah A., Defiance, MO, UNITED STATES  
Mullins, Patrick B., St. Louis, MO, UNITED STATES  
Howard, Carol Pearcy, Fenton, MO, UNITED STATES  
Rico, Joseph Gerace, Ballwin, MO, UNITED STATES  
Stehle, Nathan W., Grafton, WI, UNITED STATES  
PI US 2004048852 A1 20040311  
AI US 2003-337942 A1 20030107 (10)  
RLI Division of Ser. No. US 2000-554082, filed on 31 Jul 2000, GRANTED, Pat.  
No. US 6541489 A 371 of International Ser. No. WO 1998-US23242, filed on  
12 Nov 1998, PENDING  
PRAI WO 1997-WO9925687 19971114  
US 1997-66007P 19971114 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 16505  
INCL INCLM: 514/217.120  
INCLS: 514/227.500; 514/237.800; 514/252.120; 514/317.000; 514/357.000;  
514/365.000; 514/374.000; 514/400.000; 514/408.000; 514/575.000  
NCL NCLM: 514/217.120  
NCLS: 514/227.500; 514/237.800; 514/252.120; 514/317.000; 514/357.000;  
514/365.000; 514/374.000; 514/400.000; 514/408.000; 514/575.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-54; A61K031-537; A61K031-445; A61K031-497; A61K031-495;  
A61K031-44; A61K031-19; A61K031-421; A61K031-426; A61K031-4172  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 469 USPATFULL on STN  
AN 2004:64329 USPATFULL  
TI Novel gamma secretase inhibitors  
IN Pissarnitski, Dmitri A., Scotch Plains, NJ, UNITED STATES  
Josien, Hubert B., Hoboken, NJ, UNITED STATES  
Smith, Elizabeth M., Verona, NJ, UNITED STATES  
Clader, John W., Cranford, NJ, UNITED STATES  
Asberom, Theodros, West Orange, NJ, UNITED STATES  
Guo, Tao, Dayton, NJ, UNITED STATES  
Hobbs, Douglas W., Yardley, PA, UNITED STATES  
PA Schering-Plough Corporation and Pharmacopeia, Inc. (U.S. corporation)  
PI US 2004048848 A1 20040311  
AI US 2003-358898 A1 20030205 (10)  
PRAI US 2002-355618P 20020206 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3259  
INCL INCLM: 514/217.050  
INCLS: 514/217.040; 514/217.080; 514/235.500; 514/253.120; 514/316.000;  
514/326.000; 540/597.000; 540/598.000; 544/129.000; 544/360.000;  
546/186.000; 546/208.000  
NCL NCLM: 514/217.050  
NCLS: 514/217.040; 514/217.080; 514/235.500; 514/253.120; 514/316.000;

IC [7]  
ICM: A61K031-55  
ICS: A61K031-5377; A61K031-496; A61K031-4545; A61K031-454; C07D413-02;  
C07D043-02; C07D041-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 469 USPATFULL on STN  
AN 2004:63809 USPATFULL  
TI Aza-peptide epoxides  
IN Powers, James C., Atlanta, GA, UNITED STATES  
Asgian, Juliana L., Fullerton, CA, UNITED STATES  
James, Karen E., Cumming, GA, UNITED STATES  
Li, Zhao-Zhao, Norcross, GA, UNITED STATES  
PI US 2004048327 A1 20040311  
AI US 2003-603054 A1 20030624 (10)  
PRAI US 2002-394221P 20020705 (60)  
US 2002-394023P 20020705 (60)  
US 2002-394024P 20020705 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4866  
INCL INCLM: 435/023.000  
INCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000  
NCL NCLM: 435/023.000  
NCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000

IC [7]  
ICM: C12Q001-37  
ICS: C07K007-06; C07K005-06; C07K005-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 152 OF 469 USPATFULL on STN  
AN 2004:58251 USPATFULL  
TI Substituted phenylalkanoic acid derivatives and use thereof  
IN Shoda, Motoshi, Shizuoka, JAPAN  
Kuriyama, Hiroshi, Shizuoka, JAPAN  
PI US 2004044258 A1 20040304  
AI US 2003-368435 A1 20030220 (10)  
PRAI JP 2002-45293 20020221  
JP 2002-301543 20021016  
US 2002-358337P 20020222 (60)  
US 2002-419098P 20021018 (60)

DT Utility  
FS APPLICATION  
LN.CNT 15610  
INCL INCLM: 568/959.000  
NCL NCLM: 568/959.000  
IC [7]

ICM: C07C027-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 469 USPATFULL on STN  
AN 2004:58065 USPATFULL  
TI Substituted hydroxyethylamines  
IN TenBrink, Ruth, Kalamazoo, MI, UNITED STATES  
Maillard, Michel, Redwood Shores, CA, UNITED STATES  
Warpehoski, Martha, Portage, MI, UNITED STATES  
PI US 2004044072 A1 20040304  
AI US 2002-313849 A1 20021206 (10)  
PRAI US 2001-338452P 20011206 (60)

DT Utility  
FS APPLICATION  
LN.CNT 7547  
INCL INCLM: 514/489.000  
INCLS: 560/159.000; 560/115.000; 514/521.000; 558/410.000  
NCL NCLM: 514/489.000  
NCLS: 560/159.000; 560/115.000; 514/521.000; 558/410.000

IC [7]  
ICM: A61K031-325  
ICS: A61K031-277; C07C271-52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 469 USPATFULL on STN  
AN 2004:57970 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical

\*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2004043977 A1 20040304  
AI US 2003-336687 A1 20030106 (10)  
RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat.  
No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec  
1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25738  
INCL INCLM: 514/183.000  
INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000;  
514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000;  
540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000;  
546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000;  
514/662.000; 564/454.000  
NCL NCLM: 514/183.000  
NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000;  
514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000;  
540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000;  
546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000;  
514/662.000; 564/454.000  
IC [7]  
ICM: A61K031-5513  
ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445;  
A61K031-366; A61K031-137  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L4 ANSWER 155 OF 469 USPATFULL on STN  
AN 2004:57923 USPATFULL  
TI Novel proteins and nucleic acids encoding same  
IN Anderson, David W., Plantsville, CT, UNITED STATES  
Bento, Patricia, Wolcott, CT, UNITED STATES  
Boldog, Ferenc, North Haven, CT, UNITED STATES  
Burgess, Catherine, Wethersfield, CT, UNITED STATES  
Casman, Stacie, North Haven, CT, UNITED STATES  
Furtak, Katarzyna, Ansonia, CT, UNITED STATES  
Gorman, Linda, Branford, CT, UNITED STATES  
Gould-Rothberg, Bonnie, Guilford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Heyes, Melvyn, New Haven, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Spytek, Kimberly, Ellington, CT, UNITED STATES  
Stone, David, Guilford, CT, UNITED STATES  
Zhong, Mei, Branford, CT, UNITED STATES  
Malyankar, Uriel, Branford, CT, UNITED STATES  
Edinger, Shlomit, New Haven, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Rothenberg, Mark, Clinton, CT, UNITED STATES  
Smithson, Glennda, Guilford, CT, UNITED STATES  
PI US 2004043930 A1 20040304  
AI US 2003-403161 A1 20030331 (10)  
RLI Continuation-in-part of Ser. No. US 2001-779679, filed on 8 Feb 2001,

PRAI US 2002-370349P 20020405 (60)  
US 2002-384543P 20020530 (60)  
US 2002-370969P 20020408 (60)  
US 2002-403748P 20020815 (60)  
US 2002-372019P 20020412 (60)  
US 2002-374379P 20020422 (60)  
US 2000-181045P 20000208 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 27161  
INCL INCLM: 514/012.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 514/012.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: A61K038-17  
ICS: C07K014-47; C12P021-02; C12N005-06; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 156 OF 469 USPATFULL on STN  
AN 2004:51633 USPATFULL  
TI Amine 1,2- and 1,3-diol compounds  
IN Romero, Arthur G., Kalamazoo, MI, UNITED STATES  
Schostarez, Heinrich J., Portage, MI, UNITED STATES  
Roels, Christina M., Battle Creek, MI, UNITED STATES  
PI US 2004039064 A1 20040226  
AI US 2002-299739 A1 20021119 (10)  
PRAI US 2001-333081P 20011119 (60)  
US 2001-334000P 20011128 (60)  
US 2002-362752P 20020308 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 10130  
INCL INCLM: 514/651.000  
INCLS: 564/355.000  
NCL NCLM: 514/651.000  
NCLS: 564/355.000  
IC [7]  
ICM: A61K031-137  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 157 OF 469 USPATFULL on STN  
AN 2004:51576 USPATFULL  
TI Compositions useful as inhibitors of GSK-3  
IN Forster, Cornelia J., Pelham, NH, UNITED STATES  
Park, Larry C., Waltham, MA, UNITED STATES  
Wannamaker, Marion W., Stow, MA, UNITED STATES  
Yao, Yung-Mae M., Newton, MA, UNITED STATES  
PI US 2004039007 A1 20040226  
AI US 2003-632340 A1 20030801 (10)  
PRAI US 2002-400967P 20020802 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2000  
INCL INCLM: 514/275.000  
INCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;  
544/295.000; 544/328.000  
NCL NCLM: 514/275.000  
NCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;  
544/295.000; 544/328.000  
IC [7]  
ICM: A61K031-541  
ICS: A61K031-5377; A61K031-506; C07D417-14; C07D413-14; C07D043-14  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 158 OF 469 USPATFULL on STN  
AN 2004:50862 USPATFULL  
TI Wound healing biomarkers  
IN Burslem, Martyn Frank, Sandwich, UNITED KINGDOM  
Johnson, Claire Michelle, Sandwich, UNITED KINGDOM  
Cooper, Lisa, London, UNITED KINGDOM  
Martin, Paul, London, UNITED KINGDOM  
PI US 2004038292 A1 20040226  
AI US 2002-175184 A1 20020618 (10)  
PRAI GB 2001-14869 20010618



DI Utility  
FS APPLICATION  
LN.CNT 67123  
INCL INCLM: 435/007.100  
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/007.100  
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: G01N033-53  
ICS: C07H021-04; C12P021-02; C12N005-06; C12N009-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 159 OF 469 USPATFULL on STN  
AN 2004:50778 USPATFULL  
TI Gene expression in bladder tumors  
IN Orntoft, Torben F., Aabyhoj, DENMARK  
PI US 2004038207 A1 20040226  
AI US 2001-951968 A1 20010914 (9)  
RLI Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN  
DT Utility  
FS APPLICATION  
LN.CNT 28561  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]  
ICM: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 469 USPATFULL on STN  
AN 2004:45056 USPATFULL  
TI Promoters for the proliferation and differentiation of stem cells and/or  
neuron precursor cells  
IN Okawa, Shigenori, Osaka, JAPAN  
Miyamoto, Masaomi, Hyogo, JAPAN  
Okura, Masahiro, Osaka, JAPAN  
PI US 2004034049 A1 20040219  
AI US 2003-398278 A1 20030401 (10)  
WO 2001-JP8739 20011004  
DT Utility  
FS APPLICATION  
LN.CNT 5795  
INCL INCLM: 514/278.000  
INCLS: 514/409.000  
NCL NCLM: 514/278.000  
NCLS: 514/409.000  
IC [7]  
ICM: A61K031-4747  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 469 USPATFULL on STN  
AN 2004:44501 USPATFULL  
TI Proteins and nucleic acids encoding same  
IN Tchernev, Velizar T., Branford, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Shimkets, Richard A., West Haven, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES  
Padigar, Muralidhara, Branford, CT, UNITED STATES  
Anderson, David W., Branford, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Miller, Charles E., Hill Drive, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
Gusev, Vladimir Y., UNITED STATES  
Colman, Steven D., Guilford, CT, UNITED STATES  
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES  
Pena, Carol E. A., Guilford, CT, UNITED STATES  
Furtak, Katarzyna, Anosia, CT, UNITED STATES  
Grosse, William M., Bransford, CT, UNITED STATES  
Alsobrook, John P., II, Madison, CT, UNITED STATES  
Lepley, Denise M., Branford, CT, UNITED STATES  
Rieger, Daniel K., Branford, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES

AI	US 2002-72012	AI 20020131 (10)
PRAI	US 2001-267459P	20010208 (60)
	US 2001-266975P	20010207 (60)
	US 2001-267057P	20010207 (60)
	US 2001-266767P	20010205 (60)
	US 2001-266406P	20010202 (60)
	US 2001-265395P	20010131 (60)
	US 2001-265412P	20010131 (60)
	US 2001-265517P	20010131 (60)
	US 2001-265514P	20010131 (60)
	US 2001-267823P	20010209 (60)
	US 2001-268974P	20010215 (60)
	US 2001-271855P	20010227 (60)
	US 2001-271839P	20010227 (60)
	US 2001-273046P	20010302 (60)
	US 2001-272788P	20010302 (60)
	US 2001-275989P	20010314 (60)
	US 2001-275925P	20010314 (60)
	US 2001-275947P	20010314 (60)
	US 2001-275950P	20010314 (60)
	US 2001-276450P	20010315 (60)
	US 2001-276448P	20010315 (60)
	US 2001-276397P	20010316 (60)
	US 2001-276768P	20010316 (60)
	US 2001-278652P	20010320 (60)
	US 2001-278775P	20010326 (60)
	US 2001-278778P	20010326 (60)
	US 2001-279882P	20010329 (60)
	US 2001-279884P	20010329 (60)
	US 2001-280147P	20010330 (60)
	US 2001-283083P	20010411 (60)
	US 2001-282992P	20010411 (60)
	US 2001-285133P	20010420 (60)
	US 2001-285749P	20010423 (60)
	US 2001-288327P	20010503 (60)
	US 2001-288504P	20010503 (60)
	US 2001-294047P	20010529 (60)
	US 2001-294473P	20010530 (60)
	US 2001-296964P	20010608 (60)
	US 2001-298959P	20010618 (60)
	US 2001-299324P	20010619 (60)
	US 2001-312020P	20010813 (60)
	US 2001-312908P	20010816 (60)
	US 2001-312889P	20010816 (60)
	US 2001-313930P	20010821 (60)
	US 2001-315470P	20010828 (60)
	US 2001-316447P	20010831 (60)
	US 2001-318115P	20010907 (60)
	US 2001-318118P	20010907 (60)
	US 2001-318740P	20010912 (60)
	US 2001-323379P	20010919 (60)
	US 2001-330308P	20011018 (60)
	US 2001-330245P	20011018 (60)
	US 2001-332701P	20011114 (60)
	US 2001-271664P	20010226 (60)

DT Utility  
FS APPLICATION  
LN.CNT 59681  
INCL INCLM: 435/006.000  
INCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 435/183.000; 424/155.100  
NCL NCLM: 435/006.000  
NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 435/183.000; 424/155.100  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-574; C07H021-04; A61K039-395; C12N009-00; C12P021-02;  
C12N005-06; C07K014-47  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 162 OF 469 USPATFULL on STN  
AN 2004:39568 USPATFULL  
TI Novel proteins and nucleic acids encoding same  
IN Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
Kekuda, Ramesh, Danbury, CT, UNITED STATES

Maryankar, Uriel M., Branford, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 Liu, Xiaohong, Branford, CT, UNITED STATES  
 Gusev, Vladimir Y., Madison, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES  
 Vernet, Corine A.M., Branford, CT, UNITED STATES  
 Zerhusen, Bryan D., Branford, CT, UNITED STATES  
 Gorman, Linda, Branford, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Pena, Carol E. A., New Haven, CT, UNITED STATES  
 Smithson, Glennda, Guilford, CT, UNITED STATES  
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Padigar, Muralidhara, Branford, CT, UNITED STATES  
 Shimmets, Richard A., Guilford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Ji, Weizhen, Branford, CT, UNITED STATES  
 Anderson, David W., Branford, CT, UNITED STATES  
 Leite, Mario W., Milford, CT, UNITED STATES  
 Rastelli, Luca, Guilford, CT, UNITED STATES  
 Edinger, Shlomit R., New Haven, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 MacDougall, John R., Hamden, CT, UNITED STATES  
 Rothenberg, Mark E., Clinton, CT, UNITED STATES  
 Mazur, Ann, Bloomfield, CT, UNITED STATES  
 Millet, Isabelle, Milford, CT, UNITED STATES  
 Peyman, John A., New Haven, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES

PI	US 2004030110	A1	20040212
AI	US 2002-114270	A1	20020402 (10)
PRAI	US 2001-281086P		20010403 (60)
	US 2001-281136P		20010403 (60)
	US 2001-281863P		20010405 (60)
	US 2001-281906P		20010405 (60)
	US 2001-282020P		20010406 (60)
	US 2001-282930P		20010410 (60)
	US 2001-282934P		20010410 (60)
	US 2001-283512P		20010412 (60)
	US 2001-283710P		20010413 (60)
	US 2001-284234P		20010417 (60)
	US 2001-285325P		20010419 (60)
	US 2001-285381P		20010420 (60)
	US 2001-285609P		20010420 (60)
	US 2001-285748P		20010423 (60)
	US 2001-285890P		20010423 (60)
	US 2001-286068P		20010424 (60)
	US 2001-286292P		20010425 (60)
	US 2001-287213P		20010427 (60)
	US 2001-288257P		20010502 (60)
	US 2001-294164P		20010529 (60)
	US 2001-294484P		20010530 (60)
	US 2001-298952P		20010618 (60)
	US 2001-299237P		20010619 (60)
	US 2001-299276P		20010619 (60)
	US 2001-318750P		20010912 (60)
	US 2001-324800P		20010925 (60)
	US 2001-324802P		20010925 (60)
	US 2001-325684P		20010927 (60)
	US 2001-330143P		20011017 (60)
	US 2001-332115P		20011121 (60)
	US 2001-332131P		20011114 (60)
	US 2001-332240P		20011114 (60)
	US 2001-332779P		20011114 (60)
	US 2001-337621P		20011204 (60)
	US 2002-345783P		20020103 (60)
	US 2002-350251P		20020116 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 35659  
 INCL INCLM: 536/023.100  
 NCL NCLM: 536/023.100  
 IC [7]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 469 USPATFULL on STN  
 AN 2004:38683 USPATFULL  
 TI Proteins and nucleic acids encoding same  
 IN Edinger, Shlomit R., New Haven, CT, UNITED STATES  
 MacDougall, John R., Hamden, CT, UNITED STATES  
 Millet, Isabelle, Milford, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Grosse, William M., Branford, CT, UNITED STATES  
 Alsobrook, John P., II, Madison, CT, UNITED STATES  
 Lepley, Denise M., Branford, CT, UNITED STATES  
 Rieger, Daniel K., Branford, CT, UNITED STATES  
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Boldog, Ference L., North Haven, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES  
 Padigar, Muralidhara, Branford, CT, UNITED STATES  
 Mishra, Vishnu, Gainesville, FL, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Rastelli, Luca, Guilford, CT, UNITED STATES  
 Tchernev, Velizar T., Branford, CT, UNITED STATES  
 Vernet, Corine A.M., Branford, CT, UNITED STATES  
 Zerhusen, Bryan D., Branford, CT, UNITED STATES  
 Malyankar, Uriel M., Branford, CT, UNITED STATES  
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
 Miller, Charles E., Guilford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 Grosse, Michael, UNITED STATES LR  
 PI US 2004029222 A1 20040212  
 AI US 2002-218779 A1 20020814 (10)  
 RLI Continuation of Ser. No. US 2001-995514, filed on 28 Nov 2001, ABANDONED  
 PRAI US 2000-253834P 20001129 (60)  
 US 2000-250926P 20001130 (60)  
 US 2001-264180P 20010125 (60)  
 US 2001-313656P 20010820 (60)  
 US 2001-327456P 20011005 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 15385  
 INCL INCLM: 435/069.100  
 INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;  
 530/388.100; 435/007.230; 435/006.000  
 NCL NCLM: 435/069.100  
 NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;  
 530/388.100; 435/007.230; 435/006.000  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06;  
 C07K014-47; C07K016-30  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 469 USPATFULL on STN  
 AN 2004:38577 USPATFULL  
 TI Proteins and nucleic acids encoding same  
 IN Edinger, Shlomit R., New Haven, CT, UNITED STATES  
 MacDougall, John R., Hamden, CT, UNITED STATES  
 Millet, Isabelle, Milford, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Grosse, William M., Branford, CT, UNITED STATES  
 Alsobrook, John P., II, Madison, CT, UNITED STATES  
 Lepley, Denise M., Branford, CT, UNITED STATES  
 Rieger, Daniel K., Branford, CT, UNITED STATES  
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Boldog, Ferenc L., North Haven, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES

Mishra, Vishnu, Gainesville, FL, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES  
Vernet, Corine A.M., Branford, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
Guo, Xiaojia, Branford, CT, UNITED STATES  
Miller, Charles E., Guilford, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES

PI US 2004029116 A1 20040212  
AI US 2002-87684 A1 20020301 (10)  
PRAI US 2001-313656P 20010820 (60)  
US 2001-274194P 20010308 (60)  
US 2001-327456P 20011005 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15489  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 469 USPATFULL on STN  
AN 2004:32039 USPATFULL  
TI Novel human proteins, polynucleotides encoding them and methods of using  
the same  
IN Gangolli, Esha A., Madison, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Gilbert, Jennifer, Madison, CT, UNITED STATES  
Casman, Stacie, North Haven, CT, UNITED STATES  
Blalock, Angela, Branford, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Vernet, Corine, Branford, CT, UNITED STATES  
Shenoy, Suresh, Branford, CT, UNITED STATES  
Mishra, Vishnu S., Gainesville, FL, UNITED STATES  
Furtak, Katarzyna, Ansonia, CT, UNITED STATES  
Gerlach, Valerie L., Branford, CT, UNITED STATES  
Edinger, Shlomit, New Haven, CT, UNITED STATES  
Malyanker, Uriel, Branford, CT, UNITED STATES  
Stone, David, Guilford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
Smithson, Glennnda, Guilford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Padigar, Muralidhara, Branford, CT, UNITED STATES  
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
Anderson, David W., Branford, CT, UNITED STATES

PI US 2004024181 A1 20040205  
AI US 2001-55569 A1 20011026 (10)  
PRAI US 2000-243642P 20001026 (60)  
US 2000-243320P 20001026 (60)  
US 2000-243592P 20001026 (60)  
US 2000-243681P 20001027 (60)  
US 2000-243863P 20001027 (60)  
US 2000-244443P 20001031 (60)  
US 2000-245029P 20001101 (60)  
US 2000-244995P 20001101 (60)  
US 2000-245293P 20001102 (60)  
US 2000-245315P 20001102 (60)  
US 2000-245316P 20001102 (60)  
US 2001-262994P 20010119 (60)  
US 2001-269056P 20010215 (60)  
US 2001-272923P 20010302 (60)  
US 2001-276565P 20010315 (60)  
US 2001-318119P 20010907 (60)

DT Utility  
FS APPLICATION

INCL INCLM: 530/350.000  
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000  
NCL NCLM: 530/350.000  
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000  
IC [7]  
ICM: C07K014-705  
ICS: C12P021-02; C12N005-06; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 469 USPATFULL on STN  
AN 2004:31882 USPATFULL  
TI Aromatic sulfone hydroxamates and their use as protease inhibitors  
IN Freskos, John N., Clayton, MO, UNITED STATES  
Fobian, Y vette M., Wildwood, MO, UNITED STATES  
Awasthi, Alok K., Skokie, IL, UNITED STATES  
Barta, Thomas E., Evanston, IL, UNITED STATES  
Becker, Daniel P., Glenview, IL, UNITED STATES  
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES  
Boehm, Terri L., Ballwin, MO, UNITED STATES  
Carroll, Jeffery N., Columbia, IL, UNITED STATES  
Chandrakumar, Nizal S., Vernon Hills, IL, UNITED STATES  
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES  
Desai, Bipin N., Vernon Hills, IL, UNITED STATES  
Heron, Marcia I., Wester Springs, IL, UNITED STATES  
Hockerman, Susan L., Lincolnwood, IL, UNITED STATES  
Jull, Sara M., Villa Park, IL, UNITED STATES  
Kassab, Darren J., O' Fallon, MO, UNITED STATES  
Kolodziej, Steve A., Ballwin, MO, UNITED STATES  
McDonald, Joseph, Wildwood, MO, UNITED STATES  
Mischke, Deborah A., Defiance, MO, UNITED STATES  
Mullins, Patrick B., St. Louis, MO, UNITED STATES  
Norton, Monica B., St. Louis, MO, UNITED STATES  
Rico, Joseph G., Ballwin, MO, UNITED STATES  
Talley, John J., Cambridge, MA, UNITED STATES  
Trivedi, Mahima, Skokie, IL, UNITED STATES  
Villamil, Clara I., Glenview, IL, UNITED STATES  
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES  
PI US 2004024024 A1 20040205  
AI US 2002-291983 A1 20021112 (10)  
RLI Continuation-in-part of Ser. No. US 2002-142737, filed on 10 May 2002,  
PENDING  
PRAI US 2001-290375P 20010511 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 11028  
INCL INCLM: 514/326.000  
INCLS: 514/513.000; 514/357.000; 514/408.000; 514/575.000; 514/382.000;  
514/459.000; 546/210.000; 546/207.000; 548/252.000; 549/416.000  
NCL NCLM: 514/326.000  
NCLS: 514/513.000; 514/357.000; 514/408.000; 514/575.000; 514/382.000;  
514/459.000; 546/210.000; 546/207.000; 548/252.000; 549/416.000  
IC [7]  
ICM: C07D045-02  
ICS: C07D043-02; A61K031-451; A61K031-454; A61K031-415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 469 USPATFULL on STN  
AN 2004:31831 USPATFULL  
TI 1,2-Dihydropyridine compounds, process for preparation of the same and  
use thereof  
IN Nagato, Satoshi, Chiba, JAPAN  
Ueno, Kohshi, Ibaraki, JAPAN  
Kawano, Koki, Ibaraki, JAPAN  
Norimine, Yoshihiko, Ibaraki, JAPAN  
Ito, Koichi, Chiba, JAPAN  
Hanada, Takahisa, Ibaraki, JAPAN  
Ueno, Masataka, Ibaraki, JAPAN  
Amino, Hiroyuki, Ibaraki, JAPAN  
Ogo, Makoto, Ibaraki, JAPAN  
Hatakeyama, Shinji, Ibaraki, JAPAN  
Urawa, Yoshio, Ibaraki, JAPAN  
Naka, Hiroyuki, Ibaraki, JAPAN  
Groom, Anthony John, Wiltshire, UNITED KINGDOM  
Rivers, Leanne, Kent, UNITED KINGDOM  
PI US 2004023973 A1 20040205

WO 2001-JP4857 20010608  
PRAI JP 2000-175966 20000612  
GB 2000-22483 20000913  
DT Utility  
FS APPLICATION  
LN.CNT 9028  
INCL INCLM: 514/252.030  
INCLS: 514/256.000; 514/332.000; 514/333.000; 544/238.000; 544/333.000;  
546/256.000  
NCL NCLM: 514/252.030  
NCLS: 514/256.000; 514/332.000; 514/333.000; 544/238.000; 544/333.000;  
546/256.000  
IC [7]  
ICM: A61K031-506  
ICS: A61K031-501; A61K031-444; C07D043-02; C07D041-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 469 USPATFULL on STN  
AN 2004:31145 USPATFULL  
TI 90 human secreted proteins  
IN Ruben, Steven M., Brookeville, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Greene, John M., Gaithersburg, MD, UNITED STATES  
Ferrie, Ann M., Painted Post, NY, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Brewer, Laurie, St. Paul, MN, UNITED STATES  
Janat, Fouad, Westerly, RI, UNITED STATES  
Birse, Charles E., North Potomac, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

PI US 2004023283 A1 20040205  
AI US 2003-621363 A1 20030718 (10)  
RLI Continuation of Ser. No. US 2001-969730, filed on 4 Oct 2001, PENDING  
Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001,  
PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999,  
ABANDONED Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4  
Aug 1998, PENDING

PRAI US 2000-238291P 20001006 (60)  
US 1997-55386P 19970805 (60)  
US 1997-54807P 19970805 (60)  
US 1997-55312P 19970805 (60)  
US 1997-55309P 19970805 (60)  
US 1997-54798P 19970805 (60)  
US 1997-55310P 19970805 (60)  
US 1997-54806P 19970805 (60)  
US 1997-54809P 19970805 (60)  
US 1997-54804P 19970805 (60)  
US 1997-54803P 19970805 (60)  
US 1997-54808P 19970805 (60)  
US 1997-55311P 19970805 (60)  
US 1997-55986P 19970818 (60)  
US 1997-55970P 19970818 (60)  
US 1997-56563P 19970819 (60)  
US 1997-56557P 19970819 (60)  
US 1997-56731P 19970819 (60)  
US 1997-56365P 19970819 (60)  
US 1997-56367P 19970819 (60)  
US 1997-56370P 19970819 (60)  
US 1997-56364P 19970819 (60)  
US 1997-56366P 19970819 (60)  
US 1997-56732P 19970819 (60)  
US 1997-56371P 19970819 (60)

DT Utility  
FS APPLICATION  
LN.CNT 26395  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;

IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 469 USPATFULL on STN  
AN 2004:31067 USPATFULL  
TI Method of recovering a nucleic acid encoding a proteinaceous binding  
domain which binds a target material  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2004023205 A1 20040205  
AI US 2002-126544 A1 20020422 (10)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15868  
INCL INCLM: 435/005.000  
INCLS: 435/006.000; 536/023.100; 536/023.720  
NCL NCLM: 435/005.000  
NCLS: 435/006.000; 536/023.100; 536/023.720  
IC [7]  
ICM: C12Q001-70  
ICS: C12Q001-68; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 469 USPATFULL on STN  
AN 2004:30644 USPATFULL  
TI Proteins and nucleic acids encoding same  
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Wolenc, Adam R., New Haven, CT, UNITED STATES  
Vernet, Corine, North Branford, CT, UNITED STATES  
Eisen, Andrew J., Rockville, MD, UNITED STATES  
Liu, Xiaohong, Lexington, MA, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
Shimkets, Richard A., Guilford, CT, UNITED STATES  
Tchernev, Velizar, Branford, CT, UNITED STATES  
Spaderna, Steven K., Berlin, CT, UNITED STATES  
Gorman, Linda, Branford, CT, UNITED STATES  
Kekuda, Ramesh, Norwalk, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Gusev, Vladimir Y., Madison, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES  
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Casman, Stacie J., North Haven, CT, UNITED STATES  
Boldog, Ferenc L., North Haven, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
Edinger, Shlomit R., New Haven, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Smithson, Glennnda, Guilford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
MacDougall, John R., Hamden, CT, UNITED STATES  
PI US 2004022781 A1 20040205  
AI US 2001-38854 A1 20011231 (10)  
PRAI US 2000-258928P 20001229 (60)  
US 2001-259415P 20010102 (60)  
US 2001-259785P 20010104 (60)  
US 2001-269814P 20010220 (60)  
US 2001-279832P 20010329 (60)



US 2001-279863P 20010329 (60)  
 US 2001-283889P 20010413 (60)  
 US 2001-284447P 20010418 (60)  
 US 2001-286683P 20010425 (60)  
 US 2001-294080P 20010529 (60)  
 US 2001-312915P 20010816 (60)  
 US 2001-313325P 20010817 (60)  
 US 2001-322699P 20010917 (60)  
 US 2001-333350P 20011126 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 19237  
 INCL INCLM: 424/130.100  
 INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;  
 530/350.000; 536/023.100; 530/388.250  
 NCL NCLM: 424/130.100  
 NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;  
 530/350.000; 536/023.100; 530/388.250  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-53; G01N033-567; C07H021-04; A61K039-395; C12P021-02;  
 C12N005-06; C07K014-47; C07K016-22  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 171 OF 469 USPATFULL on STN  
 AN 2004:24674 USPATFULL  
 TI Classification and prognosis prediction of acute lymphoblastic leukemia  
 by gene expression profiling  
 IN Downing, James R., Cordova, TN, UNITED STATES  
 Yeoh, Eng-Juh, Singapore, SINGAPORE  
 Wilkins, Dawn E., Oxford, MS, UNITED STATES  
 Wong, Limsoon, Singapore, SINGAPORE  
 PI US 2004018513 A1 20040129  
 AI US 2003-391271 A1 20030318 (10)  
 PRAI US 2002-367144P 20020322 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 9169  
 INCL INCLM: 435/006.000  
 NCL NCLM: 435/006.000  
 IC [7]  
 ICM: C12Q001-68  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 172 OF 469 USPATFULL on STN  
 AN 2004:23553 USPATFULL  
 TI Pharmaceutical compositions of drug-oligomer conjugates and methods of  
 treating disease therewith  
 IN Soltero, Richard, Holly Springs, NC, UNITED STATES  
 Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES  
 Opawale, Foyeke, Raleigh, NC, UNITED STATES  
 Rehlaender, Bruce, Chapel Hill, NC, UNITED STATES  
 Hickey, Anthony, Chapel Hill, NC, UNITED STATES  
 Bovet, Li Li, Chapel Hill, NC, UNITED STATES  
 PI US 2004017387 A1 20040129  
 AI US 2003-382069 A1 20030305 (10)  
 RLI Continuation-in-part of Ser. No. US 2002-235281, filed on 5 Sep 2002,  
 PENDING Continuation-in-part of Ser. No. US 2002-235284, filed on 5 Sep  
 2002, PENDING  
 PRAI US 2001-318193P 20010907 (60)  
 US 2002-377865P 20020503 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3722  
 INCL INCLM: 345/700.000  
 NCL NCLM: 345/700.000  
 IC [7]  
 ICM: G09G005-00  
 L4 ANSWER 173 OF 469 USPATFULL on STN  
 AN 2004:21609 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
 compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
 .- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use  
 IN Wu, Jing, San Mateo, CA, United States

tnorsett, Eugene D., Moss Beach, CA, United States  
Pleiss, Michael A., Sunnyvale, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Neitz, R. Jeffrey, San Francisco, CA, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Freedman, Stephen, Walnut Creek, CA, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James A., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Henry, Steven S., New Palastine, IN, United States  
McDaniel, Stacey L., Indianapolis, IN, United States  
Scott, William Leonard, Indianapolis, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6683075 B1 20040127  
AI US 2003-336806 20030106 (10)  
RLI Division of Ser. No. US 2001-915564, filed on 27 Jul 2001 Division of  
Ser. No. US 1997-996422, filed on 22 Dec 1997  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS GRANTED  
LN.CNT 19986  
INCL INCLM: 514/220.000  
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/517.000; 540/518.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/517.000; 540/518.000  
IC [7]  
ICM: A61K031-55  
ICS: C07D487-04; C07D243-12; C07D243-24; C07D487-00  
EXF 540/496; 540/497; 540/498; 540/499; 540/504; 540/517; 540/518; 514/220;  
514/221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 469 USPATFULL on STN  
AN 2004:20717 USPATFULL  
TI Rice promoters for regulation of plant expression  
IN Budworth, Paul, San Diego, CA, UNITED STATES  
Moughamer, Todd, San Diego, CA, UNITED STATES  
Briggs, Steven P., Del Mar, CA, UNITED STATES  
Cooper, Bret, La Jolla, CA, UNITED STATES  
Glazebrook, Jane, San Diego, CA, UNITED STATES  
Goff, Stephen Arthur, Encinitas, CA, UNITED STATES  
Katagiri, Fumiaki, San Diego, CA, UNITED STATES  
Kreps, Joel, Carlsbad, CA, UNITED STATES  
Provart, Nicholas, Toronto, CANADA  
Ricke, Darrell, San Diego, CA, UNITED STATES  
Zhu, Tong, San Diego, CA, UNITED STATES

PI US 2004016025 A1 20040122  
AI US 2002-260238 A1 20020926 (10)  
PRAI US 2001-325448P 20010926 (60)  
US 2001-325277P 20010926 (60)  
US 2002-370620P 20020404 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 18818  
INCL INCLM: 800/287.000  
INCLS: 800/312.000; 800/320.000; 800/320.100; 800/320.200; 800/320.300;  
435/419.000; 435/320.100  
NCL NCLM: 800/287.000  
NCLS: 800/312.000; 800/320.000; 800/320.100; 800/320.200; 800/320.300;  
435/419.000; 435/320.100  
IC [7]  
ICM: A01H005-00  
ICS: C12N015-82; C12N005-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 469 USPATFULL on STN  
AN 2004:18798 USPATFULL  
TI In vivo production of cyclic peptides for inhibiting protein-protein  
interaction  
IN Lorenz, James B., Bones, NORWAY  
Kinsella, Todd M., Redwood City, CA, UNITED STATES  
Pray, Todd, San Francisco, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
PI US 2004014100 A1 20040122  
AI US 2003-422536 A1 20030423 (10)  
RLI Continuation of Ser. No. US 2002-232758, filed on 30 Aug 2002, PENDING  
Continuation-in-part of Ser. No. US 2001-800770, filed on 6 Mar 2001,  
PENDING  
PRAI US 2000-187130P 20000306 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4089  
INCL INCLM: 435/006.000  
INCLS: 435/007.200  
NCL NCLM: 435/006.000  
NCLS: 435/007.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; G01N033-567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 469 USPATFULL on STN  
AN 2004:18738 USPATFULL  
TI Cardiotoxin molecular toxicology modeling  
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES  
Porter, Mark, Gaithersburg, MD, UNITED STATES  
Johnson, Kory, Gaithersburg, MD, UNITED STATES  
Higgs, Brandon, Gaithersburg, MD, UNITED STATES  
Castle, Arthur, Gaithersburg, MD, UNITED STATES  
Elashoff, Michael, Gaithersburg, MD, UNITED STATES  
PI US 2004014040 A1 20040122  
AI US 2002-191803 A1 20020710 (10)  
PRAI US 2001-303819P 20010710 (60)  
US 2001-305623P 20010717 (60)  
US 2002-369351P 20020403 (60)  
US 2002-377611P 20020506 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15812  
INCL INCLM: 435/006.000  
INCLS: 702/020.000  
NCL NCLM: 435/006.000  
NCLS: 702/020.000  
IC [7]  
ICM: C12Q001-68  
ICS: G06F019-00; G01N033-48; G01N033-50  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 469 USPATFULL on STN  
AN 2004:13596 USPATFULL  
TI Novel proteins and nucleic acids encoding same  
IN Guo, Xiaojia, Branford, CT, UNITED STATES  
Fernandes, Elma, Branford, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Kekuda, Ramesh, Stamford, CT, UNITED STATES  
Liu, Yi, New Haven, CT, UNITED STATES  
Leite, Mario, Milford, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Ji, Weizhen, Branford, CT, UNITED STATES  
Casman, Stacie J., North Haven, CT, UNITED STATES  
Boldog, Ference L., North Haven, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Vernet, Corine A. M., Branford, CT, UNITED STATES  
Ballinger, Robert A., Newington, CT, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES  
Blalock, Angela D., Branford, CT, UNITED STATES  
Gusev, Vladimir Y., Madison, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Mezes, Peter D., Old Lyme, CT, UNITED STATES

Heyes, Melvyn, New Haven, CT, UNITED STATES  
Herrmann, John L., Guilford, CT, UNITED STATES  
Shimkets, Richard A., Guilford, CT, UNITED STATES  
Ioime, Noelle, Hamden, CT, UNITED STATES  
Pena, Carol E. A., New Haven, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Gorman, Linda, East Haven, CT, UNITED STATES

PI US 2004010119 A1 20040115  
AI US 2002-74978 A1 20020212 (10)  
PRAI

US 2001-268221P 20010212 (60)  
US 2001-268496P 20010213 (60)  
US 2001-268665P 20010214 (60)  
US 2001-268646P 20010214 (60)  
US 2001-269136P 20010215 (60)  
US 2001-269310P 20010216 (60)  
US 2001-269530P 20010216 (60)  
US 2001-276405P 20010315 (60)  
US 2001-276703P 20010316 (60)  
US 2001-276399P 20010316 (60)  
US 2001-278199P 20010323 (60)  
US 2001-279274P 20010328 (60)  
US 2001-280238P 20010330 (60)  
US 2001-280899P 20010402 (60)  
US 2001-310797P 20010808 (60)  
US 2001-312284P 20010814 (60)  
US 2001-322294P 20010914 (60)  
US 2001-322295P 20010914 (60)  
US 2001-330293P 20011018 (60)  
US 2001-335104P 20011031 (60)  
US 2001-335109P 20011031 (60)  
US 2001-332127P 20011121 (60)  
US 2001-331772P 20011121 (60)

DT Utility  
FS APPLICATION  
LN.CNT 23189

INCL INCLM: 530/350.000  
INCLS: 514/012.000; 435/006.000; 435/069.100; 435/320.100; 435/325.000;  
536/023.200  
NCL NCLM: 530/350.000  
NCLS: 514/012.000; 435/006.000; 435/069.100; 435/320.100; 435/325.000;  
536/023.200

IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; A61K038-17; C07K014-435; C07K014-47; C12P021-02;  
C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 469 USPATFULL on STN

AN 2004:13496 USPATFULL

TI Aromatic sulfone hydroxamates and their use as protease inhibitors

IN Freskos, John N., Clayton, MO, UNITED STATES  
Fobian, Yvette M., Wildwood, MO, UNITED STATES  
Barta, Thomas E., Evanston, IL, UNITED STATES  
Becker, Daniel P., Glenview, IL, UNITED STATES  
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES  
Boehm, Terri L., Ballwin, MO, UNITED STATES  
Carroll, Jeffery N., Columbia, IL, UNITED STATES  
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES  
Hockerman, Susan L., Chicago, IL, UNITED STATES  
Kassab, Darren J., Wildwood, MO, UNITED STATES  
Kolodziej, Steve A., Ballwin, MO, UNITED STATES  
McDonald, Joseph, Wildwood, MO, UNITED STATES  
Mischke, Deborah A., Defiance, MO, UNITED STATES  
Norton, Monica B., St. Louis, MO, UNITED STATES  
Rico, Joseph G., Ballwin, MO, UNITED STATES  
Talley, John J., Cambridge, MA, UNITED STATES  
Villamil, Clara I., Glenview, IL, UNITED STATES  
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES

PI US 2004010019 A1 20040115  
US 6689794 B2 20040210  
AI US 2002-142737 A1 20020510 (10)  
PRAI US 2001-290375P 20010511 (60)  
DT Utility

LN.CNT 15379  
 INCL INCLM: 514/346.000  
 INCLS: 514/424.000; 514/534.000; 514/507.000; 514/575.000; 546/297.000;  
 548/550.000; 560/041.000; 560/312.000; 562/621.000  
 NCL NCLM: 514/318.000  
 NCLS: 514/317.000; 514/321.000; 514/326.000; 514/336.000; 514/364.000;  
 514/365.000; 514/374.000; 514/376.000; 514/382.000; 514/389.000;  
 514/392.000; 514/422.000; 514/444.000; 546/187.000; 546/194.000;  
 546/197.000; 546/207.000; 546/209.000; 546/210.000; 546/211.000;  
 546/213.000; 546/281.700; 546/282.100; 548/131.000; 548/143.000;  
 548/204.000; 548/229.000; 548/236.000; 548/253.000; 548/311.100;  
 548/517.000; 549/060.000

IC [7]  
 ICM: C07D213-72  
 ICS: A61K031-215; C07D207-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 469 USPATFULL on STN  
 AN 2004:13385 USPATFULL  
 TI Proteins and nucleic acids encoding same  
 IN Alsobrook, John P., II, Madison, CT, UNITED STATES  
 Anderson, David W., Branford, CT, UNITED STATES  
 Ballinger, Robert A., Newington, CT, UNITED STATES  
 Boldog, Ference L., North Haven, CT, UNITED STATES  
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Gilbert, Jennifer A., Madison, CT, UNITED STATES  
 Gorman, Linda, Branford, CT, UNITED STATES  
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
 Gusev, Vladimir Y., Madison, CT, UNITED STATES  
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES  
 Liu, Xiaohong, Branford, CT, UNITED STATES  
 Malyankar, Uriel M., Branford, CT, UNITED STATES  
 Miller, Charles E., Guilford, CT, UNITED STATES  
 Millet, Isabelle, Milford, CT, UNITED STATES  
 Padigar, Muralidhara, Branford, CT, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 A. Pena, Carol E., New Haven, CT, UNITED STATES  
 Peyman, John A., New Haven, CT, UNITED STATES  
 Rastelli, Luca, Guilford, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Shinkets, Richard A., Guilford, CT, UNITED STATES  
 Smithson, Glennda, Guilford, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
 Tchernev, Velizar T., Branford, CT, UNITED STATES  
 Vernet, Corine A.M., Branford, CT, UNITED STATES  
 Zerhusen, Bryan D., Branford, CT, UNITED STATES

PI US 2004009907 A1 20040115  
 AI US 2002-85198 A1 20020225 (10)  
 PRAI US 2001-271646P 20010226 (60)  
 US 2001-276401P 20010316 (60)  
 US 2001-311981P 20010813 (60)  
 US 2001-312858P 20010816 (60)  
 US 2001-271840P 20010227 (60)  
 US 2001-277324P 20010320 (60)  
 US 2001-286096P 20010424 (60)  
 US 2001-299695P 20010620 (60)  
 US 2001-315614P 20010829 (60)  
 US 2001-272405P 20010228 (60)  
 US 2001-272410P 20010228 (60)  
 US 2001-272414P 20010228 (60)  
 US 2001-278660P 20010320 (60)  
 US 2001-280234P 20010330 (60)  
 US 2001-272404P 20010228 (60)  
 US 2001-280039P 20010330 (60)  
 US 2001-313280P 20010817 (60)  
 US 2001-322818P 20010917 (60)  
 US 2001-273300P 20010302 (60)  
 US 2001-280818P 20010402 (60)

US 2001-294834P 20010531 (60)  
US 2001-299845P 20010621 (60)  
US 2001-272922P 20010302 (60)  
US 2001-272787P 20010302 (60)  
US 2001-285754P 20010423 (60)  
US 2001-303242P 20010705 (60)  
US 2001-273048P 20010302 (60)  
US 2001-283443P 20010412 (60)  
US 2001-291703P 20010517 (60)

DT Utility  
FS APPLICATION

LN.CNT 46330

INCL INCLM: 514/012.000  
INCLS: 530/350.000; 536/023.100; 514/044.000

NCL NCLM: 514/012.000  
NCLS: 530/350.000; 536/023.100; 514/044.000

IC [7]  
ICM: A61K038-16  
ICS: A61K031-711; C07K014-435; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 469 USPATFULL on STN

AN 2004:13003 USPATFULL

TI Diagnosis, prognosis and identification of potential therapeutic targets  
of multiple myeloma based on gene expression profiling

IN Shaughnessy, John D., Little Rock, AR, UNITED STATES

Zhan, Fenghuang, Little Rock, AR, UNITED STATES

Barlogie, Bart, Little Rock, AR, UNITED STATES

PI US 2004009523 A1 20040115

AI US 2003-454263 A1 20030604 (10)

RLI Continuation-in-part of Ser. No. US 2003-409004, filed on 8 Apr 2003,  
PENDING Continuation-in-part of Ser. No. US 2002-289746, filed on 7 Nov  
2002, PENDING

PRAI US 2002-403075P 20020813 (60)

US 2001-348238P 20011107 (60)

US 2002-355386P 20020208 (60)

DT Utility  
FS APPLICATION

LN.CNT 4510

INCL INCLM: 435/006.000

NCL NCLM: 435/006.000

IC [7]  
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 469 USPATFULL on STN

AN 2004:12969 USPATFULL

TI Classification of lung carcinomas using gene expression analysis

IN Golub, Todd R., Newton, MA, UNITED STATES

Meyerson, Matthew, Concord, MA, UNITED STATES

Bhattacharjee, Arindam, Andover, MA, UNITED STATES

Staunton, Jane, Cambridge, MA, UNITED STATES

PI US 2004009489 A1 20040115

AI US 2002-259233 A1 20020927 (10)

PRAI US 2001-325962P 20010928 (60)

DT Utility  
FS APPLICATION

LN.CNT 4627

INCL INCLM: 435/006.000

NCL NCLM: 435/006.000

IC [7]  
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 182 OF 469 USPATFULL on STN

AN 2004:7810 USPATFULL

TI Substituted phenylsulfonamide inhibitors of \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* production

IN Kreft, Anthony Frank, Langhorne, PA, UNITED STATES

Cole, Derek Cecil, New City, NY, UNITED STATES

Woller, Kevin Roger, Ayer, MA, UNITED STATES

Stock, Joseph Raymond, Monroe, NY, UNITED STATES

Kutterer, Kristina Martha, Westwood, NJ, UNITED STATES

Kubrak, Dennis Martin, Philadelphia, PA, UNITED STATES

Mann, Charles William, North Wales, PA, UNITED STATES

Casebler, David Scott, Carlisle, MA, UNITED STATES  
PA Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)  
ArQule Inc., Woburn, MA, UNITED STATES (U.S. corporation)  
PI US 2004006050 A1 20040108  
AI US 2003-457641 A1 20030609 (10)  
PRAI US 2002-387690P 20020611 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3798  
INCL INCLM: 514/150.000  
INCLS: 514/602.000; 514/603.000; 514/467.000; 514/364.000; 534/844.000;  
548/144.000; 549/430.000; 564/087.000  
NCL NCLM: 514/150.000  
NCLS: 514/602.000; 514/603.000; 514/467.000; 514/364.000; 534/844.000;  
548/144.000; 549/430.000; 564/087.000  
IC [7]  
ICM: A61K031-655  
ICS: A61K031-335; A61K031-18; A61K031-4245  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 469 USPATFULL on STN  
AN 2004:7422 USPATFULL  
TI Novel GPCR-like proteins and nucleic acids encoding same  
IN Kekuda, Ramesh, Stamford, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Casman, Stacie J., North Haven, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES  
Colman, Steven D., Guilford, CT, UNITED STATES  
Ballinger, Robert A., Newington, CT, UNITED STATES  
Padigaru, Muralidhara, Branford, CT, UNITED STATES  
Wolenc, Adam R., East Haven, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Edinger, Shlomit R., New Haven, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES  
MacDougall, John R., Hamden, CT, UNITED STATES  
Smithson, Glennda, Guildford, CT, UNITED STATES  
Peyman, John A., New Haven, CT, UNITED STATES  
Stone, David J., Guilford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Grosse, William M., Branford, CT, UNITED STATES  
Alsbrook, John P., II, Madison, CT, UNITED STATES  
Lepley, Denise M., Branford, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
PI US 2004005656 A1 20040108  
AI US 2001-981566 A1 20011016 (9)  
PRAI US 2000-240704P 20001016 (60)  
US 2001-262159P 20010117 (60)  
US 2001-263340P 20010122 (60)  
US 2001-264118P 20010125 (60)  
US 2001-308203P 20010727 (60)  
US 2000-243497P 20001026 (60)  
US 2000-244542P 20001031 (60)  
US 2001-269031P 20010215 (60)  
US 2000-245484P 20001103 (60)  
US 2000-255017P 20001212 (60)  
US 2001-263216P 20010122 (60)  
US 2001-268225P 20010212 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 14022  
INCL INCLM: 435/069.100  
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C07K014-705  
ICS: C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 469 USPATFULL on STN  
AN 2004:7342 USPATFULL

1N Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 Shimkets, Richard A., Guilford, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Malyankar, Uriel M., Branford, CT, UNITED STATES  
 Tchernev, Velizar T., Branford, CT, UNITED STATES  
 Vernet, Corine A., North Branford, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Alsobrook, John P., II, Madison, CT, UNITED STATES  
 Edinger, Schlomit, New Haven, CT, UNITED STATES  
 Peyman, John A., New Haven, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 Boldog, Ferenc L., North Haven, CT, UNITED STATES  
 Colman, Steven D., Guilford, CT, UNITED STATES  
 Eisen, Andrew, Rockville, MD, UNITED STATES  
 Liu, Xiaohong, Lexington, MA, UNITED STATES  
 Padigaru, Muralidhara, Branford, CT, UNITED STATES  
 Spaderna, Steven K., Berlin, CT, UNITED STATES  
 Zerhusen, Bryan D., Branford, CT, UNITED STATES  
 PI US 2004005576 A1 20040108  
 AI US 2002-231913 A1 20020830 (10)  
 RLI Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING  
 PRAI US 2000-251660P 20001206 (60)  
 US 2001-260326P 20010108 (60)  
 US 2001-318712P 20010912 (60)  
 US 2000-255029P 20001212 (60)  
 US 2001-263800P 20010124 (60)  
 US 2001-286183P 20010424 (60)  
 US 2001-269942P 20010220 (60)  
 US 2001-313627P 20010820 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 17887  
 INCL INCLM: 435/006.000  
 INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200  
 NCL NCLM: 435/006.000  
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200  
 IC [7]  
 ICM: C12Q001-68  
 ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 185 OF 469 USPATFULL on STN  
 AN 2004:7329 USPATFULL  
 TI Methods of diagnosis of ovarian cancer, compositions and methods of  
 screening for modulators of ovarian cancer  
 IN Mack, David H., Menlo Park, CA, UNITED STATES  
 Gish, Kurt C., San Francisco, CA, UNITED STATES  
 PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)  
 PI US 2004005563 A1 20040108  
 AI US 2002-173999 A1 20020617 (10)  
 PRAI US 2002-372246P 20020412 (60)  
 US 2001-350666P 20011113 (60)  
 US 2001-315287P 20010827 (60)  
 US 2001-299234P 20010618 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 32540  
 INCL INCLM: 435/006.000  
 INCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100;  
 536/023.200  
 NCL NCLM: 435/006.000  
 NCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100;  
 536/023.200  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-08  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 186 OF 469 USPATFULL on STN  
 AN 2004:7306 USPATFULL



fusion proteins  
 IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
 Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
 Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
 Markland, William, Milford, MA, UNITED STATES  
 Ley, Arthur Charles, Newton, MA, UNITED STATES  
 Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
 PI US 2004005539 A1 20040108  
 AI US 2002-127028 A1 20020422 (10)  
 RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED  
 Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
 Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
 ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
 Sep 1988, ABANDONED  
 PRAI WO 1989-US3731 19890901  
 DT Utility  
 FS APPLICATION  
 LN.CNT 16057  
 INCL INCLM: 435/005.000  
 INCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;  
 435/320.100; 536/023.720  
 NCL NCLM: 435/005.000  
 NCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;  
 435/320.100; 536/023.720  
 IC [7]  
 ICM: C12Q001-70  
 ICS: C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N001-21;  
 C12N015-86  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 187 OF 469 USPATFULL on STN  
 AN 2004:2561 USPATFULL  
 TI Proteins, polynucleotides encoding them and methods of using the same  
 IN Pena, Carol E. A., New Haven, CT, UNITED STATES  
 Shimkets, Richard A., Guilford, CT, UNITED STATES  
 Li, Li, Branford, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Vernet, Corine A.M., Branford, CT, UNITED STATES  
 Malyankar, Uriel M., Branford, CT, UNITED STATES  
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
 Gusev, Vladimir Y., Madison, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Boldog, Ferenc L., North Haven, CT, UNITED STATES  
 Furtak, Katarzyna, Ansonia, CT, UNITED STATES  
 Tchernev, Velizar T., Branford, CT, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 Padigar, Muralidhara, Branford, CT, UNITED STATES  
 Liu, Xiaohong, Branford, CT, UNITED STATES  
 Baumgartner, Jason C., New Haven, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Spaderna, Steven K., Berlin, CT, UNITED STATES  
 Zerhusen, Bryan D., Branford, CT, UNITED STATES  
 PI US 2004002584 A1 20040101  
 AI US 2002-80334 A1 20020221 (10)  
 PRAI US 2001-270523P 20010221 (60)  
 US 2001-322712P 20010917 (60)  
 US 2001-311980P 20010813 (60)  
 US 2001-330307P 20011018 (60)  
 US 2001-278796P 20010326 (60)  
 US 2001-281521P 20010404 (60)  
 US 2001-276677P 20010316 (60)  
 US 2001-311595P 20010810 (60)  
 US 2001-270220P 20010221 (60)  
 US 2001-274295P 20010308 (60)  
 US 2001-318526P 20010910 (60)  
 US 2001-286548P 20010425 (60)  
 US 2001-291765P 20010517 (60)  
 US 2001-270797P 20010223 (60)  
 US 2001-276400P 20010316 (60)

DT Utility  
FS APPLICATION  
LN.CNT 20544  
INCL INCLM: 530/350.000  
NCL NCLM: 530/350.000  
IC [7]

ICM: C07K001-00

ICS: C07K014-00; C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 469 USPATFULL on STN  
AN 2004:2113 USPATFULL  
TI Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides  
IN Shimkets, Richard A., Guilford, CT, UNITED STATES  
Fernandes, Elma R., Branford, CT, UNITED STATES  
Herrman, John L., Guilford, CT, UNITED STATES  
Vernet, Corine A.M., Branford, CT, UNITED STATES  
PA CuraGen Corporation, New Haven, CT, 06511 (U.S. corporation)  
PI US 2004002134 A1 20040101  
AI US 2001-977819 A1 20011015 (9)  
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING  
PRAI US 2000-201388P 20000503 (60)  
US 2000-193086P 20000330 (60)  
US 2000-191158P 20000322 (60)  
US 2000-189810P 20000316 (60)  
US 1999-137322P 19990603 (60)

DT Utility  
FS APPLICATION

LN.CNT 7136  
INCL INCLM: 435/069.100  
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200  
NCL NCLM: 435/069.100  
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200  
IC [7]

ICM: C07H021-04

ICS: C12N009-00; C12P021-02; C12N005-06; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 469 USPATFULL on STN  
AN 2003:337233 USPATFULL  
TI Mutant genes in Familial British Dementia and Familial Danish Dementia  
IN Ghiso, Jorge, Elmhurst, NY, United States  
Vidal, Ruben, Great Neck, NY, United States  
Frangione, Blas, New York, NY, United States  
PA New York University, New York, NY, United States (U.S. corporation)  
PI US 6670195 B1 20031230  
AI US 2000-579012 20000526 (9)  
PRAI US 1999-136238P 19990526 (60)

DT Utility  
FS GRANTED

LN.CNT 2973  
INCL INCLM: 436/513.000  
INCLS: 530/387.100; 530/387.900; 530/388.100  
NCL NCLM: 436/513.000  
NCLS: 530/387.100; 530/387.900; 530/388.100  
IC [7]

ICM: C07K016-00

ICS: C12P021-08; G01N033-563

EXF 530/387.1; 530/388.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 469 USPATFULL on STN  
AN 2003:335511 USPATFULL  
TI Proteins, polynucleotides encoding them and methods of using the same  
IN Shimkets, Richard A., Guilford, CT, UNITED STATES  
Colman, Steven D., Guilford, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Ballinger, Robert A., Newington, CT, UNITED STATES  
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES

Casman, Stacie J., North Haven, CT, UNITED STATES  
Boldog, Ferenc, North Haven, CT, UNITED STATES  
Gusev, Vladimir Y., Madison, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
Edinger, Shlomit R., New Haven, CT, UNITED STATES  
Gangolli, Esha A., Madison, CT, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Smithson, Glennnda, Guilford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES

PI US 2003236389 A1 20031225  
AI US 2001-23634 A1 20011214 (10)  
PRAI US 2000-256025P 20001215 (60)  
US 2001-265163P 20010130 (60)  
US 2001-272929P 20010302 (60)  
US 2001-274864P 20010309 (60)  
US 2001-276688P 20010316 (60)  
US 2001-277880P 20010322 (60)  
US 2001-286409P 20010425 (60)  
US 2001-309246P 20010731 (60)  
US 2001-315600P 20010829 (60)

DT Utility  
FS APPLICATION  
LN.CNT 11197  
INCL INCLM: 530/350.000  
NCL NCLM: 530/350.000  
IC [7]

ICM: C07K001-00  
ICS: C07K014-00; C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 191 OF 469 USPATFULL on STN  
AN 2003:332380 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
.. \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Pleiss, Michael A., Sunnyvale, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Neitz, R. Jeffrey, San Francisco, CA, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Freedman, Stephen, Walnut Creek, CA, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James A., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Henry, Steven S., New Palestine, IN, United States  
McDaniel, Stacey L., Indianapolis, IN, United States  
Scott, William Leonard, Indianapolis, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6667305 B1 20031223  
AI US 2003-336745 20030106 (10)  
RLI Division of Ser. No. US 2002-915379, filed on 27 Jul 2002, now patented, Pat. No. US 6579867 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997

PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS GRANTED  
LN.CNT 19309  
INCL INCLM: 514/220.000  
INCLS: 514/221.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000

ICM: A61P025-28  
EXF 514/220; 514/221  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 469 USPATFULL on STN  
AN 2003:330769 USPATFULL  
TI Succinoylamino heterocycles as inhibitors of a beta protein production  
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES  
Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES  
PI US 2003232985 A1 20031218  
AI US 2003-409960 A1 20030409 (10)  
RLI Continuation of Ser. No. US 2001-823820, filed on 31 Mar 2001, ABANDONED  
PRAI US 2000-193490P 20000331 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3927  
INCL INCLM: 544/059.000  
INCLS: 544/162.000; 544/399.000; 546/226.000; 548/146.000; 548/215.000;  
548/530.000  
NCL NCLM: 544/059.000  
NCLS: 544/162.000; 544/399.000; 546/226.000; 548/146.000; 548/215.000;  
548/530.000  
IC [7]  
ICM: C07D279-12  
ICS: C07D277-08; C07D265-30  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 469 USPATFULL on STN  
AN 2003:330153 USPATFULL  
TI Diagnosis, prognosis and identification of potential therapeutic targets  
of multiple myeloma based on gene expression profiling  
IN Shaughnessy, John D., Little Rock, AR, UNITED STATES  
Barlogie, Bart, Little Rock, AR, UNITED STATES  
Zhan, Fenghuang, Little Rock, AR, UNITED STATES  
PI US 2003232364 A1 20031218  
AI US 2003-409004 A1 20030408 (10)  
RLI Continuation-in-part of Ser. No. US 2002-289746, filed on 7 Nov 2002,  
PENDING  
PRAI US 2002-403075P 20020813 (60)  
US 2001-348238P 20011107 (60)  
US 2002-355386P 20020208 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4100  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]  
ICM: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 469 USPATFULL on STN  
AN 2003:330121 USPATFULL  
TI Novel proteins and nucleic acids encoding same  
IN Padigar, Muralidhara, Branford, CT, UNITED STATES  
Kekuda, Ramesh, Norwalk, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Ballinger, Robert A., Newington, CT, UNITED STATES  
Casman, Stacie J., North Haven, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Colman, Steven D., Guilford, CT, UNITED STATES  
Vernet, Corine A.M., Branford, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Gusev, Vladimir Y., Madison, CT, UNITED STATES  
Malyankar, Uriel M., Branford, CT, UNITED STATES  
Edinger, Shlomit R., New Haven, CT, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Smithson, Glennda, Guilford, CT, UNITED STATES  
Stone, David J., Guilford, CT, UNITED STATES  
Sciore, Paul, North Haven, CT, UNITED STATES  
MacDougall, John R., Hamden, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Peyman, John A., New Haven, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES

woienc, Adam R., New Haven, CT, UNITED STATES

PI US 2003232332 A1 20031218  
 AI US 2001-24212 A1 20011218 (10)  
 PRAI US 2000-256635P 20001218 (60)  
 US 2001-259743P 20010104 (60)  
 US 2001-299327P 20010619 (60)  
 US 2001-261498P 20010112 (60)  
 US 2001-263689P 20010124 (60)  
 US 2001-267464P 20010208 (60)  
 US 2001-271021P 20010222 (60)  
 US 2001-275946P 20010314 (60)  
 US 2001-278150P 20010323 (60)  
 US 2001-285718P 20010423 (60)  
 US 2001-312902P 20010816 (60)  
 US 2000-257876P 20001221 (60)  
 US 2001-260718P 20010110 (60)  
 US 2001-284591P 20010418 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 24320  
 INCL INCLM: 435/006.000  
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 NCL NCLM: 435/006.000  
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 IC [7]  
 ICM: C12Q001-68  
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 469 USPATFULL on STN  
 AN 2003:327023 USPATFULL  
 TI Methods for inhibition and dissolution of amyloidoses by administration  
 of compositions comprising 2,4-dinitrophenol  
 IN Ferreira, Sergio Teixeira, Rio de Janeiro, BRAZIL  
 De Felice, Fernanda Guarino, Rio de Janeiro, BRAZIL  
 Louzada, Jr., Paulo Roberto Ferreira, Rio de Janeiro, BRAZIL  
 PA Universidade Federal do Rio de Janeiro, BRAZIL (non-U.S. corporation)  
 PI US 6664297 B1 20031216  
 AI US 2000-692743 20001018 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 723  
 INCL INCLM: 514/728.000  
 INCLS: 514/724.000; 514/727.000; 514/731.000; 514/742.000  
 NCL NCLM: 514/728.000  
 NCLS: 514/724.000; 514/727.000; 514/731.000; 514/742.000  
 IC [7]  
 ICM: A61K031-045  
 ICS: A61K031-04; A01N033-18; A01N033-24; A01N031-08  
 EXF 514/728; 514/724; 514/727; 514/731; 514/742  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 469 USPATFULL on STN  
 AN 2003:325922 USPATFULL  
 TI Transgenic non-human mammals with progressive neurologic disease  
 IN Hsiao, Karen, North Oaks, MN, UNITED STATES  
 Borchelt, David R., Baltimore, MD, UNITED STATES  
 Sisodia, Sangram S., Baltimore, MD, UNITED STATES  
 PA John Hopkins University, a Maryland corporation (U.S. corporation)  
 Regents of the University of Minnesota, a Minnesota corporation (U.S.  
 corporation)  
 PI US 2003229907 A1 20031211  
 AI US 2002-271314 A1 20021015 (10)  
 RLI Continuation of Ser. No. US 1999-260897, filed on 2 Mar 1999, GRANTED,  
 Pat. No. US 6509515 Continuation of Ser. No. US 1996-664872, filed on 17  
 Jun 1996, GRANTED, Pat. No. US 5877399 Continuation-in-part of Ser. No.  
 US 1996-644691, filed on 10 May 1996, ABANDONED Continuation of Ser. No.  
 US 1994-189064, filed on 27 Jan 1994, ABANDONED

DT Utility  
 FS APPLICATION  
 LN.CNT 2716  
 INCL INCLM: 800/012.000  
 INCLS: 800/018.000  
 NCL NCLM: 800/012.000  
 NCLS: 800/018.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 197 OF 469 USPATFULL on STN  
 AN 2003:325042 USPATFULL  
 TI Methods and compounds for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
 peptide release and/or its synthesis  
 IN Audia, James E., Indianapolis, IN, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Folmer, Beverly K., Newark, DE, UNITED STATES  
 Huffman, George W., Carmel, IN, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Wu, Jing, San Mateo, CA, UNITED STATES  
 Eid, Clark Norman, Cheshire, CT, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 PI US 2003229024 A1 20031211  
 AI US 2002-309569 A1 20021203 (10)  
 RLI Continuation of Ser. No. US 2001-789487, filed on 20 Feb 2001, PENDING  
 Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,  
 Pat. No. US 6191166  
 PRAI US 1996-108166P 19961122 (60)  
 US 1997-64859P 19970228 (60)  
 US 1997-108161P 19970228 (60)  
 US 1997-98558P 19970228 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 14968  
 INCL INCLM: 514/017.000  
 INCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000;  
 530/331.000  
 NCL NCLM: 514/017.000  
 NCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000;  
 530/331.000  
 IC [7]  
 ICM: A61K038-08  
 ICS: A61K038-06; A61K038-05; C07K007-08; C07K007-06; C07K005-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 469 USPATFULL on STN  
 AN 2003:324595 USPATFULL  
 TI Methods of diagnosis of Hepatitis C infection, compositions and methods  
 of screening for modulators of Hepatitis C infection  
 IN Yat Wah Tom, Edward, Sacramento, CA, UNITED STATES  
 Zlotnik, Albert, Palo Alto, CA, UNITED STATES  
 PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)  
 PI US 2003228570 A1 20031211  
 AI US 2003-366435 A1 20030212 (10)  
 RLI Continuation of Ser. No. US 2002-206473, filed on 24 Jul 2002, ABANDONED  
 PRAI US 2002-366782P 20020321 (60)  
 US 2001-308188P 20010726 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 22742  
 INCL INCLM: 435/005.000  
 INCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000;  
 530/388.300; 536/023.720  
 NCL NCLM: 435/005.000  
 NCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000;  
 530/388.300; 536/023.720  
 IC [7]  
 ICM: C12Q001-70  
 ICS: C12Q001-68; C07H021-04; C07K014-02; C07K016-08; C12P021-02;  
 C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 469 USPATFULL on STN  
 AN 2003:324327 USPATFULL

the same  
 Li, Li, Branford, CT, UNITED STATES  
 Furtak, Katarzyna, Ansonia, CT, UNITED STATES  
 Perna, Amanda, Hamden, CT, UNITED STATES  
 Patturajan, Meera, Branford, CT, UNITED STATES  
 Shimkets, Richard A., Guilford, CT, UNITED STATES  
 Guo, Xiaojia Sasha, Branford, CT, UNITED STATES  
 Casman, Stacie J., North Haven, CT, UNITED STATES  
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
 Malyankar, Uriel M., Branford, CT, UNITED STATES  
 Tchernev, Velizar T., Branford, CT, UNITED STATES  
 Vernet, Corine A., Branford, CT, UNITED STATES  
 Spytek, Kimberly A., New Haven, CT, UNITED STATES  
 Agee, Michele, Wallingford, CT, UNITED STATES  
 Rastelli, Luca, Guilford, CT, UNITED STATES  
 Shenoy, Suresh G., Branford, CT, UNITED STATES  
 Grosse, William M., Branford, CT, UNITED STATES  
 Alsobrook, John P., II, Madison, CT, UNITED STATES  
 Lepley, Denise M., Branford, CT, UNITED STATES  
 Gerlach, Valerie, Branford, CT, UNITED STATES  
 Edinger, Schlomit R., New Haven, CT, UNITED STATES  
 MacDougall, John R., Hamden, CT, UNITED STATES  
 Peyman, John A., New Haven, CT, UNITED STATES  
 Gunther, Erik, Branford, CT, UNITED STATES  
 Stone, David J., Guilford, CT, UNITED STATES  
 Ellerman, Karen, Branford, CT, UNITED STATES  
 Gangolli, Esha A., Madison, CT, UNITED STATES  
 I US 2003228301 A1 20031211  
 I US 2001-4378 A1 20011024 (10)  
 RAI US 2000-242882P 20001024 (60)  
 US 2000-242765P 20001024 (60)  
 US 2001-300206P 20010622 (60)  
 US 2000-242789P 20001024 (60)  
 US 2000-242768P 20001024 (60)  
 US 2000-242767P 20001024 (60)  
 US 2000-243622P 20001026 (60)  
 US 2001-273047P 20010302 (60)  
 US 2000-243591P 20001026 (60)  
 US 2000-243950P 20001027 (60)  
 US 2001-316509P 20010831 (60)  
 US 2000-243593P 20001026 (60)  
 US 2000-243502P 20001026 (60)  
 T Utility  
 S APPLICATION  
 N.CNT 10092  
 NCL INCLM: 424/130.100  
 INCLS: 435/006.000; 435/183.000; 435/069.100; 435/320.100; 435/325.000;  
 530/350.000; 530/388.100; 536/023.200  
 CL NCLM: 424/130.100  
 NCLS: 435/006.000; 435/183.000; 435/069.100; 435/320.100; 435/325.000;  
 530/350.000; 530/388.100; 536/023.200  
 C [7]  
 ICM: C12Q001-68  
 ICS: C07H021-04; A61K039-395; C12P021-02; C12N005-06; C07K014-47;  
 C07K016-40  
 AS INDEXING IS AVAILABLE FOR THIS PATENT.  
 4 ANSWER 200 OF 469 USPATFULL on STN  
 N 2003:324302 USPATFULL  
 I Mixtures of drug-oligomer conjugates comprising polyalkylene glycol,  
 uses thereof, and methods of making same  
 N Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES  
 Price, Christopher H., Chapel Hill, NC, UNITED STATES  
 Ansari, Aslam M., Rockville, MD, UNITED STATES  
 Odenbaugh, Amy L., Morrisville, NC, UNITED STATES  
 I US 2003228275 A1 20031211  
 I US 2001-873797 A1 20010604 (9)  
 T Utility  
 S APPLICATION  
 N.CNT 6027  
 NCL INCLM: 424/078.380  
 ICL NCLM: 424/078.380  
 C [7]  
 ICM: A61K038-00  
 ICS: A61K031-765

L4 ANSWER 201 OF 469 USPATFULL on STN  
 AN 2003:319260 USPATFULL  
 TI 28 human secreted proteins  
 IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Li, Yi, Sunnyvale, CA, UNITED STATES  
 Zeng, ZhiZhen, Landsdale, PA, UNITED STATES  
 Kyaw, Hla, Frederick, MD, UNITED STATES  
 Fischer, Carrie L., Burke, VA, UNITED STATES  
 Li, Haodong, Gaithersburg, MD, UNITED STATES  
 Soppet, Daniel R., Centreville, VA, UNITED STATES  
 Gentz, Reiner L., Rockville, MD, UNITED STATES  
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
 Moore, Paul A., Germantown, MD, UNITED STATES  
 Young, Paul E., Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Hastings, Gregg A., Westlake Village, CA, UNITED STATES  
 PI US 2003225009 A1 20031204  
 AI US 2002-58993 A1 20020130 (10)  
 RLI Continuation-in-part of Ser. No. US 2001-852659, filed on 11 May 2001,  
 PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep  
 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US  
 2001-852797, filed on 11 May 2001, PENDING Continuation-in-part of Ser.  
 No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230  
 Continuation-in-part of Ser. No. US 2001-853161, filed on 11 May 2001,  
 PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep  
 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. WO  
 1998-US4858, filed on 12 Mar 1998, PENDING  
 PRAI US 2001-265583P 20010202 (60)  
 US 2001-265583P 20010202 (60)  
 US 2001-265583P 20010202 (60)  
 US 2001-265583P 20010202 (60)  
 US 1997-40762P 19970314 (60)  
 US 1997-40710P 19970314 (60)  
 US 1997-50934P 19970530 (60)  
 US 1997-48100P 19970530 (60)  
 US 1997-48357P 19970530 (60)  
 US 1997-48189P 19970530 (60)  
 US 1997-57765P 19970905 (60)  
 US 1997-48970P 19970606 (60)  
 US 1997-68368P 19971219 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 29452  
 INCL INCLM: 514/044.000  
 INCLS: 435/069.100; 435/183.000; 435/455.000; 435/320.100; 435/325.000;  
 536/023.200  
 NCL NCLM: 514/044.000  
 NCLS: 435/069.100; 435/183.000; 435/455.000; 435/320.100; 435/325.000;  
 536/023.200  
 IC [7]  
 ICM: A61K048-00  
 ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C12N015-85  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 469 USPATFULL on STN  
 AN 2003:319258 USPATFULL  
 TI Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-  
 thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole  
 as inhibitors of fibrin cross-linking and transglutaminases  
 IN Tam, Tim Fat, Woodbridge, CANADA  
 Karimian, Khashayar, Toronto, CANADA  
 Leung-Toung, Regis C.S.H., Mississauga, CANADA  
 Zhao, Yanqing, Toronto, CANADA  
 Wodzinska, Jolanta Maria, Brampton, CANADA  
 Li, Wanren, Toronto, CANADA  
 Lowrie, Jayme Nicole, North York, CANADA  
 PA Apotex Inc. (non-U.S. corporation)  
 PI US 2003225007 A1 20031204  
 AI US 2003-397314 A1 20030327 (10)  
 PRAI CA 2002-2379375 20020328  
 DT Utility  
 FS APPLICATION



INCL INCLM: 514/042.000  
INCLS: 514/254.030; 514/364.000; 536/018.700; 544/368.000; 548/126.000  
NCL NCLM: 514/042.000  
NCLS: 514/254.030; 514/364.000; 536/018.700; 544/368.000; 548/126.000  
IC [7]  
ICM: A61K031-7052  
ICS: A61K031-496; A61K031-433; C07D498-02; C07H005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 469 USPATFULL on STN  
AN 2003:312777 USPATFULL  
TI Method of inhibiting amyloid protein aggregation and imaging amyloid  
deposits using aminoindane derivatives  
IN Barta, Nancy Sue, Brighton, MI, UNITED STATES  
Bigge, Christopher Franklin, Ann Arbor, MI, UNITED STATES  
PI US 2003220382 A1 20031127  
AI US 2002-275351 A1 20021104 (10)  
WO 2001-US13254 20010425  
DT Utility  
FS APPLICATION  
LN.CNT 1171  
INCL INCLM: 514/381.000  
INCLS: 514/524.000; 514/657.000; 548/254.000; 558/418.000; 564/428.000;  
514/567.000; 562/435.000  
NCL NCLM: 514/381.000  
NCLS: 514/524.000; 514/657.000; 548/254.000; 558/418.000; 564/428.000;  
514/567.000; 562/435.000  
IC [7]  
ICM: A61K031-41  
ICS: A61K031-277; A61K031-195; A61K031-135; C07D257-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 204 OF 469 USPATFULL on STN  
AN 2003:312289 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2003219886 A1 20031127  
AI US 2001-896095 A1 20010629 (9)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15529  
INCL INCLM: 435/184.000  
INCLS: 435/007.100  
NCL NCLM: 435/184.000  
NCLS: 435/007.100  
IC [7]  
ICM: C12N009-99  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 469 USPATFULL on STN  
AN 2003:312125 USPATFULL  
TI Fusion proteins, modified filamentous bacteriophage, and populations or  
libraries of same  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2003219722 A1 20031127  
AI US 2002-126685 A1 20020422 (10)

Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,  
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26  
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US  
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED

PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 16459  
INCL INCLM: 435/005.000  
INCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720  
NCL NCLM: 435/005.000  
NCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720  
IC [7]  
ICM: C07K014-01  
ICS: C12Q001-70; C07H021-04; C12P021-04; C12N001-21; C12N015-74  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 469 USPATFULL on STN  
AN 2003:309076 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
.- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Pleiss, Michael A., Sunnyvale, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Neitz, R. Jeffrey, San Francisco, CA, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Freedman, Stephen, Walnut Creek, CA, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James A., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Henry, Steven S., New Palestine, IN, United States  
McDaniel, Stacey L., Indianapolis, IN, United States  
Scott, William Leonard, Indianapolis, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6653303 B1 20031125  
AI US 2003-336824 20030106 (10)  
RLI Division of Ser. No. US 2001-915480, filed on 27 Jul 2001, now patented,  
Pat. No. US 6544978 Division of Ser. No. US 1997-996422, filed on 22 Dec  
1997  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS GRANTED  
LN.CNT 19893  
INCL INCLM: 514/220.000  
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/513.000; 540/518.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/513.000; 540/518.000  
IC [7]  
ICM: A61K031-55  
ICS: C07D487-00; C07D491-00; C07D487-04; C07D243-12  
EXF 514/220; 514/221; 540/496; 540/497; 540/498; 540/499; 540/504; 540/513;  
540/518  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 469 USPATFULL on STN  
AN 2003:306962 USPATFULL  
TI Soluble \*\*\*beta\*\*\* \*\*\*amyloid\*\*\* precursor protein secretion

LN Kakinana, Mitsuuru, Kobe-shi, JAPAN  
Kato, Kaneyoshi, Kawanishi-shi, JAPAN  
Mori, Masaaki, Tsukuba-shi, JAPAN  
Yamashita, Toshiro, Tsukuba-shi, JAPAN  
PI US 2003216398 A1 20031120  
AI US 2002-240996 A1 20021004 (10)  
WO 2001-JP2961 20010405

DT Utility  
FS APPLICATION

LN.CNT 4140

INCL INCLM: 514/249.000  
INCLS: 514/312.000; 514/313.000

NCL NCLM: 514/249.000  
NCLS: 514/312.000; 514/313.000

IC [7]  
ICM: A61K031-47  
ICS: A61K031-498

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 469 USPATFULL on STN

AN 2003:305989 USPATFULL

TI Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders

IN McDonald, John R., Baie D'Urfe, CANADA  
Coggins, Philip J., Pointe Claire, CANADA

PI US 2003215421 A1 20031120  
AI US 2003-375209 A1 20030224 (10)

RLI Continuation of Ser. No. US 2001-792793, filed on 22 Feb 2001, PENDING  
Continuation of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING  
Continuation of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING  
Continuation-in-part of Ser. No. WO 1999-CA659, filed on 21 Jul 1999,  
UNKNOWN

DT Utility  
FS APPLICATION

LN.CNT 8058

INCL INCLM: 424/085.100  
INCLS: 424/143.100; 530/351.000; 530/388.220; 435/069.500; 435/320.100;  
435/325.000; 536/023.500

NCL NCLM: 424/085.100  
NCLS: 424/143.100; 530/351.000; 530/388.220; 435/069.500; 435/320.100;  
435/325.000; 536/023.500

IC [7]  
ICM: A61K038-19  
ICS: C07H021-04; C12P021-02; A61K039-395; C12N005-06; C07K014-52;  
C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 469 USPATFULL on STN

AN 2003:294415 USPATFULL

TI Human enzyme molecules

IN Tang, Y. Tom, San Jose, CA, UNITED STATES  
Lu, Dyung Aina M., San Jose, CA, UNITED STATES  
Bandman, Olga, Mountain View, CA, UNITED STATES  
Yue, Henry, Sunnyvale, CA, UNITED STATES  
Azimzai, Yalda, Castro Valley, CA, UNITED STATES  
Burford, Neil, Durham, CT, UNITED STATES  
Lal, Preeti, Santa Clara, CA, UNITED STATES  
Baughn, Mariah R., San Leandro, CA, UNITED STATES

PI US 2003207430 A1 20031106  
AI US 2002-220381 A1 20020828 (10)  
WO 2001-US6806 20010301

DT Utility  
FS APPLICATION

LN.CNT 8111

INCL INCLM: 435/183.000  
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/388.260;  
536/023.200; 800/008.000

NCL NCLM: 435/183.000  
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/388.260;  
536/023.200; 800/008.000

IC [7]  
ICM: C12Q001-68  
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06;  
C07K016-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 469 USPATFULL on STN  
 AN 2003:285158 USPATFULL  
 TI Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation  
 IN Bush, Ashley I., Somerville, MA, United States  
 Huang, Xudong, Andover, MA, United States  
 Atwood, Craig S., Brecksville, OH, United States  
 Tanzi, Rudolph E., Hull, MA, United States  
 PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
 PI US 6638711 B1 20031028  
 AI US 2000-560883 20000428 (9)  
 RLI Continuation-in-part of Ser. No. US 380704  
 PRAI US 1999-131579P 19990429 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2783  
 INCL INCLM: 435/004.000  
 INCLS: 436/080.000; 436/084.000; 436/127.000; 530/350.000  
 NCL NCLM: 435/004.000  
 NCLS: 436/080.000; 436/084.000; 436/127.000; 530/350.000  
 IC [7]  
 ICM: C12Q001-00  
 ICS: G01N033-48; G01N033-20; C07K002-00  
 EXF 435/7.1; 435/7.7; 435/7.8; 435/7.9; 435/27; 435/4; 435/7.92; 436/501; 436/504; 436/904; 436/63; 436/80; 436/84; 514/2; 530/300; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 469 USPATFULL on STN  
 AN 2003:282760 USPATFULL  
 TI Novel amino acid sequences for human epidermal growth factor-like polypeptides  
 IN Shimkets, Richard A., West Haven, CT, UNITED STATES  
 Fernandes, Elma, Branford, CT, UNITED STATES  
 Herrman, John, Guilford, CT, UNITED STATES  
 Vernet, Corine, Gainesville, FL, UNITED STATES  
 PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S. corporation)  
 PI US 2003199103 A1 20031023  
 AI US 2001-977639 A1 20011015 (9)  
 RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING  
 PRAI US 2000-201388P 20000503 (60)  
 US 2000-193086P 20000330 (60)  
 US 2000-191158P 20000322 (60)  
 US 2000-189810P 20000316 (60)  
 US 1999-137322P 19990603 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 10459  
 INCL INCLM: 436/518.000  
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 NCL NCLM: 436/518.000  
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
 IC [7]  
 ICM: C07K014-485  
 ICS: C07H021-04; C12P021-02; C12N005-06; G01N033-543  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 469 USPATFULL on STN  
 AN 2003:282627 USPATFULL  
 TI Genostics  
 IN Roberts, Gareth Wyn, Cambs, UNITED KINGDOM  
 PA GENOSTIC PHARMA LIMITED (non-U.S. corporation)  
 PI US 2003198970 A1 20031023  
 AI US 2002-206568 A1 20020729 (10)  
 RLI Continuation of Ser. No. US 1999-325123, filed on 3 Jun 1999, ABANDONED  
 PRAI GB 1998-12098 19980606  
 GB 1998-28289 19981223  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4299  
 INCL INCLM: 435/006.000  
 INCLS: 536/024.300  
 NCL NCLM: 435/006.000

IC 171  
ICM: C12Q001-68  
ICS: C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 213 OF 469 USPATFULL on STN  
AN 2003:282611 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)  
PI US 2003198954 A1 20031023  
AI US 2001-1142 A1 20011114 (10)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25681  
INCL INCLM: 435/006.000  
INCLS: 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 214 OF 469 USPATFULL on STN  
AN 2003:279188 USPATFULL  
TI PARP inhibitors, pharmaceutical compositions comprising same, and  
methods of using same  
IN Jackson, Paul F., Bel Air, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
Maclin, Keith M., Baltimore, MD, United States  
Zhang, Jie, Ellicott City, MD, United States  
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.  
corporation)  
PI US 6635642 B1 20031021  
AI US 1998-145176 19980901 (9)  
RLI Continuation-in-part of Ser. No. US 1998-79512, filed on 15 May 1998,  
now abandoned Continuation-in-part of Ser. No. US 1997-922520, filed on  
3 Sep 1997, now abandoned Continuation-in-part of Ser. No. US  
1997-922548, filed on 3 Sep 1997, now patented, Pat. No. US 6174893,  
issued on 16 Jan 2001  
DT Utility  
FS GRANTED  
LN.CNT 2769  
INCL INCLM: 514/248.000  
INCLS: 514/247.000; 544/224.000; 544/233.000; 544/235.000  
NCL NCLM: 514/248.000  
NCLS: 514/247.000; 544/224.000; 544/233.000; 544/235.000  
IC [7]  
ICM: A61K031-50  
ICS: C07D237-26  
EXF 514/247; 514/248; 514/261; 514/439; 514/464; 514/465; 514/617; 514/379;  
544/224; 544/264; 544/233; 544/235; 549/441; 564/63; 564/164; 564/166;  
564/183  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 215 OF 469 USPATFULL on STN  
AN 2003:279186 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
.- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Pleiss, Michael A., Sunnyvale, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Neitz, R. Jeffrey, San Francisco, CA, United States

John, Varghese, San Francisco, CA, United States  
Freedman, Stephen, Walnut Creek, CA, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James A., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Henry, Steven S., New Palestine, IN, United States  
McDaniel, Stacey L., Indianapolis, IN, United States  
Scott, William Leonard, Indianapolis, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States

PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6635632 B1 20031021  
AI US 1997-996422 19971222 (8)  
PRAI US 1996-64851P 19961223 (60)

DT Utility  
FS GRANTED

LN.CNT 22179

INCL INCLM: 514/212.030  
INCLS: 514/212.040; 514/212.070; 514/212.080

NCL NCLM: 514/212.030  
NCLS: 514/212.040; 514/212.070; 514/212.080

IC [7]  
ICM: A61K031-55  
ICS: A61P025-28

EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 216 OF 469 USPATFULL on STN

AN 2003:279120 USPATFULL

TI Compound and methods of inhibiting or stimulating presenilin 1 and related pharmaceuticals and diagnostic agents

IN Telerman, Adam, Paris, FRANCE

Amson, Robert, Paris, FRANCE

PA Societe Molecular Engines Laboratories, Paris, FRANCE (non-U.S. corporation)

PI US 6635483 B1 20031021  
AI US 1999-382396 19990825 (9)

RLI Continuation of Ser. No. WO 1998-FR1387, filed on 29 Jun 1998

PRAI FR 1997-11450 19970915

DT Utility  
FS GRANTED

LN.CNT 1190

INCL INCLM: 435/458.000  
INCLS: 435/006.000; 435/091.100; 435/455.000; 435/458.000; 536/023.100; 536/024.500

NCL NCLM: 435/458.000  
NCLS: 435/006.000; 435/091.100; 435/455.000; 536/023.100; 536/024.500

IC [7]  
ICM: C12N015-88  
ICS: C12Q001-68; C12P019-34; C07H021-02; C07H021-04

EXF 435/6; 435/91.1; 435/455; 435/375; 536/23.1; 536/24.3; 536/24.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 217 OF 469 USPATFULL on STN

AN 2003:277229 USPATFULL

TI Inhibitors of nitric oxide synthase

IN Singh, Inderjit, Mount Pleasant, SC, UNITED STATES

PA MUSC Foundation for Research Development (U.S. corporation)

PI US 2003195256 A1 20031016  
AI US 2002-273557 A1 20021018 (10)

RLI Division of Ser. No. US 2000-579791, filed on 25 May 2000, GRANTED, Pat. No. US 6511800 Continuation of Ser. No. WO 1998-US25360, filed on 25 Nov 1998, PENDING

PRAI US 1997-66839P 19971125 (60)

DT Utility  
FS APPLICATION

LN.CNT 7728

INCL INCLM: 514/570.000

NCL NCLM: 514/570.000

ICM: A61K031-192  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 218 OF 469 USPATFULL on STN  
AN 2003:257841 USPATFULL  
TI Interleukin-20  
IN Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Murphy, Marianne, London, UNITED KINGDOM  
Ruben, Steven M., Brookeville, MD, UNITED STATES  
Hu, Jing-Shan, Mountain View, CA, UNITED STATES  
Duan, D. Roxanne, Bethesda, MD, UNITED STATES  
Florence, Kimberly A., Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)  
PI US 2003180892 A1 20030925  
AI US 2002-277726 A1 20021023 (10)  
RLI Division of Ser. No. US 1999-231788, filed on 15 Jan 1999, GRANTED, Pat. No. US 6486301 Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING  
PRAI US 1997-60140P 19970926 (60)  
US 1997-55952P 19970818 (60)  
US 1997-52870P 19970716 (60)  
US 1997-60140P 19970926 (60)  
US 1997-55952P 19970818 (60)  
US 1997-52870P 19970716 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 5982  
INCL INCLM: 435/069.520  
INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500  
NCL NCLM: 435/069.520  
NCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500  
IC [7]  
ICM: C07K014-54  
ICS: C07H021-04; C12P021-04; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 219 OF 469 USPATFULL on STN  
AN 2003:251659 USPATFULL  
TI Mitochondria protecting agents for treating mitochondria associated diseases  
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES  
Miller, Scott W., San Marcos, CA, UNITED STATES  
Davis, Robert E., San Diego, CA, UNITED STATES  
Moos, Walter H., Oakland, CA, UNITED STATES  
PA MitoKor, San Diego, CA, UNITED STATES, 92121 (U.S. corporation)  
PI US 2003176448 A1 20030918  
AI US 2002-233051 A1 20020830 (10)  
RLI Division of Ser. No. US 2000-733271, filed on 7 Dec 2000, GRANTED, Pat. No. US 6498191 Continuation of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED  
PRAI US 1998-72484P 19980126 (60)  
US 1998-72487P 19980126 (60)  
US 1998-72483P 19980126 (60)  
US 1998-72482P 19980126 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1700  
INCL INCLM: 514/256.000  
INCLS: 514/396.000; 514/397.000; 514/456.000; 514/533.000; 514/534.000; 514/544.000; 514/634.000; 514/406.000; 514/161.000  
NCL NCLM: 514/256.000  
NCLS: 514/396.000; 514/397.000; 514/456.000; 514/533.000; 514/534.000; 514/544.000; 514/634.000; 514/406.000; 514/161.000  
IC [7]  
ICM: A61K031-505  
ICS: A61K031-4178; A61K031-4172; A61K031-416; A61K031-415; A61K031-35; A61K031-353; A61K031-192; A61K031-155  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 469 USPATFULL on STN  
AN 2003:250985 USPATFULL  
TI Human Transcriptomes

vogelstein, Bert, Baltimore, MD, UNITED STATES  
Kinzler, Kenneth W., BelAir, MD, UNITED STATES  
PA The Johns Hopkins University, Baltimore, MD (U.S. corporation)  
PI US 2003175771 A1 20030918  
AI US 2002-330627 A1 20021230 (10)  
RLI Continuation of Ser. No. US 1999-448480, filed on 24 Nov 1999, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 8656  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]

ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 469 USPATFULL on STN  
AN 2003:250967 USPATFULL  
TI Diagnosis, prognosis and identification of potential therapeutic targets  
of multiple myeloma based on gene expression profiling  
IN Shaughnessy, John D., Little Rock, AR, UNITED STATES  
Barlogie, Bart, Little Rock, AR, UNITED STATES  
Zhan, Fenghaung, Little Rock, AR, UNITED STATES  
PI US 2003175753 A1 20030918  
AI US 2002-289746 A1 20021107 (10)  
PRAI US 2002-403075P 20020813 (60)  
US 2002-355386P 20020208 (60)  
US 2001-348238P 20011107 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3686  
INCL INCLM: 435/006.000  
INCLS: 702/020.000  
NCL NCLM: 435/006.000  
NCLS: 702/020.000  
IC [7]

ICM: C12Q001-68

ICS: G06F019-00; G01N033-48; G01N033-50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 469 USPATFULL on STN  
AN 2003:244905 USPATFULL  
TI Human chemokine beta-10 mutant polypeptides  
IN Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Li, Haodong, Gaithersburg, MD, UNITED STATES  
Adams, Mark D., Rockville, MD, UNITED STATES  
Gentz, Solange H.L., Belo Horizonte, BRAZIL  
Alderson, Ralph, Gaithersburg, MD, UNITED STATES  
Li, Yuling, Germantown, MD, UNITED STATES  
Parmelee, David, Rockville, MD, UNITED STATES  
White, John R., Coatesville, PA, UNITED STATES  
Appelbaum, Edward R., Blue Bell, PA, UNITED STATES  
Salcedo, Theodora, East Syracuse, NY, UNITED STATES  
PI US 2003171319 A1 20030911  
AI US 2002-263139 A1 20021003 (10)  
RLI Continuation-in-part of Ser. No. US 2002-125451, filed on 19 Apr 2002,  
PENDING Continuation-in-part of Ser. No. WO 2001-US18046, filed on 5 Jun  
2001, PENDING Continuation-in-part of Ser. No. US 1999-261201, filed on  
3 Mar 1999, GRANTED, Pat. No. US 6458349 Continuation-in-part of Ser.  
No. US 1996-613822, filed on 23 Feb 1996, GRANTED, Pat. No. US 6174995  
Continuation-in-part of Ser. No. US 1995-458355, filed on 2 Jun 1995,  
GRANTED, Pat. No. US 5981230 Continuation-in-part of Ser. No. WO  
1994-US9484, filed on 23 Aug 1994, PENDING Continuation-in-part of Ser.  
No. WO 1994-US9484, filed on 23 Aug 1994, PENDING  
PRAI US 2000-209578P 20000606 (60)  
US 1999-115439P 19990108 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 13207  
INCL INCLM: 514/044.000  
INCLS: 424/085.100; 435/069.500; 435/320.100; 435/325.000; 530/351.000;  
536/023.500; 435/006.000; 435/007.100  
NCL NCLM: 514/044.000  
NCLS: 424/085.100; 435/069.500; 435/320.100; 435/325.000; 530/351.000;  
536/023.500; 435/006.000; 435/007.100  
IC [7]



ICS: A61K038-19; C12Q001-68; G01N033-53; C07H021-04; C12P021-02;  
C12N005-06; C07K014-52

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 469 USPATFULL on STN

AN 2003:244221 USPATFULL

TI Proteins and nucleic acids encoding same

IN Alsobrook, John P., II, Madison, CT, UNITED STATES

Tchernev, Velizar T., Branford, CT, UNITED STATES

Liu, Xiaohong, Canton, MA, UNITED STATES

Spytek, Kimberly A., New Haven, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

Patturajan, Meera, Branford, CT, UNITED STATES

Lepley, Denise M., Branford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

Shimkets, Richard A., Guilford, CT, UNITED STATES

Grosse, William M., Branford, CT, UNITED STATES

Szekeres, Edward S., JR., Branford, CT, UNITED STATES

Vernet, Corine A.M., Branford, CT, UNITED STATES

Li, Li, Branford, CT, UNITED STATES

Casman, Stacie J., North Haven, CT, UNITED STATES

Boldog, Ference L., North Haven, CT, UNITED STATES

Gorman, Linda, Branford, CT, UNITED STATES

Gangolli, Esha A., Madison, CT, UNITED STATES

Fernandes, Elma R., Branford, CT, UNITED STATES

Rieger, Danier K., Branford, CT, UNITED STATES

Edinger, Shlomit R., New Haven, CT, UNITED STATES

Gunther, Erik, Branford, CT, UNITED STATES

Millet, Isabelle, Milford, CT, UNITED STATES

Sciore, Paul, North Haven, CT, UNITED STATES

Ellerman, Karen, Branford, CT, UNITED STATES

MacDougall, John R., Hamden, CT, UNITED STATES

Smithson, Glennda, Guilford, CT, UNITED STATES

PI US 2003170630 A1 20030911

AI US 2001-32189 A1 20011221 (10)

PRAI US 2000-257495P 20001221 (60)

US 2000-258171P 20001222 (60)

US 2001-269940P 20010220 (60)

US 2001-274192P 20010308 (60)

US 2001-277826P 20010322 (60)

US 2001-279840P 20010329 (60)

US 2001-282981P 20010411 (60)

US 2001-283656P 20010413 (60)

US 2001-309247P 20010731 (60)

US 2001-311754P 20010810 (60)

US 2001-313331P 20010817 (60)

DT Utility

FS APPLICATION

LN.CNT 16767

INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 469 USPATFULL on STN

AN 2003:244219 USPATFULL

TI Human cDNAs and proteins and uses thereof

IN Bejanin, Stephane, Paris, FRANCE

Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

PI US 2003170628 A1 20030911

AI US 2001-999570 A1 20011114 (9)

RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

PRAI WO 2001-IB1715 20010806

US 2001-305456P 20010713 (60)

US 2001-302277P 20010629 (60)

US 2001-298698P 20010615 (60)

US 2001-293574P 20010525 (60)

DT Utility

FS APPLICATION

LN.CNT 25549

INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;  
530/388.100; 536/023.500

NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;  
530/388.100; 536/023.500

IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 225 OF 469 USPATFULL on STN  
AN 2003:243794 USPATFULL  
TI Death domain containing receptors  
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Gentz, Reiner L., Belo Horizonte, BRAZIL  
Dillon, Patrick J., Carlsbad, CA, UNITED STATES  
PA Human Genome Sciences, Inc. (U.S. corporation)  
PI US 2003170203 A1 20030911  
AI US 2002-189189 A1 20020705 (10)  
RLI Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000,  
PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar  
1997, GRANTED, Pat. No. US 6153402  
PRAI US 2001-314314P 20010824 (60)  
US 2001-303155P 20010706 (60)  
US 1999-136741P 19990528 (60)  
US 1999-130488P 19990422 (60)  
US 1997-37341P 19970206 (60)  
US 1996-28711P 19961017 (60)  
US 1996-13285P 19960312 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 9858  
INCL INCLM: 424/085.100  
INCLS: 424/145.100; 514/210.090; 514/011.000  
NCL NCLM: 424/085.100  
NCLS: 424/145.100; 514/210.090; 514/011.000  
IC [7]  
ICM: A61K039-395  
ICS: A61K031-407; A61K038-19; A61K038-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 226 OF 469 USPATFULL on STN  
AN 2003:240440 USPATFULL  
TI Cysteinyl protease inhibitors  
IN Munoz, Benito, 10741 Frank Daniels Rd., San Diego, CA, United States  
92131  
Srinivasan, Kuman, 7693 Palmilla Dr., Apt. #2116, San Diego, CA, United  
States 92122  
Wang, Bowei, 7825 Roan Rd., San Diego, CA, United States 92129  
PI US 6617426 B1 20030909  
AI US 1999-338409 19990622 (9)  
DT Utility  
FS GRANTED  
LN.CNT 2060  
INCL INCLM: 530/331.000  
INCLS: 514/018.000; 514/019.000  
NCL NCLM: 530/331.000  
IC [7]  
ICM: C07K005-08  
EXF 530/331; 514/18; 514/19  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 469 USPATFULL on STN  
AN 2003:238482 USPATFULL  
TI Reverse-turn mimetics and methods relating thereto  
IN Urban, Jan, Kirkland, WA, UNITED STATES  
Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES  
Lee, Min S., Sammamish, WA, UNITED STATES  
PA Molecumetics, Ltd., Bellevue, WA (U.S. corporation)  
PI US 2003166640 A1 20030904  
AI US 2002-150481 A1 20020516 (10)  
PRAI US 2001-291663P 20010516 (60)  
DT Utility  
FS APPLICATION

INCL INCLM: 514/224.200  
INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;  
544/095.000; 544/014.000; 544/350.000; 544/345.000  
NCL NCLM: 514/224.200  
NCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;  
544/095.000; 544/014.000; 544/350.000; 544/345.000  
IC [7]  
ICM: G01N033-53  
ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 469 USPATFULL on STN  
AN 2003:238478 USPATFULL  
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of  
A-beta protein production  
IN Olson, Richard E., Wilmington, DE, UNITED STATES  
Liu, Hong, Glen Mills, PA, UNITED STATES  
Thompson, Lorin A., Wilmington, DE, UNITED STATES  
PI US 2003166636 A1 20030904  
AI US 2002-287117 A1 20021104 (10)  
RLI Division of Ser. No. US 2001-805645, filed on 14 Mar 2001, GRANTED, Pat.  
No. US 6503902 Continuation-in-part of Ser. No. US 2000-661008, filed on  
13 Sep 2000, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 6969  
INCL INCLM: 514/212.080  
INCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500;  
514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;  
546/207.000  
NCL NCLM: 514/212.080  
NCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500;  
514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;  
546/207.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4545; A61K031-454;  
C07D417-02; C07D413-02; C07D043-02; C07D041-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 469 USPATFULL on STN  
AN 2003:238432 USPATFULL  
TI Microsomal triglyceride transfer protein  
IN Wetterau, John R., II, Langhorne, PA, UNITED STATES  
Sharp, Daru Young, Perrineville, NJ, UNITED STATES  
Gregg, Richard E., Pennington, NJ, UNITED STATES  
Biller, Scott A., Ewing, NJ, UNITED STATES  
Dickson, John K., Mount Holly, NJ, UNITED STATES  
Lawrence, R. Michael, Yardley, PA, UNITED STATES  
Lawson, John E., Wallingford, CT, UNITED STATES  
Holava, Henry M., Meriden, CT, UNITED STATES  
Partyka, Richard A., Neshanic, NJ, UNITED STATES  
PI US 2003166590 A1 20030904  
AI US 2001-933593 A1 20010821 (9)  
RLI Division of Ser. No. US 1995-486929, filed on 7 Jun 1995, PENDING  
Division of Ser. No. US 1993-117362, filed on 3 Sep 1993, GRANTED, Pat.  
No. US 5595872 Continuation-in-part of Ser. No. US 1993-15449, filed on  
22 Feb 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-847503,  
filed on 6 Mar 1992, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4843  
INCL INCLM: 514/044.000  
INCLS: 536/023.200  
NCL NCLM: 514/044.000  
NCLS: 536/023.200  
IC [7]  
ICM: A61K048-00  
ICS: C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 469 USPATFULL on STN  
AN 2003:237862 USPATFULL  
TI Monoclonal \*\*\*antibody\*\*\*  
IN Wiltfang, Jens, Eddigehausen, GERMANY, FEDERAL REPUBLIC OF

Monning, Ursula, Berlin, GERMANY, FEDERAL REPUBLIC OF  
PI US 2003166019 A1 20030904  
AI US 2002-170272 A1 20020611 (10)  
PRAI EP 2001-114192 20010612  
DT Utility  
FS APPLICATION  
LN.CNT 3683  
INCL INCLM: 435/007.210  
INCLS: 530/388.260  
NCL NCLM: 435/007.210  
NCLS: 530/388.260  
IC [7]  
ICM: G01N033-567  
ICS: C07K016-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 469 USPATFULL on STN  
AN 2003:237706 USPATFULL  
TI NARC10 and NARC16, programmed cell death-associated molecules and uses thereof  
IN Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES  
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2003165863 A1 20030904  
AI US 2002-47855 A1 20020115 (10)  
PRAI US 2001-262306P 20010116 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4471  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 469 USPATFULL on STN  
AN 2003:237324 USPATFULL  
TI Amyloid peptide inactivating enzyme to treat Alzheimer's disease  
IN Hersh, Louis B., Lexington, KY, UNITED STATES  
PI US 2003165481 A1 20030904  
AI US 2002-159279 A1 20020603 (10)  
RLI Division of Ser. No. US 2001-792079, filed on 26 Feb 2001, PENDING  
PRAI US 2000-184826P 20000224 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1712  
INCL INCLM: 424/093.210  
INCLS: 435/455.000; 435/368.000  
NCL NCLM: 424/093.210  
NCLS: 435/455.000; 435/368.000  
IC [7]  
ICM: A61K048-00  
ICS: C12N005-08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 469 USPATFULL on STN  
AN 2003:232567 USPATFULL  
TI Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Shi, Qing, Carmel, IN, UNITED STATES  
PI US 2003162768 A1 20030828  
US 6696438 B2 20040224  
AI US 2002-317081 A1 20021212 (10)  
RLI Division of Ser. No. US 1999-338180, filed on 22 Jun 1999, GRANTED, Pat. No. US 6528505  
PRAI US 1998-160067P 19980622 (60)  
US 1998-155238P 19980930 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7196

INCLS: 514/212.050; 514/212.070; 514/220.000; 514/221.000; 540/490.000;  
540/496.000; 540/500.000; 540/504.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/517.000; 540/518.000  
IC [7]  
ICM: A61K031-554  
ICS: A61K031-553; A61K031-55; A61K031-5513; A61K031-551  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 469 USPATFULL on STN  
AN 2003:231986 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)  
PI US 2003162186 A1 20030828  
AI US 2002-154678 A1 20020522 (10)  
PRAI US 2001-293574P 20010525 (60)  
US 2001-298698P 20010615 (60)  
US 2001-302277P 20010629 (60)  
US 2001-305456P 20010713 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25533  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 469 USPATFULL on STN  
AN 2003:225673 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)  
PI US 2003157485 A1 20030821  
AI US 2001-992095 A1 20011113 (9)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25484  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;  
536/023.200; 530/388.260; 435/007.200  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;  
536/023.200; 530/388.260; 435/007.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;  
C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 469 USPATFULL on STN  
AN 2003:220740 USPATFULL  
TI Methods and compositions for diagnosing and treating rheumatoid  
arthritis  
IN Pittman, Debra D., Windham, NH, UNITED STATES  
Feldman, Jeffrey L., Arlington, MA, UNITED STATES  
Shields, Kathleen M., Harvard, MA, UNITED STATES  
Trepicchio, William L., Andover, MA, UNITED STATES  
PI US 2003154032 A1 20030814  
AI US 2001-23451 A1 20011217 (10)  
PRAI US 2000-255861P 20001215 (60)  
DT Utility

LN.CNT 25385  
INCL INCLM: 702/020.000  
NCL NCLM: 702/020.000  
IC [7]  
ICM: G06F019-00  
ICS: G01N033-48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 469 USPATFULL on STN  
AN 2003:220259 USPATFULL  
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same,  
and methods for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, UNITED STATES  
Thompson, Richard C., Frankfort, IN, UNITED STATES  
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
Huffman, George W., Carmel, IN, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
PI US 2003153550 A1 20030814  
US 6774125 B2 20040810  
AI US 2002-267017 A1 20021007 (10)  
RLI Division of Ser. No. US 1999-337484, filed on 21 Jun 1999, GRANTED, Pat.  
No. US 6509331  
PRAI US 1998-155265P 19980622 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6533  
INCL INCLM: 514/211.050  
INCLS: 514/221.000; 514/220.000; 514/212.040; 514/212.050; 514/151.000;  
540/490.000; 540/496.000; 540/500.000; 540/522.000; 540/523.000;  
540/520.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;  
540/504.000; 540/517.000; 540/518.000  
IC [7]  
ICM: A61K031-655  
ICS: A61K031-55; A61K031-553; A61K031-5513; A61K031-551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 469 USPATFULL on STN  
AN 2003:219631 USPATFULL  
TI Full-length human cDNAs encoding potentially secreted proteins  
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE  
PI US 2003152921 A1 20030814  
AI US 2001-876997 A1 20010608 (9)  
RLI Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000,  
PENDING  
PRAI US 1999-169629P 19991208 (60)  
US 2000-187470P 20000306 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 27600  
INCL INCLM: 435/006.000  
INCLS: 435/183.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/183.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C12N009-00; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 469 USPATFULL on STN  
AN 2003:214379 USPATFULL  
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same,  
and methods for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
Thompson, Richard C., Frankfort, IN, UNITED STATES  
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES  
Stack, Douglas R., Fishers, IN, UNITED STATES

PI US 2003149022 A1 20030807  
AI US 2002-326081 A1 20021223 (10)  
RLI Division of Ser. No. US 1999-338121, filed on 22 Jun 1999, PENDING  
PRAI US 1998-160067P 19980622 (60)  
US 1998-150704P 19980930 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7927  
INCL INCLM: 514/211.040  
INCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000  
NCL NCLM: 514/211.040  
NCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-553; A61K031-554; A61K031-5513  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 469 USPATFULL on STN  
AN 2003:197032 USPATFULL  
TI Prevention and treatment of amyloid-associated disorders  
IN Hyslop, Paul Andrew, Indianapolis, IN, United States  
Miller, Foy Dean, Camby, IN, United States  
Higgins, Linda S., Palo Alto, CA, United States  
Catalano, Rosanne, Hayward, CA, United States  
Cordell, Barbara, Palo Alto, CA, United States  
Puchacz, Elizbieta, Pleasanton, CA, United States  
PA Scios Inc., Sunnyvale, CA, United States (U.S. corporation)  
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6596474 B1 20030722  
AI US 2000-608640 20000630 (9)  
PRAI US 1999-142175P 19990701 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1226  
INCL INCLM: 435/004.000  
INCLS: 435/070.300; 435/347.000; 435/374.000; 424/562.000  
NCL NCLM: 435/004.000  
NCLS: 424/562.000; 435/070.300; 435/347.000; 435/374.000  
IC [7]  
ICM: C12Q001-00  
ICS: C12P021-04; C12N005-06; C12N005-00; A61K035-55  
EXF 424/562; 435/4; 435/70.3; 435/373; 435/347  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 241 OF 469 USPATFULL on STN  
AN 2003:194619 USPATFULL  
TI Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides  
IN Shimkets, Richard A., West Haven, CT, UNITED STATES  
Fernandes, Elma, Branford, CT, UNITED STATES  
Herrman, John, Guilford, CT, UNITED STATES  
Vernet, Corine, Gainesville, FL, UNITED STATES  
PA CuraGen Corporation, New Haven, CT (U.S. corporation)  
PI US 2003134430 A1 20030717  
AI US 2001-977751 A1 20011015 (9)  
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING  
PRAI US 2000-201388P 20000503 (60)  
US 2000-193086P 20000330 (60)  
US 2000-191158P 20000322 (60)  
US 2000-189810P 20000316 (60)  
US 1999-137322P 19990603 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 10285  
INCL INCLM: 436/518.000  
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
NCL NCLM: 436/518.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C12P021-02  
ICS: C12N005-06; C07K014-435; G01N033-543; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 469 USPATFULL on STN

TI heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
IN Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Droste, James, Indianapolis, IN, UNITED STATES  
PI US 2003130188 A1 20030710  
AI US 2002-246558 A1 20020919 (10)  
RLI Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING  
DT Utility  
FS APPLICATION  
LN.CNT 11320  
INCL INCLM: 514/012.000  
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;  
514/018.000; 514/019.000; 514/400.000; 514/419.000  
NCL NCLM: 514/012.000  
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;  
514/018.000; 514/019.000; 514/400.000; 514/419.000  
IC [7]  
ICM: A61K038-10  
ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 243 OF 469 USPATFULL on STN  
AN 2003:188372 USPATFULL  
TI Method for treating neurodegenerative disorders  
IN Reitz, Allen B., Lansdale, PA, UNITED STATES  
Demeter, David A., Fishers, IN, UNITED STATES  
Lee, Daniel H.S., Northhampton, PA, UNITED STATES  
Wang, Hoau-Yan, Philadelphia, PA, UNITED STATES  
Chen, Robert H., Belle Mead, NJ, UNITED STATES  
Ross, Tina Morgan, Audubon, PA, UNITED STATES  
Scott, Malcolm K., Lansdale, PA, UNITED STATES  
Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES  
PI US 2003130165 A1 20030710  
AI US 2002-162821 A1 20020605 (10)  
RLI Division of Ser. No. US 1999-320885, filed on 27 May 1999, GRANTED, Pat.  
No. US 6441049  
PRAI US 1998-87577P 19980601 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1505  
INCL INCLM: 514/001.000  
NCL NCLM: 514/001.000  
IC [7]  
ICM: A61K031-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 244 OF 469 USPATFULL on STN  
AN 2003:181716 USPATFULL  
TI 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives  
IN Blume, Thorsten, Schildow, GERMANY, FEDERAL REPUBLIC OF  
Halfbrodt, Wolfgang, Berlin, GERMANY, FEDERAL REPUBLIC OF  
Kuhnke, Joachim, Porsdam, GERMANY, FEDERAL REPUBLIC OF  
Monning, Ursula, Woltersdorf, GERMANY, FEDERAL REPUBLIC OF  
Schneider, Herbert, Berlin, GERMANY, FEDERAL REPUBLIC OF  
PI US 2003125550 A1 20030703  
AI US 2002-190620 A1 20020709 (10)  
PRAI DE 2001-135050 20010709  
US 2001-304124P 20010711 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2365  
INCL INCLM: 544/060.000  
INCLS: 544/139.000; 544/370.000; 546/199.000; 548/181.000; 548/215.000;  
548/304.700; 548/306.100  
NCL NCLM: 544/060.000  
NCLS: 544/139.000; 544/370.000; 546/199.000; 548/181.000; 548/215.000;  
548/304.700; 548/306.100  
IC [7]



ICS: C07D413-02; C07D043-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 245 OF 469 USPATFULL on STN  
AN 2003:180701 USPATFULL  
TI Sequence-directed DNA-binding molecules compositions and methods  
IN Edwards, Cynthia A., Menlo Park, CA, UNITED STATES  
Cantor, Charles R., Del Mar, CA, UNITED STATES  
Andrews, Beth M., Maynard, MA, UNITED STATES  
Turin, Lisa M., Redwood City, CA, UNITED STATES  
Fry, Kirk E., Palo Alto, CA, UNITED STATES  
PA Genelabs Technologies, Inc. (U.S. corporation)  
PI US 2003124530 A1 20030703  
AI US 2001-993346 A1 20011113 (9)  
RLI Division of Ser. No. US 1999-354947, filed on 15 Jul 1999, GRANTED, Pat.  
No. US 6384208 Continuation of Ser. No. US 1995-482080, filed on 7 Jun  
1995, GRANTED, Pat. No. US 6010849 Division of Ser. No. US 1993-171389,  
filed on 20 Dec 1993, GRANTED, Pat. No. US 5578444 Continuation-in-part  
of Ser. No. US 1993-123936, filed on 17 Sep 1993, GRANTED, Pat. No. US  
5726014 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec  
1992, GRANTED, Pat. No. US 5693463 Continuation-in-part of Ser. No. US  
1991-723618, filed on 27 Jun 1991, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 10851  
INCL INCLM: 435/006.000  
NCL NCLM: 435/006.000  
IC [7]  
ICM: C12Q001-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 246 OF 469 USPATFULL on STN  
AN 2003:180279 USPATFULL  
TI Human oxidoreductase proteins  
IN Yue, Henry, Sunnyvale, CA, UNITED STATES  
Lal, Preeti, Santa Clara, CA, UNITED STATES  
Tang, Y. Tom, San Jose, CA, UNITED STATES  
Hillman, Jennifer L., Mountain View, CA, UNITED STATES  
Baughn, Mariah R., San Leandro, CA, UNITED STATES  
Azimzai, Yalda, Castro Valley, CA, UNITED STATES  
Lu, Dyung Aina M., San Jose, CA, UNITED STATES  
PI US 2003124106 A1 20030703  
AI US 2002-168274 A1 20020613 (10)  
WO 2000-US33158 20001207  
PRAI US 1999-60172367 19991216  
DT Utility  
FS APPLICATION  
LN.CNT 6886  
INCL INCLM: 424/094.400  
INCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 536/023.200  
NCL NCLM: 424/094.400  
NCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 536/023.200  
IC [7]  
ICM: A61K038-44  
ICS: C12N009-02; C07H021-04; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 247 OF 469 USPATFULL on STN  
AN 2003:173967 USPATFULL  
TI Lactams substituted by cyclic succinates as inhibitors of A-beta protein  
production  
IN Olson, Richard E., Wilmington, DE, UNITED STATES  
PI US 2003119815 A1 20030626  
AI US 2002-287099 A1 20021104 (10)  
RLI Division of Ser. No. US 2001-871840, filed on 1 Jun 2001, GRANTED, Pat.  
No. US 6509333  
PRAI US 2000-208536P 20000601 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6497  
INCL INCLM: 514/212.030  
INCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;  
540/524.000; 540/527.000; 546/207.000; 546/216.000  
NCL NCLM: 514/212.030  
NCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;

IC 171  
ICM: A61K031-55  
ICS: A61K031-454; C07D043-02; C07D041-02; C07D223-12; C07D211-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 248 OF 469 USPATFULL on STN  
AN 2003:165862 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2003113717 A1 20030619  
AI US 2001-893878 A1 20010629 (9)  
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED  
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED  
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15933  
INCL INCLM: 435/006.000  
INCLS: 435/007.200; 435/455.000; 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 435/007.200; 435/455.000; 435/091.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 249 OF 469 USPATFULL on STN  
AN 2003:158903 USPATFULL  
TI Death domain containing receptor 4  
IN Ni, Jian, Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Pan, James G., Belmont, CA, UNITED STATES  
Gentz, Reiner L., Rockville, MD, UNITED STATES  
Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)  
PI US 2003108516 A1 20030612  
AI US 2002-175902 A1 20020621 (10)  
RLI Division of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat.  
No. US 6433147 Division of Ser. No. US 1998-13895, filed on 27 Jan 1998,  
GRANTED, Pat. No. US 6342363  
PRAI US 1999-132922P 19990506 (60)  
US 1997-37829P 19970205 (60)  
US 1997-35722P 19970128 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 9230  
INCL INCLM: 424/085.100  
INCLS: 424/155.100; 514/012.000  
NCL NCLM: 424/085.100  
NCLS: 424/155.100; 514/012.000  
IC [7]  
ICM: A61K039-395  
ICS: A61K038-19; A61K038-17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 250 OF 469 USPATFULL on STN  
AN 2003:153434 USPATFULL  
TI Oxo-substituted compounds, process of making, and compositions and  
methods for inhibiting PARP activity  
IN Li, Jia-He, Cockeysville, MD, UNITED STATES  
Tays, Kevin Leonard, Elkridge, MD, UNITED STATES  
Zhang, Jie, Ellicott City, MD, UNITED STATES  
PA Guilford Pharmaceuticals Inc. (U.S. corporation)  
PI US 2003105102 A1 20030605  
AI US 2002-109730 A1 20020401 (10)

Continuation-in-part of Ser. No. US 1998-79509, filed on 15 May 1998,  
ABANDONED Continuation-in-part of Ser. No. US 1997-922520, filed on 3  
Sep 1997, ABANDONED  
Utility  
APPLICATION  
N.CNT 3754  
INCL: 514/248.000  
INCL: 514/252.170; 514/252.160; 514/266.200; 514/266.220; 514/266.300;  
514/253.050; 514/309.000; 544/284.000; 544/363.000; 546/141.000;  
544/235.000  
NCL: 514/248.000  
NCL: 514/252.170; 514/252.160; 514/266.200; 514/266.220; 514/266.300;  
514/253.050; 514/309.000; 544/284.000; 544/363.000; 546/141.000;  
544/235.000  
[7]  
ICM: A61K031-502  
ICS: A61K031-517; A61K031-519; A61K031-496; C07D043-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 251 OF 469 USPTFULL on STN  
2003:146761 USPTFULL  
Carbohydrate epitope mimic compounds and uses thereof  
Simon, Maryline, Baar, SWITZERLAND  
Schachner, Melitta, Hamburg, GERMANY, FEDERAL REPUBLIC OF  
Neuberger, Timothy J., Dobbs Ferry, NY, UNITED STATES  
Herzberg, Uri, Yorktown Heights, NY, UNITED STATES  
US 2003100508 A1 20030529  
US 2002-186867 A1 20020701 (10)  
Continuation of Ser. No. US 2000-511956, filed on 23 Feb 2000, ABANDONED  
US 1999-121327P 19990224 (60)  
US 1999-155492P 19990923 (60)  
Utility  
APPLICATION  
N.CNT 5586  
INCL: 514/014.000  
INCL: 530/326.000  
NCL: 514/014.000  
NCL: 530/326.000  
[7]  
ICM: A61K038-10  
ICS: C07K007-08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 252 OF 469 USPTFULL on STN  
2003:143058 USPTFULL  
Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
.- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
Thompson, Richard C., Frankfort, IN, United States  
Wilkie, Stephen, Indianapolis, IN, United States  
Stack, Douglas R., Fishers, IN, United States  
VanMeter, Eldon E., Greenwood, IN, United States  
Shi, Qing, Carmel, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James E., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Cwi, Cynthia L., Indianapolis, IN, United States  
Henry, Steven S., New Palestine, IN, United States  
McDaniel, Stacey L., Martinsville, IN, United States  
Stucky, Russell D., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
US 6569851 B1 20030527  
US 1999-338191 19990622 (9)  
US 1998-160067P 19980622 (60)  
Utility  
GRANTED  
N.CNT 12808  
INCL: 514/219.000  
INCL: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000;

NCL NCLM: 514/219.000  
NCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000;  
540/558.000; 540/559.000; 540/560.000; 540/561.000  
IC [7]  
ICM: C07D243-24  
ICS: C07D223-18; C07D223-16; C07D243-14; A61K031-55  
EXF 540/509; 540/558; 540/559; 540/560; 540/561; 540/517; 540/518; 514/221;  
514/219; 514/220  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 253 OF 469 USPATFULL on STN  
AN 2003:141017 USPATFULL  
TI Methods for protecting cells from amyloid toxicity and for inhibiting  
amyloid protein production  
IN Schubert, David R., La Jolla, CA, UNITED STATES  
Liu, Yuanbin, San Diego, CA, UNITED STATES  
PA The Salk Institute for Biological Studies (U.S. corporation)  
PI US 2003096859 A1 20030522  
AI US 2002-269477 A1 20021011 (10)  
RLI Division of Ser. No. US 2000-617147, filed on 17 Jul 2000, GRANTED, Pat.  
No. US 6472436  
DT Utility  
FS APPLICATION  
LN.CNT 1189  
INCL INCLM: 514/456.000  
NCL NCLM: 514/456.000  
IC [7]  
ICM: A61K031-353  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 254 OF 469 USPATFULL on STN  
AN 2003:140406 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)  
PI US 2003096247 A1 20030522  
AI US 2001-986 A1 20011114 (10)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25656  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 800/008.000  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 800/008.000  
IC [7]  
ICM: C12Q001-68  
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 469 USPATFULL on STN  
AN 2003:135731 USPATFULL  
TI Transgenic animals for producing specific isotypes of human  
\*\*\*antibodies\*\*\* via non-cognate switch regions  
IN Green, Larry L., San Francisco, CA, UNITED STATES  
Ivanov, Vladimir E., Fremont, CA, UNITED STATES  
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES  
PI US 2003093820 A1 20030515  
AI US 2001-999321 A1 20011130 (9)  
PRAI WO 2000-US15782 20000608  
DT Utility  
FS APPLICATION  
LN.CNT 3765  
INCL INCLM: 800/008.000  
INCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530  
NCL NCLM: 800/008.000  
NCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530

ICM: A01K067-00

ICS: C07H021-04; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 469 USPATFULL on STN  
AN 2003:134541 USPATFULL  
TI Inhibitors of memapsin 2 and use thereof  
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES  
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES  
Ghosh, Arun K., River Forest, IL, UNITED STATES  
PA Oklahoma Medical Research Foundation, Oklahoma City, OK (U.S.  
corporation)  
PI US 2003092629 A1 20030515  
AI US 2001-32818 A1 20011228 (10)  
PRAI US 2001-275756P 20010314 (60)  
US 2000-258705P 20001228 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2203  
INCL INCLM: 514/013.000  
INCLS: 530/326.000  
NCL NCLM: 514/013.000  
NCLS: 530/326.000  
IC [7]  
ICM: A61K038-10  
ICS: C07K007-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 257 OF 469 USPATFULL on STN  
AN 2003:133926 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)  
PI US 2003092011 A1 20030515  
AI US 2001-489 A1 20011114 (10)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25607  
INCL INCLM: 435/006.000  
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;  
435/325.000; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;  
435/325.000; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02;  
C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 258 OF 469 USPATFULL on STN  
AN 2003:127742 USPATFULL  
TI Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing  
the same  
IN Kelleher, Judith A., Fremont, CA, UNITED STATES  
Maples, Kirk R., San Jose, CA, UNITED STATES  
Dykman, Alina, San Francisco, CA, UNITED STATES  
Zhang, Yong-Kang, Santa Clara, CA, UNITED STATES  
Wilcox, Allan L., Mountain View, CA, UNITED STATES  
Levell, Julian, Collegeville, PA, UNITED STATES  
PI US 2003087957 A1 20030508  
AI US 2002-74595 A1 20020211 (10)  
RLI Continuation of Ser. No. US 2000-500650, filed on 9 Feb 2000, ABANDONED  
Continuation of Ser. No. US 1998-172763, filed on 15 Oct 1998, GRANTED,  
Pat. No. US 6046232  
PRAI US 1997-62324P 19971017 (60)  
US 1997-63736P 19971029 (60)  
US 1998-90475P 19980624 (60)

FS APPLICATION  
LN.CNT 2874  
INCL INCLM: 514/466.000  
INCLS: 514/640.000; 564/253.000; 549/440.000  
NCL NCLM: 514/466.000  
NCLS: 514/640.000; 564/253.000; 549/440.000  
IC [7]  
ICM: A61K031-36  
ICS: A61K031-15; C07C251-48  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 259 OF 469 USPATFULL on STN  
AN 2003:127047 USPATFULL  
TI Methods and compositions for regulating bone and cartilage formation  
IN Clancy, Brian M., Ashland, MA, UNITED STATES  
Pittman, Debra D., Windham, NH, UNITED STATES  
PI US 2003087259 A1 20030508  
AI US 2002-125691 A1 20020418 (10)  
PRAI US 2001-284786P 20010418 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 12451  
INCL INCLM: 435/006.000  
INCLS: 702/020.000  
NCL NCLM: 435/006.000  
NCLS: 702/020.000  
IC [7]  
ICM: C12Q001-68  
ICS: G06F019-00; G01N033-48; G01N033-50  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 260 OF 469 USPATFULL on STN  
AN 2003:120793 USPATFULL  
TI Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's  
disease in patients  
IN Hersh, Louis B., Lexington, KY, UNITED STATES  
PI US 2003083277 A1 20030501  
AI US 2001-792079 A1 20010226 (9)  
PRAI US 2000-184826P 20000224 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1117  
INCL INCLM: 514/044.000  
INCLS: 424/094.630; 424/093.210  
NCL NCLM: 514/044.000  
NCLS: 424/094.630; 424/093.210  
IC [7]  
ICM: A61K048-00  
ICS: A61K038-48  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 261 OF 469 USPATFULL on STN  
AN 2003:120071 USPATFULL  
TI Novel nucleic acid sequences encoding human cell adhesion molecule  
protein-like polypeptides  
IN Shimkets, Richard A., West Haven, CT, UNITED STATES  
Herrnandes, Elma, Branford, CT, UNITED STATES  
Herrman, John, Guilford, CT, UNITED STATES  
Vernet, Corine, Gainesville, FL, UNITED STATES  
PA CuraGen Corporation, New Haven, CT, 06511  
PI US 2003082554 A1 20030501  
AI US 2001-977033 A1 20011015 (9)  
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING  
PRAI US 2000-201388P 20000503 (60)  
US 2000-193086P 20000330 (60)  
US 2000-191158P 20000322 (60)  
US 2000-189810P 20000316 (60)  
US 1999-137322P 19990603 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7063  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500

ICM: C07K014-435

ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 262 OF 469 USPATFULL on STN  
AN 2003:113554 USPATFULL  
TI Method for treating multiple sclerosis  
IN Shankar, L. Sai Latha, New York, NY, UNITED STATES  
Tatton, William G., Purchase, NY, UNITED STATES  
Tatton, Nadine A., Purchase, NY, UNITED STATES  
PI US 2003078295 A1 20030424  
AI US 2002-205747 A1 20020726 (10)  
RLI Continuation of Ser. No. US 1999-416010, filed on 8 Oct 1999, PENDING  
PRAI US 1998-103742P 19981009 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4863  
INCL INCLM: 514/478.000  
INCLS: 514/617.000; 514/649.000; 514/651.000  
NCL NCLM: 514/478.000  
NCLS: 514/617.000; 514/649.000; 514/651.000  
IC [7]  
ICM: A61K031-325  
ICS: A61K031-165; A61K031-137  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 263 OF 469 USPATFULL on STN  
AN 2003:109100 USPATFULL  
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting. \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Thompson, Richard C., Frankfort, IN, United States  
Wilkie, Stephen C., Indianapolis, IN, United States  
Stack, Douglas R., Fishers, IN, United States  
Shi, Qing, Carmel, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)  
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6552013 B1 20030422  
AI US 1999-338121 19990622 (9)  
PRAI US 1998-160067P 19980622 (60)  
US 1998-150704P 19980930 (60)  
DT Utility  
FS GRANTED  
LN.CNT 7962  
INCL INCLM: 514/212.040  
INCLS: 514/212.070; 540/522.000; 540/523.000  
NCL NCLM: 514/212.040  
NCLS: 514/212.070; 540/522.000; 540/523.000  
IC [7]  
ICM: C07D243-24  
ICS: C07D223-18; C07D223-16; C07D409-12; A61K031-55  
EXF 514/212.04; 514/212.07; 540/522; 540/523  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 264 OF 469 USPATFULL on STN  
AN 2003:106809 USPATFULL  
TI Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone  
IN Bartlett, Paul A., Oakland, CA, UNITED STATES  
Rezac, Miroslav, Chicago, IL, UNITED STATES  
Olson, Steven, Metuchen, NJ, UNITED STATES  
Phillips, Scott, Berkeley, CA, UNITED STATES  
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, Oakland, CA, UNITED STATES (U.S. corporation)  
PI US 2003073721 A1 20030417  
AI US 2002-157759 A1 20020528 (10)  
PRAI US 2001-296167P 20010605 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1727  
INCL INCLM: 514/333.000  
INCLS: 514/335.000; 514/350.000; 514/341.000; 514/339.000; 546/256.000;

NCL NCLM: 514/333.000  
NCLS: 514/335.000; 514/350.000; 514/341.000; 514/339.000; 546/256.000;  
546/261.000; 546/272.700; 546/277.400; 546/276.400; 546/298.000

IC [7]  
ICM: C07D041-14  
ICS: C07D041-02; A61K031-444; A61K031-4439; A61K031-44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 265 OF 469 USPATFULL on STN  
AN 2003:106789 USPATFULL  
TI Succinoylamino heterocycles as inhibitors of a beta protein production  
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES  
Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES  
PI US 2003073701 A1 20030417  
AI US 2001-823820 A1 20010331 (9)  
DT Utility  
FS APPLICATION  
LN.CNT 3957

INCL INCLM: 514/255.010  
INCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;  
514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000;  
544/333.000; 546/208.000

NCL NCLM: 514/255.010  
NCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;  
514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000;  
544/333.000; 546/208.000

IC [7]  
ICM: A61K031-496  
ICS: A61K031-506; A61K031-4545

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 266 OF 469 USPATFULL on STN  
AN 2003:106233 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of pancreatic  
cancer  
IN Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2003073144 A1 20030417  
AI US 2002-60036 A1 20020130 (10)  
PRAI US 2001-333626P 20011127 (60)  
US 2001-305484P 20010712 (60)  
US 2001-265305P 20010130 (60)  
US 2001-267568P 20010209 (60)  
US 2001-313999P 20010820 (60)  
US 2001-291631P 20010516 (60)  
US 2001-287112P 20010428 (60)  
US 2001-278651P 20010321 (60)  
US 2001-265682P 20010131 (60)

DT Utility  
FS APPLICATION

LN.CNT 14253

INCL INCLM: 435/007.230  
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200

NCL NCLM: 435/007.230  
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200

IC [7]  
ICM: G01N033-574  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 267 OF 469 USPATFULL on STN  
AN 2003:106163 USPATFULL  
TI DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF AB ABNORMALITIES  
IN TANZI, RUDOLPH E., CANTON, MA, UNITED STATES  
BUSH, ASHLEY I., SOMERVILLE, MA, UNITED STATES  
MOIR, ROBERT D., BOSTON, MA, UNITED STATES  
PI US 2003073074 A1 20030417  
AI US 1999-425956 A1 19991025 (9)  
RLI Continuation of Ser. No. US 1997-817423, filed on 4 Aug 1997, GRANTED,  
Pat. No. US 5972634 A 371 of International Ser. No. WO 1994-US11895,



DT Utility  
 FS APPLICATION  
 LN.CNT 2343  
 INCL INCLM: 435/006.000  
 INCLS: 435/287.200; 435/007.900  
 NCL NCLM: 435/006.000  
 NCLS: 435/287.200; 435/007.900  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543; C12M001-34  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 268 OF 469 USPATFULL on STN  
 AN 2003:102440 USPATFULL  
 TI Stable macroscopic membranes formed by self-assembly of amphiphilic  
 peptides and uses therefor  
 IN Zhang, Shuguang, Cambridge, MA, United States  
 Lockshin, Curtis, Lexington, MA, United States  
 Rich, Alexander, Cambridge, MA, United States  
 Holmes, Todd, Cambridge, MA, United States  
 PA Massachusettes Insitute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI US 6548630 B1 20030415  
 AI US 1997-898300 19970722 (8)  
 RLI Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994, now  
 patented, Pat. No. US 5670483 Continuation of Ser. No. US 1992-973326,  
 filed on 28 Dec 1992, now abandoned

DT Utility  
 FS GRANTED  
 LN.CNT 2187  
 INCL INCLM: 530/300.000  
 INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000;  
 514/012.000; 514/013.000; 514/014.000  
 NCL NCLM: 530/300.000  
 NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000  
 IC [7]  
 ICM: C07K007-00  
 ICS: C07K016-00; A61K038-00  
 EXF 514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327;  
 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 269 OF 469 USPATFULL on STN  
 AN 2003:100295 USPATFULL  
 TI 87 human secreted proteins  
 IN Young, Paul, Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Duan, Roxanne, Gaithersburg, MD, UNITED STATES  
 Hu, Jing-Shan, Mountain View, CA, UNITED STATES  
 Florence, Kimberly, Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Moore, Paul A., Germantown, MD, UNITED STATES  
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
 Lafleur, David W., Washington, DC, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.  
 corporation)  
 PI US 2003069406 A1 20030410  
 AI US 2002-143090 A1 20020513 (10)  
 RLI Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING  
 Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998,  
 UNKNOWN  
 PRAI US 1997-41277P 19970321 (60)  
 US 1997-42344P 19970321 (60)  
 US 1997-41276P 19970321 (60)  
 US 1997-41281P 19970321 (60)  
 US 1997-48094P 19970530 (60)  
 US 1997-48350P 19970530 (60)  
 US 1997-48188P 19970530 (60)  
 US 1997-48135P 19970530 (60)

US 1997-48187P 19970530 (60)  
US 1997-48099P 19970530 (60)  
US 1997-48352P 19970530 (60)  
US 1997-48186P 19970530 (60)  
US 1997-48069P 19970530 (60)  
US 1997-48095P 19970530 (60)  
US 1997-48131P 19970530 (60)  
US 1997-48096P 19970530 (60)  
US 1997-48355P 19970530 (60)  
US 1997-48160P 19970530 (60)  
US 1997-48351P 19970530 (60)  
US 1997-48154P 19970530 (60)  
US 1997-54804P 19970805 (60)  
US 1997-56370P 19970819 (60)  
US 1997-60862P 19971002 (60)

DT Utility  
FS APPLICATION

LN.CNT 15137

INCL INCLM: 536/023.200  
INCLS: 435/006.000; 435/183.000; 435/069.100; 435/325.000; 435/320.100;  
530/350.000

NCL NCLM: 536/023.200  
NCLS: 435/006.000; 435/183.000; 435/069.100; 435/325.000; 435/320.100;  
530/350.000

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 270 OF 469 USPATFULL on STN

AN 2003:100060 USPATFULL

TI Pharmaceutical compositions of drug-oligomer conjugates and methods of  
treating diseases therewith

IN Soltero, Richard, Holly Springs, NC, UNITED STATES

Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES

Opawale, Foyeke, Raleigh, NC, UNITED STATES

Rehlander, Bruce, Chapel Hill, NC, UNITED STATES

Hickey, Anthony, Chapel Hill, NC, UNITED STATES

Li Li, Bovet, Chapel Hill, NC, UNITED STATES

PI US 2003069170 A1 20030410

US 6770625 B2 20040803

AI US 2002-235284 A1 20020905 (10)

PRAI US 2001-318193P 20010907 (60)

US 2002-377865P 20020503 (60)

DT Utility  
FS APPLICATION

LN.CNT 3615

INCL INCLM: 514/002.000  
INCLS: 514/012.000; 514/171.000; 514/560.000

NCL NCLM: 514/012.000  
NCLS: 514/003.000; 514/021.000; 514/784.000; 514/808.000

IC [7]

ICM: A61K038-23

ICS: A61K031-56; A61K031-202; A61K038-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 271 OF 469 USPATFULL on STN

AN 2003:96167 USPATFULL

TI Catalytically active recombinant memapsin and methods of use thereof

IN Tang, Jordan J. N., Edmond, OK, United States

Lin, Xinli, Edmond, OK, United States

Koelsch, Gerald, Oklahoma City, OK, United States

Hong, Lin, Oklahoma City, OK, United States

PA Oklahoma Medical Research Foundation, Oklahoma City, OK, United States  
(U.S. corporation)

PI US 6545127 B1 20030408

AI US 2000-604608 20000627 (9)

PRAI US 1999-141363P 19990628 (60)

US 1999-168060P 19991130 (60)

US 2000-177836P 20000125 (60)

US 2000-178368P 20000127 (60)

US 2000-210292P 20000608 (60)

DT Utility  
FS GRANTED

LN.CNT 2563

INCLS: 702/019.000; 530/300.000; 536/023.100  
NCL NCLM: 530/350.000  
NCLS: 530/300.000; 536/023.100; 702/019.000  
IC [7]  
ICM: G01N033-48  
ICS: G01N031-00; G06F019-00; A16K038-00; C07K001-00; C07K014-00;  
C07K017-00; C07M021-02; C07M021-04  
EXF 435/212; 435/183; 435/7.1; 435/226; 435/15; 530/300; 536/350; 536/23.1;  
702/19; 702/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 272 OF 469 USPATFULL on STN  
AN 2003:94733 USPATFULL  
TI Transgenic animals and cell lines for screening drugs effective for the  
treatment or prevention of Alzheimer's Disease  
IN Monte, Suzanne De La, East Greenwich, RI, UNITED STATES  
Wands, Jack R., Waban, MA, UNITED STATES  
PI US 2003066097 A1 20030403  
AI US 2001-964678 A1 20010928 (9)  
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371  
of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN  
PRAI US 1997-38908P 19970226 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2091  
INCL INCLM: 800/012.000  
INCLS: 435/325.000; 435/320.100; 536/023.200  
NCL NCLM: 800/012.000  
NCLS: 435/325.000; 435/320.100; 536/023.200  
IC [7]  
ICM: A01K067-027  
ICS: C12N005-06; C07H021-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 273 OF 469 USPATFULL on STN  
AN 2003:93790 USPATFULL  
TI Secreted protein HCEJQ69  
IN Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Young, Paul, Gaithersburg, MD, UNITED STATES  
Florence, Kimberly, Rockville, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Mucenski, Michael, Cincinnati, OH, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Olsen, Henrik, Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Komatsoulis, George, Silver Spring, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.  
corporation)  
PI US 2003065151 A1 20030403  
US 6774216 B2 20040810  
AI US 2002-115123 A1 20020404 (10)  
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING  
Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999,  
UNKNOWN  
PRAI US 1998-89507P 19980616 (60)  
US 1998-89508P 19980616 (60)  
US 1998-89509P 19980616 (60)  
US 1998-89510P 19980616 (60)  
US 1998-90112P 19980622 (60)  
US 1998-90113P 19980622 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 18779  
INCL INCLM: 530/388.260  
NCL NCLM: 530/387.900  
NCLS: 530/387.100; 530/387.700; 530/388.100; 530/388.150; 430/069.100;  
430/320.000; 536/023.500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 274 OF 469 USPATFULL on STN  
 AN 2003:89394 USPATFULL  
 TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor  
 IN Barta, Thomas E., Evanston, IL, United States  
 Becker, Daniel P., Glenview, IL, United States  
 Boehm, Terri L., Ballwin, MO, United States  
 De Crescenzo, Gary A., St. Charles, MO, United States  
 Villamil, Clara I., Glenview, IL, United States  
 McDonald, Joseph J., Ballwin, MO, United States  
 Freskos, John N., Clayton, MO, United States  
 Getman, Daniel P., Chesterfield, MO, United States  
 PA G. D. Searle & Company, St. Louis, MO, United States (U.S. corporation)  
 PI US 6541489 B1 20030401  
 WO 9925687 19990527  
 AI US 2000-554082 20000731 (9)  
 WO 1998-US23242 19981112  
 20000731 PCT 371 date  
 PRAI US 1997-66007P 19971114 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 13579  
 INCL INCLM: 514/330.000  
 INCLS: 546/192.000; 546/225.000  
 NCL NCLM: 514/330.000  
 NCLS: 546/192.000; 546/225.000  
 IC [7]  
 ICM: A61K031-445  
 ICS: C07D211-06  
 EXF 546/192; 546/225; 514/330  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 275 OF 469 USPATFULL on STN  
 AN 2003:87011 USPATFULL  
 TI Secreted protein HFEAF41  
 IN Young, Paul, Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Tewksbury, MA, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Duan, Roxanne, Bethesda, MD, UNITED STATES  
 Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES  
 Florence, Kimberly, Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Moore, Paul A., Germantown, MD, UNITED STATES  
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
 Lafleur, David W., Washington, DC, UNITED STATES  
 Ni, Jian, Rockville, MD, UNITED STATES  
 PI US 2003060619 A1 20030327  
 AI US 2001-983966 A1 20011026 (9)  
 RLI Division of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING  
 Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998,  
 UNKNOWN  
 PRAI US 1997-41277P 19970321 (60)  
 US 1997-42344P 19970321 (60)  
 US 1997-41276P 19970321 (60)  
 US 1997-41281P 19970321 (60)  
 US 1997-48094P 19970530 (60)  
 US 1997-48350P 19970530 (60)  
 US 1997-48188P 19970530 (60)  
 US 1997-48135P 19970530 (60)  
 US 1997-50937P 19970530 (60)  
 US 1997-48187P 19970530 (60)  
 US 1997-48099P 19970530 (60)  
 US 1997-48352P 19970530 (60)  
 US 1997-48186P 19970530 (60)  
 US 1997-48069P 19970530 (60)  
 US 1997-48095P 19970530 (60)  
 US 1997-48131P 19970530 (60)  
 US 1997-48096P 19970530 (60)  
 US 1997-48355P 19970530 (60)

US 1997-48351P 19970530 (60)  
 US 1997-48154P 19970530 (60)  
 US 1997-54804P 19970805 (60)  
 US 1997-56370P 19970819 (60)  
 US 1997-60862P 19971002 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 15264  
 INCL INCLM: 536/023.530  
 INCLS: 530/388.150; 530/391.100  
 NCL NCLM: 536/023.530  
 NCLS: 530/388.150; 530/391.100  
 IC [7]  
 ICM: C07H021-04  
 ICS: C07K016-46  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 276 OF 469 USPATFULL on STN  
 AN 2003:78523 USPATFULL  
 TI 90 human secreted proteins  
 IN Ruben, Steven M., Olney, MD, UNITED STATES  
 Soppet, Daniel R., Centreville, VA, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Young, Paul E., Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Janat, Fouad, Westerly, RI, UNITED STATES  
 Birse, Charles E., North Potomac, MD, UNITED STATES  
 PI US 2003054443 A1 20030320  
 AI US 2001-969730 A1 20011004 (9)  
 RLI Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001,  
 PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999,  
 ABANDONED Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4  
 Aug 1998, UNKNOWN  
 PRAI US 2000-238291P 20001006 (60)  
 US 1997-55386P 19970805 (60)  
 US 1997-54807P 19970805 (60)  
 US 1997-55312P 19970805 (60)  
 US 1997-55309P 19970805 (60)  
 US 1997-54798P 19970805 (60)  
 US 1997-55310P 19970805 (60)  
 US 1997-54806P 19970805 (60)  
 US 1997-54809P 19970805 (60)  
 US 1997-54804P 19970805 (60)  
 US 1997-54803P 19970805 (60)  
 US 1997-54808P 19970805 (60)  
 US 1997-55311P 19970805 (60)  
 US 1997-55986P 19970818 (60)  
 US 1997-55970P 19970818 (60)  
 US 1997-56563P 19970819 (60)  
 US 1997-56557P 19970819 (60)  
 US 1997-56731P 19970819 (60)  
 US 1997-56365P 19970819 (60)  
 US 1997-56367P 19970819 (60)  
 US 1997-56370P 19970819 (60)  
 US 1997-56364P 19970819 (60)  
 US 1997-56366P 19970819 (60)  
 US 1997-56732P 19970819 (60)  
 US 1997-56371P 19970819 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 26693  
 INCL INCLM: 435/069.100  
 INCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;  
 536/023.100; 530/350.000  
 NCL NCLM: 435/069.100  
 NCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;  
 536/023.100; 530/350.000  
 IC [7]  
 ICM: C12P021-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 277 OF 469 USPATFULL on STN  
 AN 2003:72174 USPATFULL  
 TI Secreted protein HFEAF41  
 IN Young, Paul, Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Tewksbury, MA, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Duan, Roxanne, Bethesda, MD, UNITED STATES  
 Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES  
 Florence, Kimberly, Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Brewer, Lauie A., St. Paul, MN, UNITED STATES  
 Moore, Paul A., Germantown, MD, UNITED STATES  
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
 Lafleur, David W., Washington, DC, UNITED STATES  
 Ni, Jian, Rockville, MD, UNITED STATES  
 PI US 2003050461 A1 20030313  
 AI US 2001-966262 A1 20011001 (9)  
 RLI Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING  
 Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998,  
 UNKNOWN  
 PRAI US 1997-41277P 19970321 (60)  
 US 1997-42344P 19970321 (60)  
 US 1997-41276P 19970321 (60)  
 US 1997-41281P 19970321 (60)  
 US 1997-48094P 19970530 (60)  
 US 1997-48350P 19970530 (60)  
 US 1997-48188P 19970530 (60)  
 US 1997-48135P 19970530 (60)  
 US 1997-50937P 19970530 (60)  
 US 1997-48187P 19970530 (60)  
 US 1997-48099P 19970530 (60)  
 US 1997-48352P 19970530 (60)  
 US 1997-48186P 19970530 (60)  
 US 1997-48069P 19970530 (60)  
 US 1997-48095P 19970530 (60)  
 US 1997-48131P 19970530 (60)  
 US 1997-48096P 19970530 (60)  
 US 1997-48355P 19970530 (60)  
 US 1997-48160P 19970530 (60)  
 US 1997-48351P 19970530 (60)  
 US 1997-48154P 19970530 (60)  
 US 1997-54804P 19970805 (60)  
 US 1997-56370P 19970819 (60)  
 US 1997-60862P 19971002 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 15105  
 INCL INCLM: 536/023.200  
 INCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000;  
 424/094.100  
 NCL NCLM: 536/023.200  
 NCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000;  
 424/094.100  
 IC [7]  
 ICM: C12Q001-68  
 ICS: C07H021-04; A61K038-43; C12N009-00; C12P021-02; C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 278 OF 469 USPATFULL on STN  
 AN 2003:65430 USPATFULL  
 TI Novel compounds for the management of aging-related and diabetic  
 vascular complications, process for their preparation, therapeutic and  
 cosmetic uses thereof  
 IN Sankaranarayanan, Alangudi, Ahmedabad, INDIA  
 PA TORRENT PHARMACEUTICALS LTD. (non-U.S. corporation)  
 PI US 2003045554 A1 20030306  
 AI US 2002-116135 A1 20020405 (10)  
 PRAI US 2001-281380P 20010405 (60)  
 DT Utility

LN.CNT 4729  
INCL INCLM: 514/340.000  
INCLS: 546/275.400; 546/276.400  
NCL NCLM: 514/340.000  
NCLS: 546/275.400; 546/276.400  
IC [7]  
ICM: A61K031-4439  
ICS: C07D041-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 279 OF 469 USPATFULL on STN  
AN 2003:64730 USPATFULL  
TI Secreted protein HCEJQ69  
IN Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Florence, Kimberly A., Rockville, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Mucenski, Michael, Cincinnati, OH, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Komatsoulis, George A., Silver Spring, MD, UNITED STATES  
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.  
corporation)  
PI US 2003044851 A1 20030306  
US 6627741 B2 20030930  
AI US 2001-12542 A1 20011212 (10)  
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING  
Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999,  
UNKNOWN  
PRAI US 1998-89507P 19980616 (60)  
US 1998-89508P 19980616 (60)  
US 1998-89509P 19980616 (60)  
US 1998-89510P 19980616 (60)  
US 1998-90112P 19980622 (60)  
US 1998-90113P 19980622 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 18831  
INCL INCLM: 435/007.200  
INCLS: 530/387.100; 435/326.000  
NCL NCLM: 530/389.200  
NCLS: 530/387.100; 530/387.300; 530/387.700; 530/387.900; 530/388.100;  
530/388.150; 530/389.100  
IC [7]  
ICM: G01N033-53  
ICS: C07K016-00; C12N005-16; C12N005-06; G01N033-567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 280 OF 469 USPATFULL on STN  
AN 2003:64662 USPATFULL  
TI Human genes and gene expression products  
IN Williams, Lewis T., Mill Valley, CA, UNITED STATES  
Escobedo, Jaime, Alamo, CA, UNITED STATES  
Innis, Michael A., UNITED STATES  
Garcia, Pablo Dominguez, San Francisco, CA, UNITED STATES  
Sudduth-Klinger, Julie, Kensington, CA, UNITED STATES  
Reinhard, Christoph, Alameda, CA, UNITED STATES  
Randazzo, Filippo, Oakland, CA, UNITED STATES  
Kennedy, Giulia C., San Francisco, CA, UNITED STATES  
Pot, David, Arlington, VA, UNITED STATES  
Kassam, Altaf, Oakland, CA, UNITED STATES  
Lamson, George, Moraga, CA, UNITED STATES  
Drmanac, Radjoe, Palo Alto, CA, UNITED STATES  
Dickson, Mark, Hollister, CA, UNITED STATES  
Labat, Ivan, Mountain View, CA, UNITED STATES  
Jones, Lee William, Sunnyvale, CA, UNITED STATES

PI US 2003044783 A1 20030306  
AI US 2001-803719 A1 20010309 (9)  
PRAI US 2000-188609P 20000309 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 23459  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 530/388.100  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 530/388.100  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-435;  
C07K016-40  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 281 OF 469 USPATFULL on STN  
AN 2003:60218 USPATFULL  
TI Cyclic amino acid compounds pharmaceutical compositions comprising same  
and methods for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, United States  
Dressman, Bruce A., Indianapolis, IN, United States  
Shi, Qing, Carmel, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6528505 B1 20030304  
AI US 1999-338180 19990622 (9)  
PRAI US 1998-160067P 19980622 (60)  
US 1998-155238P 19980930 (60)  
DT Utility  
FS GRANTED  
LN.CNT 7113  
INCL INCLM: 514/212.040  
INCLS: 514/212.070; 540/522.000; 540/523.000  
NCL NCLM: 514/212.040  
NCLS: 514/212.070; 540/522.000; 540/523.000  
IC [7]  
ICM: C07D223-14  
ICS: C07D243-06; C07D243-10; C07D243-12; A61K031-55  
EXF 540/522; 540/523; 514/212.04; 514/212.07  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 282 OF 469 USPATFULL on STN  
AN 2003:46308 USPATFULL  
TI Transgenic animals and cell lines for screening drugs effective for the  
treatment or prevention of Alzheimer's disease  
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES  
Wands, Jack R., Waban, MA, UNITED STATES  
PI US 2003033621 A1 20030213  
AI US 2001-964667 A1 20010928 (9)  
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371  
of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN  
PRAI US 1997-38908P 19970226 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2088  
INCL INCLM: 800/012.000  
INCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100  
NCL NCLM: 800/012.000  
NCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100  
IC [7]  
ICM: A01K067-027  
ICS: C07H021-04; C12N005-06; C12N015-86  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 283 OF 469 USPATFULL on STN  
AN 2003:37603 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)



AI US 2001-924340 AI 20010806 (9)  
PRAI US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25650  
INCL INCLM: 435/069.100  
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;  
435/006.000  
NCL NCLM: 435/069.100  
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;  
435/006.000  
IC [7]  
ICM: C12P021-02  
ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 284 OF 469 USPATFULL on STN  
AN 2003:37516 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)  
PI US 2003027161 AI 20030206  
AI US 2001-992600 AI 20011113 (9)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)

DT Utility  
FS APPLICATION  
LN.CNT 25529  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 800/008.000  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;  
536/023.200; 800/008.000  
IC [7]  
ICM: C12Q001-68  
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 285 OF 469 USPATFULL on STN  
AN 2003:37513 USPATFULL  
TI Novel nucleic acid sequences encoding human breast tumor-associated  
protein 47-like polypeptides  
IN Shimkets, Richard A., West Haven, CT, UNITED STATES  
Fernandes, Elma, Branford, CT, UNITED STATES  
Herrman, John, Guilford, CT, UNITED STATES  
Vernet, Corine, Gainesville, FL, UNITED STATES  
PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S.  
corporation)  
PI US 2003027158 AI 20030206  
AI US 2001-977418 AI 20011015 (9)  
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING  
PRAI US 2000-201388P 20000503 (60)  
US 2000-193086P 20000330 (60)  
US 2000-191158P 20000322 (60)  
US 2000-189810P 20000316 (60)  
US 1999-137322P 19990603 (60)

DT Utility  
FS APPLICATION  
LN.CNT 7101  
INCL INCLM: 435/006.000  
INCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200  
NCL NCLM: 435/006.000  
NCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06

L4 ANSWER 286 OF 469 USPATFULL on STN  
 AN 2003:37187 USPATFULL  
 TI Anionic liposomes for delivery of bioactive agents  
 IN Lakkaraju, Aparna, Minneapolis, MN, UNITED STATES  
 Dubinsky, Janet M., St. Paul, MN, UNITED STATES  
 Low, Walter, Shorewood, MN, UNITED STATES  
 Rahman, Yueh-Erh, LaJolla, CA, UNITED STATES  
 PI US 2003026831 A1 20030206  
 AI US 2002-131786 A1 20020422 (10)  
 PRAI US 2001-285337P 20010420 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3617  
 INCL INCLM: 424/450.000  
 NCL NCLM: 424/450.000  
 IC [7]  
 ICM: A61K009-127  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 287 OF 469 USPATFULL on STN  
 AN 2003:33487 USPATFULL  
 TI Compounds, methods and pharmaceutical compositions for treating neural  
 or cardiovascular tissue damage  
 IN Li, Jia-He, Cockeysville, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 Jackson, Paul F., Bel Air, MD, United States  
 Maclin, Keith M., Baltimore, MD, United States  
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.  
 corporation)  
 PI US 6514983 B1 20030204  
 AI US 1998-145181 19980901 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-47502, filed on 25 Mar 1998,  
 now patented, Pat. No. US 6306889 Continuation-in-part of Ser. No. US  
 1997-922548, filed on 3 Sep 1997, now patented, Pat. No. US 6346536  
 DT Utility  
 FS GRANTED  
 LN.CNT 3587  
 INCL INCLM: 514/285.000  
 INCLS: 514/183.000; 514/410.000; 546/061.000; 546/062.000; 546/066.000;  
 548/421.000  
 NCL NCLM: 514/285.000  
 NCLS: 514/183.000; 514/410.000; 546/061.000; 546/062.000; 546/066.000;  
 548/421.000  
 IC [7]  
 ICM: A61K031-47  
 ICS: C07D217-22; C07D217-18; C07D401-04  
 EXF 546/61; 546/62; 546/66; 514/183; 514/288; 514/298; 514/285; 514/410;  
 548/421  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 288 OF 469 USPATFULL on STN  
 AN 2003:30934 USPATFULL  
 TI Compounds and their use  
 IN Ferraris, Dana V., Eldersburg, MD, UNITED STATES  
 Li, Jia-He, Cockeysville, MD, UNITED STATES  
 Kalish, Vincent J., Annapolis, MD, UNITED STATES  
 Zhang, Jie, Ellicott City, MD, UNITED STATES  
 PI US 2003022883 A1 20030130  
 AI US 2001-996776 A1 20011130 (9)  
 PRAI US 2000-250132P 20001201 (60)  
 US 2001-310274P 20010807 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4519  
 INCL INCLM: 514/212.060  
 INCLS: 514/221.000; 514/220.000; 514/291.000; 540/496.000; 540/495.000;  
 540/521.000; 546/081.000  
 NCL NCLM: 514/212.060  
 NCLS: 514/221.000; 514/220.000; 514/291.000; 540/496.000; 540/495.000;  
 540/521.000; 546/081.000  
 IC [7]  
 ICM: C07D491-04  
 ICS: C07D471-04; A61K031-551; A61K031-55; A61K031-4745  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 289 OF 469 USPATFULL on STN  
 AN 2003:26240 USPATFULL  
 TI Methods of treating nitric oxide and cytokine mediated disorders  
 IN Singh, Inderjit, Mount Pleasant, SC, United States  
 PA Medical University of South Carolina, Charleston, SC, United States  
 (U.S. corporation)  
 MUSC Foundation for Research Development, Charleston, SC, United States  
 (U.S. corporation)  
 PI US 6511800 B1 20030128  
 AI US 2000-579791 20000525 (9)  
 RLI Continuation of Ser. No. WO 1998-US25360, filed on 25 Nov 1998  
 PRAI US 1997-66839P 19971125 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 7562  
 INCL INCLM: 435/004.000  
 INCLS: 435/026.000  
 NCL NCLM: 435/004.000  
 NCLS: 435/026.000  
 IC [7]  
 ICM: C12Q001-00  
 EXF 435/4; 435/26; 514/440; 514/562; 514/563; 514/564  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 290 OF 469 USPATFULL on STN  
 AN 2003:24336 USPATFULL  
 TI Secreted protein HFEAF41  
 IN Young, Paul, Gaithersburg, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Duan, Roxanne, Bethesda, MD, UNITED STATES  
 Hu, Jing-Shan, Mountain View, CA, UNITED STATES  
 Florence, Kimberly, Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Moore, Paul A., Germantown, MD, UNITED STATES  
 Shi, Yanggu, Gaithersburg, VA, UNITED STATES  
 Lafleur, David W., Washington, DC, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)  
 PI US 2003018180 A1 20030123  
 AI US 2002-59395 A1 20020131 (10)  
 RLI Division of Ser. No. US 2001-966262, filed on 1 Oct 2001, PENDING  
 Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING  
 Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998,  
 UNKNOWN  
 PRAI US 1997-41277P 19970321 (60)  
 US 1997-42344P 19970321 (60)  
 US 1997-41276P 19970321 (60)  
 US 1997-41281P 19970321 (60)  
 US 1997-48094P 19970530 (60)  
 US 1997-48350P 19970530 (60)  
 US 1997-48188P 19970530 (60)  
 US 1997-48135P 19970530 (60)  
 US 1997-50937P 19970530 (60)  
 US 1997-48187P 19970530 (60)  
 US 1997-48099P 19970530 (60)  
 US 1997-48352P 19970530 (60)  
 US 1997-48186P 19970530 (60)  
 US 1997-48069P 19970530 (60)  
 US 1997-48095P 19970530 (60)  
 US 1997-48131P 19970530 (60)  
 US 1997-48096P 19970530 (60)  
 US 1997-48355P 19970530 (60)  
 US 1997-48160P 19970530 (60)  
 US 1997-48351P 19970530 (60)  
 US 1997-48154P 19970530 (60)  
 US 1997-54804P 19970805 (60)  
 US 1997-56370P 19970819 (60)  
 US 1997-60862P 19971002 (60)  
 DT Utility  
 FS APPLICATION

INCL INCLM: 536/023.200  
INCLS: 530/350.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000  
NCL NCLM: 536/023.200  
NCLS: 530/350.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000  
IC [7]  
ICM: C07K014-435  
ICS: C12P021-02; C12N005-06; C07H021-04; C12N009-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 291 OF 469 USPATFULL on STN  
AN 2003:20224 USPATFULL  
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
IN Audia, James E., Indianapolis, IN, United States  
Thompson, Richard C., Frankfort, IN, United States  
Wilkie, Stephen C., Indianapolis, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Huffman, George W., Carmel, IN, United States  
Latimer, Lee H., Oakland, CA, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6509331 B1 20030121  
AI US 1999-337484 19990621 (9)  
PRAI US 1998-155265P 19980622 (60)  
DT Utility  
FS GRANTED  
LN.CNT 6167  
INCL INCLM: 514/212.040  
INCLS: 514/212.070; 540/522.000; 540/523.000  
NCL NCLM: 514/212.040  
NCLS: 514/212.070; 540/522.000; 540/523.000  
IC [7]  
ICM: C07D487-00  
ICS: C07D491-00; C07D498-00; C07D513-00; A61K031-55  
EXF 540/522; 540/523; 514/212.04; 514/212.07  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 292 OF 469 USPATFULL on STN  
AN 2003:18018 USPATFULL  
TI Composition, synthesis and therapeutic applications of polyamines  
IN Murphy, Michael A., La Jolla, CA, UNITED STATES  
MaLachowski, Mitchell R., San Diego, CA, UNITED STATES  
PI US 2003013772 A1 20030116  
AI US 2001-17235 A1 20011218 (10)  
RLI Continuation-in-part of Ser. No. US 2000-486310, filed on 23 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US17301, filed on 21 Aug 1998, UNKNOWN A 371 of International Ser. No. US 1997-915660, filed on 21 Aug 1997, GRANTED, Pat. No. US 5906996  
DT Utility  
FS APPLICATION  
LN.CNT 3034  
INCL INCLM: 514/674.000  
INCLS: 564/512.000  
NCL NCLM: 514/674.000  
NCLS: 564/512.000  
IC [7]  
ICM: A61K031-13  
ICS: C07C211-14  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 293 OF 469 USPATFULL on STN  
AN 2003:13325 USPATFULL  
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
IN Thorsett, Eugene D., Moss Beach, CA, United States  
Porter, Warren J., Indianapolis, IN, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Latimer, Lee H., Oakland, CA, United States  
Audia, James E., Indianapolis, IN, United States  
Droste, James, Indianapolis, IN, United States  
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.

Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6506782 B1 20030114  
AI US 1998-32019 19980227 (9)  
DT Utility  
FS GRANTED  
LN.CNT 9870  
INCL INCLM: 514/364.000  
NCL NCLM: 514/364.000  
IC [7]  
ICM: A61K031-4245  
EXF 514/364  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 294 OF 469 USPATFULL on STN  
AN 2003:3520 USPATFULL  
TI 90 human secreted proteins  
IN Ruben, Steven M., Olney, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Greene, John M., Gaithersburg, MD, UNITED STATES  
Ferrie, Ann M., Tewksbury, MA, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Janat, Fouad, Westerly, RI, UNITED STATES  
PI US 2003003555 A1 20030102  
AI US 2001-774639 A1 20010201 (9)  
RLI Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED  
Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998,  
UNKNOWN  
PRAI US 1997-55386P 19970805 (60)  
US 1997-54807P 19970805 (60)  
US 1997-55312P 19970805 (60)  
US 1997-55309P 19970805 (60)  
US 1997-54798P 19970805 (60)  
US 1997-55310P 19970805 (60)  
US 1997-54806P 19970805 (60)  
US 1997-54809P 19970805 (60)  
US 1997-54804P 19970805 (60)  
US 1997-54803P 19970805 (60)  
US 1997-54808P 19970805 (60)  
US 1997-55311P 19970805 (60)  
US 1997-55986P 19970818 (60)  
US 1997-55970P 19970818 (60)  
US 1997-56563P 19970819 (60)  
US 1997-56557P 19970819 (60)  
US 1997-56731P 19970819 (60)  
US 1997-56365P 19970819 (60)  
US 1997-56367P 19970819 (60)  
US 1997-56370P 19970819 (60)  
US 1997-56364P 19970819 (60)  
US 1997-56366P 19970819 (60)  
US 1997-56732P 19970819 (60)  
US 1997-56371P 19970819 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15472  
INCL INCLM: 435/183.000  
INCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;  
536/023.200  
NCL NCLM: 435/183.000  
NCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;  
536/023.200  
IC [7]  
ICM: C12Q001-68  
ICS: C07H021-04; C12N009-00; C12N005-06; C07K016-40; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 295 OF 469 USPATFULL on STN  
AN 2002:343934 USPATFULL  
TI Novel molecules of the PYRIN domain protein family and uses thereof  
IN Bertin, John, Watertown, MA, UNITED STATES

PI US 2002197660 A1 20021226  
AI US 2001-27629 A1 20011220 (10)  
RLI Continuation-in-part of Ser. No. US 2001-964955, filed on 26 Sep 2001,  
PENDING Continuation-in-part of Ser. No. US 2000-653901, filed on 1 Sep  
2000, PENDING Continuation-in-part of Ser. No. US 2000-506067, filed on  
17 Feb 2000, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 4278  
INCL INCLM: 435/007.920  
NCL NCLM: 435/007.920  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-537; G01N033-543  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 296 OF 469 USPATFULL on STN  
AN 2002:326008 USPATFULL  
TI Microsomal triglyceride transfer protein  
IN Wetterau, II, John R., Langhorne, PA, United States  
Sharp, Daru Young, Perrineville, NJ, United States  
Gregg, Richard E., Pennington, NJ, United States  
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S.  
corporation)  
PI US 6492365 B1 20021210  
AI US 1995-486929 19950607 (8)  
RLI Division of Ser. No. US 1993-117362, filed on 3 Sep 1993, now patented,  
Pat. No. US 5595872 Continuation-in-part of Ser. No. US 1993-15449,  
filed on 22 Feb 1993, now abandoned Continuation-in-part of Ser. No. US  
1992-847503, filed on 6 Mar 1992, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 5043  
INCL INCLM: 514/247.000  
INCLS: 514/277.000  
NCL NCLM: 514/247.000  
NCLS: 514/277.000  
IC [7]  
ICM: C07D261-06  
EXF 514/247; 514/277  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 297 OF 469 USPATFULL on STN  
AN 2002:323196 USPATFULL  
TI Method for treating fibrotic diseases or other indications IIIC  
IN Wagle, Dilip, New York, NY, UNITED STATES  
Gall, Martin, Morristown, NJ, UNITED STATES  
Bell, Stanley C., Narberth, PA, UNITED STATES  
LaVoie, Edmond J., Princeton Junction, NJ, UNITED STATES  
PI US 2002183365 A1 20021205  
AI US 2001-36857 A1 20011231 (10)  
PRAI US 2001-296246P 20010606 (60)  
US 2001-259238P 20010102 (60)  
US 2000-259294P 20001229 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3334  
INCL INCLM: 514/341.000  
INCLS: 514/252.050; 514/255.050; 514/256.000; 514/242.000; 514/396.000;  
514/406.000; 544/182.000; 544/238.000; 544/333.000; 544/405.000;  
546/272.700; 546/275.400; 548/346.100; 548/377.100  
NCL NCLM: 514/341.000  
NCLS: 514/252.050; 514/255.050; 514/256.000; 514/242.000; 514/396.000;  
514/406.000; 544/182.000; 544/238.000; 544/333.000; 544/405.000;  
546/272.700; 546/275.400; 548/346.100; 548/377.100  
IC [7]  
ICM: A61K031-53  
ICS: A61K031-506; A61K031-501; A61K031-497; A61K031-4439; C07D043-04  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 298 OF 469 USPATFULL on STN  
AN 2002:323192 USPATFULL  
TI Heterocyclic sulfonamide inhibitors of \*\*\*beta\*\*\* \*\*\*amyloid\*\*\*  
production  
IN Kreft, Anthony F., Langhorne, PA, UNITED STATES

woller, Kevin R., Ayer, MA, UNITED STATES  
Stock, Joseph R., Monroe, NY, UNITED STATES  
Diamantidis, George, Randolph, NJ, UNITED STATES  
Kubrak, Dennis M., Philadelphia, PA, UNITED STATES  
Kutterer, Kristina M., Westwood, NJ, UNITED STATES  
Moore, William J., Marlborough, MA, UNITED STATES  
Casebier, David S., Carlisle, MA, UNITED STATES

PA ArQule, Woburn, MA, 01801 (U.S. corporation)  
PI US 2002183361 A1 20021205  
US 6610734 B2 20030826  
AI US 2001-14304 A1 20011211 (10)  
PRAI US 2000-255105P 20001213 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3972  
INCL INCLM: 514/326.000  
INCLS: 514/340.000; 514/381.000; 514/382.000; 514/397.000; 514/398.000;  
546/210.000; 546/268.400; 548/315.400; 548/316.400  
NCL NCLM: 514/445.000  
NCLS: 514/342.000; 514/432.000; 514/444.000; 546/280.400; 549/013.000;  
549/060.000; 549/065.000  
IC [7]  
ICM: C07D045-02  
ICS: C07D041-02; A61K031-454; A61K031-4439; A61K031-4178  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 299 OF 469 USPATFULL on STN  
AN 2002:315104 USPATFULL  
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor  
IN Barta, Thomas E., Evanston, IL, UNITED STATES  
Becker, Daniel P., Glenview, IL, UNITED STATES  
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES  
Boehm, Terri L., Ballwin, MO, UNITED STATES  
Carroll, Jeffery N., Collinsville, IL, UNITED STATES  
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES  
Fobian, Yvette M., Labadie, MO, UNITED STATES  
Freskos, John N., Clayton, MO, UNITED STATES  
Getman, Daniel P., Chesterfield, MO, UNITED STATES  
McDonald, Joseph J., Ballwin, MO, UNITED STATES  
Hanson, Gunnar J., Skokie, IL, UNITED STATES  
Hockerman, Susan L., Chicago, IL, UNITED STATES  
Howard, Susan C., Fenton, MO, UNITED STATES  
Kolodziej, Steve A., Ballwin, MO, UNITED STATES  
Li, Hui, Vernon Hills, IL, UNITED STATES  
Mischke, Deborah A., Defiance, MO, UNITED STATES  
Rico, Joseph G., Ballwin, MO, UNITED STATES  
Stehle, Nathan W., Ballwin, MO, UNITED STATES  
Tollefson, Michael B., O'Fallon, MO, UNITED STATES  
Vernier, William F., St. Louis, MO, UNITED STATES  
Villamil, Clara I., Glenview, IL, UNITED STATES  
PI US 2002177588 A1 20021128  
US 6750233 B2 20040615  
AI US 2001-954451 A1 20010917 (9)  
RLI Division of Ser. No. US 1999-256948, filed on 24 Feb 1999, ABANDONED  
PRAI US 1997-66007P 19971114 (60)  
US 1998-95347P 19980804 (60)  
US 1998-95501P 19980806 (60)  
US 1998-101080P 19980918 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 16676  
INCL INCLM: 514/211.010  
INCLS: 514/217.110; 514/218.000; 514/227.500; 514/237.500; 514/255.010;  
514/247.000; 514/327.000; 514/369.000; 514/385.000; 514/423.000  
NCL NCLM: 514/336.000  
NCLS: 514/342.000; 514/383.000; 514/432.000; 544/374.000; 546/280.100;  
548/265.800; 549/028.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-553; A61K031-554; A61K031-551; A61K031-54; A61K031-535;  
A61K031-495  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 300 OF 469 USPATFULL on STN  
AN 2002:311025 USPATFULL

EN Ebner, Reinhard, Gaithersburg, MD, United States  
Murphy, Marianne, Richmond, UNITED KINGDOM  
Ruben, Steven M., Olney, MD, United States  
Hu, Jing-Shan, Sunnyvale, CA, United States  
Duan, D. Roxanne, Bethesda, MD, United States  
Florence, Kimberly A., Rockville, MD, United States  
Rosen, Craig A., Laytonsville, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6486301 B1 20021126  
AI US 1999-231788 19990115 (9)  
RLI Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998  
PRAI US 1997-52870P 19970716 (60)  
US 1997-60140P 19970926 (60)  
US 1997-55952P 19970818 (60)  
DT Utility  
FS GRANTED  
LN.CNT 5643  
INCL INCLM: 530/351.000  
INCLS: 424/085.100  
NCL NCLM: 530/351.000  
NCLS: 424/085.100  
IC [7]  
ICM: C07K014-475  
ICS: A61K038-19  
EXF 530/351; 424/85.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 301 OF 469 USPATFULL on STN  
AN 2002:308378 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting B-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002173504 A1 20021121  
AI US 2001-915519 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25650  
INCL INCLM: 514/212.040  
INCLS: 514/327.000; 514/424.000; 514/659.000  
NCL NCLM: 514/212.040  
NCLS: 514/327.000; 514/424.000; 514/659.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-4015; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 302 OF 469 USPATFULL on STN  
AN 2002:301209 USPATFULL  
TI In vitro formation of congophilic maltese-cross amyloid plaques to  
identify anti-plaque therapeutics for the treatment of Alzheimer's and  
Prion diseases



Snow, Alan D., Lynnwood, WA, UNITED STATES  
PI US 2002168753 A1 20021114  
AI US 2001-7779 A1 20011130 (10)  
RLI Continuation of Ser. No. US 1999-267795, filed on 12 Mar 1999, ABANDONED  
PRAI US 1998-77924P 19980313 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 3150  
INCL INCLM: 435/226.000  
INCLS: 435/068.100  
NCL NCLM: 435/226.000  
NCLS: 435/068.100  
IC [7]  
ICM: C12P021-06  
ICS: C12N009-64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 303 OF 469 USPATFULL on STN  
AN 2002:300827 USPATFULL  
TI Methods and compositions for treating secondary tissue damage and other  
inflammatory conditions and disorders  
IN McDonald, John R., Calgary, AB, UNITED STATES  
Coggins, Philip J., Calgary, AB, UNITED STATES  
PI US 2002168370 A1 20021114  
AI US 2001-792793 A1 20010222 (9)  
RLI Division of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING  
Division of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING  
Continuation of Ser. No. US 1998-120523, filed on 22 Jul 1998, ABANDONED  
PRAI WO 1999-CA659 19990721  
US 1998-155186P 19980722 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7972  
INCL INCLM: 424/178.100  
INCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;  
435/325.000  
NCL NCLM: 424/178.100  
NCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;  
435/325.000  
IC [7]  
ICM: A61K039-395  
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-46  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 304 OF 469 USPATFULL on STN  
AN 2002:295324 USPATFULL  
TI Secreted protein HFEAF41  
IN Young, Paul, Gaithersburg, MD, UNITED STATES  
Greene, John M., Gaithersburg, MD, UNITED STATES  
Ferrie, Ann M., Tewksburg, MA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Rosen, Craig A., Laytonville, MD, UNITED STATES  
Duan, Roxanne, Bethesda, MD, UNITED STATES  
Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES  
Florence, Kimberly, Rockville, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Brewer, Lauie A., St. Paul, MN, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Lafleur, David W., Washington, DC, UNITED STATES  
Ni, Jian, Rockville, MD, UNITED STATES  
PI US 2002165374 A1 20021107  
AI US 2001-984245 A1 20011029 (9)  
RLI Division of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING  
Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998,  
UNKNOWN  
PRAI US 1997-41277P 19970321 (60)  
US 1997-42344P 19970321 (60)  
US 1997-41276P 19970321 (60)  
US 1997-41281P 19970321 (60)  
US 1997-48094P 19970530 (60)  
US 1997-48350P 19970530 (60)  
US 1997-48188P 19970530 (60)  
US 1997-48135P 19970530 (60)

US 1997-48187P 19970530 (60)  
US 1997-48099P 19970530 (60)  
US 1997-48352P 19970530 (60)  
US 1997-48186P 19970530 (60)  
US 1997-48069P 19970530 (60)  
US 1997-48095P 19970530 (60)  
US 1997-48131P 19970530 (60)  
US 1997-48096P 19970530 (60)  
US 1997-48355P 19970530 (60)  
US 1997-48160P 19970530 (60)  
US 1997-48351P 19970530 (60)  
US 1997-48154P 19970530 (60)  
US 1997-54804P 19970805 (60)  
US 1997-56370P 19970819 (60)  
US 1997-60862P 19971002 (60)

DT Utility  
FS APPLICATION

LN.CNT 15075

INCL INCLM: 536/023.100  
INCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100;  
435/325.000

NCL NCLM: 536/023.100  
NCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100;  
435/325.000

IC [7]  
ICM: C07H021-04  
ICS: C12Q001-68; G01N033-53; C12N009-00; C12N005-06; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 305 OF 469 USPATFULL on STN

AN 2002:294717 USPATFULL

TI Catalytically active recombinant memapsin and methods of use thereof

IN Lin, Xinli, Edmond, OK, UNITED STATES  
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES  
Tang, Jordan J.N., Edmond, OK, UNITED STATES

PA Oklahoma Medical Research Foundation

PI US 2002164760 A1 20021107

AI US 2001-795903 A1 20010228 (9)

RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING

PRAI US 1999-141363P 19990628 (60)

US 1999-168060P 19991130 (60)

US 2000-177836P 20000125 (60)

US 2000-178368P 20000127 (60)

US 2000-210292P 20000608 (60)

DT Utility  
FS APPLICATION

LN.CNT 2440

INCL INCLM: 435/220.000  
INCLS: 435/069.100; 435/252.300; 435/320.100

NCL NCLM: 435/220.000  
NCLS: 435/069.100; 435/252.300; 435/320.100

IC [7]  
ICM: C12N009-52  
ICS: C12P021-02; C12N001-21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 306 OF 469 USPATFULL on STN

AN 2002:291111 USPATFULL

TI Compounds for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis

IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Reel, Jon K., Carmel, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Folmer, Beverly K., Newark, DE, United States  
Droste, James J., Indianapolis, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James E., Indianapolis, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 6476263 B1 20021105  
AI US 2001-826412 20010403 (9)  
RLI Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now  
patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US  
1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166  
PRAI US 1996-108166P 19961122 (60)  
US 1997-64859P 19970228 (60)  
US 1997-108161P 19970228 (60)  
US 1997-98558P 19970228 (60)  
DT Utility  
FS GRANTED  
LN.CNT 12409  
INCL INCLM: 564/152.000  
INCLS: 564/153.000; 564/159.000; 564/160.000; 564/161.000; 564/041.000;  
560/041.000; 562/450.000  
NCL NCLM: 564/152.000  
NCLS: 560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000;  
564/160.000; 564/161.000  
IC [7]  
ICM: C07C233-00  
EXF 564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 307 OF 469 USPATFULL on STN  
AN 2002:290742 USPATFULL  
TI 94 Human Secreted Proteins  
IN Ruben, Steven M., Olney, MD, United States  
Ni, Jian, Rockville, MD, United States  
Rosen, Craig A., Laytonsville, MD, United States  
Wei, Ying-Fei, Berkeley, CA, United States  
Young, Paul, Gaithersburg, MD, United States  
Florence, Kimberly, Rockville, MD, United States  
Soppet, Daniel R., Centreville, VA, United States  
Brewer, Laurie A., St. Paul, MN, United States  
Endress, Gregory A., Potomac, MD, United States  
Carter, Kenneth C., Potomac, MD, United States  
Mucenski, Michael, Cincinnati, OH, United States  
Ebner, Reinhard, Gaithersburg, MD, United States  
Lafleur, David W., Washington, DC, United States  
Olsen, Henrik, Gaithersburg, MD, United States  
Shi, Yanggu, Gaithersburg, MD, United States  
Moore, Paul A., Germantown, MD, United States  
Komatsoulis, George, Silver Spring, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)  
PI US 6475753 B1 20021105  
AI US 1999-461325 19991214 (9)  
RLI Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999  
PRAI US 1998-89507P 19980616 (60)  
US 1998-89508P 19980616 (60)  
US 1998-89509P 19980616 (60)  
US 1998-89510P 19980616 (60)  
US 1998-90112P 19980622 (60)  
US 1998-90113P 19980622 (60)  
DT Utility  
FS GRANTED  
LN.CNT 18031  
INCL INCLM: 435/069.100  
INCLS: 435/069.400; 435/071.100; 435/252.300; 435/032.500; 435/320.100;  
435/471.000; 536/023.500; 530/350.000  
NCL NCLM: 435/069.100  
NCLS: 435/069.400; 435/071.100; 435/252.300; 435/320.100; 435/325.000;  
435/471.000; 530/350.000; 536/023.500  
IC [7]  
ICM: C12P021-02  
ICS: C12N015-12; C12N005-10; C07K014-47  
EXF 435/69.1; 435/69.4; 435/71.1; 435/91.1; 435/252.3; 435/325; 435/320.1;  
435/471; 536/23.5; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 308 OF 469 USPATFULL on STN  
AN 2002:290736 USPATFULL  
TI Identification of agents that protect against inflammatory injury to  
neurons  
IN Giulian, Dana, Houston, TX, United States

corporation)  
PI US 6475745 B1 20021105  
AI US 1997-922889 19970903 (8)  
RLI Division of Ser. No. US 1996-717551, filed on 20 Sep 1996  
DT Utility  
FS GRANTED  
LN.CNT 2755  
INCL INCLM: 435/007.200  
INCLS: 530/300.000; 530/350.000; 530/402.000  
NCL NCLM: 435/007.200  
NCLS: 530/300.000; 530/350.000; 530/402.000  
IC [7]  
ICM: G01N033-53  
ICS: C07K007-00; C07K004-12  
EXF 435/7.2; 435/7.1; 530/300; 530/350; 530/402; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 309 OF 469 USPATFULL on STN  
AN 2002:288118 USPATFULL  
TI Compounds co-inducing cholinergic up-regulation and inflammation  
down-regulation and uses thereof  
IN Amitai, Gabriel, Rehovot, ISRAEL  
Adani, Rachel, Moshav Gealia, ISRAEL  
Rabinovitz, Ishai, Nes Ziona, ISRAEL  
Sod-Moriah, Gali, Rehovot, ISRAEL  
Meshulam, Haim, Bat Yam, ISRAEL  
PA Israel Institute for Biological Research (non-U.S. corporation)  
PI US 2002160988 A1 20021031  
AI US 2001-906952 A1 20010716 (9)  
PRAI US 2001-269343P 20010220 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2876  
INCL INCLM: 514/159.000  
INCLS: 514/094.000; 514/063.000; 514/406.000  
NCL NCLM: 514/159.000  
NCLS: 514/094.000; 514/063.000; 514/406.000  
IC [7]  
ICM: A61K031-695  
ICS: A61K031-675; A61K031-415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 310 OF 469 USPATFULL on STN  
AN 2002:288114 USPATFULL  
TI Fused tricyclic compounds, methods and compositions for inhibiting parp  
activity  
IN Li, Jia-He, Cockeysville, MD, UNITED STATES  
Zhang, Jie, Ellicott City, MD, UNITED STATES  
PA Guilford Pharmaceuticals Inc. (U.S. corporation)  
PI US 2002160984 A1 20021031  
AI US 2002-109645 A1 20020401 (10)  
RLI Continuation of Ser. No. US 1998-145184, filed on 1 Sep 1998, GRANTED,  
Pat. No. US 6380193 Continuation-in-part of Ser. No. US 1998-79510,  
filed on 15 May 1998, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 3225  
INCL INCLM: 514/080.000  
INCLS: 514/295.000; 546/098.000; 546/023.000  
NCL NCLM: 514/080.000  
NCLS: 514/295.000; 546/098.000; 546/023.000  
IC [7]  
ICM: A61K031-675  
ICS: C07D221-04; A61K031-473  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 311 OF 469 USPATFULL on STN  
AN 2002:283310 USPATFULL  
TI Methods for protecting cells from amyloid toxicity and for inhibiting  
amyloid protein production  
IN Schubert, David R., La Jolla, CA, United States  
Liu, Yuanbin, San Diego, CA, United States  
PA The Salk Institute for Biological Studies, La Jolla, CA, United States  
(U.S. corporation)  
PI US 6472436 B1 20021029

UTILITY  
S GRANTED  
N.CNT 1189  
NCL INCLM: 514/731.000  
INCLS: 514/453.000; 514/456.000  
CL NCLM: 514/731.000  
NCLS: 514/453.000; 514/456.000  
C [7]  
ICM: A61K031-05  
ICS: A61K031-35  
XF 514/731; 514/453; 514/456  
AS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 312 OF 469 USPATFULL on STN  
N 2002:282980 USPATFULL  
I Methods for the prevention or treatment of alzheimer's disease  
N Anderson, Stephen, Princeton, NJ, United States  
PA Rutgers, the State University, New Brunswick, NJ, United States (U.S.  
corporation)  
PI US 6471960 B1 20021029  
AI US 2000-660954 20000913 (9)  
LI Division of Ser. No. US 1999-388890, filed on 2 Sep 1999, now patented,  
Pat. No. US 6136548 Continuation of Ser. No. US 1996-686959, filed on 26  
Jul 1996, now abandoned Continuation-in-part of Ser. No. WO  
1995-US15007, filed on 22 Nov 1995 Continuation-in-part of Ser. No. US  
1994-347144, filed on 22 Nov 1994, now patented, Pat. No. US 5589154  
UTILITY  
S GRANTED  
N.CNT 1730  
NCL INCLM: 424/094.640  
INCLS: 424/001.410; 424/001.490; 435/007.100; 435/172.100  
NCL NCLM: 424/094.640  
NCLS: 424/001.410; 424/001.490; 435/007.100; 435/455.000  
C [7]  
ICM: A61K038-48  
ICS: A61M036-14; G01N033-53; C12N013-00  
EXF 424/1.41; 424/1.49; 424/94.64; 435/172.1; 435/7.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 313 OF 469 USPATFULL on STN  
N 2002:280605 USPATFULL  
TI Carboxamine compounds, methods and compositions for inhibiting PARP  
IN activity  
PA Li, Jia-He, Cockeysville, MD, UNITED STATES  
PI Zhang, Jie, Ellicott City, MD, UNITED STATES  
AI Guilford Pharmaceuticals Inc. (U.S. corporation)  
RLI US 2002156050 A1 20021024  
US 2002-109646 A1 20020401 (10)  
Continuation of Ser. No. US 1998-145178, filed on 1 Sep 1998, GRANTED,  
Pat. No. US 6395749 Continuation-in-part of Ser. No. US 1998-79514,  
filed on 15 May 1998, ABANDONED  
UTILITY  
FS APPLICATION  
N.CNT 3539  
INCL INCLM: 514/080.000  
INCLS: 514/224.200; 514/230.500; 514/247.000; 514/266.200; 514/266.230;  
514/266.240; 514/314.000; 514/312.000; 544/014.000; 544/105.000;  
544/244.000; 544/284.000; 544/285.000; 546/153.000; 546/156.000  
NCL NCLM: 514/080.000  
NCLS: 514/224.200; 514/230.500; 514/247.000; 514/266.200; 514/266.230;  
514/266.240; 514/314.000; 514/312.000; 544/014.000; 544/105.000;  
544/244.000; 544/284.000; 544/285.000; 546/153.000; 546/156.000  
IC [7]  
ICM: A61K031-675  
ICS: A61K031-5415; A61K031-538; A61K031-517; A61K031-4709  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 314 OF 469 USPATFULL on STN  
N 2002:280116 USPATFULL  
TI "PRIONINS", HIGHLY SPECIFIC MARKERS FOR NONINVASIVE PRE-SYMPTOMATIC  
IN DETECTION OF TSE DISEASES, AND TARGETS FOR THERAPEUTIC REAGENTS TO  
PREVENT AND CONTROL TSE DISEASES IN ANIMALS AND HUMANS  
PI BERGMANN, JOHANNA, HAMBURG, GERMANY, FEDERAL REPUBLIC OF  
PREDDIE, ENRIQUE, MONTREAL, CANADA  
US 2002155552 A1 20021024

WO 1998-EP3609 19980616  
 PRAI CA 1997-2206774 19970616  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1040  
 INCL INCLM: 435/110.000  
 NCL NCLM: 435/110.000  
 IC [7]  
 ICM: C12P013-14  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 315 OF 469 USPATFULL on STN  
 AN 2002:279992 USPATFULL  
 TI Prevention and treatment of amyloid-associated disorders  
 IN Cordell, Barbara, Palo Alto, CA, UNITED STATES  
 Xu, Qiang, Cupertino, CA, UNITED STATES  
 Naidu, Asha, Fremont, CA, UNITED STATES  
 Paul, Steven M., Carmel, IN, UNITED STATES  
 Bales, Kelly R., Cloverdale, IN, UNITED STATES  
 PI US 2002155426 A1 20021024  
 AI US 2002-172268 A1 20020614 (10)  
 RLI Division of Ser. No. US 1999-447452, filed on 22 Nov 1999, GRANTED, Pat.  
 No. US 6428950  
 PRAI US 1998-109910P 19981125 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1484  
 INCL INCLM: 435/004.000  
 INCLS: 435/007.210  
 NCL NCLM: 435/004.000  
 NCLS: 435/007.210  
 IC [7]  
 ICM: C12Q001-00  
 ICS: G01N033-567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 316 OF 469 USPATFULL on STN  
 AN 2002:273410 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
 compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
 compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James A., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2002151538 A1 20021017  
 US 6579867 B2 20030617  
 AI US 2001-915379 A1 20010727 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 26543  
 INCL INCLM: 514/212.040  
 INCLS: 514/327.000; 514/424.000; 514/659.000  
 NCL NCLM: 514/211.060  
 NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080  
 IC [7]  
 ICM: A61K031-55

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 317 OF 469 USPATFULL on STN  
AN 2002:272761 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES  
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES  
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES  
Markland, William, Milford, MA, UNITED STATES  
Ley, Arthur Charles, Newton, MA, UNITED STATES  
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES  
PI US 2002150881 A1 20021017  
AI US 2001-781988 A1 20010214 (9)  
RLI Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED  
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED  
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED  
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED  
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2  
Sep 1988, ABANDONED  
PRAI WO 1989-US3731 19890901  
DT Utility  
FS APPLICATION  
LN.CNT 15696  
INCL INCLM: 435/005.000  
INCLS: 435/006.000; 435/007.100; 435/235.100  
NCL NCLM: 435/005.000  
NCLS: 435/006.000; 435/007.100; 435/235.100  
IC [7]  
ICM: C12Q001-70  
ICS: C12Q001-68; G01N033-53; C12N007-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 318 OF 469 USPATFULL on STN  
AN 2002:259529 USPATFULL  
TI Discordant helix stabilization for prevention of amyloid formation  
IN Johansson, Jan, Stockholm, SWEDEN  
PI US 2002143105 A1 20021003  
US 6716589 B2 20040406  
AI US 2001-988842 A1 20011119 (9)  
PRAI US 2000-253695P 20001120 (60)  
US 2000-251662P 20001206 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1541  
INCL INCLM: 525/054.100  
NCL NCLM: 435/007.200  
IC [7]  
ICM: C08H001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 319 OF 469 USPATFULL on STN  
AN 2002:259408 USPATFULL  
TI Gene expression profiles in liver cancer  
IN Horne, Darci T., Gaithersburg, MD, UNITED STATES  
Scherf, Uwe, Gaithersburg, MD, UNITED STATES  
Vockley, Joseph, Damascus, MD, UNITED STATES  
PI US 2002142981 A1 20021003  
AI US 2001-880107 A1 20010614 (9)  
PRAI US 2000-211379P 20000614 (60)  
US 2000-237054P 20001002 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15937  
INCL INCLM: 514/044.000  
INCLS: 435/006.000  
NCL NCLM: 514/044.000  
NCLS: 435/006.000  
IC [7]  
ICM: A61K048-00  
ICS: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 320 OF 469 USPATFULL on STN  
AN 2002:251785 USPATFULL

compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002137738 A1 20020926

US 6559141 B2 20030506

AI US 2001-915564 A1 20010727 (9)

RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING

PRAI US 1996-64851P 19961223 (60)

DT Utility

FS APPLICATION

LN.CNT 26049

INCL INCLM: 514/212.030

INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/211.060

NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
540/527.000

IC [7]

ICM: A61K031-55

ICS: A61K031-445; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 321 OF 469 USPATFULL on STN

AN 2002:251784 USPATFULL

TI Lactams substituted by cyclic succinates as inhibitors of a beta protein  
production

IN Olson, Richard E., Wilmington, DE, UNITED STATES

PI US 2002137737 A1 20020926

US 6509333 B2 20030121

AI US 2001-871840 A1 20010601 (9)

PRAI US 2000-208536P 20000601 (60)

DT Utility

FS APPLICATION

LN.CNT 6581

INCL INCLM: 514/212.030

INCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000

NCL NCLM: 514/221.000

NCLS: 540/509.000

IC [7]

ICM: A61K031-55

ICS: A61K031-445; A61K031-4015; C07D211-54; C07D223-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 322 OF 469 USPATFULL on STN

AN 2002:243133 USPATFULL

TI Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and  
materials and method for identification of inhibitors thereof

IN Abreo, Melwyn A., Jamul, CA, UNITED STATES

Agree, Charles S., San Diego, CA, UNITED STATES

Aust, Robert M., Alpine, CA, UNITED STATES

Kissinger, Charles R., San Diego, CA, UNITED STATES

Margosiak, Stephen, Escondido, CA, UNITED STATES

Meng, Jerry J., San Diego, CA, UNITED STATES

Pelletier, Laura A., Escondido, CA, UNITED STATES



Snowalter, Richard Edward, Santee, CA, UNITED STATES  
 Thomson, James Arthur, San Diego, CA, UNITED STATES  
 Tempczyk-Russell, Anna, Ramona, CA, UNITED STATES  
 Vanderpool, Darin, San Diego, CA, UNITED STATES  
 Villafranca, Jesus Ernesto, San Diego, CA, UNITED STATES  
 PI US 2002132319 A1 20020919  
 AI US 2001-931186 A1 20010817 (9)  
 PRAI US 2000-226123P 20000818 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 12914  
 INCL INCLM: 435/189.000  
 INCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000  
 NCL NCLM: 435/189.000  
 NCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000  
 IC [7]  
 ICM: C12N009-02  
 ICS: C12N009-64; G06F019-00; G01N033-48; G01N033-50; C07H021-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 323 OF 469 USPATFULL on STN  
 AN 2002:237182 USPATFULL  
 TI Transgenic animals and cell lines for screening drugs effective for the  
 treatment or prevention of alzheimer's disease  
 IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES  
 Wands, Jack R., Waban, MA, UNITED STATES  
 PI US 2002129391 A1 20020912  
 AI US 2001-964412 A1 20010928 (9)  
 RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371  
 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN  
 PRAI US 1997-38908P 19970226 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2087  
 INCL INCLM: 800/012.000  
 INCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200  
 NCL NCLM: 800/012.000  
 NCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200  
 IC [7]  
 ICM: A01K067-027  
 ICS: C07H021-04; C12N015-74  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 324 OF 469 USPATFULL on STN  
 AN 2002:228326 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
 compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
 compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James E., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2002123486 A1 20020905  
 US 6632811 B2 20031014  
 AI US 2001-915342 A1 20010727 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)

FS APPLICATION  
LN.CNT 26177  
INCL INCLM: 514/212.020  
INCLS: 514/659.000  
NCL NCLM: 514/220.000  
NCLS: 514/221.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 325 OF 469 USPATFULL on STN  
AN 2002:217305 USPATFULL  
TI Alpha-(4-Ethoxyphenyl)-N-tert-butylnitron, pharmaceutical compositions  
and their medical use  
IN Kelleher, Judith A., Fremont, CA, United States  
Maples, Kirk R., San Jose, CA, United States  
Dykman, Alina, San Francisco, CA, United States  
Zhang, Yong-Kang, Santa Clara, CA, United States  
Wilcox, Allan L., Mountain View, CA, United States  
Levell, Julian, Collegeville, PA, United States  
PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.  
corporation)  
PI US 6441032 B1 20020827  
AI US 2000-635527 20000809 (9)  
RLI Division of Ser. No. US 2000-500650, filed on 9 Feb 2000 Continuation of  
Ser. No. US 1998-172763, filed on 15 Oct 1998, now patented, Pat. No. US  
6046232  
PRAI US 1997-62324P 19971017 (60)  
US 1997-63736P 19971029 (60)  
US 1998-90475P 19980624 (60)

DT Utility  
FS GRANTED  
LN.CNT 2317  
INCL INCLM: 514/464.000  
INCLS: 514/640.000; 514/645.000; 564/300.000; 564/265.000  
NCL NCLM: 514/464.000  
NCLS: 514/640.000; 514/645.000; 564/265.000; 564/300.000  
IC [7]  
ICM: A61K031-34  
EXF 514/464; 514/640; 514/645; 564/300; 564/265; 564/434; 564/432  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 326 OF 469 USPATFULL on STN  
AN 2002:214328 USPATFULL  
TI Amyloid targeting imaging agents and uses thereof  
IN Gervais, Francine, Ile Bizard, CANADA  
Kong, Xianqi, Dollard-des-Ormeaux, CANADA  
Chalifour, Robert, Ile Bizard, CANADA  
Migneault, David, Laval, CANADA

PI US 2002115717 A1 20020822  
AI US 2001-915092 A1 20010724 (9)  
PRAI US 2000-220808P 20000725 (60)

DT Utility  
FS APPLICATION  
LN.CNT 2210

INCL INCLM: 514/553.000  
INCLS: 424/001.110  
NCL NCLM: 514/553.000  
NCLS: 424/001.110  
IC [7]  
ICM: A61K031-185  
ICS: A61K051-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 327 OF 469 USPATFULL on STN  
AN 2002:214264 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
\*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES

Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002115652 A1 20020822  
US 6541466 B2 20030401  
AI US 2001-915362 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25618  
INCL INCLM: 514/212.010  
INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000  
NCL NCLM: 514/211.060  
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
540/527.000

IC [7]  
ICM: A61K031-55  
ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 328 OF 469 USPATFULL on STN  
AN 2002:214213 USPATFULL  
TI Inhibitors of memapsin 2 and use thereof  
IN Koelsch, Gerald, Oklahoma City, OK, UNITED STATES  
Tang, Jordan J.N., Edmond, OK, UNITED STATES  
Hong, Lin, Oklahoma City, OK, UNITED STATES  
Ghosh, Arun K., River Forest, IL, UNITED STATES  
PA Oklahoma Medical Research Foundation (U.S. corporation)  
PI US 2002115600 A1 20020822  
AI US 2001-845226 A1 20010430 (9)  
RLI Division of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING  
PRAI US 1999-141363P 19990628 (60)  
US 1999-168060P 19991130 (60)  
US 2000-177836P 20000125 (60)  
US 2000-178368P 20000127 (60)  
US 2000-210292P 20000608 (60)

DT Utility  
FS APPLICATION  
LN.CNT 2377  
INCL INCLM: 514/012.000  
INCLS: 435/184.000; 530/326.000  
NCL NCLM: 514/012.000  
NCLS: 435/184.000; 530/326.000

IC [7]  
ICM: A61K038-17  
ICS: A61K038-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 329 OF 469 USPATFULL on STN  
AN 2002:213843 USPATFULL  
TI In vitro system for determining formation of \*\*\*abeta\*\*\* amyloid  
IN Tanzi, Rudolph E., Hull, MA, UNITED STATES  
Bush, Ashley I., Sommerville, MA, UNITED STATES  
PA The General Hospital Corporation (U.S. corporation)  
PI US 2002115223 A1 20020822  
AI US 2002-41605 A1 20020110 (10)  
RLI Division of Ser. No. US 1994-294819, filed on 26 Aug 1994, GRANTED, Pat.  
No. US 6365414  
DT Utility  
FS APPLICATION

INCL INCLM: 436/086.000  
INCLS: 422/061.000  
NCL NCLM: 436/086.000  
NCLS: 422/061.000  
IC [7]  
ICM: G01N033-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 330 OF 469 USPATFULL on STN  
AN 2002:209571 USPATFULL  
TI Modulation of nitric oxide production  
IN Vitek, Michael P., Apex, NC, United States  
Colton, Carol A., Silver Spring, MD, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
Georgetown University, Washington, DC, United States (U.S. corporation)  
PI US 6436996 B1 20020820  
AI US 1997-940594 19970930 (8)  
DT Utility  
FS GRANTED  
LN.CNT 567  
INCL INCLM: 514/565.000  
INCLS: 514/506.000; 514/561.000; 514/625.000; 514/626.000; 514/627.000;  
514/706.000; 514/742.000; 514/724.000; 514/747.000  
NCL NCLM: 514/565.000  
NCLS: 514/506.000; 514/561.000; 514/625.000; 514/626.000; 514/627.000;  
514/706.000; 514/724.000; 514/742.000; 514/747.000  
IC [7]  
ICM: A61K031-195  
ICS: A61K031-21; A61K031-16; A61K031-04  
EXF 514/561; 514/742; 514/565; 514/724; 514/747; 514/706; 514/625; 514/626;  
514/627; 514/506  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 331 OF 469 USPATFULL on STN  
AN 2002:206646 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
\*\*\*Amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
Varghese, John, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002111343 A1 20020815  
AI US 2001-915547 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25803  
INCL INCLM: 514/212.030  
INCLS: 514/327.000; 514/424.000; 514/659.000  
NCL NCLM: 514/212.030  
NCLS: 514/327.000; 514/424.000; 514/659.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-4015; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 332 OF 469 USPATFULL on STN  
 AN 2002:202241 USPATFULL  
 TI Death domain containing receptor-4  
 IN Ni, Jian, Rockville, MD, United States  
 Rosen, Craig A., Laytonsville, MD, United States  
 Pan, James G., Belmont, CA, United States  
 Gentz, Reiner L., Rockville, MD, United States  
 Dixit, Vishva M., Los Altos Hills, CA, United States  
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)  
 The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)  
 PI US 6433147 B1 20020813  
 AI US 2000-565918 20000505 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998, now patented, Pat. No. US 6342363  
 PRAI US 1999-132922P 19990506 (60)  
 US 1997-35722P 19970128 (60)  
 US 1997-37829P 19970205 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 8675  
 INCL INCLM: 530/387.300  
 INCLS: 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500; 435/069.100; 435/325.000; 435/252.300; 435/254.110; 424/178.100  
 NCL NCLM: 530/387.300  
 NCLS: 424/178.100; 435/069.100; 435/252.300; 435/254.110; 435/325.000; 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500  
 IC [7]  
 ICM: C07K014-705  
 EXF 530/300; 530/350; 530/402; 530/387.3; 536/23.1; 536/23.5; 536/23.4; 435/69.1; 435/375; 435/252.3; 435/254.11; 424/178.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 333 OF 469 USPATFULL on STN  
 AN 2002:202122 USPATFULL  
 TI .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same  
 IN Kelleher, Judith A., Fremont, CA, United States  
 Maples, Kirk R., San Jose, CA, United States  
 Dykman, Alina, San Fransisco, CA, United States  
 Zhang, Yong-Kang, San Jose, CA, United States  
 Wilcox, Allan L., Mountain View, CA, United States  
 Levell, Julian, Bridgewater, NJ, United States  
 PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S. corporation)  
 PI US 6433008 B1 20020813  
 AI US 2000-529555 20000718 (9)  
 PRAI US 1997-62324P 19971017 (60)  
 US 1997-63736P 19971029 (60)  
 US 1998-90475P 19980624 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2452  
 INCL INCLM: 514/464.000  
 NCL NCLM: 514/464.000  
 IC [7]  
 ICM: A61K031-36  
 EXF 514/464  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 334 OF 469 USPATFULL on STN  
 AN 2002:194690 USPATFULL  
 TI Assay to identify compounds that alter apolipoprotein E expression  
 IN Cordell, Barbara, Palo Alto, CA, United States  
 Xu, Qiang, Cupertino, CA, United States  
 Naidu, Asha, Fremont, CA, United States  
 Paul, Steven M., Carmel, IN, United States  
 Bales, Kelly R., Cloverdale, IN, United States  
 PA Scios Inc., Sunnyvale, CA, United States (U.S. corporation)  
 Eli Lilly & Co., Indianapolis, IN, United States (U.S. corporation)  
 PI US 6428950 B1 20020806  
 AI US 1999-447452 19991122 (9)  
 PRAI US 1998-109910P 19981125 (60)  
 DT Utility

LN.CNT 1499  
INCL INCLM: 435/004.000  
INCLS: 435/007.210; 435/070.300; 424/570.000; 424/572.000; 424/577.000;  
514/001.000  
NCL NCLM: 435/004.000  
NCLS: 424/570.000; 424/572.000; 424/577.000; 435/007.210; 435/070.300;  
514/001.000  
IC [7]  
ICM: C12Q001-00  
ICS: G01N033-567; C12P021-04; A61K035-30; A61K035-12  
EXF 424/562; 435/4; 435/7.21; 435/70.3; 514/1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 335 OF 469 USPATFULL on STN  
AN 2002:193030 USPATFULL  
TI Transgenic animals and cell lines for screening drugs effective for the  
treatment or prevention of alzheimer's disease  
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES  
Wands, Jack R., Waban, MA, UNITED STATES  
PI US 2002104108 A1 20020801  
AI US 2001-964666 A1 20010928 (9)  
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371  
of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN  
PRAI US 1997-38908P 19970226 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2100  
INCL INCLM: 800/012.000  
INCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200  
NCL NCLM: 800/012.000  
NCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200  
IC [7]  
ICM: A01K067-027  
ICS: C07H021-04; C12N005-08  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 336 OF 469 USPATFULL on STN  
AN 2002:192156 USPATFULL  
TI Composition and method for use of pyridinium derivatives in cosmetic and  
therapeutic applications  
IN Sankaranarayanan, Alangudi, Ahmedabad, INDIA  
PA TORRENT PHARMACEUTICALS LTD. (non-U.S. corporation)  
PI US 2002103228 A1 20020801  
AI US 2001-995731 A1 20011129 (9)  
RLI Continuation-in-part of Ser. No. US 2000-590143, filed on 9 Jun 2000,  
PENDING Continuation of Ser. No. WO 1999-IB1687, filed on 15 Oct 1999,  
UNKNOWN Continuation of Ser. No. US 2001-939702, filed on 28 Aug 2001,  
PENDING Continuation-in-part of Ser. No. US 2001-801778, filed on 9 Mar  
2001, PENDING Continuation-in-part of Ser. No. US 2000-598410, filed on  
21 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 1999-IB1683,  
filed on 15 Oct 1999, UNKNOWN  
PRAI IN 1999-82899 19991006  
IN 1999-82799 19991006  
DT Utility  
FS APPLICATION  
LN.CNT 5800  
INCL INCLM: 514/336.000  
INCLS: 424/401.000; 514/354.000  
NCL NCLM: 514/336.000  
NCLS: 424/401.000; 514/354.000  
IC [7]  
ICM: A61K031-44  
ICS: A61K007-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 337 OF 469 USPATFULL on STN  
AN 2002:191539 USPATFULL  
TI Full-length human cDNAs encoding potentially secreted proteins  
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE  
PI US 2002102604 A1 20020801  
AI US 2000-731872 A1 20001207 (9)  
PRAI US 1999-169629P 19991208 (60)  
US 2000-187470P 20000306 (60)

FS APPLICATION  
LN.CNT 28061  
INCL INCLM: 435/007.100  
INCLS: 536/023.100; 530/350.000  
NCL NCLM: 435/007.100  
NCLS: 536/023.100; 530/350.000  
IC [7]  
ICM: G01N033-53  
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 338 OF 469 USPATFULL on STN  
AN 2002:188403 USPATFULL  
TI Alkoxy-substituted compounds, methods and compositions for inhibiting  
parp activity  
IN Jackson, Paul F., Bel Air, MD, United States  
Maclin, Keith M., Baltimore, MD, United States  
Zhang, Jie, Ellicott City, MD, United States  
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.  
corporation)  
PI US 6426415 B1 20020730  
AI US 1998-79508 19980515 (9)  
RLI Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997  
DT Utility  
FS GRANTED  
LN.CNT 2307  
INCL INCLM: 544/237.000  
INCLS: 546/137.000  
NCL NCLM: 544/237.000  
NCLS: 546/137.000  
IC [7]  
ICM: C07D237-30  
EXF 546/137; 544/237  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 339 OF 469 USPATFULL on STN  
AN 2002:178549 USPATFULL  
TI Vaccine for the prevention and treatment of alzheimer's and amyloid  
related diseases  
IN Chalifour, Robert, Ile Bizard, CANADA  
Hebert, Lise, Brossard, CANADA  
Kong, Xianqi, Dollard-des-Oremaux, CANADA  
Gervais, Francine, Ile Bizard, CANADA  
PI US 2002094335 A1 20020718  
AI US 2001-867847 A1 20010529 (9)  
RLI Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000,  
PENDING  
PRAI US 1999-168594P 19991129 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1946  
INCL INCLM: 424/185.100  
NCL NCLM: 424/185.100  
IC [7]  
ICM: A61K039-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 340 OF 469 USPATFULL on STN  
AN 2002:174785 USPATFULL  
TI Assay for compounds which affect conformationally altered proteins  
IN Prusiner, Stanley B., San Francisco, CA, United States  
Supattapone, Surachai, San Francisco, CA, United States  
Scott, Michael R., San Francisco, CA, United States  
PA The Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6419916 B1 20020716  
AI US 1999-406972 19990928 (9)  
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999,  
now patented, Pat. No. US 6214366  
DT Utility  
FS GRANTED  
LN.CNT 1807  
INCL INCLM: 424/078.320  
INCLS: 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/DIG.016  
NCL NCLM: 424/078.320

IC [7]  
ICM: A61K031-785  
EXF 424/78.16; 424/78.32; 424/78.35-78.38; 514/772.3-732.7; 435/238;  
435/339; 523/105; 523/122  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 341 OF 469 USPATFULL on STN  
AN 2002:157666 USPATFULL  
TI Agents for use in the treatment of alzheimer's disease  
IN Bush, Ashley I., Somerville, MA, UNITED STATES  
Huang, Xudong, Cambridge, MA, UNITED STATES  
Atwood, Craig S., Somerville, MA, UNITED STATES  
Tanzi, Rudolph E., Canton, MA, UNITED STATES  
PI US 2002082273 A1 20020627  
AI US 2001-956980 A1 20010921 (9)  
RLI Division of Ser. No. US 1998-38154, filed on 11 Mar 1998, PATENTED  
DT Utility  
FS APPLICATION  
LN.CNT 4007  
INCL INCLM: 514/291.000  
INCLS: 514/298.000; 514/562.000; 514/566.000; 514/420.000; 514/707.000  
NCL NCLM: 514/291.000  
NCLS: 514/298.000; 514/562.000; 514/566.000; 514/420.000; 514/707.000  
IC [7]  
ICM: A61K031-4745  
ICS: A61K031-473; A61K031-195; A61K031-198; A61K031-405; A61K031-105  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 342 OF 469 USPATFULL on STN  
AN 2002:157080 USPATFULL  
TI NARC8 programmed cell-death-associated molecules and uses thereof  
IN Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES  
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)  
PI US 2002081679 A1 20020627  
AI US 2001-775009 A1 20010201 (9)  
RLI Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000,  
PENDING  
PRAI US 1999-161188P 19991022 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 4095  
INCL INCLM: 435/183.000  
INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000  
NCL NCLM: 435/183.000  
NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000  
IC [7]  
ICM: C12N009-00  
ICS: C12N009-64; C07H021-04; C12N005-06; C12P021-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 343 OF 469 USPATFULL on STN  
AN 2002:152685 USPATFULL  
TI Compositions and methods for advanced glycosylation endproduct-mediated  
modulation of amyloidosis  
IN Vitek, Michael P., 205 Park Knoll La., Apex, NC, United States 27502  
Cerami, Anthony, Ram Island Dr., Shelter Island, NY, United States  
11964  
Bucala, Richard J., 504 E. 63rd St. Apt. 33-0, New York, NY, United  
States 10021  
Ulrich, Peter C., 148 DeWolf Rd., Old Tappan, NJ, United States 07675  
Vlassara, Helen, Ram Island Dr., Shelter Island, NY, United States  
11964  
Zhang, Xini, 150 Fairhaven Dr. Apt. D1, Jericho, NY, United States  
117534)  
PI US 6410598 B1 20020625  
AI US 1995-477364 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1995-457169, filed on 1 Jun 1995  
Continuation-in-part of Ser. No. WO 1995-US1380, filed on 2 Feb 1995  
Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994,  
now abandoned Continuation of Ser. No. US 1994-191579, filed on 3 Feb  
1994, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 2202  
INCL INCLM: 514/632.000



NCL NCLM: 514/632.000  
 NCLS: 514/020.000; 514/229.800; 514/331.000; 514/634.000  
 IC [7]  
 ICM: A01N037-52  
 ICS: A61K031-155  
 EXF 514/632; 514/634; 514/400; 514/562; 514/866; 514/20; 514/45; 514/229.8;  
 514/331  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 344 OF 469 USPATFULL on STN  
 AN 2002:133892 USPATFULL  
 TI Mitochondria protecting agents for treating mitochondria associated diseases  
 IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES  
 Miller, Scott W., San Marcos, CA, UNITED STATES  
 Davis, Robert E., San Diego, CA, UNITED STATES  
 Moos, Walter H., Oakland, CA, UNITED STATES  
 PI US 2002068750 A1 20020606  
 AI US 2001-919684 A1 20010731 (9)  
 RLI Continuation of Ser. No. US 1999-461488, filed on 14 Dec 1999, ABANDONED  
 Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED  
 PRAI US 1998-72484P 19980126 (60)  
 US 1998-72487P 19980126 (60)  
 US 1998-72483P 19980126 (60)  
 US 1998-72482P 19980126 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1685  
 INCL INCLM: 514/311.000  
 INCLS: 514/456.000; 514/547.000; 514/634.000; 514/646.000; 514/658.000  
 NCL NCLM: 514/311.000  
 NCLS: 514/456.000; 514/547.000; 514/634.000; 514/646.000; 514/658.000  
 IC [7]  
 ICM: A61K031-47  
 ICS: A61K031-135; A61K031-155; A61K031-225  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 345 OF 469 USPATFULL on STN  
 AN 2002:133883 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\* -  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James E., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2002068741 A1 20020606  
 AI US 2001-915263 A1 20010726 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 25726  
 INCL INCLM: 514/248.000  
 INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;  
 514/410.000; 514/411.000  
 NCL NCLM: 514/248.000

IC [7]  
 ICM: A61K031-517  
 ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 346 OF 469 USPATFULL on STN  
 AN 2002:129982 USPATFULL  
 TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions  
 comprising same, and methods for inhibiting alpha- amyloid peptide  
 release and/or its synthesis by use of such compounds  
 IN Audia, James E., Indianapolis, IN, United States  
 Folmer, Beverly K., Newark, DE, United States  
 John, Varghese, San Francisco, CA, United States  
 Latimer, Lee H., Oakland, CA, United States  
 Nissen, Jeffrey S., Indianapolis, IN, United States  
 Reel, Jon K., Carmel, IN, United States  
 Thorsett, Eugene D., Moss Beach, CA, United States  
 Whitesitt, Celia A., Greenwood, IN, United States  
 PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S.  
 corporation)  
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
 PI US 6399628 B1 20020604  
 AI US 1999-266908 19990312 (9)  
 RLI Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now  
 patented, Pat. No. US 5965614  
 PRAI US 1996-104593P 19961122 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2944  
 INCL INCLM: 514/311.000  
 INCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;  
 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;  
 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;  
 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;  
 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000  
 NCL NCLM: 514/311.000  
 NCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;  
 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000;  
 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000;  
 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000;  
 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000

IC [7]  
 ICM: C07D215-38  
 ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02;  
 C07C229-28  
 EXF 514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471;  
 514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496;  
 548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161;  
 562/433; 562/457  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 347 OF 469 USPATFULL on STN  
 AN 2002:129731 USPATFULL  
 TI Methods of detection of amyloidogenic proteins  
 IN Krishnamurthy, Girija, Chestnut Ridge, NY, United States  
 PA American Cyanamid Company, Madison, NY, United States (U.S. corporation)  
 PI US 6399314 B1 20020604  
 AI US 1999-474970 19991229 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1359  
 INCL INCLM: 435/007.100  
 INCLS: 514/001.000; 514/002.000; 530/387.100  
 NCL NCLM: 435/007.100  
 NCLS: 514/001.000; 514/002.000; 530/387.100  
 IC [7]  
 ICM: G01N033-53  
 ICS: A01N061-00; A61K031-00; C07K016-00  
 EXF 514/1; 514/2; 435/7.1; 530/387.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 348 OF 469 USPATFULL on STN  
 AN 2002:126782 USPATFULL  
 TI Mitochondria protecting agents for treating mitochondria associated

IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES  
 Miller, Scott W., San Marcos, CA, UNITED STATES  
 Davis, Robert E., San Diego, CA, UNITED STATES  
 Moos, Walter H., Oakland, CA, UNITED STATES  
 PI US 2002065299 A1 20020530  
 AI US 2001-935845 A1 20010822 (9)  
 RLI Continuation of Ser. No. US 1999-461483, filed on 14 Dec 1999, ABANDONED  
 Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED  
 PRAI US 1998-72484P 19980126 (60)  
 US 1998-72487P 19980126 (60)  
 US 1998-72483P 19980126 (60)  
 US 1998-72482P 19980126 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1691  
 INCL INCLM: 514/311.000  
 INCLS: 514/456.000; 514/546.000; 514/534.000; 514/585.000; 514/727.000;  
 514/731.000  
 NCL NCLM: 514/311.000  
 NCLS: 514/456.000; 514/546.000; 514/534.000; 514/585.000; 514/727.000;  
 514/731.000  
 IC [7]  
 ICM: A61K031-47  
 ICS: A61K031-353; A61K031-192; A61K031-06; A61K031-05  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 349 OF 469 USPATFULL on STN  
 AN 2002:126781 USPATFULL  
 TI Mitochondria protecting agents for treating mitochondria associated  
 diseases  
 IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES  
 Miller, Scott W., San Marcos, CA, UNITED STATES  
 Davis, Robert E., San Diego, CA, UNITED STATES  
 Moos, Walter H., Oakland, CA, UNITED STATES  
 PI US 2002065298 A1 20020530  
 US 6511966 B2 20030128  
 AI US 2001-933911 A1 20010820 (9)  
 RLI Continuation of Ser. No. US 1999-461485, filed on 14 Dec 1999, ABANDONED  
 Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED  
 PRAI US 1998-72484P 19980126 (60)  
 US 1998-72487P 19980126 (60)  
 US 1998-72483P 19980126 (60)  
 US 1998-72482P 19980126 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1696  
 INCL INCLM: 514/311.000  
 INCLS: 514/456.000; 514/546.000; 514/634.000; 514/658.000  
 NCL NCLM: 514/034.000  
 NCLS: 514/312.000; 546/168.000  
 IC [7]  
 ICM: A61K031-47  
 ICS: A61K031-22; A61K031-353; A61K031-155; A61K031-135  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 350 OF 469 USPATFULL on STN  
 AN 2002:126775 USPATFULL  
 TI Pyrazole compounds, pharmaceutical compositions, and methods for  
 modulating or inhibiting ERAB or HADH2 activity  
 IN Abreo, Melwyn A., Jamul, CA, UNITED STATES  
 Meng, Jerry J., San Diego, CA, UNITED STATES  
 Agree, Charles S., San Diego, CA, UNITED STATES  
 PI US 2002065292 A1 20020530  
 AI US 2001-931166 A1 20010817 (9)  
 PRAI US 2000-226123P 20000818 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 4718  
 INCL INCLM: 514/258.000  
 INCLS: 514/303.000; 544/262.000; 546/119.000  
 NCL NCLM: 514/258.000  
 NCLS: 514/303.000; 544/262.000; 546/119.000  
 IC [7]  
 ICM: C07D491-02  
 ICS: C07D471-02; A61K031-519; A61K031-4745

L4 ANSWER 351 OF 469 USPATFULL on STN  
 AN 2002:126344 USPATFULL  
 TI Novel proteases  
 IN Plowman, Gregory, San Carlos, CA, UNITED STATES  
 Whyte, David, Belmont, CA, UNITED STATES  
 Caenepeel, Sean, Oakland, CA, UNITED STATES  
 Charydczak, Glen, Kentfield, CA, UNITED STATES  
 Manning, Gerard, Menlo Park, CA, UNITED STATES  
 Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES  
 PI US 2002064856 A1 20020530  
 AI US 2001-888615 A1 20010626 (9)  
 PRAI US 2000-214047P 20000626 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 8220  
 INCL INCLM: 435/226.000  
 INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000  
 NCL NCLM: 435/226.000  
 NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000  
 IC [7]  
 ICM: C12N009-64  
 ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 352 OF 469 USPATFULL on STN  
 AN 2002:126316 USPATFULL  
 TI Method of controlling the binding of calmyrin to presenilin  
 IN Monteiro, Mervyn J., Columbia, MD, UNITED STATES  
 Stabler, Stacy, Baltimore, MD, UNITED STATES  
 PI US 2002064828 A1 20020530  
 AI US 2001-878454 A1 20010611 (9)  
 PRAI US 2000-210939P 20000612 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2409  
 INCL INCLM: 435/069.100  
 INCLS: 435/252.300; 435/325.000; 435/410.000; 514/012.000; 530/350.000;  
 435/320.100; 536/023.500  
 NCL NCLM: 435/069.100  
 NCLS: 435/252.300; 435/325.000; 435/410.000; 514/012.000; 530/350.000;  
 435/320.100; 536/023.500  
 IC [7]  
 ICM: A61K038-17  
 ICS: C07K014-435; C12P021-02; C12N005-04; C12N005-06; C07H021-04  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 353 OF 469 USPATFULL on STN  
 AN 2002:122647 USPATFULL  
 TI Carboxamide compounds, methods, and compositions for inhibiting PARP  
 activity  
 IN Li, Jia-He, Cockeysville, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.  
 corporation)  
 PI US 6395749 B1 20020528  
 AI US 1998-145178 19980901 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-79514, filed on 15 May 1998,  
 now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 3095  
 INCL INCLM: 514/310.000  
 INCLS: 514/082.000; 514/255.000; 514/307.000; 514/309.000; 514/311.000;  
 514/312.000; 514/313.000; 514/314.000; 544/337.000; 544/363.000;  
 546/021.000; 546/141.000; 546/143.000; 546/144.000; 546/146.000;  
 546/153.000; 546/157.000; 546/158.000; 546/165.000; 546/167.000;  
 546/169.000; 424/485.000; 424/486.000; 424/487.000  
 NCL NCLM: 514/310.000  
 NCLS: 424/485.000; 424/486.000; 424/487.000; 514/082.000; 514/253.060;  
 514/307.000; 514/309.000; 514/311.000; 514/312.000; 514/313.000;  
 514/314.000; 544/337.000; 544/363.000; 546/021.000; 546/141.000;  
 546/143.000; 546/144.000; 546/146.000; 546/153.000; 546/157.000;  
 546/158.000; 546/165.000; 546/167.000; 546/169.000  
 IC [7]

ICS: A61K031-47; C07F009-02; C07D217-22; C07D215-16  
EXF 546/21; 546/141; 546/144; 546/153; 546/167; 546/143; 546/146; 546/157;  
546/158; 546/165; 546/169; 544/337; 544/363; 514/82; 514/255; 514/307;  
514/309; 514/312; 514/314; 514/310; 514/311; 514/313; 424/485; 424/486;  
424/487

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 354 OF 469 USPATFULL on STN  
AN 2002:109040 USPATFULL  
TI Phenazine compounds, methods and pharmaceutical compositions for  
inhibiting PARP  
IN Zhang, Jie, Ellicott City, MD, United States  
Tays, Kevin Leonard, Elkridge, MD, United States  
Li, Jia-He, Cockeysville, MD, United States  
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S.  
corporation)  
PI US 6387902 B1 20020514  
AI US 1998-224293 19981231 (9)  
DT Utility  
FS GRANTED  
LN.CNT 2616  
INCL INCLM: 514/249.000  
INCLS: 544/347.000; 544/348.000  
NCL NCLM: 514/249.000  
NCLS: 544/347.000; 544/348.000  
IC [7]  
ICM: A61K031-50  
ICS: C07D241-46  
EXF 514/249; 544/347; 544/348  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 355 OF 469 USPATFULL on STN  
AN 2002:106291 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting B-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
PI US 2002055500 A1 20020509  
AI US 2001-916440 A1 20010730 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25439  
INCL INCLM: 514/212.030  
INCLS: 514/327.000; 514/424.000; 514/659.000  
NCL NCLM: 514/212.030  
NCLS: 514/327.000; 514/424.000; 514/659.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-45; A61K031-4015; A61K031-13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 356 OF 469 USPATFULL on STN  
AN 2002:102627 USPATFULL

IN Edwards, Cynthia A., Menlo Park, CA, United States  
Cantor, Charles R., Boston, MA, United States  
Andrews, Beth M., Maynard, MA, United States  
Turin, Lisa M., Redwood City, CA, United States  
Fry, Kirk E., Palo Alto, CA, United States  
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.  
corporation)  
PI US 6384208 B1 20020507  
AI US 1999-354947 19990715 (9)  
RLI Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now  
patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No.  
US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444,  
issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936,  
filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10  
Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23  
Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997  
Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,  
now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 5215  
INCL INCLM: 536/024.100  
INCLS: 536/023.100  
NCL NCLM: 536/024.100  
NCLS: 536/023.100  
IC [7]  
ICM: C07H021-04  
EXF 435/6; 536/24.1; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 357 OF 469 USPATFULL on STN  
AN 2002:99459 USPATFULL  
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of a  
beta protein production  
IN Olson, Richard E., Wilmington, DE, UNITED STATES  
Liu, Hong, Glen Mills, PA, UNITED STATES  
Thompson III, Lorin A., Wilmington, DE, UNITED STATES  
PI US 2002052360 A1 20020502  
US 6503902 B2 20030107  
AI US 2001-805645 A1 20010314 (9)  
RLI Continuation-in-part of Ser. No. US 2000-661008, filed on 13 Sep 2000,  
PENDING  
PRAI US 1999-153511P 19990913 (60)  
US 2000-224388P 20000809 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6949  
INCL INCLM: 514/212.040  
INCLS: 514/218.000; 514/220.000; 540/522.000; 540/523.000; 540/504.000  
NCL NCLM: 514/221.000  
NCLS: 540/509.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-5513; A61K031-551  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 358 OF 469 USPATFULL on STN  
AN 2002:99458 USPATFULL  
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical  
compositions comprising same, and methods for inhibiting B-amyloid  
peptide release and/or its synthesis by use of such compounds  
IN Wu, Jing, San Mateo, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Audia, James E., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Dressman, Bruce A., Indianapolis, IN, UNITED STATES

Droste, James J., Indianapolis, IN, UNITED STATES  
Henry, Steven S., New Palestine, IN, UNITED STATES  
McDaniel, Stacey L., Bloomington, IN, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
Stucky, Russell D., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002052359 A1 20020502  
US 6544978 B2 20030408  
AI US 2001-915480 A1 20010727 (9)  
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
PRAI US 1996-64851P 19961223 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 25908  
INCL INCLM: 514/212.010  
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000;  
514/676.000  
NCL NCLM: 514/211.060  
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;  
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;  
540/527.000  
IC [7]  
ICM: A61K031-55  
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 359 OF 469 USPATFULL on STN  
AN 2002:99421 USPATFULL  
TI Methods and compounds for inhibiting \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\*  
peptide release and/or its synthesis  
IN Audia, James E., Indianapolis, IN, UNITED STATES  
Britton, Thomas C., Carmel, IN, UNITED STATES  
Droste, James J., Indianapolis, IN, UNITED STATES  
Folmer, Beverly K., Newark, DE, UNITED STATES  
Huffman, George W., Carmel, IN, UNITED STATES  
Varghese, John, San Francisco, CA, UNITED STATES  
Latimer, Lee H., Oakland, CA, UNITED STATES  
Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
Porter, Warren J., Indianapolis, IN, UNITED STATES  
Reel, Jon K., Carmel, IN, UNITED STATES  
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
Tung, Jay S., Belmont, CA, UNITED STATES  
Wu, Jing, San Mateo, CA, UNITED STATES  
Eid, Clark Norman, Cheshire, CT, UNITED STATES  
Scott, William Leonard, Indianapolis, IN, UNITED STATES  
PI US 2002052322 A1 20020502  
AI US 2001-789487 A1 20010220 (9)  
RLI Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,  
Pat. No. US 6191166  
PRAI US 1996-108166P 19961122 (60)  
US 1997-108161P 19970228 (60)  
US 1997-98558P 19970228 (60)  
US 1997-64859P 19970228 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 14911  
INCL INCLM: 514/018.000  
INCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000  
NCL NCLM: 514/018.000  
NCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000  
IC [7]  
ICM: A61K038-06  
ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 360 OF 469 USPATFULL on STN  
AN 2002:95805 USPATFULL  
TI Alkoxy-substituted compounds, methods, and compositions for inhibiting  
PARP activity  
IN Jackson, Paul F., Bel Air, MD, United States  
Maclin, Keith M., Baltimore, MD, United States  
Zhang, Jie, Ellicott City, MD, United States  
PA Guilford Pharmaceutical Inc., Baltimore, MD, United States (U.S.  
corporation)

AI US 2000-711953 20001115 (9)  
 RLI Continuation of Ser. No. US 1998-145166, filed on 1 Sep 1998, now patented, Pat. No. US 6197785 Continuation-in-part of Ser. No. US 1998-79508, filed on 15 May 1998 Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 2724  
 INCL INCLM: 514/309.000  
 INCLS: 514/233.500; 546/141.000; 544/128.000  
 NCL NCLM: 514/309.000  
 NCLS: 514/233.500; 544/128.000; 546/141.000  
 IC [7]  
 ICM: A61K031-47  
 EXF 546/141; 514/309; 514/233.5; 544/128  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 361 OF 469 USPATFULL on STN  
 AN 2002:95790 USPATFULL  
 TI Fused tricyclic compounds, methods and compositions for inhibiting PARP activity  
 IN Li, Jia-He, Cockeysville, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
 PI US 6380193 B1 20020430  
 AI US 1998-145184 19980901 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-79510, filed on 15 May 1998  
 DT Utility  
 FS GRANTED  
 LN.CNT 2371  
 INCL INCLM: 514/243.000  
 INCLS: 514/283.000; 514/249.000; 514/257.000; 514/286.000; 514/293.000; 514/296.000; 514/292.000; 544/182.000; 544/234.000; 544/233.000; 544/245.000; 544/247.000; 544/250.000; 546/048.000; 546/063.000; 546/086.000; 546/081.000; 546/084.000; 546/098.000  
 NCL NCLM: 514/243.000  
 NCLS: 514/249.000; 514/257.000; 514/283.000; 514/286.000; 514/292.000; 514/293.000; 514/296.000; 544/182.000; 544/233.000; 544/234.000; 544/245.000; 544/247.000; 544/250.000; 546/048.000; 546/063.000; 546/081.000; 546/084.000; 546/086.000; 546/098.000  
 IC [7]  
 ICM: A61K031-53  
 ICS: A61K031-44; A61K031-50; A61K031-505  
 EXF 546/81; 546/84; 546/98; 546/48; 546/63; 546/86; 514/292; 514/296; 514/243; 514/283; 514/249; 514/257; 514/286; 514/293; 544/182; 544/234; 544/233; 544/245; 544/247; 544/250  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 362 OF 469 USPATFULL on STN  
 AN 2002:92777 USPATFULL  
 TI Catalytically active recombinant memapsin and methods of use thereof  
 IN Tang, Jordan J. N., Edmond, OK, UNITED STATES  
 Lin, Xinli, Edmond, OK, UNITED STATES  
 Koelsch, Gerald, Oklahoma City, OK, UNITED STATES  
 Hong, Lin, Oklahoma City, OK, UNITED STATES  
 PI US 2002049303 A1 20020425  
 AI US 2001-796264 A1 20010228 (9)  
 RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING  
 PRAI US 1999-141363P 19990628 (60)  
 US 1999-168060P 19991130 (60)  
 US 2000-177836P 20000125 (60)  
 US 2000-178368P 20000127 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2441  
 INCL INCLM: 530/350.000  
 INCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200; 514/002.000; 530/387.900  
 NCL NCLM: 530/350.000  
 NCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200; 514/002.000; 530/387.900  
 IC [7]  
 ICM: C12N015-09  
 ICS: C12N009-64; C12N015-74



L4 ANSWER 363 OF 469 USPATFULL on STN  
 AN 2002:85701 USPATFULL  
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, UNITED STATES  
 Tung, Jay S., Belmont, CA, UNITED STATES  
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES  
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES  
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES  
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES  
 Latimer, Lee H., Oakland, CA, UNITED STATES  
 John, Varghese, San Francisco, CA, UNITED STATES  
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES  
 Britton, Thomas C., Carmel, IN, UNITED STATES  
 Audia, James A., Indianapolis, IN, UNITED STATES  
 Reel, Jon K., Carmel, IN, UNITED STATES  
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES  
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES  
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES  
 Droste, James J., Indianapolis, IN, UNITED STATES  
 Henry, Steven S., New Palestine, IN, UNITED STATES  
 McDaniel, Stacey L., Indianapolis, IN, UNITED STATES  
 Scott, William Leonard, Indianapolis, IN, UNITED STATES  
 Stucky, Russell D., Indianapolis, IN, UNITED STATES  
 Porter, Warren J., Indianapolis, IN, UNITED STATES  
 PI US 2002045747 A1 20020418  
 AI US 2001-916282 A1 20010730 (9)  
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING  
 PRAI US 1996-64851P 19961223 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 26053  
 INCL INCLM: 540/450.000  
 INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000  
 NCL NCLM: 540/450.000  
 NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000  
 IC [7]  
 ICM: A61K031-551  
 ICS: C07D243-12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 364 OF 469 USPATFULL on STN  
 AN 2002:78209 USPATFULL  
 TI Method of sterilizing  
 IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES  
 Supattapone, Surachai, San Francisco, CA, UNITED STATES  
 Scott, Michael R., San Francisco, CA, UNITED STATES  
 PI US 2002041862 A1 20020411  
 US 6517855 B2 20030211  
 AI US 2001-956705 A1 20010919 (9)  
 RLI Continuation of Ser. No. US 2000-494814, filed on 31 Jan 2000, GRANTED,  
 Pat. No. US 6322802 Continuation-in-part of Ser. No. US 1999-447456,  
 filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US  
 1999-322903, filed on 1 Jun 1999, GRANTED, Pat. No. US 6214366  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1727  
 INCL INCLM: 424/078.270  
 INCLS: 422/028.000  
 NCL NCLM: 424/408.000  
 NCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/456.000;  
 424/DIG.016; 514/578.000; 523/105.000; 523/122.000; 525/410.000;  
 525/419.000; 528/363.000  
 IC [7]  
 ICM: A61K031-74  
 ICS: A61L009-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 365 OF 469 USPATFULL on STN  
 AN 2002:69833 USPATFULL  
 TI Vitro system for determining formation of A. \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\*

PA Busn, Ashley 1., Boston, MA, United States  
The General Hospital Corporation, Boston, MA, United States (U.S.  
corporation)  
PI US 6365414 B1 20020402  
AI US 1994-294819 19940826 (8)  
DT Utility  
FS GRANTED  
LN.CNT 1937  
INCL INCLM: 436/086.000  
INCLS: 436/164.000; 436/177.000; 436/811.000  
NCL NCLM: 436/086.000  
NCLS: 436/164.000; 436/177.000; 436/811.000  
IC [7]  
ICM: G01N021-75  
ICS: G01N033-50  
EXF 436/86; 436/164; 436/177; 436/811  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 366 OF 469 USPATFULL on STN  
AN 2002:67251 USPATFULL  
TI Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones,  
derivatives thereof and their uses  
IN Li, Jia-He, Cockeysville, MD, UNITED STATES  
Zhang, Jie, Ellicott City, MD, UNITED STATES  
Kalish, Vincent J., Annapolis, MD, UNITED STATES  
PI US 2002037904 A1 20020328  
US 6545011 B2 20030408  
AI US 2001-895262 A1 20010702 (9)  
PRAI US 2000-218037P 20000713 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2628  
INCL INCLM: 514/288.000  
INCLS: 546/066.000  
NCL NCLM: 514/284.000  
NCLS: 514/232.800; 514/253.020; 514/288.000; 544/125.000; 544/361.000;  
546/062.000; 546/066.000; 546/070.000; 546/076.000  
IC [7]  
ICM: A61K031-4745  
ICS: A61K031-4741; C07D471-06  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 367 OF 469 USPATFULL on STN  
AN 2002:48621 USPATFULL  
TI THIOALKYL COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP  
ACTIVITY  
IN JACKSON, PAUL F., BEL AIR, MD, UNITED STATES  
MACLIN, KEITH M., BALTIMORE, MD, UNITED STATES  
ZHANG, JIE, ELLICOTT CITY, MD, UNITED STATES  
PI US 2002028813 A1 20020307  
AI US 1998-145179 A1 19980901 (9)  
RLI Continuation-in-part of Ser. No. US 1998-79513, filed on 15 May 1998,  
ABANDONED Continuation-in-part of Ser. No. US 1997-922520, filed on 3  
Sep 1997, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 2979  
INCL INCLM: 514/248.000  
INCLS: 514/309.000; 544/237.000; 546/141.000  
NCL NCLM: 514/248.000  
NCLS: 514/309.000; 544/237.000; 546/141.000  
IC [7]  
ICM: A61K031-502  
ICS: A61K031-47; C07D217-22; C07D237-30  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 368 OF 469 USPATFULL on STN  
AN 2002:48271 USPATFULL  
TI Alpha-2-macroglobulin isotype diagnostic test for Alzheimer's disease  
IN Tanzi, Rudolph E., Hull, MA, UNITED STATES  
Blacker, Deborah L., Newton, MA, UNITED STATES  
PA The General Hospital Corporation (U.S. corporation)  
PI US 2002028462 A1 20020307  
AI US 2001-925313 A1 20010810 (9)  
RLI Division of Ser. No. US 1998-148503, filed on 4 Sep 1998, PENDING

US 1998-93297P 19980717 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1955  
INCL INCLM: 435/006.000  
INCLS: 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 435/091.200  
IC [7]  
ICM: C12Q001-68  
ICS: C12P019-34  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 369 OF 469 USPATFULL on STN  
AN 2002:40045 USPATFULL  
TI Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases  
IN O'Brien, Patrick Michael, Stockbridge, MI, United States  
Picard, Joseph Armand, Canton, MI, United States  
Sliskovic, Drago Robert, Saline, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)  
PI US 6350885 B1 20020226  
WO 2000006560 20000210  
AI US 2001-719026 20010220 (9)  
WO 1999-US12272 19990602  
20010220 PCT 371 date  
PRAI US 1998-94705P 19980730 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2382  
INCL INCLM: 549/460.000  
INCLS: 549/461.000; 514/468.000; 514/443.000  
NCL NCLM: 549/460.000  
NCLS: 549/461.000  
IC [7]  
ICM: C07D307-91  
ICS: A61K031-38; A61K031-343  
EXF 514/443; 514/468; 549/460; 549/461  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 370 OF 469 USPATFULL on STN  
AN 2002:37916 USPATFULL  
TI OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY  
IN LI, JIA-HE, COCKEYSVILLE, MD, UNITED STATES  
TAYS, KEVIN LEONARD, ELKRIDGE, MD, UNITED STATES  
ZHANG, JIE, ELLICOTT CITY, MD, UNITED STATES  
PI US 2002022636 A1 20020221  
AI US 1998-145180 A1 19980901 (9)  
RLI Continuation-in-part of Ser. No. US 1998-79509, filed on 15 May 1998, ABANDONED  
Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, ABANDONED  
DT Utility  
FS APPLICATION  
LN.CNT 3766  
INCL INCLM: 514/307.000  
INCLS: 514/308.000; 514/290.000; 514/298.000; 514/309.000  
NCL NCLM: 514/307.000  
NCLS: 514/308.000; 514/290.000; 514/298.000; 514/309.000  
IC [7]  
ICM: A61K031-44  
ICS: A61K031-47; A61K031-415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 371 OF 469 USPATFULL on STN  
AN 2002:33166 USPATFULL  
TI TRANSGENIC NON-HUMAN MAMMALS WITH PROGRESSIVE NEUROLOGIC DISEASE  
IN HSIAO, KAREN, NORTH OAKS, MN, UNITED STATES  
BORCHELT, DAVID R., BALTIMORE, MD, UNITED STATES  
SISODIA, SANGRAM, BALTIMORE, MD, UNITED STATES  
PI US 2002019992 A1 20020214  
US 6509515 B2 20030121  
AI US 1999-260897 A1 19990302 (9)  
RLI Continuation of Ser. No. US 1996-664872, filed on 17 Jun 1996, GRANTED,

filed on 10 May 1996, ABANDONED Continuation-in-part of Ser. No. US  
1994-189064, filed on 27 Jan 1994, ABANDONED

DT Utility  
FS APPLICATION  
LN.CNT 2655  
INCL INCLM: 800/003.000  
INCLS: 800/013.000; 800/014.000; 800/018.000  
NCL NCLM: 800/012.000  
NCLS: 800/003.000; 800/018.000  
IC [7]  
ICM: A01K067-027  
ICS: G01N033-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 372 OF 469 USPATFULL on STN  
AN 2002:32581 USPATFULL  
TI Methods to treat alzheimer's disease  
IN Hom, Roy, San Francisco, CA, UNITED STATES  
Mamo, Shumeye S., Oakland, CA, UNITED STATES  
Tung, Jay, Belmont, CA, UNITED STATES  
Gailunas, Andrea, San Francisco, CA, UNITED STATES  
John, Varghese, San Francisco, CA, UNITED STATES  
Fang, Lawrence Y., Foster City, CA, UNITED STATES  
PI US 2002019403 A1 20020214  
AI US 2001-816876 A1 20010323 (9)  
PRAI US 2000-191528P 20000323 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 8655  
INCL INCLM: 514/256.000  
INCLS: 514/519.000; 514/520.000; 514/534.000  
NCL NCLM: 514/256.000  
NCLS: 514/519.000; 514/520.000; 514/534.000  
IC [7]  
ICM: A61K031-505  
ICS: A61K031-275; A61K031-277; A61K031-24

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 373 OF 469 USPATFULL on STN  
AN 2002:22538 USPATFULL  
TI METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF  
\*\*\*AMYLOID\*\*\* \*\*\*BETA\*\*\* PEPTIDE BINDING  
IN REITZ, ALLEN B., LANSDALE, PA, UNITED STATES  
DEMETER, DAVID A., FISHERS, IN, UNITED STATES  
LEE, DANIEL H.S., NORTHHAMPTON, PA, UNITED STATES  
WANG, HOAU-YAN, PHILADELPHIA, PA, UNITED STATES  
CHEN, ROBERT H., BELLE MEAD, NJ, UNITED STATES  
ROSS, TINA MORGAN, AUDUBON, PA, UNITED STATES  
SCOTT, MALCOLM K., LANSDALE, PA, UNITED STATES  
PLATA-SALAMAN, CARLOS R., AMBLER, PA, UNITED STATES  
PI US 2002013374 A1 20020131  
US 6441049 B2 20020827  
AI US 1999-320885 A1 19990527 (9)  
PRAI US 1998-87577P 19980601 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1507  
INCL INCLM: 514/657.000  
INCLS: 564/428.000; 564/429.000  
NCL NCLM: 514/657.000  
NCLS: 564/428.000; 564/429.000  
IC [7]  
ICM: A61K031-135  
ICS: C07C211-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 374 OF 469 USPATFULL on STN  
AN 2002:19174 USPATFULL  
TI Alpha-2-macroglobulin diagnostic test  
IN Tanzi, Rudolph E., Hull, MA, United States  
Hyman, Bradley T., Swampscott, MA, United States  
Rebeck, George W., Somerville, MA, United States  
Blacker, Deborah L., Newton, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S.  
corporation)

AI US 1998-148503 19980904 (9)  
PRAI US 1998-93297P 19980717 (60)  
US 1997-57655P 19970905 (60)

DT Utility  
FS GRANTED

LN.CNT 2070

INCL INCLM: 435/006.000  
INCLS: 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 435/091.200

IC [7]

ICM: C12Q001-68

EXF 435/6; 435/91.2; 536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 375 OF 469 USPATFULL on STN

AN 2002:17315 USPATFULL

TI Mitochondria protecting agents for treating mitochondria associated diseases

IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES

Miller, Scott W., San Marcos, CA, UNITED STATES

Davis, Robert E., San Diego, CA, UNITED STATES

Moos, Walter H., Oakland, CA, UNITED STATES

PI US 2002010195 A1 20020124

US 6498191 B2 20021224

AI US 2000-733271 A1 20001207 (9)

RLI Continuation of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED

PRAI US 1998-72484P 19980126 (60)

US 1998-72487P 19980126 (60)

US 1998-72483P 19980126 (60)

US 1998-72482P 19980126 (60)

DT Utility

FS APPLICATION

LN.CNT 1688

INCL INCLM: 514/312.000

INCLS: 514/313.000; 514/456.000; 514/534.000; 514/543.000

NCL NCLM: 514/547.000

NCLS: 514/648.000; 514/721.000; 514/741.000

IC [7]

ICM: A61K031-47

ICS: A61K031-352; A61K031-216

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 376 OF 469 USPATFULL on STN

AN 2002:12546 USPATFULL

TI Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses

IN Li, Jia-He, Cockeysville, MD, UNITED STATES

Kalish, Vincent J., Annapolis, MD, UNITED STATES

Zhang, Jie, Ellicott City, MD, UNITED STATES

Serdyuk, Larisa E., Baltimore, MD, UNITED STATES

Ferraris, Dana Victor, Towson, MD, UNITED STATES

Xiao, Ge, Baltimore, MD, UNITED STATES

Kletzly, Paul W., Arlington, VA, UNITED STATES

PI US 2002006927 A1 20020117

US 6723733 B2 20040420

AI US 2001-854455 A1 20010515 (9)

PRAI US 2000-205259P 20000519 (60)

DT Utility

FS APPLICATION

LN.CNT 2682

INCL INCLM: 514/253.030

INCLS: 514/290.000; 544/361.000; 546/108.000

NCL NCLM: 514/298.000

NCLS: 514/232.800; 514/253.030; 544/126.000; 544/361.000; 546/108.000

IC [7]

ICM: C07D221-12

ICS: C07D041-02; A61K031-496; A61K031-473

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 377 OF 469 USPATFULL on STN

AN 2001:235319 USPATFULL

TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof

IN Markland, William, Milford, MA, United States

Ladner, Robert Charles, Ijamsville, MD, United States

PI US 6333402 B1 20011225  
AI US 1999-421097 19991019 (9)  
RLI Division of Ser. No. US 1994-208264, filed on 10 Mar 1994, now patented,  
Pat. No. US 6057287 Continuation-in-part of Ser. No. US 1994-179964,  
filed on 11 Jan 1994, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 3154  
INCL INCLM: 536/023.500  
INCLS: 536/023.200; 435/007.000; 435/252.300; 435/320.100; 530/317.000  
NCL NCLM: 536/023.500  
NCLS: 435/007.100; 435/252.300; 435/254.230; 435/320.100; 435/325.000;  
530/317.000; 536/023.200  
IC [7]  
ICM: C07H021-04  
ICS: A61K038-12; C12N001-20; C12N015-00; G01N033-53  
EXF 435/7; 435/252.3; 435/320.1; 514/2; 530/317; 536/23.1; 536/23.2;  
536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 378 OF 469 USPATFULL on STN  
AN 2001:231143 USPATFULL  
TI Arrays for identifying agents which mimic or inhibit the activity of  
interferons  
IN Silverman, Robert H., Beachwood, OH, United States  
Williams, Bryan R. G., Cleveland, OH, United States  
Der, Sandy, Cleveland, OH, United States  
PA The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.  
corporation)  
PI US 6331396 B1 20011218  
AI US 1999-405438 19990923 (9)  
PRAI US 1998-101497P 19980923 (60)  
DT Utility  
FS GRANTED  
LN.CNT 9639  
INCL INCLM: 435/006.000  
INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
NCL NCLM: 435/006.000  
NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310  
IC [7]  
ICM: C12Q001-68  
ICS: C12M001-36; C07H021-04  
EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 379 OF 469 USPATFULL on STN  
AN 2001:231048 USPATFULL  
TI Food additives which affect conformationally altered proteins  
IN Prusiner, Stanley B., 400 Pacheco St., San Francisco, CA, United States  
94116  
Supattapone, Surachai, 225 Buckingham Way #702, San Francisco, CA,  
United States 94132  
Scott, Michael R., 1200 Clayton St., #9, San Francisco, CA, United  
States 94114  
PI US 6331296 B1 20011218  
AI US 1999-447456 19991122 (9)  
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999,  
now patented, Pat. No. US 6214366  
DT Utility  
FS GRANTED  
LN.CNT 1764  
INCL INCLM: 424/078.080  
INCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320;  
424/405.000; 424/439.000; 424/442.000; 424/438.000; 424/078.330;  
424/078.340; 424/078.350; 426/271.000; 426/532.000; 525/512.000;  
525/513.000; 525/514.000; 523/122.000  
NCL NCLM: 424/078.080  
NCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320;  
424/078.330; 424/078.340; 424/078.350; 424/405.000; 424/438.000;  
424/439.000; 424/442.000; 426/271.000; 426/532.000; 523/122.000;  
525/512.000; 525/513.000; 525/514.000  
IC [7]  
ICM: A01N025-10  
EXF 424/DIG.76; 424/78.32; 424/78.35-78.38; 424/438-442; 424/405; 424/78.08;  
424/78.17; 424/78.18; 424/78.27; 424/78.31; 514/772.3-772.7; 523/122;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 380 OF 469 USPATFULL on STN  
AN 2001:226655 USPATFULL  
TI Formamide compounds as therapeutic agents  
IN Andrews, Robert Carl, Durham, NC, United States  
Andersen, Marc Werner, Raleigh, NC, United States  
Bubacz, Dulce Garrido, Cary, NC, United States  
Chan, Joseph Howing, Chapel Hill, NC, United States  
Cowan, David John, Hillsborough, NC, United States  
Gaul, Michael David, Apex, NC, United States  
McDougald, Daryl Lynn, Durham, NC, United States  
Musso, David Lee, Raleigh, NC, United States  
Rabinowitz, Michael Howard, Durham, NC, United States  
Stanford, Jennifer Badiang, Cary, NC, United States  
Wiethe, Robert William, Durham, NC, United States  
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)  
PI US 6329400 B1 20011211  
AI US 1999-382924 19990825 (9)  
PRAI GB 1998-18608 19980826  
US 1998-97958P 19980826 (60)  
DT Utility  
FS GRANTED  
LN.CNT 3877  
INCL INCLM: 514/336.000  
INCLS: 514/352.000; 546/281.400; 546/309.000  
NCL NCLM: 514/336.000  
NCLS: 514/352.000; 546/281.400; 546/309.000  
IC [7]  
ICM: C07D409-12  
ICS: C07D213-74; A61K031-4436; A61K031-4409  
EXF 514/336; 514/337; 514/338; 514/352; 546/271.7; 546/281.1; 546/281.4; 546/282.4; 546/284.1; 546/283.4; 546/309  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 381 OF 469 USPATFULL on STN  
AN 2001:215066 USPATFULL  
TI Agents for use in the treatment of Alzheimer's disease  
IN Bush, Ashley I., Somerville, MA, United States  
Huang, Xudong, Cambridge, MA, United States  
Atwood, Craig S., Somerville, MA, United States  
Tanzi, Rudolph E., Canton, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
PI US 6323218 B1 20011127  
AI US 1998-38154 19980311 (9)  
DT Utility  
FS GRANTED  
LN.CNT 4192  
INCL INCLM: 514/311.000  
INCLS: 514/244.000; 514/420.000; 514/707.000  
NCL NCLM: 514/311.000  
NCLS: 514/244.000; 514/420.000; 514/707.000  
IC [7]  
ICM: A61K031-47  
ICS: A61K031-53; A61K031-40; A61K031-105  
EXF 514/311; 514/244; 514/420; 514/707  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 382 OF 469 USPATFULL on STN  
AN 2001:214671 USPATFULL  
TI Method of sterilizing  
IN Prusiner, Stanley B., San Francisco, CA, United States  
Supattapone, Surachai, San Francisco, CA, United States  
Scott, Michael R., San Francisco, CA, United States  
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
PI US 6322802 B1 20011127  
AI US 2000-494814 20000131 (9)  
RLI Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999  
Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366  
DT Utility  
FS GRANTED

INCL INCLM: 424/405.000  
 INCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/DIG.016;  
 528/363.000; 128/114.100; 128/832.000; 128/899.000; 600/003.000;  
 600/029.000; 600/030.000; 600/036.000; 600/372.000; 602/508.000;  
 604/890.100; 623/001.100; 623/920.000

NCL NCLM: 424/405.000  
 NCLS: 128/114.100; 128/832.000; 128/899.000; 422/027.000; 424/078.080;  
 424/078.180; 424/078.270; 424/078.350; 424/DIG.016; 528/363.000;  
 600/003.000; 600/029.000; 600/030.000; 600/036.000; 600/372.000;  
 604/890.100; 623/001.100; 623/920.000

IC [7]  
 ICM: A01N025-10

EXF 424/DIG.16; 424/405; 424/76.8; 424/78.07; 424/78.08; 424/78.17;  
 424/78.18; 424/78.26; 424/78.27; 424/78.31; 424/78.35; 424/78.37;  
 623/920; 623/11.11; 623/1.1; 623/2.1; 623/3.1; 623/4.1; 623/7; 623/9;  
 623/10; 604/890.1; 602/48; 602/508; 128/114.1; 128/832; 128/842;  
 128/899; 600/372; 600/478; 600/462; 600/488; 600/466; 600/3; 600/29;  
 600/30; 600/36

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 383 OF 469 USPATFULL on STN  
 AN 2001:200180 USPATFULL  
 TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR  
 IN BARTA, THOMAS E, EVANSTON, IL, United States  
 BECKER, DANIEL P, GLENVIEW, IL, United States  
 BOEHM, TERRI L, BALLWIN, MO, United States  
 DECRESCENZO, GARY A, ST CHARLES, MO, United States  
 WILLAMI, CLARA I, GLENVIEW, IL, United States  
 MCDONALD, JOSEPH J, BALLWIN, MO, United States  
 FRESKOS, JOHN N, CLAYTON, MO, United States  
 GETMAN, DANIEL P, CHESTERFIELD, MO, United States  
 HANSON, GUNNAR J, SKOKIE, IL, United States

PI US 2001039287 A1 20011108  
 AI US 1999-256948 A1 19990224 (9)  
 PRAI US 1997-66007P 19971114 (60)  
 US 1998-95347P 19980804 (60)  
 US 1998-95501P 19980806 (60)  
 US 1998-101080P 19980918 (60)

DT Utility  
 FS APPLICATION  
 LN.CNT 16461

INCL INCLM: 514/330.000  
 INCLS: 546/019.000; 546/094.000; 546/191.000; 546/159.000; 546/207.000;  
 546/227.000; 546/225.000; 544/147.000; 548/315.100; 548/311.100;  
 549/028.000; 549/419.000; 549/427.000

NCL NCLM: 514/330.000  
 NCLS: 546/019.000; 546/094.000; 546/191.000; 546/159.000; 546/207.000;  
 546/227.000; 546/225.000; 544/147.000; 548/315.100; 548/311.100;  
 549/028.000; 549/419.000; 549/427.000

IC [7]  
 ICM: C07D491-20

ICS: C07D211-08; C07D215-38; A61K031-445  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 384 OF 469 USPATFULL on STN  
 AN 2001:158250 USPATFULL  
 TI Compounds, methods and pharmaceutical compositions for treating cellular  
 damage, such as neural or cardiovascular tissue damage  
 IN Li, Jia-He, Cockeysville, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.  
 corporation)

PI US 6291425 B1 20010918  
 AI US 1999-387767 19990901 (9)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2878

INCL INCLM: 514/008.000D  
 INCLS: 544/233.000; 544/232.000; 514/081.000; 514/080.000; 514/248.000

NCL NCLM: 514/080.000  
 NCLS: 514/081.000; 514/248.000; 544/232.000; 544/233.000

IC [7]  
 ICM: C07D491-04

EXF ICS: C07D498-04; C07F009-141; A61K031-47; A61K031-50  
 544/233; 514/248



L4 ANSWER 385 OF 469 USPATFULL on STN  
 AN 2001:150648 USPATFULL  
 TI N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS  
 COMPRISING SAME, AND METHODS FOR INHIBITING \*\*\*BETA\*\*\* -  
 \*\*\*AMYLOID\*\*\* PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH  
 COMPOUNDS  
 IN AUDIA, JAMES E., INDIANAPOLIS, IN, United States  
 FOLMER, BEVERLY K., NEWARK, DE, United States  
 JOHN, VARGHESE, SAN FRANCISCO, CA, United States  
 LATIMER, LEE H., OAKLAND, CA, United States  
 NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States  
 PORTER, WARREN J., INDIANAPOLIS, IN, United States  
 THORSETT, EUGENE D., MOSS BEACH, CA, United States  
 WU, JING, SAN MATEO, CA, United States  
 PI US 2001020097 A1 20010906  
 US 6495693 B2 20021217  
 AI US 1999-280966 A1 19990330 (9)  
 RLI Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED,  
 Pat. No. US 6096782  
 DT Utility  
 FS APPLICATION  
 LN.CNT 3729  
 INCL INCLM: 546/162.000  
 INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000;  
 514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000;  
 560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000;  
 548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000  
 NCL NCLM: 546/162.000  
 NCLS: 546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000;  
 560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000;  
 564/163.000; 564/168.000  
 IC [7]  
 ICM: C07D277-82  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 386 OF 469 USPATFULL on STN  
 AN 2001:150564 USPATFULL  
 TI Ortho-diphenol compounds, methods and pharmaceutical compositions for  
 inhibiting parp  
 IN Zhang, Jie, Ellicott City, MD, United States  
 Serdyuk, Larisa E., Baltimore, MD, United States  
 Li, Jia-He, Cockeysville, MD, United States  
 PA GUILFORD PHARMACEUTICALS, INC. (U.S. corporation)  
 PI US 2001020013 A1 20010906  
 AI US 2000-745858 A1 20001226 (9)  
 RLI Continuation of Ser. No. US 1998-224294, filed on 31 Dec 1998, GRANTED,  
 Pat. No. US 6201020  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2874  
 INCL INCLM: 514/150.000  
 INCLS: 514/423.000; 514/427.000; 514/539.000; 514/456.000; 534/848.000  
 NCL NCLM: 514/150.000  
 NCLS: 514/423.000; 514/427.000; 514/539.000; 514/456.000; 534/848.000  
 IC [7]  
 ICM: A61K031-655  
 ICS: A61K031-40  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 387 OF 469 USPATFULL on STN  
 AN 2001:147440 USPATFULL  
 TI Method for identifying . \*\*\*beta\*\*\* ..- \*\*\*amyloid\*\*\* peptide  
 production inhibitors  
 IN Schenk, Dale B., Pacifica, CA, United States  
 Schlossmacher, Michael G., Vienna, Australia  
 Selkoe, Dennis J., Jamaica Plain, MA, United States  
 Seubert, Peter A., South San Francisco, CA, United States  
 Vigo-Pelfrey, Carmen, Mountain View, CA, United States  
 PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
 corporation)  
 Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.  
 corporation)

AI US 1996-733202 19961018 (8)  
RLI Division of Ser. No. US 1995-437067, filed on 9 May 1995, now patented,  
Pat. No. US 5593846 Continuation of Ser. No. US 1992-911647, filed on 10  
Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1992-911647,  
filed on 10 Jul 1992, now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 1410  
INCL INCLM: 424/009.200  
INCLS: 424/009.100; 800/018.000; 435/007.100  
NCL NCLM: 424/009.200  
NCLS: 424/009.100; 435/007.100; 800/018.000  
IC [7]  
ICM: A61K049-00  
ICS: A01K067-027  
EXF 424/9.1; 424/9.2; 424/9.34; 435/7.1; 435/7.2; 435/7.21; 435/7.92;  
435/7.94; 435/7.95; 435/41; 435/69.1; 536/23.5; 800/2; 800/18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 388 OF 469 USPATFULL on STN  
AN 2001:134239 USPATFULL  
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR  
IN BARTA, THOMAS E., EVANSTON, IL, United States  
BECKER, DANIEL P., GLENVIEW, IL, United States  
BOEHM, TERRI L., BALLWIN, MO, United States  
DECRESCENZO, GARY A., ST.CHARLES, MO, United States  
WILLAMIL, CLARA I., GLENVIEW, IL, United States  
MCDONALD, JOSEPH J., BALLWIN, MO, United States  
FRESKOS, JOHN N., CLAYTON, MO, United States  
GETMAN, DANIEL P., CHESTERFIELD, MO, United States  
HANSON, GUNNAR J., STOKIE, IL, United States  
PI US 2001014688 A1 20010816  
AI US 1998-191129 A1 19981113 (9)  
PRAI US 1997-66007P 19971114 (60)  
US 1998-95347P 19980804 (60)  
US 1998-95501P 19980806 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 15774  
INCL INCLM: 514/318.000  
INCLS: 514/330.000; 514/328.000; 546/225.000; 549/220.000; 546/193.000  
NCL NCLM: 514/318.000  
NCLS: 514/330.000; 514/328.000; 546/225.000; 549/220.000; 546/193.000  
IC [7]  
ICM: A61K031-445  
ICS: C07D211-30; C07F009-06; C07D211-68  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 389 OF 469 USPATFULL on STN  
AN 2001:112599 USPATFULL  
TI Transgenic mice expressing APP mutant at amino acids 717, 721 and 722  
IN Hsiao, Karen, North Oaks, MN, United States  
Borchelt, David R., Baltimore, MD, United States  
Sisodia, Sangram S., Baltimore, MD, United States  
PA Johns Hopkins University, Baltimore, MD, United States (U.S.  
corporation)  
Regents of the University of Minnesota, Minneapolis, MN, United States  
(U.S. corporation)  
PI US 6262335 B1 20010717  
AI US 1998-19973 19980206 (9)  
RLI Continuation of Ser. No. US 1994-189064, filed on 27 Jan 1994, now  
abandoned  
DT Utility  
FS GRANTED  
LN.CNT 1104  
INCL INCLM: 800/012.000  
INCLS: 800/003.000; 800/018.000; 800/025.000  
NCL NCLM: 800/012.000  
NCLS: 800/003.000; 800/018.000; 800/025.000  
IC [7]  
ICM: A01K067-00  
ICS: A01K067-027; G01N033-00; C12N015-00  
EXF 800/3; 800/8; 800/12; 800/13; 800/14; 800/18; 800/25; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:112566 USPATFULL  
 TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
 .- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such compounds  
 IN Wu, Jing, San Mateo, CA, United States  
 Tung, Jay S., Belmont, CA, United States  
 Nissen, Jeffrey S., Indianapolis, IN, United States  
 Mabry, Thomas E., Indianapolis, IN, United States  
 Latimer, Lee H., Oakland, CA, United States  
 Eid, Clark N., Cheshire, CT, United States  
 Audia, James E., Indianapolis, IN, United States  
 PA Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S. corporation)  
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
 PI US 6262302 B1 20010717  
 AI US 1999-398211 19990917 (9)  
 RLI Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now patented, Pat. No. US 6153652  
 PRAI US 1996-98551P 19961122 (60)  
 US 1997-113671P 19970228 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 4050  
 INCL INCLM: 564/152.000  
 INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 549/303.000; 549/304.000; 548/471.000; 548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000  
 NCL NCLM: 564/152.000  
 NCLS: 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000; 564/158.000; 564/168.000  
 IC [7]  
 ICM: C07C229-38  
 ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00  
 EXF 560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168; 564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 391 OF 469 USPATFULL on STN  
 AN 2001:105177 USPATFULL  
 TI VARIANT HUMAN ALPHA7 ACETYLCHOLINE RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF  
 IN BRIGGS, CLARK A., LIBERTYVILLE, IL, United States  
 GOPALAKRISHNAN, MURALI, GRAYSLAKE, IL, United States  
 MC KENNA, DAVID G., MCHENRY, IL, United States  
 MONTEGGIA, LISA M., LINDERHURST, IL, United States  
 ROCH, JEAN-MARC, WAUKEGAN, IL, United States  
 SULLIVAN, JAMES P., DEERFIELD, IL, United States  
 TOUMA, EDWARD, NORTH CHICAGO, IL, United States  
 PI US 2001006796 A1 20010705  
 US 6323000 B2 20011127  
 AI US 1996-771737 A1 19961220 (8)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1634  
 INCL INCLM: 435/069.100  
 INCLS: 536/023.500; 435/325.000; 435/320.100; 530/350.000; 435/007.200; 514/002.000; 435/006.000; 530/387.900  
 NCL NCLM: 435/069.100  
 NCLS: 435/071.100; 435/254.200; 435/320.100; 435/325.000; 536/023.500  
 IC [7]  
 ICM: A01N037-18  
 ICS: A61K038-00; C12Q001-68; G01N033-53; G01N033-567; C07H021-04; C12P021-06; C12N015-00; C12N015-09; C12N015-63  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 392 OF 469 USPATFULL on STN  
 AN 2001:86665 USPATFULL  
 TI Transgenic rodent comprising APP-Swedish  
 IN McLonogue, Lisa C., San Francisco, CA, United States  
 Zhao, Jun, La Jolla, CA, United States  
 Sinha, Sukanto, San Francisco, CA, United States

corporation)  
 PI US 6245964 B1 20010612  
 AI US 1998-209647 19981210 (9)  
 RLI Continuation of Ser. No. US 1997-785943, filed on 22 Jan 1997, now patented, Pat. No. US 5850003 Continuation of Ser. No. US 1993-148211, filed on 1 Nov 1993, now patented, Pat. No. US 5612486  
 Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993, now patented, Pat. No. US 5604102  
 DT Utility  
 FS GRANTED  
 LN.CNT 2117  
 INCL INCLM: 800/012.000  
 INCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000  
 NCL NCLM: 800/012.000  
 NCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000  
 IC [7]  
 ICM: A01K067-00  
 ICS: A01K067-027; G01N033-00; C12N015-00  
 EXF 800/3; 800/12; 800/14; 800/18; 800/22; 424/9.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 393 OF 469 USPATFULL on STN  
 AN 2001:75401 USPATFULL  
 TI Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity  
 IN Li, Jia-He, Cockeysville, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
 PI US 6235748 B1 20010522  
 AI US 2000-524750 20000314 (9)  
 RLI Division of Ser. No. US 1998-79509, filed on 15 May 1998, now abandoned  
 Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2242  
 INCL INCLM: 514/285.000  
 INCLS: 546/062.000; 546/070.000; 428/451.000; 428/455.000; 428/464.000  
 NCL NCLM: 514/285.000  
 NCLS: 428/451.000; 428/455.000; 428/464.000; 546/062.000; 546/070.000  
 IC [7]  
 ICM: A61K031-4353  
 ICS: C07D221-18; C07D471-02  
 EXF 546/108; 546/62; 546/70; 514/285; 428/451; 428/455; 428/464; 534/560; 424/451; 424/463; 424/464; 424/474  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 394 OF 469 USPATFULL on STN  
 AN 2001:51793 USPATFULL  
 TI Methods for screening for inhibitors of Alzheimer .beta.-peptide filament formation  
 IN Potter, Huntington, Boston, MA, United States  
 PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)  
 PI US 6214569 B1 20010410  
 AI US 1997-914694 19970819 (8)  
 RLI Continuation of Ser. No. US 1995-417937, filed on 6 Apr 1995, now patented, Pat. No. US 5780587 Continuation-in-part of Ser. No. US 1994-328491, filed on 25 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1994-290198, filed on 15 Aug 1994, now abandoned  
 Continuation-in-part of Ser. No. US 1994-179574, filed on 10 Jan 1994, now patented, Pat. No. US 5506097 Continuation-in-part of Ser. No. US 1992-819361, filed on 13 Jan 1992, now patented, Pat. No. US 5338663  
 Continuation-in-part of Ser. No. US 572671, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1742  
 INCL INCLM: 435/007.800  
 NCL NCLM: 435/007.800  
 IC [7>]  
 ICM: G01N033-55  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 395 OF 469 USPATFULL on STN

TI Clearance and inhibition of conformationally altered proteins  
IN Prusiner, Stanley B., San Francisco, CA, United States  
Supattapone, Surachai, San Francisco, CA, United States  
Scott, Michael, San Francisco, CA, United States  
PA The Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6214366 B1 20010410  
AI US 1999-322903 19990601 (9)  
DT Utility  
FS Granted  
LN.CNT 1037  
INCL INCLM: 424/405.000  
INCLS: 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 424/078.320;  
424/078.350; 424/078.360; 424/078.370; 424/078.380; 514/772.300;  
514/772.400; 514/772.500; 514/772.600; 514/772.700  
NCL NCLM: 424/405.000  
NCLS: 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380;  
424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 514/772.300;  
514/772.400; 514/772.500; 514/772.600; 514/772.700  
IC [7]  
ICM: A01N025-10  
EXF 424/78.32; 424/78.35; 424/78.38; 424/405; 424/438; 424/442; 424/DIG.16;  
514/772.3-772.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 396 OF 469 USPATFULL on STN  
AN 2001:48108 USPATFULL  
TI Compounds for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis  
IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Reel, Jon K., Carmel, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Latimer, Lee H., Oakland, CA, United States  
John, Varghese, San Francisco, CA, United States  
Folmer, Beverly K., Newark, DE, United States  
Droste, James J., Indianapolis, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Audia, James E., Indianapolis, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)  
PI US 6211235 B1 20010403  
AI US 1998-164448 19980930 (9)  
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997  
PRAI US 1996-108166P 19961122 (60)  
US 1997-64859P 19970228 (60)  
US 1997-98558P 19970228 (60)  
DT Utility  
FS Granted  
LN.CNT 14056  
INCL INCLM: 514/534.000  
INCLS: 514/619.000; 560/041.000; 560/040.000; 564/163.000  
NCL NCLM: 514/534.000  
NCLS: 514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000;  
548/479.000; 548/496.000; 560/040.000; 560/041.000; 564/163.000  
IC [7]  
ICM: A01N037-12  
ICS: C07C229-00; C07C233-00  
EXF 514/534; 514/619; 564/163; 560/40; 560/41  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 397 OF 469 USPATFULL on STN  
AN 2001:44268 USPATFULL  
TI Compounds for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* peptide  
release and/or its synthesis  
IN Audia, James E., Indianapolis, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Folmer, Beverly K., Newark, DE, United States  
Huffman, George W., Carmel, IN, United States  
John, Varghese, San Francisco, CA, United States

Mabry, Thomas E., Indianapolis, IN, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Wu, Jing, San Mateo, CA, United States

PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6207710 B1 20010327

AI US 1998-164385 19980930 (9)

RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997

PRAI US 1996-108166P 19961122 (60)

US 1997-64859P 19970228 (60)

US 1997-108161P 19970228 (60)

US 1997-98558P 19970228 (60)

DT Utility

FS Granted

LN.CNT 12026

INCL INCLM: 514/551.000

INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000;  
560/041.000; 654/123.000; 654/155.000

NCL NCLM: 514/551.000

NCLS: 514/534.000; 514/563.000; 530/331.000; 560/037.000; 560/038.000;  
560/040.000; 560/041.000; 564/123.000; 564/155.000

IC [7]

ICM: A01N037-12

ICS: C07C229-00; C07C233-00

EXF 514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123;  
564/155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 398 OF 469 USPATFULL on STN

AN 2001:36867 USPATFULL

TI Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp

IN Zhang, Jie, Ellicott, MD, United States

Serdyuk, Larisa E., Baltimore, MD, United States

Li, Jia-He, Cockeysville, MD, United States

PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S. corporation)

PI US 6201020 B1 20010313

AI US 1998-224294 19981231 (9)

DT Utility

FS Granted

LN.CNT 2960

INCL INCLM: 514/544.000

INCLS: 514/532.000; 514/538.000; 514/546.000; 514/551.000; 560/015.000;  
560/029.000; 560/035.000; 560/064.000; 560/065.000; 560/073.000;  
560/100.000; 560/103.000; 560/109.000; 560/125.000

NCL NCLM: 514/544.000

NCLS: 514/532.000; 514/538.000; 514/546.000; 514/551.000; 560/015.000;  
560/029.000; 560/035.000; 560/064.000; 560/065.000; 560/073.000;  
560/100.000; 560/103.000; 560/109.000; 560/125.000

IC [7]

ICM: A61K031-235

ICS: C07C069-035; C07C069-76

EXF 558/392; 558/396; 560/1; 560/15; 560/20; 560/19; 560/35; 560/25; 560/63;  
560/64; 560/65; 560/100; 560/103; 560/109; 560/125; 560/56; 560/73;  
560/121; 560/122; 560/123; 560/124; 514/529; 514/532; 514/538; 514/544;  
514/546; 514/551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 399 OF 469 USPATFULL on STN

AN 2001:33282 USPATFULL

TI Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity

IN Jackson, Paul F., Bel Air, MD, United States

Maclin, Keith M., Baltimore, MD, United States

Zhang, Jie, Ellicott City, MD, United States

PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)

PI US 6197785 B1 20010306

AI US 1998-145166 19980901 (9)

said Ser. NO. US 145166 And Ser. NO. US 1997-922520, filed on 3 Sep 1997, now abandoned

DT Utility  
FS Granted  
LN.CNT 2403  
INCL INCLM: 514/309.000  
INCLS: 514/233.500; 514/299.000; 544/128.000; 546/141.000; 546/183.000  
NCL NCLM: 514/309.000  
NCLS: 514/233.500; 514/299.000; 544/128.000; 546/141.000; 546/183.000  
IC [7]  
ICM: C07D217-24  
ICS: A61K031-47  
EXF 514/309; 514/233.5; 546/141; 546/183; 544/128  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 400 OF 469 USPATFULL on STN  
AN 2001:25931 USPATFULL  
TI Methods and compounds for inhibiting . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\*  
peptide release and/or its synthesis  
IN Audia, James E., Indianapolis, IN, United States  
Britton, Thomas C., Carmel, IN, United States  
Droste, James J., Indianapolis, IN, United States  
Folmer, Beverly K., Newark, DE, United States  
Huffman, George W., Carmel, IN, United States  
Varghese, John, San Francisco, CA, United States  
Latimer, Lee H., Oakland, CA, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Porter, Warren J., Indianapolis, IN, United States  
Reel, Jon K., Carmel, IN, United States  
Thorsett, Eugene D., Moss Beach, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Wu, Jing, San Mateo, CA, United States  
Eid, Clark Norman, Cheshire, CT, United States  
Scott, William Leonard, Indianapolis, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6191166 B1 20010220  
AI US 1997-976289 19971121 (8)  
PRAI US 1996-108166P 19961122 (60)  
US 1997-64859P 19970228 (60)  
US 1997-108161P 19970228 (60)  
US 1997-698556P 19970228 (60)  
DT Utility  
FS Granted  
LN.CNT 12827  
INCL INCLM: 514/534.000  
INCLS: 514/535.000; 514/616.000; 514/619.000  
NCL NCLM: 514/534.000  
NCLS: 514/535.000; 514/616.000; 514/619.000  
IC [7]  
ICM: A01N037-12  
EXF 574/534; 574/535; 574/616; 574/619  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 401 OF 469 USPATFULL on STN  
AN 2001:4738 USPATFULL  
TI Formamides as therapeutic agents  
IN Andrews, Robert Carl, Durham, NC, United States  
Andersen, Marc Werner, Raleigh, NC, United States  
Cowan, David John, Hillsborough, NC, United States  
Deaton, David Norman, Cary, NC, United States  
Dickerson, Scott Howard, Chapel Hill, NC, United States  
Drewry, David Harold, Durham, NC, United States  
Gaul, Michael David, Apex, NC, United States  
Luzzio, Michael Joseph, Durham, NC, United States  
Marron, Brian Edward, Durham, NC, United States  
Rabinowitz, Michael Howard, Durham, NC, United States  
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)  
PI US 6172064 B1 20010109  
AI US 1999-382333 19990825 (9)  
PRAI US 1998-97956P 19980826 (60)  
DT Patent

LN.CNT 3155  
INCL INCLM: 514/237.800  
INCLS: 514/357.000; 514/428.000; 514/438.000; 514/575.000; 546/337.000;  
546/168.000; 548/568.000; 549/076.000; 562/621.000; 562/623.000  
NCL NCLM: 514/237.800  
NCLS: 514/357.000; 514/428.000; 514/438.000; 514/575.000; 546/168.000;  
546/337.000; 548/568.000; 549/076.000; 562/621.000; 562/623.000  
IC [7]  
ICM: C07D211-70  
ICS: C07D207-08; C07D333-22; C07C259-04; A61K031-535; A61K031-40;  
A61K031-38; A61K031-19; A61K031-44  
EXF 562/621; 562/623; 514/515; 514/438; 514/357; 514/237.8; 514/428; 549/76;  
546/337; 546/168; 548/568  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 402 OF 469 USPATFULL on STN  
AN 2000:161048 USPATFULL  
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical  
compositions comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
- \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
compounds  
IN Wu, Jing, San Mateo, CA, United States  
Tung, Jay S., Belmont, CA, United States  
Nissen, Jeffrey S., Indianapolis, IN, United States  
Mabry, Thomas E., Indianapolis, IN, United States  
Latimer, Lee H., Oakland, CA, United States  
Eid, Clark N., Cheshire, CT, United States  
Audia, James E., Indianapolis, IN, United States  
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 6153652 20001128  
AI US 1997-976295 19971121 (8)  
PRAI US 1996-1551P 19961122 (60)  
US 1997-113671P 19970228 (60)  
DT Utility  
FS Granted  
LN.CNT 3652  
INCL INCLM: 514/619.000  
INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;  
514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;  
549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;  
560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000  
NCL NCLM: 514/619.000  
NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;  
514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000;  
549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000;  
560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000  
IC [7]  
ICM: A01N037-18  
ICS: A01N037-12; A01N037-44; A61K031-165  
EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303;  
549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357;  
514/417; 514/470; 514/535; 514/539; 514/619  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 403 OF 469 USPATFULL on STN  
AN 2000:142115 USPATFULL  
TI Methods for identifying useful T-PA mutant derivatives for treatment of  
vascular hemorrhaging  
IN Anderson, Stephen, Princeton, NJ, United States  
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United  
States (U.S. corporation)  
PI US 6136548 20001024  
AI US 1999-388890 19990902 (9)  
RLI Continuation of Ser. No. US 1996-686959, filed on 26 Jul 1996, now  
abandoned And a continuation-in-part of Ser. No. WO 1995-US15007, filed  
on 22 Nov 1995 which is a continuation-in-part of Ser. No. US  
1994-347144, filed on 22 Nov 1994, now patented, Pat. No. US 5589154  
DT Utility  
FS Granted  
LN.CNT 1820  
INCL INCLM: 435/007.100  
INCLS: 435/069.200; 435/172.100; 435/226.000; 436/086.000; 514/002.000  
NCL NCLM: 435/007.100



IC [7]  
 ICM: G01N033-53  
 ICS: G01N033-00; C12N015-09; C12N009-64; A01N037-18  
 EXF 424/9.2; 424/184.1; 435/7.1; 435/7.8; 435/69.1; 435/69.2; 435/172.1;  
 435/359; 435/212; 435/215; 435/226; 530/350; 530/380; 530/381; 530/382;  
 514/2; 436/86; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 404 OF 469 USPATFULL on STN  
 AN 2000:125055 USPATFULL  
 TI Di-n-heterocyclic compounds, methods, and compositions for inhibiting  
 parp activity  
 IN Jackson, Paul F., Bel Air, MD, United States  
 Maclin, Keith M., Baltimore, MD, United States  
 Zhang, Jie, Ellicott City, MD, United States  
 PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S.  
 corporation)  
 PI US 6121278 20000919  
 AI US 1998-145185 19980901 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-79510, filed on 15 May 1998,  
 now abandoned And a continuation-in-part of Ser. No. US 1997-922520,  
 filed on 3 Sep 1997  
 DT Utility  
 FS Granted  
 LN.CNT 2709  
 INCL INCLM: 514/292.000  
 INCLS: 514/081.000; 514/222.800; 514/224.500; 514/226.200; 514/229.200;  
 514/229.800; 514/243.000; 514/248.000; 514/267.000; 514/291.000;  
 514/293.000; 544/032.000; 544/066.000; 544/095.000; 544/183.000;  
 544/234.000; 544/250.000; 546/021.000; 546/081.000; 546/082.000;  
 546/083.000; 546/084.000  
 NCL NCLM: 514/292.000  
 NCLS: 514/081.000; 514/222.800; 514/224.500; 514/226.200; 514/229.200;  
 514/229.800; 514/243.000; 514/248.000; 514/267.000; 514/291.000;  
 514/293.000; 544/032.000; 544/066.000; 544/095.000; 544/183.000;  
 544/234.000; 544/250.000; 546/021.000; 546/081.000; 546/082.000;  
 546/083.000; 546/084.000

IC [7]  
 ICM: A61K031-4375  
 ICS: C07D471-06  
 EXF 546/21; 546/81; 514/81; 514/292  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 405 OF 469 USPATFULL on STN  
 AN 2000:98466 USPATFULL  
 TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions  
 comprising same and methods for inhibiting . \*\*\*beta\*\*\* .-  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
 compounds  
 IN Audia, James E., Indianapolis, IN, United States  
 Folmer, Beverly K., Newark, DE, United States  
 John, Varghese, San Francisco, CA, United States  
 Latimer, Lee H., Oakland, CA, United States  
 Nissen, Jeffrey S., Indianapolis, IN, United States  
 Porter, Warren J., Indianapolis, IN, United States  
 Thorsett, Eugene D., Moss Beach, CA, United States  
 Wu, Jing, San Mateo, CA, United States  
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)  
 PI US 6096782 20000801  
 AI US 1997-976191 19971121 (8)  
 PRAI US 1996-77175P 19961122 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 3343  
 INCL INCLM: 514/506.000  
 INCLS: 514/399.000; 548/335.500; 560/041.000  
 NCL NCLM: 514/506.000  
 NCLS: 514/399.000; 548/335.500; 560/041.000

IC [7]  
 ICM: A01N037-20  
 ICS: A01N043-50; C07C229-24; C07D233-61  
 EXF 560/41; 514/506; 514/399; 548/335.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 406 OF 469 USPATFULL on STN  
 AN 2000:91941 USPATFULL  
 TI Serine proteases, their activity and their synthetic inhibitors  
 IN Augustyns, Koen Jan Ludovicus, Minderhout, Belgium  
 Vanhoof, Greta Constantia, Mortsel, Belgium  
 Borloo, Marianne Jean Frieda, Deurne, Belgium  
 De Meester, Ingrid Anna Jozef, Wilrijk, Belgium  
 Goossens, Filip Jozef Anny, Lokeren, Belgium  
 Haemers, Achiel Jean-Marie, Gent, Belgium  
 Hendriks, Dirk Frans, Aartselaar, Belgium  
 Lambeir, Anne-Marie Virginie Renee, Heverlee, Belgium  
 Scharpe, Simon Lodewijk, Wieze, Belgium  
 PA FondaTech Benelux N.V., Belgium (non-U.S. corporation)  
 PI US 6090786 20000718  
 WO 9534538 19951221  
 AI US 1997-750484 19970219 (8)  
 WO 1995-EP2255 19950609  
 19970219 PCT 371 date  
 19970219 PCT 102(e) date  
 PRAI EP 1994-201668 19940610  
 EP 1994-203707 19941220  
 DT Utility  
 FS Granted  
 LN.CNT 1511  
 INCL INCLM: 514/019.000  
 INCLS: 514/020.000; 514/002.000; 530/330.000; 540/130.000  
 NCL NCLM: 514/019.000  
 NCLS: 514/002.000; 514/020.000; 530/330.000; 540/130.000  
 IC [7]  
 ICM: A61K038-05  
 ICS: C07K005-078  
 EXF 514/19; 514/20; 514/2; 530/330; 540/130  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 407 OF 469 USPATFULL on STN  
 AN 2000:54070 USPATFULL  
 TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof  
 IN Markland, William, Milford, MA, United States  
 Ladner, Robert Charles, Ijamsville, MD, United States  
 PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)  
 PI US 6057287 20000502  
 AI US 1994-208264 19940310 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3820  
 INCL INCLM: 514/002.000  
 INCLS: 514/012.000; 530/300.000; 530/317.000; 530/324.000; 435/004.000;  
 435/007.400; 435/007.720; 435/069.100  
 NCL NCLM: 514/002.000  
 NCLS: 435/004.000; 435/007.400; 435/007.720; 435/069.100; 514/012.000;  
 530/300.000; 530/317.000; 530/324.000  
 IC [7]  
 ICM: A61K038-16  
 ICS: C07K014-00  
 EXF 530/317; 530/300; 530/324; 514/12; 514/2; 435/69.1; 435/4; 435/7.4;  
 435/7.72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 408 OF 469 USPATFULL on STN  
 AN 2000:50364 USPATFULL  
 TI Organometallic ligands for the localization and quantification of  
 amyloid in vivo and in vitro  
 IN Lansbury, Jr., Peter T., Brookline, MA, United States  
 Han, Hogyu, Seoul, Korea, Republic of  
 Cho, Cheon-Gyu, Seoul, Korea, Republic of  
 Zhen, Weiguo, Waltham, MA, United States  
 Harper, James D., Cambridge, MA, United States  
 Davison, Alan, West Roxbury, MA, United States  
 PA Massachusetts Institute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI US 6054114 20000425  
 AI US 1997-852825 19970507 (8)  
 PRAI US 1996-16599P 19960508 (60)

DT Utility  
FS Granted  
LN.CNT 2848  
INCL INCLM: 424/001.110  
INCLS: 424/009.100; 534/010.000; 534/012.000; 534/014.000; 534/883.000;  
556/045.000  
NCL NCLM: 424/001.110  
NCLS: 424/009.100; 534/010.000; 534/012.000; 534/014.000; 534/883.000;  
556/045.000  
IC [7]  
ICM: A61K051-00  
ICS: A61K049-00; C07F013-00  
EXF 534/10; 534/12; 534/14; 534/670; 534/671; 534/883; 424/1.11; 424/1.37;  
424/9.1; 556/45  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 409 OF 469 USPATFULL on STN  
AN 2000:41077 USPATFULL  
TI .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing  
the same  
IN Kelleher, Judith A., Fremont, CA, United States  
Maples, Kirk R., San Jose, CA, United States  
Dykman, Alina, San Francisco, CA, United States  
Zhang, Yong-Kang, Santa Clara, CA, United States  
Wilcox, Allan L., Mountain View, CA, United States  
Levell, Julian, Collegeville, PA, United States  
PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S.  
corporation)  
PI US 6046232 20000404  
AI US 1998-172763 19981015 (9)  
PRAI US 1997-62324P 19971017 (60)  
US 1997-63736P 19971029 (60)  
US 1998-90475P 19980624 (60)  
DT Utility  
FS Granted  
LN.CNT 2793  
INCL INCLM: 514/464.000  
INCLS: 514/640.000; 514/645.000; 564/300.000; 564/265.000; 549/434.000  
NCL NCLM: 514/464.000  
NCLS: 514/640.000; 514/645.000; 549/434.000; 564/265.000; 564/300.000  
IC [7]  
ICM: A61K031-34  
EXF 514/645; 514/640; 514/464; 564/300; 564/265; 549/434; 549/432  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 410 OF 469 USPATFULL on STN  
AN 2000:37839 USPATFULL  
TI Tyramine compounds and their neuronal effects  
IN Giulian, Dana J., Houston, TX, United States  
PA Baylor College of Medicine, Houston, TX, United States (U.S.  
corporation)  
PI US 6043283 20000328  
AI US 1997-870967 19970606 (8)  
RLI Continuation-in-part of Ser. No. US 1996-717551, filed on 20 Sep 1996  
DT Utility  
FS Granted  
LN.CNT 3153  
INCL INCLM: 514/617.000  
NCL NCLM: 514/617.000  
IC [7]  
ICM: A61K031-165  
EXF 514/152; 514/617  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 411 OF 469 USPATFULL on STN  
AN 2000:31594 USPATFULL  
TI Transgenic mouse expressing an . \*\*\*beta\*\*\* .- \*\*\*Amyloid\*\*\*  
transgene  
IN Sato, Masahiro, Kawagoe, Japan  
Kobayashi, Takashi, Fukuoka, Japan  
Tada, Norihiro, Kawagoe, Japan  
Shoji, Mikio, Gunma-gun, Japan  
Kawarabayashi, Takeshi, Maebashi, Japan  
PA Hoechst Japan Limited, Tokyo, Japan (non-U.S. corporation)  
PI US 6037521 20000314

PRAI JP 1993-306026 19931112  
DT Utility  
FS Granted  
LN.CNT 1316  
INCL INCLM: 800/018.000  
INCLS: 800/009.000; 800/012.000; 800/003.000; 424/009.100; 424/009.200  
NCL NCLM: 800/018.000  
NCLS: 424/009.100; 424/009.200; 800/003.000; 800/009.000; 800/012.000  
IC [7]  
ICM: A01K067-00  
ICS: A01K067-027  
EXF 800/2; 435/172.3; 424/9; 424/9.1; 424/9.2

L4 ANSWER 412 OF 469 USPATFULL on STN  
AN 2000:28107 USPATFULL  
TI .beta.-sheet nucleating peptidomimetics  
IN Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United States 77840  
PI US 6034211 20000307  
AI US 1996-664379 19960614 (8)  
PRAI US 1996-18925P 19960603 (60)  
DT Utility  
FS Granted  
LN.CNT 1635  
INCL INCLM: 530/317.000  
INCLS: 546/101.000  
NCL NCLM: 530/317.000  
NCLS: 546/101.000  
IC [7]  
ICM: C07K005-00  
EXF 548/427; 546/101; 514/323-328; 530/317  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 413 OF 469 USPATFULL on STN  
AN 2000:21390 USPATFULL  
TI Methods of detecting Alzheimer's disease  
IN Roses, Allen D., Durham, NC, United States  
Strittmatter, Warren J., Durham, NC, United States  
Salvesen, Guy S., Chapel Hill, NC, United States  
Enghild, Jan, Durham, NC, United States  
Schmechel, Donald E., Durham, NC, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
PI US 6027896 20000222  
AI US 1998-60459 19980415 (9)  
RLI Continuation of Ser. No. US 1997-835503, filed on 8 Apr 1997, now patented, Pat. No. US 5767248 which is a continuation of Ser. No. US 1995-440900, filed on 15 May 1995, now abandoned which is a division of Ser. No. US 1994-227044, filed on 13 Apr 1994, now patented, Pat. No. US 5508167 which is a continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-959992, filed on 13 Oct 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1614  
INCL INCLM: 435/006.000  
INCLS: 435/007.100; 435/091.200; 536/023.100; 536/024.300; 530/387.100; 530/350.000  
NCL NCLM: 435/006.000  
NCLS: 435/007.100; 435/091.200; 530/350.000; 530/387.100; 536/023.100; 536/024.300  
IC [7]  
ICM: C12Q001-68  
ICS: G01N033-53; C12P019-34; C07H021-02  
EXF 435/6; 435/7.1; 435/91.2; 536/23.1; 536/24.3; 530/387.1; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 414 OF 469 USPATFULL on STN  
AN 2000:1862 USPATFULL  
TI Vasoactive effects and free radical generation by . \*\*\*beta\*\*\* .-  
\*\*\*amyloid\*\*\* peptides  
IN Thomas, Thomas N., Palm Harbor, FL, United States  
Mullan, Michael, Tampa, FL, United States  
Arendash, Gary W., Lutz, FL, United States  
Crawford, Fiona C., Tampa, FL, United States  
Suo, Zhiming, Tampa, FL, United States

PI US 6011019 20000104  
 AI US 1996-747457 19961112 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-615593, filed on 12 Mar 1996  
 DT Utility  
 FS Granted  
 LN.CNT 2634  
 INCL INCLM: 514/043.000  
 INCLS: 424/718.000; 424/094.400  
 NCL NCLM: 514/043.000  
 NCLS: 424/094.400; 424/718.000  
 IC [6]  
 ICM: A01N043-04  
 EXF 514/43; 424/718; 424/94.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 415 OF 469 USPATFULL on STN  
 AN 2000:1692 USPATFULL  
 TI Sequence-directed DNA binding molecules compositions and methods  
 IN Edwards, Cynthia A., Menlo Park, CA, United States  
 Cantor, Charles R., Boston, MA, United States  
 Andrews, Beth M., Maynard, MA, United States  
 Turin, Lisa M., Redwood City, CA, United States  
 Fry, Kirk E., Palo Alto, CA, United States  
 PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)  
 PI US 6010849 20000104  
 AI US 1995-482080 19950607 (8)  
 RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 10022  
 INCL INCLM: 435/006.000  
 INCLS: 435/007.100  
 NCL NCLM: 435/006.000  
 NCLS: 435/007.100  
 IC [6]  
 ICM: C12Q001-68  
 ICS: G01N033-53  
 EXF 435/6; 435/7.1; 436/501; 536/23.1; 536/24.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 416 OF 469 USPATFULL on STN  
 AN 1999:132524 USPATFULL  
 TI Diagnostic assay for Alzheimer's disease: assessment of A.beta. abnormalities  
 IN Tanzi, Rudolph E., Canton, MA, United States  
 Bush, Ashley I., Somerville, MA, United States  
 Moir, Robert D., Boston, MA, United States  
 PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
 PI US 5972634 19991026  
 WO 9612544 19960502  
 AI US 1997-817423 19970804 (8)  
 WO 1994-US11895 19941019  
 19970804 PCT 371 date  
 19970804 PCT 102(e) date  
 DT Utility  
 FS Granted  
 LN.CNT 2476  
 INCL INCLM: 435/007.940  
 INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000; 436/525.000; 436/164.000; 436/172.000  
 NCL NCLM: 435/007.940  
 NCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000; 436/164.000; 436/172.000; 436/525.000  
 IC [6]  
 ICM: G01N033-53  
 EXF 435/7.1; 435/7.92; 435/7.94; 435/7.95; 435/975; 435/7.9; 436/525; 436/164; 436/172; 436/63

L4 ANSWER 417 OF 469 USPATFULL on STN  
 AN 1999:124950 USPATFULL  
 TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions  
 comprising same, and methods for inhibiting . \*\*\*beta\*\*\*  
 \*\*\*amyloid\*\*\* peptide release and/or its synthesis by use of such  
 compounds  
 IN Audia, James E., Indianapolis, IN, United States  
 Folmer, Beverly K., Newark, DE, United States  
 John, Varghese, San Francisco, CA, United States  
 Latimer, Lee H., Oakland, CA, United States  
 Nissen, Jeffrey S., Indianapolis, IN, United States  
 Reel, Jon K., Carmel, IN, United States  
 Thorsett, Eugene D., Moss Beach, CA, United States  
 Whitesitt, Celia A., Greenwood, IN, United States  
 PA Athena Neurosciences, Inc., United States (U.S. corporation)  
 PI US 5965614 19991012  
 AI US 1997-975977 19971121 (8)  
 PRAI US 1996-104593P 19961122 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 2939  
 INCL INCLM: 514/538.000  
 INCLS: 514/508.000; 560/043.000; 560/035.000  
 NCL NCLM: 514/538.000  
 NCLS: 514/508.000; 560/035.000; 560/043.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-52; C07C229-28  
 EXF 514/538; 514/508; 560/43; 560/35  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 418 OF 469 USPATFULL on STN  
 AN 1999:117454 USPATFULL  
 TI Animal models of human amyloidoses  
 IN Snow, Alan D., Seattle, WA, United States  
 PA Board of Regents of the University of Washington Office of Technology,  
 Seattle, WA, United States (U.S. corporation)  
 PI US 5958883 19990928  
 AI US 1995-461216 19950605 (8)  
 RLI Continuation of Ser. No. US 1992-969734, filed on 23 Oct 1992, now  
 abandoned which is a continuation-in-part of Ser. No. US 1992-950417,  
 filed on 23 Sep 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 4323  
 INCL INCLM: 514/016.000  
 INCLS: 514/017.000; 530/328.000; 530/329.000  
 NCL NCLM: 514/016.000  
 NCLS: 514/017.000; 530/328.000; 530/329.000  
 IC [6]  
 ICM: A61K038-08  
 ICS: C07K007-06  
 EXF 514/16; 514/17; 530/300; 530/328; 530/329  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 419 OF 469 USPATFULL on STN  
 AN 1999:113631 USPATFULL  
 TI Stable macroscopic membranes formed by self-assembly of amphiphilic  
 peptides and uses therefor  
 IN Holmes, Todd, Somerville, MA, United States  
 Zhang, Shuguang, Cambridge, MA, United States  
 Rich, Alexander, Cambridge, MA, United States  
 DiPersio, C. Michael, Norton, MA, United States  
 Lockshin, Curtis, Lexington, MA, United States  
 PA Massachusetts Institute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI US 5955343 19990921  
 AI US 1994-293284 19940822 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2516  
 INCL INCLM: 435/240.100

NCL NCLM: 435/325.000  
 NCLS: 435/378.000; 435/395.000; 435/401.000  
 IC [6]  
 ICM: C12N005-02  
 EXF 435/240.1; 435/240.2; 435/240.23; 435/240.241  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 420 OF 469 USPATFULL on STN  
 AN 1999:92643 USPATFULL  
 TI Compositions and methods for stimulating amyloid removal in  
 IN amyloidogenic diseases using advanced glycosylation endproducts  
 Vitek, Michael P., East Norwich, NY, United States  
 Cerami, Anthony, Shelter Island, NY, United States  
 Bucala, Richard J., New York, NY, United States  
 Ulrich, Peter C., Old Tappan, NJ, United States  
 Vlassara, Helen, Shelter Island, NJ, United States  
 Zhang, Xini, Jericho, NJ, United States  
 PA The Picower Institute For Medical Research, Manhasset, NY, United States  
 (U.S. corporation)  
 PI US 5935927 19990810  
 WO 9520979 19950810  
 AI US 1996-501127 19960810 (8)  
 WO 1995-US1380 19950202  
 19960810 PCT 371 date  
 19960810 PCT 102(e) date  
 RLI Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1994-191579, filed on 3 Feb 1994, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2154  
 INCL INCLM: 514/012.000  
 INCLS: 514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000;  
 514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000;  
 514/647.000; 548/100.000; 548/121.000; 548/122.000; 530/300.000;  
 530/322.000; 536/001.110  
 NCL NCLM: 514/012.000  
 NCLS: 514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000;  
 514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000;  
 514/647.000; 530/300.000; 530/322.000; 536/001.110; 548/100.000;  
 548/121.000; 548/122.000  
 IC [6]  
 ICM: A61K038-00  
 ICS: A61K031-135; A61K031-70  
 EXF 530/300; 530/322; 514/2; 514/647; 514/12; 514/23; 514/569; 514/663;  
 514/665; 514/79; 514/91; 514/95; 514/359; 514/438; 514/439; 514/443;  
 514/642; 548/100; 548/121; 548/122; 536/1.11  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 421 OF 469 USPATFULL on STN  
 AN 1999:67429 USPATFULL  
 TI Transgenic non-human mice displaying the amyloid-forming pathology of  
 IN alzheimer's disease  
 Cordell, Barbara, Palo Alto, CA, United States  
 PA Scios Inc., Mountain View, CA, United States (U.S. corporation)  
 PI US 5912410 19990615  
 AI US 1995-422333 19950413 (8)  
 RLI Continuation of Ser. No. US 1994-327381, filed on 21 Oct 1994, now  
 abandoned which is a continuation-in-part of Ser. No. US 1991-716725,  
 filed on 17 Jun 1991, now patented, Pat. No. US 5387742 which is a  
 continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2702  
 INCL INCLM: 800/002.000  
 INCLS: 800/DIG.001; 424/009.200; 935/062.000  
 NCL NCLM: 800/012.000  
 NCLS: 424/009.200  
 IC [6]  
 ICM: C12N015-00  
 ICS: C12N005-00; A61K049-00  
 EXF 800/2; 800/DIG.1; 935/62; 424/9.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:27850 USPATFULL  
TI Transgenic mice expressing APP-Swedish mutation develop progressive  
neurologic disease  
IN Hsiao, Karen, North Oaks, MN, United States  
Borchelt, David R., Baltimore, MD, United States  
Sisodia, Sangram S., Baltimore, MD, United States  
PA Johns Hopkins University, Baltimore, MD, United States (U.S.  
corporation)  
Regents of the University of Minnesota, Minneapolis, MN, United States  
(U.S. corporation)  
PI US 5877399 19990302  
AI US 1996-664872 19960617 (8)  
RLI Continuation-in-part of Ser. No. US 1996-644691, filed on 10 May 1996,  
now abandoned which is a continuation of Ser. No. US 1994-189064, filed  
on 27 Jan 1994  
DT Utility  
FS Granted  
LN.CNT 2823  
INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 424/009.200; 935/060.000  
NCL NCLM: 800/003.000  
NCLS: 424/009.200; 800/009.000; 800/012.000  
IC [6]  
ICM: C12N005-00  
ICS: C12N015-00; A61K049-00  
EXF 800/2; 800/DIG.1; 424/9.2; 435/320.1; 536/23.1; 935/60  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 423 OF 469 USPATFULL on STN  
AN 1999:27412 USPATFULL  
TI Screening methods to identify neurotoxin inhibitors  
IN Yankner, Bruce A., Boston, MA, United States  
PA The Children's Medical Center Corporation, Boston, MA, United States  
(U.S. corporation)  
PI US 5876948 19990302  
AI US 1991-737371 19910729 (7)  
RLI Continuation-in-part of Ser. No. US 1990-559173, filed on 27 Jul 1990,  
now patented, Pat. No. US 5137873  
DT Utility  
FS Granted  
LN.CNT 1037  
INCL INCLM: 435/007.210  
INCLS: 435/007.900; 435/007.950; 435/040.500; 435/960.000; 436/519.000;  
436/811.000  
NCL NCLM: 435/007.210  
NCLS: 435/007.900; 435/007.950; 435/040.500; 435/960.000; 436/519.000;  
436/811.000  
IC [6]  
ICM: G01N033-53  
EXF 435/7.21; 435/7.9; 435/7.95; 435/29; 435/240.2; 435/960; 435/40.5;  
436/518; 436/519; 436/811  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 424 OF 469 USPATFULL on STN  
AN 1999:18912 USPATFULL  
TI Method of determining DNA sequence preference of a DNA-binding molecule  
IN Edwards, Cynthia A., Menlo Park, CA, United States  
Cantor, Charles R., Boston, MA, United States  
Andrews, Beth M., Maynard, MA, United States  
Turin, Lisa M., Redwood City, CA, United States  
Fry, Kirk E., Palo Alto, CA, United States  
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.  
corporation)  
PI US 5869241 19990209  
AI US 1995-475228 19950607 (8)  
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented,  
Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US  
1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014  
which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23  
Dec 1992, now patented, Pat. No. US 5693463 which is a  
continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 9840



NCL INCLS: 435/911.000; 435/912.000; 935/077.000; 935/078.000  
NCLM: 435/006.000  
NCLS: 435/091.100; 435/091.200  
IC [6]  
ICM: C12Q001-68  
ICS: C12P019-34  
EXF 435/6; 435/91.1; 435/91.2; 935/77; 935/78  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 425 OF 469 USPATFULL on STN  
AN 1998:159959 USPATFULL  
TI Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity  
IN Fisher, Abraham, Holon, Israel  
Karton, Yishai, Ness-Ziona, Israel  
Marciano, Daniele, Ramat-Hasharon, Israel  
Barak, Dov, Rehovot, Israel  
Meshulam, Haim, Bat Yam, Israel  
PA Israel Institute for Biological Research, Nessziona, Israel (non-U.S. corporation)  
PI US 5852029 19981222  
AI US 1996-627222 19960118 (8)  
RLI Continuation-in-part of Ser. No. US 1993-94855, filed on 20 Jul 1993, now patented, Pat. No. US 5534520 which is a continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4189  
INCL INCLM: 514/278.000  
INCLS: 546/016.000; 546/019.000; 546/020.000  
NCL NCLM: 514/278.000  
NCLS: 546/016.000; 546/019.000; 546/020.000  
IC [6]  
ICM: C07D491-10  
ICS: C07D491-20; A61K031-445; A61K031-46  
EXF 546/19; 546/16; 546/20; 514/278  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 426 OF 469 USPATFULL on STN  
AN 1998:157599 USPATFULL  
TI Transgenic rodents harboring APP allele having swedish mutation  
IN McLonogue, Lisa C., San Francisco, CA, United States  
Zhao, Jun, San Diego, CA, United States  
PA Athena Neurosciences, South San Francisco, CA, United States (U.S. corporation)  
PI US 5850003 19981215  
AI US 1997-785943 19970122 (8)  
RLI Continuation of Ser. No. US 1993-148211, filed on 1 Nov 1993, now patented, Pat. No. US 5612486 which is a continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993, now patented, Pat. No. US 5604102  
DT Utility  
FS Granted  
LN.CNT 1766  
INCL INCLM: 800/002.000  
INCLS: 800/DIG.001; 935/062.000  
NCL NCLM: 800/009.000  
NCLS: 800/012.000; 800/014.000; 800/018.000  
IC [6]  
ICM: C12N005-00  
ICS: C12N015-00  
EXF 800/2; 800/DIG.1; 935/62  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 427 OF 469 USPATFULL on STN  
AN 1998:147551 USPATFULL  
TI Process for enhancing the activity of \*\*\*amyloid\*\*\* . \*\*\*beta\*\*\* . peptides  
IN Hensley, Kenneth, Lexington, KY, United States  
Butterfield, D. Allan, Lexington, KY, United States  
Carney, John M., Lexington, KY, United States  
Aksenov, Michael, Lexington, KY, United States  
PA University of Kentucky Research Foundation, Lexington, KY, United States

PI US 5840838 19981124  
AI US 1996-609090 19960229 (8)  
DT Utility  
FS Granted  
LN.CNT 560  
INCL INCLM: 530/324.000  
INCLS: 530/326.000; 530/327.000; 530/328.000; 530/344.000  
NCL NCLM: 530/324.000  
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/344.000  
IC [6]  
ICM: C07K007-00  
ICS: C07K014-00  
EXF 530/324; 530/326; 530/327; 530/328; 530/344  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 428 OF 469 USPATFULL on STN  
AN 1998:144072 USPATFULL  
TI Methods and compositions for the detection of soluble . \*\*\*beta\*\*\* .-  
\*\*\*amyloid\*\*\* peptide  
IN Schenk, Dale B., Pacifica, CA, United States  
Schlossmacher, Michael G., Vienna, Austria  
Selkoe, Dennis J., Jamaica Plain, MA, United States  
Seubert, Peter A., South San Francisco, CA, United States  
Vigo-Pelfrey, Carmen, Mountain View, CA, United States  
PA Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S. corporation)  
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)  
PI US 5837672 19981117  
AI US 1995-456347 19950601 (8)  
RLI Division of Ser. No. US 1995-437067, filed on 9 May 1995, now patented, Pat. No. US 5593846 And a continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1445  
INCL INCLM: 514/002.000  
INCLS: 514/002.000; 514/042.000; 514/076.900; 514/222.200; 424/520.000; 435/007.900; 435/007.200; 436/518.000; 436/811.000  
NCL NCLM: 514/002.000  
NCLS: 424/520.000; 435/007.200; 435/007.900; 436/518.000; 436/811.000; 514/042.000; 514/169.000; 514/222.200  
IC [6]  
ICM: A61K031-00  
ICS: A61K038-00  
EXF 435/7.9; 435/4; 435/7.8; 435/6; 435/7.1; 435/7.2; 435/7.4; 436/518; 436/547; 436/548; 436/63; 436/811; 424/9.1; 424/184.1; 424/277.1; 424/520; 514/2; 514/42; 514/169; 514/222.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 429 OF 469 USPATFULL on STN  
AN 1998:143904 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert Charles, Ijamsville, MD, United States  
Guterman, Sonia Kosow, Belmont, MA, United States  
Roberts, Bruce Lindsay, Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur Charles, Newton, MA, United States  
Kent, Rachel Baribault, Boxborough, MA, United States  
PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)  
PI US 5837500 19981117  
AI US 1995-415922 19950403 (8)  
RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now patented, Pat. No. US 5403484 which is a division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 15973  
INCL INCLM: 435/069.700  
INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400

NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;  
536/023.400

IC [6]  
ICM: C12N015-62  
ICS: C07K019-00  
EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 430 OF 469 USPATFULL on STN  
AN 1998:115560 USPATFULL  
TI Methods and compositions for binding tau and MAP2c proteins  
IN Strittmatter, Warren J., Durham, NC, United States  
Roses, Allen D., Durham, NC, United States  
Goedert, Michel, Cambridge, England  
Weisgraber, Karl H., Walnut Creek, CA, United States  
Saunders, Ann M., Durham, NC, United States  
Schmechel, Donald E., Durham, NC, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
PI US 5811243 19980922  
AI US 7402325 19961025 (8)  
RLI Division of Ser. No. 287218, filed on 8 Aug 1994 which is a  
continuation-in-part of Ser. No. 114910, filed on 31 Aug 1993, now  
abandoned

DT Utility  
FS Granted  
LN.CNT 1122  
INCL INCLM: 435/007.100  
INCLS: 530/350.000  
NCL NCLM: 435/007.100  
NCLS: 530/350.000

IC [6]  
ICM: C12Q001-00  
ICS: G01N033-53; C07K014-00  
EXF 530/350; 435/7.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 431 OF 469 USPATFULL on STN  
AN 1998:88671 USPATFULL  
TI Monoclonal \*\*\*antibody\*\*\* 369.2B specific for .beta. A4 peptide  
IN Konig, Gerhard, Branford, CT, United States  
Graham, Paul, New Haven, CT, United States  
PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)  
PI US 5786180 19980728  
AI US 1995-388463 19950214 (8)  
DT Utility  
FS Granted  
LN.CNT 926  
INCL INCLM: 435/070.210  
INCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900;  
530/388.100; 530/389.100  
NCL NCLM: 435/070.210  
NCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900;  
530/388.100; 530/389.100

IC [6]  
ICM: A61K039-395  
EXF 435/70.21; 435/240.27; 435/70.2; 435/326; 435/331; 530/388.1; 530/388.2;  
530/327; 530/387.9; 530/389.1; 436/548; 436/547; 424/184.1; 424/185.1;  
424/193.1; 424/194.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 432 OF 469 USPATFULL on STN  
AN 1998:69161 USPATFULL  
TI Apolipoprotein E isoform-specific monoclonal \*\*\*antibodies\*\*\*  
IN Roses, Allen D., Durham, NC, United States  
Strittmatter, Warren J., Durham, NC, United States  
Salvesen, Guy S., Chapel Hill, NC, United States  
Engchild, Jan, Durham, NC, United States  
Schmechel, Donald E., Durham, NC, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
PI US 5767248 19980616  
AI US 1997-835503 19970408 (8)  
RLI Continuation of Ser. No. US 1995-440900, filed on 15 May 1995, now  
abandoned which is a division of Ser. No. US 1994-227044, filed on 13  
Apr 1994, now patented, Pat. No. US 5508167 which is a  
continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993,

1992-959992, filed on 13 Oct 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1603  
INCL INCLM: 530/388.250  
INCLS: 530/387.900; 530/388.100; 530/391.100; 530/391.300  
NCL NCLM: 530/388.250  
NCLS: 530/387.900; 530/388.100; 530/391.100; 530/391.300  
IC [6]  
ICM: C07K016-00  
EXF 530/387.9; 530/388.1; 530/388.25; 530/391.1; 530/391.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 433 OF 469 USPATFULL on STN  
AN 1998:68773 USPATFULL  
TI Methods of screening for compounds which inhibit soluble . \*\*\*beta\*\*\*  
.- \*\*\*amyloid\*\*\* peptide production  
IN Schlossmacher, Michael G., Vienna, Austria  
Selkoe, Dennis J., Jamaica Plain, MA, United States  
PA Athena Neurosciences, South San Francisco, CA, United States (U.S.  
corporation)  
Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5766846 19980616  
AI US 1993-79511 19930617 (8)  
RLI Division of Ser. No. US 1992-965972, filed on 26 Oct 1992, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-911647, filed on 10  
Jul 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1465  
INCL INCLM: 435/006.000  
INCLS: 435/007.100; 435/007.200; 435/007.210; 435/041.000; 435/069.100;  
435/007.920; 435/007.940  
NCL NCLM: 435/006.000  
NCLS: 435/007.100; 435/007.200; 435/007.210; 435/007.920; 435/007.940;  
435/041.000; 435/069.100  
IC [6]  
ICM: G01N033-53  
EXF 435/6; 435/7.1; 435/7.2; 435/7.21; 435/29; 435/41; 435/69.1; 435/70.1;  
435/70.3; 435/7.92; 435/7.94  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 434 OF 469 USPATFULL on STN  
AN 1998:45106 USPATFULL  
TI Methods for the detection of soluble \*\*\*amyloid\*\*\* . \*\*\*beta\*\*\*  
.-protein (.beta.AP) or soluble transthyretin (TTR)  
IN Goldgaber, Dmitry Y., Setauket, NY, United States  
Schwarzman, Alexander L., St. James, NY, United States  
PA Eisenberg-Grunberg, Moises, Port Jefferson Station, NY, United States  
Research Foundation of State University of New York, Albany, NY, United  
States (U.S. corporation)  
PI US 5744368 19980428  
AI US 1993-148117 19931104 (8)  
DT Utility  
FS Granted  
LN.CNT 1187  
INCL INCLM: 436/501.000  
INCLS: 435/007.800; 436/503.000; 436/504.000; 436/518.000; 436/804.000  
NCL NCLM: 436/501.000  
NCLS: 435/007.800; 436/503.000; 436/504.000; 436/518.000; 436/804.000  
IC [6]  
ICM: G01N033-566  
ICS: G01N033-53  
EXF 436/501; 436/504; 436/503; 436/518; 436/528; 436/531; 436/804; 435/7.93;  
435/7.8; 435/7.9  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 435 OF 469 USPATFULL on STN  
AN 1998:45071 USPATFULL  
TI DNA encoding fused di-beta globins and production of pseudotetrameric  
hemoglobin  
IN Hoffman, Stephen J., Denver, CO, United States  
Looker, Douglas L., Lafayette, CO, United States  
Rosendahl, Mary S., Broomfield, CO, United States

wagenbach, Michael, Osaka, Japan  
 Anderson, David C., Lafayette, CO, United States  
 Mathews, Antony James, Louisville, CO, United States  
 Nagai, Kiyoshi, Cambridge, England  
 PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)  
 PI US 5744329 19980428  
 AI US 1995-444942 19950519 (8)  
 RLI Division of Ser. No. US 1991-789179, filed on 8 Nov 1991, now patented,  
 Pat. No. US 5545727 which is a continuation-in-part of Ser. No. US  
 1991-671707, filed on 1 Apr 1991, now abandoned which is a  
 continuation-in-part of Ser. No. US 1989-374161, filed on 30 Jun 1989,  
 now abandoned Ser. No. Ser. No. US 1989-379116, filed on 13 Jul 1989,  
 now abandoned And Ser. No. US 1989-349623, filed on 10 May 1989, now  
 abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 6645  
 INCL INCLM: 435/696.000  
 INCLS: 435/069.700; 435/069.100; 530/385.000; 536/023.400  
 NCL NCLM: 435/069.600  
 NCLS: 435/069.100; 435/069.700; 530/385.000; 536/023.400  
 IC [6]  
 ICM: C12P021-06  
 ICS: C07H017-00; C07K014-805  
 EXF 530/385; 536/23.1; 536/23.4; 435/69.1; 435/69.6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 436 OF 469 USPATFULL on STN  
 AN 1998:45052 USPATFULL  
 TI Bax promoter sequence and screening assays for indentifying agents that  
 regulate bax gene expression  
 IN Reed, John C., Rancho Santa Fe, CA, United States  
 PA The Burnham Institute, La Jolla, CA, United States (U.S. corporation)  
 PI US 5744310 19980428  
 AI US 1996-688145 19960729 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1938  
 INCL INCLM: 435/006.000  
 INCLS: 435/691.000; 435/091.400; 435/325.000; 536/024.100  
 NCL NCLM: 435/006.000  
 NCLS: 435/069.100; 435/091.400; 435/325.000; 536/024.100  
 IC [6]  
 ICM: C12Q001-68  
 ICS: C12P021-00; C12N005-10; C07H021-04  
 EXF 435/6; 435/69.1; 435/91.1; 435/240.2; 435/91.4; 435/325; 536/24.1;  
 536/23.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 437 OF 469 USPATFULL on STN  
 AN 1998:44877 USPATFULL  
 TI Sequence-directed DNA-binding molecules compositions and methods  
 IN Edwards, Cynthia A., Menlo Park, CA, United States  
 Fry, Kirk E., Palo Alto, CA, United States  
 Cantor, Charles R., Boston, MA, United States  
 Andrews, Beth M., Maynard, MA, United States  
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.  
 corporation)  
 PI US 5744131 19980428  
 AI US 1995-476876 19950607 (8)  
 RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a  
 continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5113  
 INCL INCLM: 424/078.080  
 INCLS: 436/501.000; 514/001.000  
 NCL NCLM: 424/078.080  
 NCLS: 436/501.000; 514/001.000  
 IC [6]  
 ICM: A61K031-74  
 ICS: G01N033-566; G01N033-558  
 EXF 536/23.1; 536/27.1; 546/109; 436/501; 514/1; 424/78.08  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 438 OF 469 USPATFULL on STN  
 AN 1998:39383 USPATFULL  
 TI Sequence-directed DNA-binding molecules compositions and methods  
 IN Edwards, Cynthia A., Menlo Park, CA, United States  
 Fry, Kirk E., Palo Alto, CA, United States  
 Cantor, Charles R., Boston, MA, United States  
 Andrews, Beth M., Maynard, MA, United States  
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)  
 PI US 5738990 19980414  
 AI US 1995-475221 19950607 (8)  
 RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5040  
 INCL INCLM: 435/006.000  
 INCLS: 435/691.000; 435/172.300; 435/320.100; 536/024.100; 935/036.000; 935/039.000  
 NCL NCLM: 435/006.000  
 NCLS: 435/069.100; 435/320.100; 536/024.100  
 IC [6]  
 ICM: C12P021-02  
 ICS: C12N015-67; C07H021-04  
 EXF 435/172.1; 435/69.1; 435/6; 435/320.1; 435/172.3; 536/24.1; 935/36; 935/39  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 439 OF 469 USPATFULL on STN  
 AN 1998:25075 USPATFULL  
 TI Screening assay for the detection of DNA-binding molecules  
 IN Edwards, Cynthia A., Menlo Park, CA, United States  
 Cantor, Charles R., Boston, MA, United States  
 Andrews, Beth M., Watertown, MA, United States  
 Turin, Lisa M., Berkeley, CA, United States  
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)  
 PI US 5726014 19980310  
 AI US 1993-123936 19930917 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5659  
 INCL INCLM: 435/006.000  
 INCLS: 435/091.200; 436/501.000  
 NCL NCLM: 435/006.000  
 NCLS: 435/091.200; 436/501.000  
 IC [6]  
 ICM: C12Q001-68  
 ICS: C12P019-34; G01N033-566  
 EXF 435/6; 435/235; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.2; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 440 OF 469 USPATFULL on STN  
 AN 1998:19582 USPATFULL  
 TI In Vitro method for screening . \*\*\*beta\*\*\* .- \*\*\*amyloid\*\*\* deposition  
 IN Maggio, John E., Brookline, MA, United States  
 Mantyh, Patrick W., Edina, MN, United States  
 PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)  
 President and Fellows of Harvard College, Boston, MA, United States (U.S. corporation)  
 PI US 5721106 19980224  
 AI US 1994-304585 19940912 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-744767, filed on 13 Aug 1991, now patented, Pat. No. US 5434050  
 DT Utility  
 FS Granted  
 LN.CNT 1977  
 INCL INCLM: 435/007.800

NCL NCLM: 435/007.800  
 NCLS: 435/007.100; 435/007.900; 436/501.000; 436/504.000  
 IC [6]  
 ICM: G01N033-53  
 EXF 435/4; 435/7.1; 435/7.21; 435/7.8; 435/7.9; 436/501; 436/86; 436/504  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 441 OF 469 USPATFULL on STN  
 AN 1998:14680 USPATFULL  
 TI Kit for detecting the ApoE4 allele, and for diagnosing the existence or  
 risk of developing Alzheimer's disease  
 IN Roses, Allen D., Durham, NC, United States  
 Strittmatter, Warren J., Durham, NC, United States  
 Salvesen, Guy S., Chapel Hill, NC, United States  
 Enghild, Jan, Durham, NC, United States  
 Schmechel, Donald E., Durham, NC, United States  
 PA Duke University, Durham, NC, United States (U.S. corporation)  
 PI US 5716828 19980210  
 AI US 1995-441001 19950515 (8)  
 RLI Division of Ser. No. US 1994-227044, filed on 13 Apr 1994, now patented,  
 Pat. No. US 5508167 which is a continuation-in-part of Ser. No. US  
 1993-114448, filed on 31 Aug 1993, now abandoned which is a  
 continuation-in-part of Ser. No. US 1992-959992, filed on 13 Oct 1992,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1604  
 INCL INCLM: 435/006.000  
 INCLS: 435/007.100; 435/810.000  
 NCL NCLM: 435/006.000  
 NCLS: 435/007.100; 435/810.000  
 IC [6]  
 ICM: C12Q001-68  
 ICS: G01N033-53  
 EXF 435/6; 435/7.1; 435/810; 204/182.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 442 OF 469 USPATFULL on STN  
 AN 1998:14634 USPATFULL  
 TI Method of constructing sequence-specific DNA-binding molecules  
 IN Edwards, Cynthia A., Menlo Park, CA, United States  
 Fry, Kirk E., Palo Alto, CA, United States  
 Cantor, Charles R., Boston, MA, United States  
 Andrews, Beth M., Watertown, MA, United States  
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.  
 corporation)  
 PI US 5716780 19980210  
 AI US 1995-484499 19950607 (8)  
 RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a  
 continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 4929  
 INCL INCLM: 435/006.000  
 INCLS: 436/501.000  
 NCL NCLM: 435/006.000  
 NCLS: 436/501.000  
 IC [6]  
 ICM: C12Q001-68  
 ICS: G01N033-566  
 EXF 435/6; 536/24.5; 935/33; 935/34; 935/36; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 443 OF 469 USPATFULL on STN  
 AN 97:112579 USPATFULL  
 TI Method of isolating .beta.A4 peptide species ending at carboxy-terminals  
 residue 42 using monoclonal \*\*\*antibody\*\*\* 369.2B  
 IN Konig, Gerhard, Branford, CT, United States  
 Graham, Paul, New Haven, CT, United States  
 PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)  
 PI US 5693753 19971202  
 AI US 1995-472627 19950607 (8)  
 RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995  
 DT Utility

LN.CNT 924  
INCL INCLM: 530/344.000  
INCLS: 530/412.000; 530/413.000  
NCL NCLM: 530/344.000  
NCLS: 530/412.000; 530/413.000  
IC [6]  
ICM: C07K001-22  
EXF 530/387.9; 530/388.1; 530/389.1; 530/391.1; 530/391.3; 530/391.5;  
530/391.9; 530/344; 530/412; 530/413  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 444 OF 469 USPATFULL on STN  
AN 97:112300 USPATFULL  
TI Method of ordering sequence binding preferences of a DNA-binding molecule  
IN Edwards, Cynthia A., Menlo Park, CA, United States  
Fry, Kirk E., Palo Alto, CA, United States  
Cantor, Charles R., Boston, MA, United States  
Andrews, Beth M., Maynard, MA, United States4)  
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5693463 19971202  
AI US 1992-996783 19921223 (7)  
RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4908  
INCL INCLM: 435/006.000  
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000  
NCL NCLM: 435/006.000  
NCLS: 435/007.230; 536/023.100  
IC [6]  
ICM: C12Q001-68  
ICS: G01N033-574; C07H021-02; C12N015-00  
EXF 435/6; 435/235; 536/23.1; 536/23.2; 514/44; 530/350; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 445 OF 469 USPATFULL on STN  
AN 97:96730 USPATFULL  
TI Methods of detecting .beta.A4 peptide species ending at carboxy-terminus residue 42 using monoclonal \*\*\*antibody\*\*\* 369.2B  
IN Konig, Gerhard, Branford, CT, United States  
Graham, Paul, New Haven, CT, United States  
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)  
PI US 5679531 19971021  
AI US 1995-484969 19950607 (8)  
RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995  
DT Utility  
FS Granted  
LN.CNT 932  
INCL INCLM: 435/007.100  
INCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900; 530/388.100  
NCL NCLM: 435/007.100  
NCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900; 530/388.100  
IC [6]  
ICM: G01N033-53  
ICS: C07K016-18  
EXF 435/70.21; 435/240.27; 435/387.9; 435/7.1; 435/7.21; 435/7.9; 435/40.52; 435/40.5; 435/7.92; 435/7.95; 530/388.1; 530/358.2; 530/327; 436/548; 424/184.1; 424/185.1; 424/193.1; 424/194.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 446 OF 469 USPATFULL on STN  
AN 97:86591 USPATFULL  
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor  
IN Zhang, Shuguang, Cambridge, MA, United States  
Lockshin, Curtis, Lexington, MA, United States  
Rich, Alexander, Cambridge, MA, United States  
Holmes, Todd, Cambridge, MA, United States  
PA Massachusetts Insititute of Technology, Cambridge, MA, United States (U.S. corporation)



AI US 1994-346849 19941130 (8)  
 RLI Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2210  
 INCL INCLM: 514/014.000  
 INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000  
 NCL NCLM: 514/014.000  
 NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000  
 IC [6]  
 ICM: A61K007-08  
 ICS: A61K014-00; C07K038-10; C07K038-16  
 EXF 530/300; 530/350; 514/12; 514/13; 514/14  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 447 OF 469 USPATFULL on STN  
 AN 97:22926 USPATFULL  
 TI Transgenic animals harboring APP allele having swedish mutation  
 IN McConlogue, Lisa C., San Francisco, CA, United States  
 Zhao, Jun, San Diego, CA, United States  
 PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)  
 Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
 PI US 5612486 19970318  
 AI US 1993-148211 19931101 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993  
 DT Utility  
 FS Granted  
 LN.CNT 1759  
 INCL INCLM: 800/002.000  
 INCLS: 435/172.300; 536/023.500; 536/023.100  
 NCL NCLM: 800/012.000  
 NCLS: 536/023.100; 536/023.500; 800/018.000  
 IC [6]  
 ICM: C12N015-00  
 ICS: C07H021-04  
 EXF 800/2; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 448 OF 469 USPATFULL on STN  
 AN 97:15968 USPATFULL  
 TI Methods and compositions for monitoring cellular processing of  
 \*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* precursor protein  
 IN Seubert, Peter A., South San Francisco, CA, United States  
 Schenk, Dale B., Pacifica, CA, United States  
 Fritz, Lawrence C., San Francisco, CA, United States  
 PA Athena Neurosciences, Inc., South San Francisco, United States (U.S. corporation)  
 Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
 PI US 5605811 19970225  
 AI US 1995-440261 19950512 (8)  
 RLI Division of Ser. No. US 1992-965971, filed on 26 Oct 1992, now patented, Pat. No. US 5441870 which is a continuation-in-part of Ser. No. US 1995-868949, filed on 15 Apr 1995, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1012  
 INCL INCLM: 435/029.000  
 INCLS: 435/023.000; 435/069.200; 424/009.200  
 NCL NCLM: 435/029.000  
 NCLS: 424/009.200; 435/023.000; 435/069.200  
 IC [6]  
 ICM: C12Q001-02  
 EXF 435/7.4; 435/23; 435/24; 435/29; 435/41; 435/69.2; 435/184; 424/9.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 449 OF 469 USPATFULL on STN  
 AN 96:120572 USPATFULL  
 TI Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease

PA Rutgers, The State University of New Jersey, Piscataway, NJ, United States (U.S. corporation)  
PI US 5589154 19961231  
AI US 1994-347144 19941122 (8)  
DT Utility  
FS Granted  
LN.CNT 1362  
INCL INCLM: 424/001.410  
INCLS: 424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100; 424/145.100; 436/543.000; 436/547.000; 435/007.100; 530/380.000  
NCL NCLM: 424/001.410  
NCLS: 424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100; 424/145.100; 435/007.100; 436/543.000; 436/547.000; 530/380.000  
IC [6]  
ICM: A61K051-00  
ICS: A61K039-395; A61K035-14; G01N033-53  
EXF 424/1.49; 424/1.69; 424/1.41; 424/9.34; 424/9.6; 424/130.1; 424/145.1; 436/543; 436/547; 435/7.1; 530/380  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 450 OF 469 USPATFULL on STN  
AN 96:108816 USPATFULL  
TI Sequence-directed DNA-binding molecules compositions and methods  
IN Edwards, Cynthia A., Menlo Park, CA, United States  
Cantor, Charles R., Boston, MA, United States  
Andrews, Beth M., Maynard, MA, United States  
Turin, Lisa M., Redwood City, CA, United States  
Fry, Kirk E., Palo Alto, CA, United States  
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5578444 19961126  
AI US 1993-171389 19931220 (8)  
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 5845  
INCL INCLM: 435/006.000  
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000  
NCL NCLM: 435/006.000  
NCLS: 435/007.230; 536/023.100  
IC [6]  
ICM: C12Q001-68  
ICS: C12N015-00; G01N033-574; C07H021-02  
EXF 435/6; 536/23.1; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 451 OF 469 USPATFULL on STN  
AN 96:101466 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States  
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)  
PI US 5571698 19961105  
AI US 1993-57667 19930618 (8)  
RLI Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 15323  
INCL INCLM: 435/069.700  
INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100  
NCL NCLM: 435/069.700  
NCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000  
IC [6]

EXF 435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 452 OF 469 USPATFULL on STN  
AN 96:92082 USPATFULL  
TI Phospholipase A.sub.2 inhibitors  
IN Clemens, James A., Indianapolis, IN, United States  
Sofia, Michael J., Lawrenceville, NJ, United States  
Stephenson, Diane T., Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5563164 19961008  
AI US 1995-464030 19950605 (8)  
RLI Division of Ser. No. US 1993-173544, filed on 23 Dec 1993, now patented,  
Pat. No. US 5478857  
DT Utility  
FS Granted  
LN.CNT 1858  
INCL INCLM: 514/381.000  
INCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000;  
514/568.000; 514/570.000; 514/571.000; 514/622.000  
NCL NCLM: 514/381.000  
NCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000;  
514/568.000; 514/570.000; 514/571.000; 514/622.000  
IC [6]  
ICM: A61K031-41  
ICS: A61K031-35; A61K031-335; A61K031-19; A61K031-165  
EXF 514/381; 514/454; 514/455; 514/456; 514/457; 514/458; 514/568; 514/570;  
514/571; 514/622  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 453 OF 469 USPATFULL on STN  
AN 96:80293 USPATFULL  
TI Methods for treating a physiological disorder associated with .  
\*\*\*beta\*\*\* - \*\*\*amyloid\*\*\* peptide  
IN Lunn, William H. W., Indianapolis, IN, United States  
Monn, James A., Indianapolis, IN, United States  
Zimmerman, Dennis M., Mooresville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5552426 19960903  
AI US 1994-235400 19940429 (8)  
DT Utility  
FS Granted  
LN.CNT 3104  
INCL INCLM: 514/394.000  
INCLS: 514/395.000; 548/304.400; 548/306.400; 548/306.700; 548/309.700;  
548/310.100; 548/310.400; 548/310.700  
NCL NCLM: 514/394.000  
NCLS: 514/395.000; 548/304.400; 548/306.400; 548/306.700; 548/309.700;  
548/310.100; 548/310.400; 548/310.700  
IC [6]  
ICM: A61K031-415  
ICS: C07D235-18; C07D235-08  
EXF 514/394; 514/395; 548/304.4; 548/304.7; 548/305.1; 548/305.4; 548/306.4;  
548/306.7; 548/309.7; 548/310.1; 548/310.4; 548/310.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 454 OF 469 USPATFULL on STN  
AN 96:31717 USPATFULL  
TI Methods of screening for Alzheimer's disease  
IN Roses, Allen D., Durham, NC, United States  
Strittmatter, Warren J., Durham, NC, United States  
Salvesen, Guy S., Chapel Hill, NC, United States  
Enghild, Jan, Durham, NC, United States  
Schmechel, Donald E., Durham, NC, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
PI US 5508167 19960416  
AI US 1994-227044 19940413 (8)  
RLI Continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-959992, filed on 13 Oct 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1653

NCL INCL: 435/004.000; 435/091.200; 435/091.520  
NCLM: 435/006.000  
NCLS: 435/004.000; 435/091.200; 435/091.520  
IC [6]  
ICM: C12Q001-68  
ICS: C12Q001-00; C12P019-34  
EXF 435/4; 435/6; 435/91.2; 435/91.52; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 455 OF 469 USPATFULL on STN  
AN 96:29429 USPATFULL  
TI Method for inhibiting .beta.-protein enzymatic activity  
IN Potter, Huntington, Boston, MA, United States  
Kayyali, Usamah, Watertown, MA, United States  
PA President and Fellows of Harvard College, Cambridge, MA, United States  
(U.S. corporation)  
PI US 5506097 19960409  
AI US 1994-179574 19940110 (8)  
RLI Continuation-in-part of Ser. No. US 1992-819361, filed on 13 Jan 1992,  
now patented, Pat. No. US 5338663 which is a continuation-in-part of  
Ser. No. US 1990-572671, filed on 24 Aug 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1041  
INCL INCLM: 435/004.000  
INCLS: 435/019.000; 435/020.000; 435/184.000  
NCL NCLM: 435/004.000  
NCLS: 435/019.000; 435/020.000; 435/184.000  
IC [6]  
ICM: C12Q001-00  
ICS: C12Q001-46  
EXF 435/4; 435/7.4; 435/19; 435/23; 435/183; 435/184; 435/210; 435/20  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 456 OF 469 USPATFULL on STN  
AN 96:5937 USPATFULL  
TI Substituted 3-indolyl-5-pyrazolone compounds  
IN Grant, Francine S., 800 Gateway Blvd., South San Francisco, CA, United  
States 94080  
Fang, Lawrence Y., 800 Gateway Blvd., South San Francisco, CA, United  
States 94080  
John, Varghese, 800 Gateway Blvd., South San Francisco, CA, United  
States 94080  
Thorsett, Eugene D., 800 Gateway Blvd., South San Francisco, CA, United  
States 94080  
PI US 5484940 19960116  
AI US 1994-345973 19941128 (8)  
DT Utility  
FS Granted  
LN.CNT 2464  
INCL INCLM: 548/364.700  
INCLS: 544/238.000; 544/284.000  
NCL NCLM: 548/364.700  
NCLS: 544/238.000; 544/284.000  
IC [6]  
ICM: C07D403-08  
ICS: C07D403-14  
EXF 548/364.7; 544/238; 544/284  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 457 OF 469 USPATFULL on STN  
AN 96:1451 USPATFULL  
TI Method of providing external nutritional support to persons infected  
with human immunodeficiency virus  
IN Cope, Frederick O., Worthington, OH, United States  
DeWille, Normanella T., Upper Arlington, OH, United States  
Richards, Ernest W., Columbus, OH, United States  
Mazer, Terrence B., Reynoldsburg, OH, United States  
Abruzzese, Bonnie C., Dublin, OH, United States  
Snowden, Gregory A., Pickerington, OH, United States  
Chandler, Michael A., Gahanna, OH, United States  
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)  
PI US 5480872 19960102  
AI US 1993-69066 19930528 (8)  
DT Utility

LN.CNT 1369  
INCL INCLM: 514/021.000  
INCLS: 426/648.000; 426/654.000; 426/656.000; 426/641.000; 426/657.000  
NCL NCLM: 514/021.000  
NCLS: 426/641.000; 426/648.000; 426/654.000; 426/656.000; 426/657.000  
IC [6]  
ICM: A23J003-16  
ICS: A23L001-052; A61K038-17; A61K047-42  
EXF 514/21; 514/23; 426/800; 426/656; 426/648; 426/654; 426/667; 426/641;  
426/657  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 458 OF 469 USPATFULL on STN  
AN 95:114771 USPATFULL  
TI Use of PLA.sub.2 inhibitors as treatment for alzheimer's disease  
IN Clemens, James A., Indianapolis, IN, United States  
Sofia, Michael J., Lawrenceville, NJ, United States  
Stephenson, Diane T., Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5478857 19951226  
AI US 1993-173544 19931223 (8)  
DT Utility  
FS Granted  
LN.CNT 1801  
INCL INCLM: 514/381.000  
INCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000;  
514/568.000; 514/570.000; 514/571.000; 514/622.000  
NCL NCLM: 514/381.000  
NCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000;  
514/568.000; 514/570.000; 514/571.000; 514/622.000  
IC [6]  
ICM: A61K031-41  
ICS: A61K031-35; A61K031-335; A61K031-19; A61K031-165  
EXF 514/381; 514/454; 514/455; 514/456; 514/457; 514/458; 514/568; 514/570;  
514/571; 514/622  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 459 OF 469 USPATFULL on STN  
AN 95:82203 USPATFULL  
TI Chromosome 14 and familial Alzheimers disease genetic markers and assays  
IN Schellenberg, Gerard D., Seattle, WA, United States  
Bird, Thomas D., Seattle, WA, United States  
Wijisman, Ellen M., Seattle, WA, United States  
PA University of Washington, Seattle, WA, United States (U.S. corporation)  
PI US 5449604 19950912  
AI US 1992-964151 19921021 (7)  
DT Utility  
FS Granted  
LN.CNT 3278  
INCL INCLM: 435/006.000  
INCLS: 435/091.200  
NCL NCLM: 435/006.000  
NCLS: 128/925.000; 435/091.200  
IC [6]  
ICM: C12Q001-68  
ICS: C12P019-34  
EXF 435/6; 435/91.2; 536/24.31; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 460 OF 469 USPATFULL on STN  
AN 95:29628 USPATFULL  
TI Nutritional product for persons infected with human immunodeficiency  
virus  
IN Cope, Frederick O., Worthington, OH, United States  
DeWille, Normanella T., Upper Arlington, OH, United States  
Richards, Ernest W., Columbus, OH, United States  
Mazer, Terrence B., Reynoldsburg, OH, United States  
Abbruzzese, Bonnie C., Dublin, OH, United States  
Snowden, Gregory A., Pickerington, OH, United States  
Chandler, Michael A., Gahanna, OH, United States  
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)  
PI US 5403826 19950404  
AI US 1993-69269 19930528 (8)  
DT Utility

LN.CNT 1375  
INCL INCLM: 514/021.000  
INCLS: 514/002.000; 514/023.000; 426/656.000; 426/800.000  
NCL NCLM: 514/021.000  
NCLS: 426/656.000; 426/800.000; 514/002.000; 514/023.000  
IC [6]  
ICM: A16K037-02  
ICS: A16K031-70; A16K035-60  
EXF 514/21; 514/23; 514/2; 426/800; 426/656; 426/648; 426/654; 426/607  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 461 OF 469 USPATFULL on STN  
AN 95:29292 USPATFULL  
TI Viruses expressing chimeric binding proteins  
IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States  
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)  
PI US 5403484 19950404  
AI US 1993-9319 19930126 (8)  
RLI Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned  
PRAI WO 1989-3731 19890901  
DT Utility  
FS Granted  
LN.CNT 14368  
INCL INCLM: 435/235.100  
INCLS: 435/069.700; 435/172.300; 435/252.300; 435/320.100; 530/350.000; 536/023.400  
NCL NCLM: 435/235.100  
NCLS: 435/069.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400  
IC [6]  
ICM: C07K013-00  
ICS: C12N007-01  
EXF 435/69.7; 435/172.3; 435/235.1; 435/320.1; 536/23.4; 530/380  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 462 OF 469 USPATFULL on STN  
AN 95:11757 USPATFULL  
TI Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease  
IN Cordell, Barbara, Palo Alto, CA, United States  
PA Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)  
PI US 5387742 19950207  
AI US 1991-716725 19910617 (7)  
RLI Continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2014  
INCL INCLM: 800/002.000  
INCLS: 424/009.000; 435/142.300; 536/023.500  
NCL NCLM: 800/012.000  
NCLS: 536/023.500; 800/018.000  
IC [6]  
ICM: A61K049-00  
ICS: C12N015-00; C07H015-12  
EXF 800/2; 435/6; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 463 OF 469 USPATFULL on STN  
AN 94:70947 USPATFULL  
TI Method of identifying inhibitors of .beta.-protein esterase activity  
IN Potter, Huntington, Boston, MA, United States  
Kayyali, Usamah, Somerville, MA, United States  
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)  
PI US 5338663 19940816

RLI Continuation-in-part of Ser. No. US1990-572671, filed on 24 Aug 1990,  
now abandoned

DT Utility

FS Granted

LN.CNT 875

INCL INCLM: 435/004.000  
INCLS: 435/007.400; 435/019.000; 435/023.000; 435/219.000

NCL NCLM: 435/004.000  
NCLS: 435/007.400; 435/019.000; 435/023.000; 435/219.000

IC [5]  
ICM: C12Q001-00  
ICS: C12Q001-44; C12Q001-37; C12N009-50

EXF 435/4; 435/7.4; 435/19; 435/23; 435/219; 436/86

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 464 OF 469 USPATFULL on STN

AN 94:62434 USPATFULL

TI Method of impeding apoptosis of CD4 cells in persons infected with human  
immunodeficiency virus

IN Cope, Frederick O., Worthington, OH, United States

PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 5330972 19940719

AI US 1993-69264 19930528 (8)

DT Utility

FS Granted

LN.CNT 1305

INCL INCLM: 514/002.000  
INCLS: 514/021.000; 530/378.000; 426/044.000; 426/046.000; 426/656.000;  
426/800.000; 426/658.000; 426/419.000

NCL NCLM: 514/002.000  
NCLS: 426/044.000; 426/046.000; 426/419.000; 426/656.000; 426/658.000;  
426/800.000; 514/021.000; 530/378.000

IC [5]  
ICM: A61K037-02

EXF 514/2; 514/21; 426/656; 426/46; 426/44; 426/800; 426/658; 426/419;  
530/378

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 465 OF 469 USPATFULL on STN

AN 93:61009 USPATFULL

TI \*\*\*Antibodies\*\*\* to A4 amyloid peptide

IN Majocha, Ron, Wayland, MA, United States  
Marotta, Charles A., Cambridge, MA, United States  
Zain, Sayeeda, Pittsford, NY, United States

PA The McLean Hospital, Belmont, MA, United States (U.S. corporation)  
University of Rochester, Rochester, NY, United States (U.S. corporation)

PI US 5231000 19930727

AI US 1991-733375 19910722 (7)

RLI Continuation of Ser. No. US 1987-105751, filed on 8 Oct 1987

DT Utility

FS Granted

LN.CNT 687

INCL INCLM: 435/007.100  
INCLS: 435/007.200; 435/007.210; 435/240.270; 530/388.100; 436/501.000;  
436/506.000

NCL NCLM: 435/007.100  
NCLS: 435/007.200; 435/007.210; 435/331.000; 436/501.000; 436/506.000;  
530/388.100

IC [5]  
ICM: G01N033-53  
ICS: G01N033-564; G01N033-577; C12N005-20

EXF 530/387; 435/240.27; 435/7.1; 435/960; 435/7.2; 435/388.2; 436/518;  
436/529-530; 436/548; 436/512; 436/501; 436/507; 424/85.8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 466 OF 469 USPATFULL on STN

AN 93:52487 USPATFULL

TI Directed evolution of novel binding proteins

IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States

PA Protein Engineering Corp., Cambridge, MA, United States (U.S.

PI US 5223409 19930629  
 AI US 1991-664989 19910301 (7)  
 RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
 now abandoned And a continuation-in-part of Ser. No. US 1988-240160,  
 filed on 2 Sep 1988, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 15410  
 INCL INCLM: 435/069.700  
 INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300;  
 530/387.500  
 NCL NCLM: 435/069.700  
 NCLS: 435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000;  
 530/387.300; 530/387.500  
 IC [5]  
 ICM: C12N015-09  
 ICS: C12N015-62; C12N015-63  
 EXF 435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 467 OF 469 USPATFULL on STN  
 AN 92:65951 USPATFULL  
 TI Substance P and tachykinin agonists for treatment of Alzheimer's disease  
 IN Yankner, Bruce A., Boston, MA, United States  
 PA The Children's Medical Center Corporation, Boston, MA, United States  
 (U.S. corporation)  
 PI US 5137873 19920811  
 AI US 1990-559173 19900727 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 376  
 INCL INCLM: 514/015.000  
 INCLS: 514/002.000; 530/327.000; 530/839.000  
 NCL NCLM: 514/015.000  
 NCLS: 514/002.000; 530/327.000; 530/839.000  
 IC [5]  
 ICM: A61K037-42  
 ICS: A61K037-02; C07K007-06; C07K007-22  
 EXF 514/14; 514/15; 514/18; 530/327; 530/328; 530/331; 530/839; 436/811  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L4 ANSWER 468 OF 469 USPAT2 on STN  
 AN 2002:141109 USPAT2  
 TI Death domain containing receptor 5  
 IN Ni, Jian, Rockville, MD, United States  
 Gentz, Reiner L., Rockville, MD, United States  
 Yu, Guo-Liang, Berkeley, CA, United States  
 Rosen, Craig A., Laytonsville, MD, United States  
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
 corporation)  
 PI US 6743625 B2 20040601  
 AI US 2001-874138 20010606 (9)  
 RLI Continuation of Ser. No. US 2000-565009, filed on 4 May 2000  
 Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998  
 PRAI US 1999-148939P 19990813 (60)  
 US 1999-133238P 19990507 (60)  
 US 1999-132498P 19990504 (60)  
 US 1998-42583P 19980317 (60)  
 US 1997-54021P 19970729 (60)  
 US 1997-40846P 19970317 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 8567  
 INCL INCLM: 435/325.000  
 INCLS: 530/350.000; 536/023.100; 536/023.400; 536/023.500; 435/069.100;  
 435/252.300; 435/254.110  
 NCL NCLM: 435/325.000  
 NCLS: 435/069.100; 435/252.300; 435/254.110; 530/350.000; 536/023.100;  
 536/023.400; 536/023.500  
 IC [7]  
 ICM: C07K014-705  
 ICS: C12N005-10; C12N015-12  
 EXF 530/350; 536/23.1; 536/23.5; 536/23.4; 435/320.1; 435/69.1; 435/325;  
 435/252.3; 435/254.11  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L4 ANSWER 469 OF 469 USPAT2 on STN  
AN 2002:37941 USPAT2  
TI Methods for treating multiple sclerosis  
IN Shankar, L. Sai Latha, 323 E. 88th St., Apt. 19, New York, NY, United States 10128  
Tatton, William G., 8 Halliday Ct., Purchase, NY, United States 10577  
Tatton, Nadine A., 8 Halliday Ct., Purchase, NY, United States 10577  
PI US 6492427 B2 20021210  
AI US 1999-416010 19991008 (9)  
PRAI US 1998-103742P 19981009 (60)  
DT Utility  
FS GRANTED  
LN.CNT 4782  
INCL INCLM: 514/646.000  
INCLS: 514/647.000; 514/654.000  
NCL NCLM: 514/646.000  
NCLS: 514/647.000; 514/654.000  
IC [7]  
ICM: A61K031-135  
EXF 514/646; 514/647; 514/651; 514/654  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
STN INTERNATIONAL LOGOFF AT 16:00:41 ON 31 AUG 2004